id
stringlengths 1
5
| document_id
stringlengths 5
8
| passages
list | entities
list | events
sequence | coreferences
sequence | relations
sequence |
|---|---|---|---|---|---|---|
65114 | 24732169 | [
{
"id": "65115",
"type": "document",
"text": [
"Effect of a mixed kinesio taping-compression technique on quality of life and clinical and gait parameters in postmenopausal women with chronic venous insufficiency : double-blinded , randomized controlled trial . OBJECTIVE To investigate the short-term effect of a mixed Kinesio taping ( KT ) model on range of ankle motion ( ROAM ) , gait , pain , perimeter of lower limbs , and quality of life in postmenopausal women with chronic venous insufficiency ( CVI ) . DESIGN Double-blinded , randomized controlled trial . SETTING Clinical setting . PARTICIPANTS Consecutive postmenopausal women ( N=130 ; mean age ± SD , 65.44±14.7y ) with mild CVI . No participant withdrew because of adverse effects . INTERVENTION Participants were randomly assigned to either ( 1 ) an experimental group to receive a mixed KT-compression treatment following KT recommendations for gastrocnemius muscle enhancement and functional correction of the ankle , and adding 2 tapes to simulate traditional compression bandages ( no KT guidelines ) ; or ( 2 ) a placebo control group for sham KT . Both interventions were performed 3 times a week during a 4-week period . MAIN OUTCOME MEASURES ROAM , gait , pain , perimeter of right and left lower limb , and quality of life were assessed at baseline and 48 hours posttreatment . RESULTS Quality of life was better in the intervention group by a mean of 8.76 points ( 95 % confidence interval [ CI ] , 4.96-12.55 ) . The experimental group also showed significant pre-/posttreatment improvements in both lower limbs in gait dorsiflexion ROAM ( 95 % CI , 1.02-2.49 ) , cadence ( 95 % CI , 3.45-1.47 ) , stride length ( 95 % CI , 21.48-10.83 ) , step length ( 95 % CI , 1.68-6.61 ) , stance phase ( 95 % CI , 61-107 ) , and foot ( 95 % CI , .56-.92 ) and malleolus ( 95 % CI , 1.15-1.63 ) circumference . None of these variables were significantly modified in the placebo group . Both groups reported a significant reduction in pain . CONCLUSIONS Ankle dorsiflexion during gait , walking parameters , peripheral edema , venous pain , and quality of life remain improved in patients with CVI at 1 month after mixed KT-compression therapy . KT may have a placebo effect on pain perception ."
],
"offsets": [
[
0,
2212
]
]
}
] | [
{
"id": "65116",
"type": "Intervention_Physical",
"text": [
"mixed kinesio taping-compression technique"
],
"offsets": [
[
12,
54
]
],
"normalized": []
},
{
"id": "65117",
"type": "Intervention_Physical",
"text": [
"Kinesio taping"
],
"offsets": [
[
272,
286
]
],
"normalized": []
},
{
"id": "65118",
"type": "Outcome_Other",
"text": [
"quality of life"
],
"offsets": [
[
58,
73
]
],
"normalized": []
},
{
"id": "65119",
"type": "Outcome_Other",
"text": [
"clinical"
],
"offsets": [
[
78,
86
]
],
"normalized": []
},
{
"id": "65120",
"type": "Outcome_Physical",
"text": [
"gait parameters"
],
"offsets": [
[
91,
106
]
],
"normalized": []
},
{
"id": "65121",
"type": "Outcome_Physical",
"text": [
"range of ankle motion ( ROAM ) , gait ,"
],
"offsets": [
[
303,
342
]
],
"normalized": []
},
{
"id": "65122",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
343,
347
]
],
"normalized": []
},
{
"id": "65123",
"type": "Outcome_Physical",
"text": [
", perimeter of lower limbs , and quality of life"
],
"offsets": [
[
348,
396
]
],
"normalized": []
},
{
"id": "65124",
"type": "Participant_Condition",
"text": [
"postmenopausal"
],
"offsets": [
[
110,
124
]
],
"normalized": []
},
{
"id": "65125",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
125,
130
]
],
"normalized": []
},
{
"id": "65126",
"type": "Participant_Condition",
"text": [
"chronic venous insufficiency"
],
"offsets": [
[
136,
164
]
],
"normalized": []
},
{
"id": "65127",
"type": "Participant_Condition",
"text": [
"postmenopausal"
],
"offsets": [
[
110,
124
]
],
"normalized": []
},
{
"id": "65128",
"type": "Participant_Condition",
"text": [
"chronic venous insufficiency ( CVI )"
],
"offsets": [
[
426,
462
]
],
"normalized": []
}
] | [] | [] | [] |
65129 | 24732316 | [
{
"id": "65130",
"type": "document",
"text": [
"The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905 . OBJECTIVE To explore the association of a functional germline variant in the 3'-UTR of KRAS with endometrial cancer risk , as well as the association of microRNA ( miRNA ) signatures and the KRAS-variant with clinical characteristics and survival outcomes in two prospective RTOG endometrial cancer trials . METHODS/MATERIALS The association of the KRAS-variant with endometrial cancer risk was evaluated by case-control analysis of 467 women with type 1 or 2 endometrial cancer and 582 age-matched controls . miRNA and DNA were isolated for expression profiling and genotyping from tumor specimens of 46 women with type 1 endometrial cancer enrolled in RTOG trials 9708 and 9905. miRNA expression levels and KRAS-variant genotype were correlated with patient and tumor characteristics , and survival outcomes were evaluated by variant allele type . RESULTS The KRAS-variant was not significantly associated with overall endometrial cancer risk ( 14 % controls and 17 % type 1 cancers ) , although was enriched in type 2 endometrial cancers ( 24 % , p = 0.2 ) . In the combined analysis of RTOG 9708/9905 , miRNA expression differed by age , presence of lymphovascular invasion and KRAS-variant status . Overall survival rates at 3 years for patients with the variant and wild-type alleles were 100 % and 77 % ( HR 0.3 , p = 0.24 ) , respectively , favoring the variant . CONCLUSIONS The KRAS-variant may be a genetic marker of risk for type 2 endometrial cancers . In addition , tumor miRNA expression appears to be associated with patient age , lymphovascular invasion and the KRAS-variant , supporting the hypothesis that altered tumor biology can be measured by miRNA expression , and that the KRAS-variant likely impacts endometrial tumor biology ."
],
"offsets": [
[
0,
1850
]
]
}
] | [
{
"id": "65131",
"type": "Outcome_Physical",
"text": [
"overall endometrial cancer risk"
],
"offsets": [
[
1010,
1041
]
],
"normalized": []
},
{
"id": "65132",
"type": "Outcome_Other",
"text": [
"9708/9905 , miRNA expression"
],
"offsets": [
[
1192,
1220
]
],
"normalized": []
},
{
"id": "65133",
"type": "Outcome_Other",
"text": [
"status"
],
"offsets": [
[
1292,
1298
]
],
"normalized": []
},
{
"id": "65134",
"type": "Outcome_Mortality",
"text": [
"Overall survival rates"
],
"offsets": [
[
1301,
1323
]
],
"normalized": []
},
{
"id": "65135",
"type": "Participant_Condition",
"text": [
"endometrial cancer"
],
"offsets": [
[
46,
64
]
],
"normalized": []
},
{
"id": "65136",
"type": "Participant_Sample-size",
"text": [
"467"
],
"offsets": [
[
530,
533
]
],
"normalized": []
},
{
"id": "65137",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
534,
539
]
],
"normalized": []
},
{
"id": "65138",
"type": "Participant_Condition",
"text": [
"type 1 or 2 endometrial cancer"
],
"offsets": [
[
545,
575
]
],
"normalized": []
},
{
"id": "65139",
"type": "Participant_Condition",
"text": [
"tumor"
],
"offsets": [
[
680,
685
]
],
"normalized": []
},
{
"id": "65140",
"type": "Participant_Sample-size",
"text": [
"46"
],
"offsets": [
[
530,
532
]
],
"normalized": []
},
{
"id": "65141",
"type": "Participant_Condition",
"text": [
"type 1 endometrial cancer"
],
"offsets": [
[
713,
738
]
],
"normalized": []
},
{
"id": "65142",
"type": "Participant_Condition",
"text": [
"variant and wild-type alleles"
],
"offsets": [
[
1357,
1386
]
],
"normalized": []
}
] | [] | [] | [] |
65143 | 24737062 | [
{
"id": "65144",
"type": "document",
"text": [
"Classification of motor imagery performance in acute stroke . OBJECTIVE Effective motor imagery performance , seen as strong suppression of the sensorimotor rhythm , is the key element in motor imagery therapy . Therefore , optimization of methods to classify whether the subject is performing the imagery task is a prerequisite . An optimal classification method should have high performance accuracy and use a small number of channels . We investigated the additional benefit of the common spatial pattern filtering ( CSP ) to a linear discriminant analysis ( LDA ) classifier , for different channel configurations . METHODS Ten hemispheric acute stroke patients and 11 healthy subjects were included . EEGs were recorded using 60 channels . The classifier was trained with a motor execution task . For both healthy controls and patients , analysis of recordings was initially limited to 3 and 11 electrodes recording from the motor cortex area , and later repeated using 45 electrodes . RESULTS No significant improvement on the addition of CSP to LDA was found ( in both cases , the area under the receiving operating characteristic ( AU-ROC ) ≈ 0.70 ( acceptable ) ) . We then repeated the LDA+CSP method on recordings of 45 electrodes , since the use of imagery neuronal circuits may well extend beyond the motor area . AU-ROC rose to 0.90 , but no virtual 'most responsible ' electrode was observed . Finally , in mild-to-moderate stroke patients we could successfully use the EEG data recorded from the healthy hemisphere to train the classifier ( AU-ROC ≈ 0.70 ) . SIGNIFICANCE Including only the channels on the unaffected motor cortex is sufficient to train a classifier ."
],
"offsets": [
[
0,
1684
]
]
}
] | [
{
"id": "65145",
"type": "Intervention_Physical",
"text": [
"motor imagery therapy ."
],
"offsets": [
[
188,
211
]
],
"normalized": []
},
{
"id": "65146",
"type": "Intervention_Physical",
"text": [
"EEGs"
],
"offsets": [
[
706,
710
]
],
"normalized": []
},
{
"id": "65147",
"type": "Outcome_Other",
"text": [
"motor imagery performance"
],
"offsets": [
[
18,
43
]
],
"normalized": []
},
{
"id": "65148",
"type": "Outcome_Other",
"text": [
"Effective motor imagery performance"
],
"offsets": [
[
72,
107
]
],
"normalized": []
},
{
"id": "65149",
"type": "Outcome_Other",
"text": [
"LDA"
],
"offsets": [
[
562,
565
]
],
"normalized": []
},
{
"id": "65150",
"type": "Outcome_Other",
"text": [
"area under the receiving operating characteristic ( AU-ROC )"
],
"offsets": [
[
1088,
1148
]
],
"normalized": []
},
{
"id": "65151",
"type": "Outcome_Other",
"text": [
"no virtual 'most responsible ' electrode"
],
"offsets": [
[
1353,
1393
]
],
"normalized": []
},
{
"id": "65152",
"type": "Participant_Condition",
"text": [
"acute stroke"
],
"offsets": [
[
47,
59
]
],
"normalized": []
},
{
"id": "65153",
"type": "Participant_Sample-size",
"text": [
"Ten"
],
"offsets": [
[
628,
631
]
],
"normalized": []
},
{
"id": "65154",
"type": "Participant_Sample-size",
"text": [
"11"
],
"offsets": [
[
670,
672
]
],
"normalized": []
},
{
"id": "65155",
"type": "Participant_Condition",
"text": [
"in mild-to-moderate stroke patients"
],
"offsets": [
[
1419,
1454
]
],
"normalized": []
}
] | [] | [] | [] |
65156 | 24738609 | [
{
"id": "65157",
"type": "document",
"text": [
"Effectiveness and Safety of Tapentadol Prolonged Release ( PR ) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe , Chronic Low Back Pain With a Neuropathic Component : A Randomized , Double-blind , Phase 3b Study . OBJECTIVE To evaluate the effectiveness and tolerability of tapentadol PR monotherapy versus tapentadol PR/pregabalin combination therapy for severe , chronic low back pain with a neuropathic component . METHODS Eligible patients had painDETECT \" unclear \" or \" positive \" ratings and average pain intensity ≥ 6 ( 11-point NRS-3 [ average 3-day pain intensity ] ) at baseline . Patients were titrated to tapentadol PR 300 mg/day over 3 weeks . Patients with ≥ 1-point decrease in pain intensity and average pain intensity ≥ 4 were randomized to tapentadol PR ( 500 mg/day ) or tapentadol PR ( 300 mg/day ) /pregabalin ( 300 mg/day ) during an 8-week comparative period . RESULTS In the per-protocol population ( n = 288 ) , the effectiveness of tapentadol PR was clinically and statistically comparable to tapentadol PR/pregabalin based on the change in pain intensity from randomization to final evaluation ( LOCF ; LSMD [ 95 % CI ] , -0.066 [ -0.57 , 0.43 ] ; P < 0.0001 for noninferiority ) . Neuropathic pain and quality-of-life measures improved significantly in both groups . Tolerability was good in both groups , in line with prior trials in the high dose range of 500 mg/day for tapentadol PR monotherapy , and favorable compared with historical combination trials of strong opioids and anticonvulsants for combination therapy . The incidence of the composite of dizziness and/or somnolence was significantly lower with tapentadol PR ( 16.9 % ) than tapentadol PR/pregabalin ( 27.0 % ; P = 0.0302 ) . CONCLUSIONS Tapentadol PR 500 mg is associated with comparable improvements in pain intensity and quality-of-life measures to tapentadol PR 300 mg/pregabalin 300 mg , with improved central nervous system tolerability , suggesting that tapentadol PR monotherapy may offer a favorable treatment option for severe low back pain with a neuropathic component ."
],
"offsets": [
[
0,
2113
]
]
}
] | [
{
"id": "65158",
"type": "Intervention_Pharmacological",
"text": [
"Tapentadol"
],
"offsets": [
[
28,
38
]
],
"normalized": []
},
{
"id": "65159",
"type": "Intervention_Pharmacological",
"text": [
"Combination of Tapentadol PR and Pregabalin"
],
"offsets": [
[
73,
116
]
],
"normalized": []
},
{
"id": "65160",
"type": "Intervention_Pharmacological",
"text": [
"tapentadol PR"
],
"offsets": [
[
308,
321
]
],
"normalized": []
},
{
"id": "65161",
"type": "Intervention_Pharmacological",
"text": [
"tapentadol PR/pregabalin"
],
"offsets": [
[
341,
365
]
],
"normalized": []
},
{
"id": "65162",
"type": "Intervention_Pharmacological",
"text": [
"tapentadol"
],
"offsets": [
[
308,
318
]
],
"normalized": []
},
{
"id": "65163",
"type": "Intervention_Pharmacological",
"text": [
"tapentadol PR ( 300 mg/day ) /pregabalin"
],
"offsets": [
[
825,
865
]
],
"normalized": []
},
{
"id": "65164",
"type": "Outcome_Other",
"text": [
"Effectiveness and Safety"
],
"offsets": [
[
0,
24
]
],
"normalized": []
},
{
"id": "65165",
"type": "Outcome_Other",
"text": [
"effectiveness and tolerability"
],
"offsets": [
[
274,
304
]
],
"normalized": []
},
{
"id": "65166",
"type": "Outcome_Pain",
"text": [
"decrease in pain intensity"
],
"offsets": [
[
716,
742
]
],
"normalized": []
},
{
"id": "65167",
"type": "Outcome_Pain",
"text": [
"average pain intensity"
],
"offsets": [
[
533,
555
]
],
"normalized": []
},
{
"id": "65168",
"type": "Outcome_Other",
"text": [
"( n = 288 ) , the"
],
"offsets": [
[
958,
975
]
],
"normalized": []
},
{
"id": "65169",
"type": "Outcome_Mental",
"text": [
"for noninferiority ) ."
],
"offsets": [
[
1221,
1243
]
],
"normalized": []
},
{
"id": "65170",
"type": "Outcome_Pain",
"text": [
"Neuropathic pain and quality-of-life"
],
"offsets": [
[
1244,
1280
]
],
"normalized": []
},
{
"id": "65171",
"type": "Outcome_Adverse-effects",
"text": [
"of the composite of dizziness"
],
"offsets": [
[
1600,
1629
]
],
"normalized": []
},
{
"id": "65172",
"type": "Outcome_Pain",
"text": [
"associated with comparable improvements in pain intensity and quality-of-life"
],
"offsets": [
[
1794,
1871
]
],
"normalized": []
},
{
"id": "65173",
"type": "Participant_Condition",
"text": [
"Chronic Low Back Pain With a Neuropathic Component"
],
"offsets": [
[
148,
198
]
],
"normalized": []
},
{
"id": "65174",
"type": "Participant_Condition",
"text": [
"severe , chronic low back pain with a neuropathic component ."
],
"offsets": [
[
390,
451
]
],
"normalized": []
},
{
"id": "65175",
"type": "Participant_Condition",
"text": [
"severe low back pain"
],
"offsets": [
[
2062,
2082
]
],
"normalized": []
}
] | [] | [] | [] |
65176 | 2474057 | [
{
"id": "65177",
"type": "document",
"text": [
"LNH-84 regimen : a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma . From July 1984 to September 1987 , 737 patients with aggressive malignant lymphoma ( ML ) were treated by an intensive regimen ( LNH-84 ) comprising three or four courses of doxorubicin , 75 mg/m2 ; cyclophosphamide , 1,200 mg/m2 ; vindesine , 2 mg/m2 x 2 ; bleomycin , 10 mg x 2 ; and prednisolone , 60 mg/m2 x 5 ( ACVB ) , consolidation with high-dose methotrexate , ifosfamide , etoposide , asparaginase , and cytarabine , and a randomized late intensification with two courses of cytarabine , cyclophosphamide , teniposide , bleomycin , and prednisone ( AraCVmB ) . Four hundred forty-two patients had intermediate-grade ML , 221 highgrade ML , and 74 unclassified ML . Most of the patients had advanced disease : stage IIE ( 23 % ) , III ( 13 % ) , or IV ( 47 % ) ; 38 % disseminated nodes ; 38 % two or more extranodal sites ; and 41 % a tumoral mass greater than 10 cm . Five hundred fifty-three patients ( 75 % ) went into complete remission ( CR ) , 63 ( 9 % ) into partial remission , 62 ( 8 % ) failed to respond , and 59 ( 8 % ) died during ACVB courses , 17 of them from progression of the disease . With a median follow-up of 23 months , the estimated 2-year overall survival time to failure ( TTF ) , and time to relapse ( TTR ) survival are 67 % , 56 % , and 67 % , respectively . Patients receiving a late intensification had the same relapse rate as the other patients . A persistent fibronecrotic mass was found in 150 patients ( 20 % ) and did not influence the relapse rate . Toxicity was mainly neutropenia and infection during the ACVB courses , with 40 patients ( 5 % ) dying from septic complications while responding to treatment . Fifty-three percent of the patients had a neutropenia less than 0.500 x 10 ( 9 ) /L , 58 % fever ( 6 % grade 4 ) , and 49 % a documented infection ( 8 % grade 4 ) . These results obtained with the LNH-84 regimen demonstrate that this therapeutic scheme is an effective treatment for aggressive ML ."
],
"offsets": [
[
0,
2072
]
]
}
] | [
{
"id": "65178",
"type": "Intervention_Pharmacological",
"text": [
"intensive regimen ( LNH-84 )"
],
"offsets": [
[
225,
253
]
],
"normalized": []
},
{
"id": "65179",
"type": "Intervention_Pharmacological",
"text": [
"doxorubicin"
],
"offsets": [
[
290,
301
]
],
"normalized": []
},
{
"id": "65180",
"type": "Intervention_Pharmacological",
"text": [
"cyclophosphamide"
],
"offsets": [
[
315,
331
]
],
"normalized": []
},
{
"id": "65181",
"type": "Intervention_Pharmacological",
"text": [
"vindesine"
],
"offsets": [
[
348,
357
]
],
"normalized": []
},
{
"id": "65182",
"type": "Intervention_Pharmacological",
"text": [
"bleomycin"
],
"offsets": [
[
374,
383
]
],
"normalized": []
},
{
"id": "65183",
"type": "Intervention_Pharmacological",
"text": [
"prednisolone"
],
"offsets": [
[
402,
414
]
],
"normalized": []
},
{
"id": "65184",
"type": "Intervention_Pharmacological",
"text": [
"methotrexate , ifosfamide , etoposide , asparaginase , and cytarabine"
],
"offsets": [
[
470,
539
]
],
"normalized": []
},
{
"id": "65185",
"type": "Intervention_Pharmacological",
"text": [
"cytarabine , cyclophosphamide , teniposide , bleomycin , and prednisone"
],
"offsets": [
[
600,
671
]
],
"normalized": []
},
{
"id": "65186",
"type": "Outcome_Physical",
"text": [
"complete remission ( CR )"
],
"offsets": [
[
1047,
1072
]
],
"normalized": []
},
{
"id": "65187",
"type": "Outcome_Physical",
"text": [
"partial remission"
],
"offsets": [
[
1091,
1108
]
],
"normalized": []
},
{
"id": "65188",
"type": "Outcome_Physical",
"text": [
"failed to respond"
],
"offsets": [
[
1122,
1139
]
],
"normalized": []
},
{
"id": "65189",
"type": "Outcome_Mortality",
"text": [
"died"
],
"offsets": [
[
1157,
1161
]
],
"normalized": []
},
{
"id": "65190",
"type": "Outcome_Mortality",
"text": [
"overall survival time to failure ( TTF )"
],
"offsets": [
[
1289,
1329
]
],
"normalized": []
},
{
"id": "65191",
"type": "Outcome_Mortality",
"text": [
"time to relapse ( TTR ) survival"
],
"offsets": [
[
1336,
1368
]
],
"normalized": []
},
{
"id": "65192",
"type": "Outcome_Physical",
"text": [
"relapse rate"
],
"offsets": [
[
1468,
1480
]
],
"normalized": []
},
{
"id": "65193",
"type": "Outcome_Physical",
"text": [
"persistent fibronecrotic mass"
],
"offsets": [
[
1507,
1536
]
],
"normalized": []
},
{
"id": "65194",
"type": "Outcome_Physical",
"text": [
"relapse rate ."
],
"offsets": [
[
1598,
1612
]
],
"normalized": []
},
{
"id": "65195",
"type": "Outcome_Adverse-effects",
"text": [
"Toxicity"
],
"offsets": [
[
1613,
1621
]
],
"normalized": []
},
{
"id": "65196",
"type": "Outcome_Adverse-effects",
"text": [
"neutropenia"
],
"offsets": [
[
1633,
1644
]
],
"normalized": []
},
{
"id": "65197",
"type": "Outcome_Adverse-effects",
"text": [
"infection"
],
"offsets": [
[
1649,
1658
]
],
"normalized": []
},
{
"id": "65198",
"type": "Outcome_Mortality",
"text": [
"dying from septic complications"
],
"offsets": [
[
1710,
1741
]
],
"normalized": []
},
{
"id": "65199",
"type": "Outcome_Adverse-effects",
"text": [
"neutropenia"
],
"offsets": [
[
1633,
1644
]
],
"normalized": []
},
{
"id": "65200",
"type": "Outcome_Physical",
"text": [
"documented infection"
],
"offsets": [
[
1900,
1920
]
],
"normalized": []
},
{
"id": "65201",
"type": "Participant_Age",
"text": [
"Four hundred forty-two patients"
],
"offsets": [
[
686,
717
]
],
"normalized": []
}
] | [] | [] | [] |
65202 | 24740733 | [
{
"id": "65203",
"type": "document",
"text": [
"Correlations between the clinical , histological and neurophysiological examinations in patients before and after parotid gland tumor surgery : verification of facial nerve transmission . Parotid gland tumor surgery sometimes leads to facial nerve paralysis . Malignant more than benign tumors determine nerve function preoperatively , while postoperative observations based on clinical , histological and neurophysiological studies have not been reported in detail . The aims of this pilot study were evaluation and correlations of histological properties of tumor ( its size and location ) and clinical and neurophysiological assessment of facial nerve function pre- and post-operatively ( 1 and 6 months ) . Comparative studies included 17 patients with benign ( n = 13 ) and malignant ( n = 4 ) tumors . Clinical assessment was based on House-Brackmann scale ( H-B ) , neurophysiological diagnostics included facial electroneurography [ ENG , compound muscle action potential ( CMAP ) ] , mimetic muscle electromyography ( EMG ) and blink-reflex examinations ( BR ) . Mainly grade I of H-B was recorded both pre- ( n = 13 ) and post-operatively ( n = 12 ) in patients with small ( 1.5-2.4 cm ) benign tumors located in superficial lobes . Patients with medium size ( 2.5-3.4 cm ) malignant tumors in both lobes were scored at grade I ( n = 2 ) and III ( n = 2 ) pre- and mainly VI ( n = 4 ) post-operatively . CMAP amplitudes after stimulation of mandibular marginal branch were reduced at about 25 % in patients with benign tumors after surgery . In the cases of malignant tumors CMAPs were not recorded following stimulation of any branch . A similar trend was found for BR results . H-B and ENG results revealed positive correlations between the type of tumor and surgery with facial nerve function . Neurophysiological studies detected clinically silent facial nerve neuropathy of mandibular marginal branch in postoperative period . Needle EMG , ENG and BR examinations allow for the evaluation of face muscles reinnervation and facial nerve regeneration ."
],
"offsets": [
[
0,
2065
]
]
}
] | [
{
"id": "65204",
"type": "Intervention_Surgical",
"text": [
"parotid gland tumor surgery"
],
"offsets": [
[
114,
141
]
],
"normalized": []
},
{
"id": "65205",
"type": "Intervention_Surgical",
"text": [
"pre- and post-operatively"
],
"offsets": [
[
664,
689
]
],
"normalized": []
},
{
"id": "65206",
"type": "Intervention_Physical",
"text": [
"facial electroneurography"
],
"offsets": [
[
913,
938
]
],
"normalized": []
},
{
"id": "65207",
"type": "Intervention_Physical",
"text": [
"mimetic muscle electromyography"
],
"offsets": [
[
993,
1024
]
],
"normalized": []
},
{
"id": "65208",
"type": "Intervention_Physical",
"text": [
"blink-reflex examinations"
],
"offsets": [
[
1037,
1062
]
],
"normalized": []
},
{
"id": "65209",
"type": "Outcome_Physical",
"text": [
"clinical , histological and neurophysiological examinations"
],
"offsets": [
[
25,
84
]
],
"normalized": []
},
{
"id": "65210",
"type": "Outcome_Physical",
"text": [
"histological properties of tumor ( its size and location )"
],
"offsets": [
[
533,
591
]
],
"normalized": []
},
{
"id": "65211",
"type": "Outcome_Physical",
"text": [
"clinical and neurophysiological assessment of facial nerve function pre- and post-operatively"
],
"offsets": [
[
596,
689
]
],
"normalized": []
},
{
"id": "65212",
"type": "Outcome_Physical",
"text": [
"House-Brackmann scale ( H-B ) , neurophysiological diagnostics included facial electroneurography [ ENG , compound muscle action potential ( CMAP ) ] , mimetic muscle electromyography ( EMG ) and blink-reflex examinations ( BR )"
],
"offsets": [
[
841,
1069
]
],
"normalized": []
},
{
"id": "65213",
"type": "Outcome_Physical",
"text": [
"H-B"
],
"offsets": [
[
865,
868
]
],
"normalized": []
},
{
"id": "65214",
"type": "Outcome_Physical",
"text": [
"CMAP amplitudes"
],
"offsets": [
[
1414,
1429
]
],
"normalized": []
},
{
"id": "65215",
"type": "Outcome_Physical",
"text": [
"CMAPs"
],
"offsets": [
[
1585,
1590
]
],
"normalized": []
},
{
"id": "65216",
"type": "Outcome_Physical",
"text": [
"BR results . H-B and ENG"
],
"offsets": [
[
1677,
1701
]
],
"normalized": []
},
{
"id": "65217",
"type": "Outcome_Physical",
"text": [
"clinically silent facial nerve neuropathy of mandibular marginal branch"
],
"offsets": [
[
1844,
1915
]
],
"normalized": []
},
{
"id": "65218",
"type": "Outcome_Physical",
"text": [
"Needle EMG , ENG and BR examinations"
],
"offsets": [
[
1942,
1978
]
],
"normalized": []
},
{
"id": "65219",
"type": "Outcome_Physical",
"text": [
"face muscles reinnervation and facial nerve regeneration ."
],
"offsets": [
[
2007,
2065
]
],
"normalized": []
},
{
"id": "65220",
"type": "Participant_Condition",
"text": [
"parotid gland tumor surgery"
],
"offsets": [
[
114,
141
]
],
"normalized": []
},
{
"id": "65221",
"type": "Participant_Sample-size",
"text": [
"17"
],
"offsets": [
[
740,
742
]
],
"normalized": []
},
{
"id": "65222",
"type": "Participant_Condition",
"text": [
"benign"
],
"offsets": [
[
280,
286
]
],
"normalized": []
},
{
"id": "65223",
"type": "Participant_Sample-size",
"text": [
"13"
],
"offsets": [
[
770,
772
]
],
"normalized": []
},
{
"id": "65224",
"type": "Participant_Condition",
"text": [
"malignant"
],
"offsets": [
[
779,
788
]
],
"normalized": []
},
{
"id": "65225",
"type": "Participant_Sample-size",
"text": [
"4"
],
"offsets": [
[
795,
796
]
],
"normalized": []
},
{
"id": "65226",
"type": "Participant_Condition",
"text": [
"tumors"
],
"offsets": [
[
287,
293
]
],
"normalized": []
},
{
"id": "65227",
"type": "Participant_Condition",
"text": [
"small ( 1.5-2.4 cm ) benign tumors located in superficial lobes"
],
"offsets": [
[
1177,
1240
]
],
"normalized": []
},
{
"id": "65228",
"type": "Participant_Condition",
"text": [
"medium size ( 2.5-3.4 cm ) malignant tumors in both lobes"
],
"offsets": [
[
1257,
1314
]
],
"normalized": []
},
{
"id": "65229",
"type": "Participant_Condition",
"text": [
"benign tumors"
],
"offsets": [
[
280,
293
]
],
"normalized": []
}
] | [] | [] | [] |
65230 | 2474103 | [
{
"id": "65231",
"type": "document",
"text": [
"Moderate sodium restriction , angiotensin converting enzyme inhibition , and thiazide diuretic in the management of essential hypertension . Dietary sodium restriction alone is effective in lowering blood pressure in some , but not all , patients with essential hypertension . Homeostatic mechanisms , including activation of the renin-aldosterone system , may counteract the effects of sodium restriction . Angiotensin converting enzyme ( ACE ) inhibitors are also effective as sole therapy in many patients with essential hypertension , but may be less effective in those with low-renin hypertension . The combination of dietary sodium restriction with blockade of the renin system by an ACE inhibitor is a particularly effective way to improve blood pressure control . Addition of a thiazide diuretic will reduce pressure further ."
],
"offsets": [
[
0,
834
]
]
}
] | [
{
"id": "65232",
"type": "Intervention_Physical",
"text": [
"Moderate sodium restriction"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "65233",
"type": "Intervention_Pharmacological",
"text": [
"angiotensin converting enzyme inhibition"
],
"offsets": [
[
30,
70
]
],
"normalized": []
},
{
"id": "65234",
"type": "Intervention_Pharmacological",
"text": [
"thiazide diuretic"
],
"offsets": [
[
77,
94
]
],
"normalized": []
},
{
"id": "65235",
"type": "Intervention_Pharmacological",
"text": [
"Dietary sodium restriction"
],
"offsets": [
[
141,
167
]
],
"normalized": []
},
{
"id": "65236",
"type": "Intervention_Pharmacological",
"text": [
"sodium"
],
"offsets": [
[
9,
15
]
],
"normalized": []
},
{
"id": "65237",
"type": "Intervention_Pharmacological",
"text": [
"Angiotensin converting enzyme ( ACE ) inhibitors"
],
"offsets": [
[
408,
456
]
],
"normalized": []
},
{
"id": "65238",
"type": "Intervention_Pharmacological",
"text": [
"combination of"
],
"offsets": [
[
608,
622
]
],
"normalized": []
},
{
"id": "65239",
"type": "Intervention_Physical",
"text": [
"dietary sodium restriction"
],
"offsets": [
[
623,
649
]
],
"normalized": []
},
{
"id": "65240",
"type": "Intervention_Pharmacological",
"text": [
"ACE inhibitor"
],
"offsets": [
[
690,
703
]
],
"normalized": []
},
{
"id": "65241",
"type": "Intervention_Pharmacological",
"text": [
"thiazide diuretic"
],
"offsets": [
[
77,
94
]
],
"normalized": []
},
{
"id": "65242",
"type": "Outcome_Physical",
"text": [
"blood pressure"
],
"offsets": [
[
199,
213
]
],
"normalized": []
},
{
"id": "65243",
"type": "Outcome_Other",
"text": [
"effective"
],
"offsets": [
[
177,
186
]
],
"normalized": []
},
{
"id": "65244",
"type": "Outcome_Physical",
"text": [
"blood pressure control ."
],
"offsets": [
[
747,
771
]
],
"normalized": []
},
{
"id": "65245",
"type": "Outcome_Physical",
"text": [
"pressure"
],
"offsets": [
[
205,
213
]
],
"normalized": []
},
{
"id": "65246",
"type": "Participant_Condition",
"text": [
"essential hypertension"
],
"offsets": [
[
116,
138
]
],
"normalized": []
}
] | [] | [] | [] |
65247 | 24749259 | [
{
"id": "65248",
"type": "document",
"text": [
"[ Dexmedetomidine use for postoperative adrenergic analgesia and sedation in abdominal surgery ] . Comparative study of postoperative analgesia and sedation with trimeperidine and dexmedetomidine and their effects on haemodynamics and vegetative nervous system was performed . Assessment of analgesia and sedation during vagotonia ( first part of the study ) and hypokinetic type of haemodynamics ( second part of the study ) was carried out with visual analogue scale ( VAS ) and Richmond scale . Results of the study showed that dexmedetomidine is more effective and safer than trimeperidine for analgesia and sedation in patients with spontaneous breathing after abdominal surgery . Dexmedetomidine use allows keeping optimal type of haemodynamics and vegetative nervous system parameters on first day of postoperative period ."
],
"offsets": [
[
0,
830
]
]
}
] | [
{
"id": "65249",
"type": "Intervention_Pharmacological",
"text": [
"Dexmedetomidine"
],
"offsets": [
[
2,
17
]
],
"normalized": []
},
{
"id": "65250",
"type": "Intervention_Pharmacological",
"text": [
"trimeperidine"
],
"offsets": [
[
162,
175
]
],
"normalized": []
},
{
"id": "65251",
"type": "Intervention_Pharmacological",
"text": [
"dexmedetomidine"
],
"offsets": [
[
180,
195
]
],
"normalized": []
},
{
"id": "65252",
"type": "Intervention_Pharmacological",
"text": [
"dexmedetomidine"
],
"offsets": [
[
180,
195
]
],
"normalized": []
},
{
"id": "65253",
"type": "Intervention_Pharmacological",
"text": [
"trimeperidine"
],
"offsets": [
[
162,
175
]
],
"normalized": []
},
{
"id": "65254",
"type": "Intervention_Pharmacological",
"text": [
"Dexmedetomidine"
],
"offsets": [
[
2,
17
]
],
"normalized": []
},
{
"id": "65255",
"type": "Outcome_Physical",
"text": [
"postoperative adrenergic analgesia and sedation"
],
"offsets": [
[
26,
73
]
],
"normalized": []
},
{
"id": "65256",
"type": "Outcome_Physical",
"text": [
"visual analogue scale ( VAS )"
],
"offsets": [
[
447,
476
]
],
"normalized": []
},
{
"id": "65257",
"type": "Outcome_Physical",
"text": [
"Richmond scale"
],
"offsets": [
[
481,
495
]
],
"normalized": []
},
{
"id": "65258",
"type": "Outcome_Other",
"text": [
"effective and safer"
],
"offsets": [
[
555,
574
]
],
"normalized": []
},
{
"id": "65259",
"type": "Outcome_Physical",
"text": [
"analgesia and sedation"
],
"offsets": [
[
51,
73
]
],
"normalized": []
},
{
"id": "65260",
"type": "Participant_Condition",
"text": [
"spontaneous breathing after abdominal surgery"
],
"offsets": [
[
638,
683
]
],
"normalized": []
}
] | [] | [] | [] |
65261 | 24752311 | [
{
"id": "65262",
"type": "document",
"text": [
"Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients . The aim of this study was to investigate the association of PAX4 variants with therapeutic effect of oral antidiabetic drugs in Chinese type 2 diabtes mellitus ( T2DM ) patients . A total of 209 newly diagnosed T2DM patients were randomly assigned to treatment with repaglinide or rosiglitazone for 48 weeks , and the therapeutic effects were compared . In the rosiglitazone cohort , rs6467136 GA+AA carriers showed greater decrease in 2-h glucose levels ( P=0.0063 ) and higher cumulative attainment rates of target 2-h glucose levels ( Plog rank=0.0093 ) than GG homozygotes . In the subgroup with defective β-cell function , rs6467136 GA+AA carriers exhibited greater decrements of 2-h glucose level and improvement of homeostasis model assessment of insulin resistance ( P=0.0143 ) . Moreover , GA+AA carriers were more likely to attain the target fasting and 2-h glucose level ( Plog rank=0.0091 and 0.007 , respectively ) . However , these single-nucleotide polymorphisms showed no effect on repaglinide efficacy . In conclusion , PAX4 variant rs6467136 was associated with the therapeutic effect of rosiglitazone in Chinese T2DM patients ."
],
"offsets": [
[
0,
1259
]
]
}
] | [
{
"id": "65263",
"type": "Intervention_Pharmacological",
"text": [
"oral antidiabetic drugs"
],
"offsets": [
[
42,
65
]
],
"normalized": []
},
{
"id": "65264",
"type": "Intervention_Pharmacological",
"text": [
"oral antidiabetic drugs"
],
"offsets": [
[
42,
65
]
],
"normalized": []
},
{
"id": "65265",
"type": "Intervention_Pharmacological",
"text": [
"repaglinide"
],
"offsets": [
[
379,
390
]
],
"normalized": []
},
{
"id": "65266",
"type": "Intervention_Pharmacological",
"text": [
"rosiglitazone"
],
"offsets": [
[
394,
407
]
],
"normalized": []
},
{
"id": "65267",
"type": "Intervention_Pharmacological",
"text": [
"rosiglitazone"
],
"offsets": [
[
394,
407
]
],
"normalized": []
},
{
"id": "65268",
"type": "Participant_Condition",
"text": [
"Chinese type 2 diabetes patients"
],
"offsets": [
[
78,
110
]
],
"normalized": []
},
{
"id": "65269",
"type": "Participant_Condition",
"text": [
"PAX4 variants"
],
"offsets": [
[
173,
186
]
],
"normalized": []
},
{
"id": "65270",
"type": "Participant_Condition",
"text": [
"Chinese type 2 diabtes mellitus ( T2DM ) patients"
],
"offsets": [
[
241,
290
]
],
"normalized": []
},
{
"id": "65271",
"type": "Participant_Sample-size",
"text": [
"A total"
],
"offsets": [
[
293,
300
]
],
"normalized": []
},
{
"id": "65272",
"type": "Participant_Sample-size",
"text": [
"209"
],
"offsets": [
[
304,
307
]
],
"normalized": []
},
{
"id": "65273",
"type": "Participant_Condition",
"text": [
"in Chinese"
],
"offsets": [
[
75,
85
]
],
"normalized": []
}
] | [] | [] | [] |
65274 | 24761456 | [
{
"id": "65275",
"type": "document",
"text": [
"Evidence-based narratives to improve recall of opioid prescribing guidelines : a randomized experiment . OBJECTIVES Physicians adopt evidence-based guidelines with variable consistency . Narratives , or stories , offer a novel dissemination strategy for clinical recommendations . The study objective was to compare whether evidence-based narrative versus traditional summary improved recall of opioid prescribing guidelines from the American College of Emergency Physicians ( ACEP ) . METHODS This was a prospective , randomized controlled experiment to compare whether narrative versus summary promoted short-term recall of six themes contained in the ACEP opioid guideline . The experiment was modeled after the free-recall test , an established technique in studies of memory . At a regional conference , emergency physicians ( EPs ) were randomized to read either a summary of the guideline ( control ) or a narrative ( intervention ) . The fictional narrative was constructed to match the summary in content and length . One hour after reading the text , participants listed all content that they could recall . Two reviewers independently scored the responses to assess recall of the six themes . The primary outcome was the total number of themes recalled per participant . Secondary outcomes included the proportion of responses in each study arm that recalled individual themes and the proportion of responses in each arm that contained falsely recalled or extraneous information . RESULTS Ninety-five physicians were randomized . Eighty-two physicians completed the experiment , for a response rate of 86 % . The mean of the total number of themes recalled per participant was 3.1 in the narrative arm versus 2.0 in the summary arm ( difference = 1.1 , 95 % confidence interval [ CI ] = 0.6 to 1.7 ) . For three themes , the proportion of responses that recalled the theme was significantly greater in the narrative arm compared to the summary arm , with the differences ranging from 20 % to 51 % . For one theme , recall was significantly greater in the summary arm . For two themes , there was no statistically significant difference in recall between the arms . In the summary arm , 54 % of responses were found to contain falsely recalled or extraneous information versus 21 % of responses in the narrative arm ( difference = 33 % , 95 % CI = 14 % to 53 % ) . CONCLUSIONS Physicians exposed to a narrative about opioid guidelines were more likely to recall guideline content at 1 hour than those exposed to a summary of the guidelines . Future studies should examine whether the incorporation of narratives in dissemination campaigns improves guideline adoption and changes clinical practice"
],
"offsets": [
[
0,
2706
]
]
}
] | [
{
"id": "65276",
"type": "Intervention_Educational",
"text": [
"Evidence-based narratives"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "65277",
"type": "Intervention_Educational",
"text": [
"evidence-based narrative"
],
"offsets": [
[
324,
348
]
],
"normalized": []
},
{
"id": "65278",
"type": "Intervention_Educational",
"text": [
"traditional summary"
],
"offsets": [
[
356,
375
]
],
"normalized": []
},
{
"id": "65279",
"type": "Intervention_Educational",
"text": [
"narrative"
],
"offsets": [
[
15,
24
]
],
"normalized": []
},
{
"id": "65280",
"type": "Intervention_Educational",
"text": [
"summary"
],
"offsets": [
[
368,
375
]
],
"normalized": []
},
{
"id": "65281",
"type": "Intervention_Educational",
"text": [
"read either a summary of the guideline ( control ) or a narrative ( intervention )"
],
"offsets": [
[
857,
939
]
],
"normalized": []
},
{
"id": "65282",
"type": "Intervention_Educational",
"text": [
"opioid guidelines"
],
"offsets": [
[
2427,
2444
]
],
"normalized": []
},
{
"id": "65283",
"type": "Outcome_Mental",
"text": [
"recall"
],
"offsets": [
[
37,
43
]
],
"normalized": []
},
{
"id": "65284",
"type": "Outcome_Mental",
"text": [
"assess recall"
],
"offsets": [
[
1170,
1183
]
],
"normalized": []
},
{
"id": "65285",
"type": "Outcome_Mental",
"text": [
"total number of themes recalled per participant"
],
"offsets": [
[
1232,
1279
]
],
"normalized": []
},
{
"id": "65286",
"type": "Outcome_Mental",
"text": [
"proportion of responses"
],
"offsets": [
[
1314,
1337
]
],
"normalized": []
},
{
"id": "65287",
"type": "Outcome_Mental",
"text": [
"recalled individual"
],
"offsets": [
[
1361,
1380
]
],
"normalized": []
},
{
"id": "65288",
"type": "Outcome_Mental",
"text": [
"falsely recalled or extraneous information"
],
"offsets": [
[
1447,
1489
]
],
"normalized": []
},
{
"id": "65289",
"type": "Outcome_Mental",
"text": [
"mean of the total number of themes recalled"
],
"offsets": [
[
1624,
1667
]
],
"normalized": []
},
{
"id": "65290",
"type": "Outcome_Mental",
"text": [
"proportion of responses"
],
"offsets": [
[
1314,
1337
]
],
"normalized": []
},
{
"id": "65291",
"type": "Outcome_Mental",
"text": [
"recall"
],
"offsets": [
[
37,
43
]
],
"normalized": []
},
{
"id": "65292",
"type": "Outcome_Mental",
"text": [
"recall"
],
"offsets": [
[
37,
43
]
],
"normalized": []
},
{
"id": "65293",
"type": "Outcome_Mental",
"text": [
"falsely recalled or extraneous information"
],
"offsets": [
[
1447,
1489
]
],
"normalized": []
},
{
"id": "65294",
"type": "Participant_Sample-size",
"text": [
"Ninety-five"
],
"offsets": [
[
1500,
1511
]
],
"normalized": []
},
{
"id": "65295",
"type": "Participant_Sample-size",
"text": [
"Eighty-two"
],
"offsets": [
[
1541,
1551
]
],
"normalized": []
}
] | [] | [] | [] |
65296 | 24763663 | [
{
"id": "65297",
"type": "document",
"text": [
"MRI-detected skull-base invasion : prognostic value and therapeutic implication in intensity-modulated radiotherapy treatment for nasopharyngeal carcinoma . PURPOSE With advances in imaging and radiotherapy , the prognostic value of skull-base invasion in nasopharyngeal carcinoma ( NPC ) needs to be reassessed . We aimed to define a classification system and evaluate the prognostic value of the classification of magnetic resonance imaging ( MRI ) -detected skull-base invasion in NPC treated with intensity-modulated radiotherapy ( IMRT ) . PATIENTS AND MATERIALS We retrospectively reviewed 749 patients who underwent MRI and were subsequently histologically diagnosed with nondisseminated NPC and treated with IMRT . RESULTS MRI-detected skull-base invasion was not found to be an independent prognostic factor for overall survival ( OS ) , distant metastasis-free survival ( DMFS ) , local relapse-free survival ( LRFS ) , or disease-free survival ( DFS ; p > 0.05 for all ) . Skull-base invasion was classified according to the incidence of each site ( type I sites inside pharyngobasilar fascia and clivus vs. type II sites outside pharyngobasilar fascia ) . The 5-year OS , DMFS , LRFS , and DFS rates in the classification of skull-base invasion in NPC were 83 vs. 67 % , 85 vs.75 % , 95 vs. 88 % , and 76 vs. 62 % , respectively ( p < 0.05 for all ) . Multivariate analysis indicated the classification of skull-base invasion was an independent prognostic factor . CONCLUSION MRI-detected skull-base invasion is not an independent prognostic factor in patients with NPC treated with IMRT . However , classification according to the site of invasion has prognostic value . Therefore , patients with various subclassifications of stage T3 disease may receive treatment with different intensities ; however , further studies are warranted to prove this ."
],
"offsets": [
[
0,
1863
]
]
}
] | [
{
"id": "65298",
"type": "Intervention_Physical",
"text": [
"intensity-modulated radiotherapy"
],
"offsets": [
[
83,
115
]
],
"normalized": []
},
{
"id": "65299",
"type": "Intervention_Physical",
"text": [
"MRI and were subsequently histologically diagnosed with nondisseminated NPC and treated with IMRT"
],
"offsets": [
[
623,
720
]
],
"normalized": []
},
{
"id": "65300",
"type": "Outcome_Mortality",
"text": [
"overall survival ( OS ) , distant metastasis-free survival ( DMFS ) , local relapse-free survival ( LRFS ) , or disease-free survival ( DFS ;"
],
"offsets": [
[
821,
962
]
],
"normalized": []
},
{
"id": "65301",
"type": "Outcome_Mortality",
"text": [
"5-year OS"
],
"offsets": [
[
1172,
1181
]
],
"normalized": []
},
{
"id": "65302",
"type": "Outcome_Mortality",
"text": [
"DMFS"
],
"offsets": [
[
882,
886
]
],
"normalized": []
},
{
"id": "65303",
"type": "Outcome_Mortality",
"text": [
"LRFS"
],
"offsets": [
[
921,
925
]
],
"normalized": []
},
{
"id": "65304",
"type": "Outcome_Mortality",
"text": [
"DFS"
],
"offsets": [
[
957,
960
]
],
"normalized": []
},
{
"id": "65305",
"type": "Participant_Condition",
"text": [
"nasopharyngeal carcinoma ."
],
"offsets": [
[
130,
156
]
],
"normalized": []
},
{
"id": "65306",
"type": "Participant_Sample-size",
"text": [
"749"
],
"offsets": [
[
596,
599
]
],
"normalized": []
},
{
"id": "65307",
"type": "Participant_Condition",
"text": [
"nondisseminated NPC"
],
"offsets": [
[
679,
698
]
],
"normalized": []
}
] | [] | [] | [] |
65308 | 24767004 | [
{
"id": "65309",
"type": "document",
"text": [
"Cognitive control therapy and transcranial direct current stimulation for depression : a randomized , double-blinded , controlled trial . BACKGROUND Based on findings that major depressive disorder ( MDD ) is associated to decreased dorsolateral prefrontal cortical ( DLPFC ) activity ; interventions that increase DLPFC activity might theoretically present antidepressant effects . Two of them are cognitive control therapy ( CCT ) , a neurocognitive intervention that uses computer-based working memory exercises , and transcranial direct current stimulation ( tDCS ) , which delivers weak , electric direct currents over the scalp . METHODS We investigated whether tDCS enhanced the effects of CCT in a double-blind trial , in which participants were randomized to sham tDCS and CCT ( n=17 ) vs. active tDCS and CCT ( n=20 ) . CCT and tDCS were applied for 10 consecutive workdays . Clinicaltrials.gov identifier : NCT01434836 . RESULTS Both CCT alone and combined with tDCS ameliorated depressive symptoms after the acute treatment period and at follow-up , with a response rate of approximately 25 % . Older patients and those who presented better performance in the task throughout the trial ( possibly indicating greater engagement and activation of the DLPFC ) had greater depression improvement in the combined treatment group . LIMITATIONS Our exploratory findings should be further confirmed in prospective controlled trials . DISCUSSION CCT and tDCS combined might be beneficial for older depressed patients , particularly for those who have cognitive resources to adequately learn and improve task performance over time . This combined therapy might be specifically relevant in this subgroup that is more prone to present cognitive decline and prefrontal cortical atrophy ."
],
"offsets": [
[
0,
1786
]
]
}
] | [
{
"id": "65310",
"type": "Intervention_Psychological",
"text": [
"Cognitive control therapy"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "65311",
"type": "Intervention_Physical",
"text": [
"transcranial direct current stimulation"
],
"offsets": [
[
30,
69
]
],
"normalized": []
},
{
"id": "65312",
"type": "Intervention_Psychological",
"text": [
"cognitive control therapy ( CCT )"
],
"offsets": [
[
399,
432
]
],
"normalized": []
},
{
"id": "65313",
"type": "Intervention_Physical",
"text": [
"transcranial direct current stimulation"
],
"offsets": [
[
30,
69
]
],
"normalized": []
},
{
"id": "65314",
"type": "Intervention_Psychological",
"text": [
"CCT"
],
"offsets": [
[
427,
430
]
],
"normalized": []
},
{
"id": "65315",
"type": "Intervention_Control",
"text": [
"sham tDCS"
],
"offsets": [
[
768,
777
]
],
"normalized": []
},
{
"id": "65316",
"type": "Intervention_Educational",
"text": [
"CCT"
],
"offsets": [
[
427,
430
]
],
"normalized": []
},
{
"id": "65317",
"type": "Intervention_Physical",
"text": [
"active tDCS"
],
"offsets": [
[
799,
810
]
],
"normalized": []
},
{
"id": "65318",
"type": "Intervention_Psychological",
"text": [
"CCT"
],
"offsets": [
[
427,
430
]
],
"normalized": []
},
{
"id": "65319",
"type": "Intervention_Psychological",
"text": [
"CCT"
],
"offsets": [
[
427,
430
]
],
"normalized": []
},
{
"id": "65320",
"type": "Intervention_Physical",
"text": [
"tDCS"
],
"offsets": [
[
563,
567
]
],
"normalized": []
},
{
"id": "65321",
"type": "Outcome_Mental",
"text": [
"stimulation for depression :"
],
"offsets": [
[
58,
86
]
],
"normalized": []
},
{
"id": "65322",
"type": "Outcome_Mental",
"text": [
"effects of CCT"
],
"offsets": [
[
686,
700
]
],
"normalized": []
},
{
"id": "65323",
"type": "Outcome_Mental",
"text": [
"ameliorated depressive symptoms"
],
"offsets": [
[
978,
1009
]
],
"normalized": []
},
{
"id": "65324",
"type": "Outcome_Mental",
"text": [
"response rate"
],
"offsets": [
[
1069,
1082
]
],
"normalized": []
},
{
"id": "65325",
"type": "Outcome_Mental",
"text": [
"depression improvement"
],
"offsets": [
[
1281,
1303
]
],
"normalized": []
},
{
"id": "65326",
"type": "Outcome_Mental",
"text": [
"task performance"
],
"offsets": [
[
1606,
1622
]
],
"normalized": []
},
{
"id": "65327",
"type": "Participant_Sample-size",
"text": [
"n=17"
],
"offsets": [
[
788,
792
]
],
"normalized": []
},
{
"id": "65328",
"type": "Participant_Age",
"text": [
"Older patients"
],
"offsets": [
[
1107,
1121
]
],
"normalized": []
},
{
"id": "65329",
"type": "Participant_Age",
"text": [
"older"
],
"offsets": [
[
1495,
1500
]
],
"normalized": []
}
] | [] | [] | [] |
65330 | 24767206 | [
{
"id": "65331",
"type": "document",
"text": [
"[ The effects of tirofiban on acute non-ST segment elevation myocardial infarction patients not receiving early reperfusion intervention ] . OBJECTIVE To study the efficacy and safety of tirofiban in patients with acute non-ST- segment elevation myocardial infarction ( NSTEMI ) without early reperfusion intervention . METHODS A total of 151 NSTEMI patients without early reperfusion intervention were enrolled in the study and randomized to the tirofiban group ( n = 76 ) and the control group ( n = 75 ) . Coronary angiography was performed at day 3 and day 7 , while percutaneous coronary intervention ( PCI ) was performed when necessary . Parameters including thrombolysis in myocardial infarction ( TIMI ) flow , bleeding complications and clinic events within 30 days were compared between the two groups . RESULTS Before PCI , no increase in the percentage of patient with TIMI flow better than TIMI-2 was observed by the treatment of tirofiban ( 69.3 % vs 78.9 % , P = 0.10 ) . While after PCI , significant increase in the percentage of patient with TIMI flow better than TIMI-2 was manifested in the tirofiban group ( 96.0 % vs 100.0 % , P = 0.04 ) . Tirofiban treatment also significantly decreased the rate of poor myocardial perfusion after PCI ( 19.7 % vs 34.7 % , P = 0.04 ) . There were 0 and 4 major adverse cardiovascular events ( MACE ) within 30 days observed in the tirofiban group and the control group ( 0.0 % vs 5.3 % , P = 0.05 ) . No difference between the two groups was found in the bleeding complications within 30 days including the mild hemorrhage ( 5 vs 4 cases , P = 0.75 ) , severe hemorrhage ( 2 vs 1 cases , P = 0.56 ) or severe thrombocytopenia ( 2 vs 0 cases , P = 0.49 ) . CONCLUSIONS Tirofiban treatment does not increase the bleeding complications in NSTEMI patients without early PCI . Tirofiban can improve the TIMI flow and the myocardial perfusion after PCI with less MACE within 30 days ."
],
"offsets": [
[
0,
1936
]
]
}
] | [
{
"id": "65332",
"type": "Intervention_Pharmacological",
"text": [
"tirofiban"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "65333",
"type": "Intervention_Pharmacological",
"text": [
"tirofiban"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "65334",
"type": "Intervention_Pharmacological",
"text": [
"tirofiban"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "65335",
"type": "Intervention_Control",
"text": [
"control group"
],
"offsets": [
[
482,
495
]
],
"normalized": []
},
{
"id": "65336",
"type": "Intervention_Surgical",
"text": [
"Coronary angiography"
],
"offsets": [
[
509,
529
]
],
"normalized": []
},
{
"id": "65337",
"type": "Intervention_Surgical",
"text": [
"intervention"
],
"offsets": [
[
124,
136
]
],
"normalized": []
},
{
"id": "65338",
"type": "Intervention_Pharmacological",
"text": [
"tirofiban"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "65339",
"type": "Intervention_Pharmacological",
"text": [
"tirofiban"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "65340",
"type": "Intervention_Pharmacological",
"text": [
"tirofiban"
],
"offsets": [
[
17,
26
]
],
"normalized": []
},
{
"id": "65341",
"type": "Outcome_Physical",
"text": [
"myocardial infarction"
],
"offsets": [
[
61,
82
]
],
"normalized": []
},
{
"id": "65342",
"type": "Outcome_Other",
"text": [
"efficacy and safety"
],
"offsets": [
[
164,
183
]
],
"normalized": []
},
{
"id": "65343",
"type": "Outcome_Physical",
"text": [
"thrombolysis in myocardial infarction ( TIMI ) flow"
],
"offsets": [
[
666,
717
]
],
"normalized": []
},
{
"id": "65344",
"type": "Outcome_Adverse-effects",
"text": [
"bleeding complications"
],
"offsets": [
[
720,
742
]
],
"normalized": []
},
{
"id": "65345",
"type": "Outcome_Physical",
"text": [
"percentage of patient with TIMI flow"
],
"offsets": [
[
855,
891
]
],
"normalized": []
},
{
"id": "65346",
"type": "Outcome_Physical",
"text": [
"percentage of patient with TIMI flow"
],
"offsets": [
[
855,
891
]
],
"normalized": []
},
{
"id": "65347",
"type": "Outcome_Physical",
"text": [
"rate of poor myocardial perfusion"
],
"offsets": [
[
1216,
1249
]
],
"normalized": []
},
{
"id": "65348",
"type": "Outcome_Adverse-effects",
"text": [
"major adverse cardiovascular events ( MACE )"
],
"offsets": [
[
1313,
1357
]
],
"normalized": []
},
{
"id": "65349",
"type": "Outcome_Adverse-effects",
"text": [
"bleeding complications"
],
"offsets": [
[
720,
742
]
],
"normalized": []
},
{
"id": "65350",
"type": "Outcome_Adverse-effects",
"text": [
"mild hemorrhage"
],
"offsets": [
[
1565,
1580
]
],
"normalized": []
},
{
"id": "65351",
"type": "Outcome_Adverse-effects",
"text": [
"severe hemorrhage"
],
"offsets": [
[
1611,
1628
]
],
"normalized": []
},
{
"id": "65352",
"type": "Outcome_Adverse-effects",
"text": [
"severe thrombocytopenia"
],
"offsets": [
[
1660,
1683
]
],
"normalized": []
},
{
"id": "65353",
"type": "Outcome_Adverse-effects",
"text": [
"bleeding complications"
],
"offsets": [
[
720,
742
]
],
"normalized": []
},
{
"id": "65354",
"type": "Participant_Condition",
"text": [
"myocardial infarction"
],
"offsets": [
[
61,
82
]
],
"normalized": []
},
{
"id": "65355",
"type": "Participant_Condition",
"text": [
"acute non-ST- segment elevation myocardial infarction ( NSTEMI )"
],
"offsets": [
[
214,
278
]
],
"normalized": []
},
{
"id": "65356",
"type": "Participant_Sample-size",
"text": [
"151"
],
"offsets": [
[
339,
342
]
],
"normalized": []
},
{
"id": "65357",
"type": "Participant_Condition",
"text": [
"NSTEMI"
],
"offsets": [
[
270,
276
]
],
"normalized": []
},
{
"id": "65358",
"type": "Participant_Condition",
"text": [
"NSTEMI"
],
"offsets": [
[
270,
276
]
],
"normalized": []
}
] | [] | [] | [] |
65359 | 24768960 | [
{
"id": "65360",
"type": "document",
"text": [
"To excise or ablate endometriosis ? A prospective randomized double-blinded trial after 5-year follow-up . STUDY OBJECTIVE To compare reduction of pain after laparoscopy for ablation or excision of endometriosis . DESIGN Prospective , randomized , double-blind study ( Canadian Task Force classification I ) . SETTING Endometriosis and pelvic pain clinic at a university teaching hospital . PATIENTS Women of reproductive age with pelvic pain and visually proved endometriosis . INTERVENTIONS Subjects completed a questionnaire rating various kinds of pain using visual analog scales ( VAS ) . After visual identification subjects were randomized to treatment via ablation or excision by supervised training gynecologists as primary surgeons . Follow-up questionnaires documented pain levels every 3 months for 1 year and then every 6 months for 5 years . MEASUREMENTS AND MAIN RESULTS Change in pain VAS scores during 5 years after the operation and rates of pregnancy , repeat surgery , and use of hormone therapy were evaluated . There was a reduction in all pain scores over the 5-year follow-up in both treatment groups . A significantly greater reduction in dyspareunia VAS scores was observed in the excision group at 5 years ( p = .03 at univariate analysis , and p = .007 at multivariate analysis ) . More women in the ablation group continued to receive medical treatment of endometriosis at 5 years ( p = .004 ) . CONCLUSIONS Surgical treatment of endometriosis provides symptom reduction for up to 5 years . In some limited areas such as deep dyspareunia , excision is more effective than ablation ."
],
"offsets": [
[
0,
1611
]
]
}
] | [
{
"id": "65361",
"type": "Intervention_Physical",
"text": [
"excise"
],
"offsets": [
[
3,
9
]
],
"normalized": []
},
{
"id": "65362",
"type": "Intervention_Educational",
"text": [
"or"
],
"offsets": [
[
10,
12
]
],
"normalized": []
},
{
"id": "65363",
"type": "Intervention_Physical",
"text": [
"ablate"
],
"offsets": [
[
13,
19
]
],
"normalized": []
},
{
"id": "65364",
"type": "Intervention_Physical",
"text": [
"ablation"
],
"offsets": [
[
174,
182
]
],
"normalized": []
},
{
"id": "65365",
"type": "Intervention_Surgical",
"text": [
"excision"
],
"offsets": [
[
186,
194
]
],
"normalized": []
},
{
"id": "65366",
"type": "Intervention_Educational",
"text": [
"questionnaire rating"
],
"offsets": [
[
514,
534
]
],
"normalized": []
},
{
"id": "65367",
"type": "Intervention_Physical",
"text": [
"ablation"
],
"offsets": [
[
174,
182
]
],
"normalized": []
},
{
"id": "65368",
"type": "Intervention_Educational",
"text": [
"or"
],
"offsets": [
[
10,
12
]
],
"normalized": []
},
{
"id": "65369",
"type": "Intervention_Physical",
"text": [
"excision"
],
"offsets": [
[
186,
194
]
],
"normalized": []
},
{
"id": "65370",
"type": "Intervention_Surgical",
"text": [
"excision"
],
"offsets": [
[
186,
194
]
],
"normalized": []
},
{
"id": "65371",
"type": "Intervention_Physical",
"text": [
"ablation"
],
"offsets": [
[
174,
182
]
],
"normalized": []
},
{
"id": "65372",
"type": "Outcome_Pain",
"text": [
"pain levels"
],
"offsets": [
[
780,
791
]
],
"normalized": []
},
{
"id": "65373",
"type": "Outcome_Pain",
"text": [
"Change in pain VAS scores"
],
"offsets": [
[
886,
911
]
],
"normalized": []
},
{
"id": "65374",
"type": "Outcome_Physical",
"text": [
"rates of pregnancy"
],
"offsets": [
[
951,
969
]
],
"normalized": []
},
{
"id": "65375",
"type": "Outcome_Physical",
"text": [
"repeat surgery"
],
"offsets": [
[
972,
986
]
],
"normalized": []
},
{
"id": "65376",
"type": "Outcome_Physical",
"text": [
"use of hormone therapy"
],
"offsets": [
[
993,
1015
]
],
"normalized": []
},
{
"id": "65377",
"type": "Outcome_Pain",
"text": [
"pain scores"
],
"offsets": [
[
1062,
1073
]
],
"normalized": []
},
{
"id": "65378",
"type": "Outcome_Pain",
"text": [
"dyspareunia VAS scores"
],
"offsets": [
[
1164,
1186
]
],
"normalized": []
},
{
"id": "65379",
"type": "Outcome_Physical",
"text": [
"medical treatment of endometriosis"
],
"offsets": [
[
1364,
1398
]
],
"normalized": []
},
{
"id": "65380",
"type": "Participant_Condition",
"text": [
"endometriosis"
],
"offsets": [
[
20,
33
]
],
"normalized": []
},
{
"id": "65381",
"type": "Participant_Condition",
"text": [
"Endometriosis"
],
"offsets": [
[
318,
331
]
],
"normalized": []
},
{
"id": "65382",
"type": "Participant_Condition",
"text": [
"pelvic pain"
],
"offsets": [
[
336,
347
]
],
"normalized": []
},
{
"id": "65383",
"type": "Participant_Sex",
"text": [
"Women"
],
"offsets": [
[
400,
405
]
],
"normalized": []
},
{
"id": "65384",
"type": "Participant_Condition",
"text": [
"pelvic pain"
],
"offsets": [
[
336,
347
]
],
"normalized": []
},
{
"id": "65385",
"type": "Participant_Condition",
"text": [
"endometriosis"
],
"offsets": [
[
20,
33
]
],
"normalized": []
}
] | [] | [] | [] |
65386 | 24771618 | [
{
"id": "65387",
"type": "document",
"text": [
"Evaluation of early weight loss thresholds for identifying nonresponders to an intensive lifestyle intervention . OBJECTIVE Weight losses in lifestyle interventions are variable , yet prediction of long-term success is difficult . The utility of using various weight loss thresholds in the first 2 months of treatment for predicting 1-year outcomes was examined . METHODS Participants included 2327 adults with type 2 diabetes ( BMI:35.8 ± 6.0 ) randomized to the intensive lifestyle intervention ( ILI ) of the Look AHEAD trial . ILI included weekly behavioral sessions designed to increase physical activity and reduce caloric intake . 1-month , 2-month , and 1-year weight changes were calculated . RESULTS Participants failing to achieve a ≥2 % weight loss at Month 1 were 5.6 ( 95 % CI:4.5 , 7.0 ) times more likely to also not achieve a ≥10 % weight loss at Year 1 , compared to those losing ≥2 % initially . These odds were increased to 11.6 ( 95 % CI:8.6 , 15.6 ) when using a 3 % weight loss threshold at Month 2 . Only 15.2 % and 8.2 % of individuals failing to achieve the ≥2 % and ≥3 % thresholds at Months 1 and 2 , respectively , go on to achieve a ≥10 % weight loss at Year 1 . CONCLUSIONS Given the association between initial and 1-year weight loss , the first few months of treatment may be an opportune time to identify those who are unsuccessful and utilize rescue efforts . TRIAL REGISTRATION clinicaltrials.gov Identifier : NCT00017953 ."
],
"offsets": [
[
0,
1459
]
]
}
] | [
{
"id": "65388",
"type": "Outcome_Physical",
"text": [
"early weight loss"
],
"offsets": [
[
14,
31
]
],
"normalized": []
},
{
"id": "65389",
"type": "Outcome_Physical",
"text": [
"increase physical activity"
],
"offsets": [
[
583,
609
]
],
"normalized": []
},
{
"id": "65390",
"type": "Outcome_Physical",
"text": [
"reduce caloric intake"
],
"offsets": [
[
614,
635
]
],
"normalized": []
},
{
"id": "65391",
"type": "Outcome_Physical",
"text": [
"1-year weight changes"
],
"offsets": [
[
662,
683
]
],
"normalized": []
},
{
"id": "65392",
"type": "Outcome_Physical",
"text": [
"achieve a ≥2 % weight loss at Month"
],
"offsets": [
[
734,
769
]
],
"normalized": []
},
{
"id": "65393",
"type": "Outcome_Physical",
"text": [
"a ≥10 % weight loss at"
],
"offsets": [
[
841,
863
]
],
"normalized": []
},
{
"id": "65394",
"type": "Outcome_Physical",
"text": [
"using a 3 % weight"
],
"offsets": [
[
977,
995
]
],
"normalized": []
},
{
"id": "65395",
"type": "Outcome_Physical",
"text": [
"on to achieve a ≥10 % weight"
],
"offsets": [
[
1147,
1175
]
],
"normalized": []
},
{
"id": "65396",
"type": "Outcome_Physical",
"text": [
"1-year"
],
"offsets": [
[
333,
339
]
],
"normalized": []
},
{
"id": "65397",
"type": "Participant_Sample-size",
"text": [
"2327"
],
"offsets": [
[
394,
398
]
],
"normalized": []
},
{
"id": "65398",
"type": "Participant_Age",
"text": [
"adults"
],
"offsets": [
[
399,
405
]
],
"normalized": []
},
{
"id": "65399",
"type": "Participant_Condition",
"text": [
"type 2 diabetes"
],
"offsets": [
[
411,
426
]
],
"normalized": []
}
] | [] | [] | [] |
65400 | 24781441 | [
{
"id": "65401",
"type": "document",
"text": [
"Comparison of olanzapine long-acting injection and oral olanzapine : a 2-year , randomized , open-label study in outpatients with schizophrenia . We compared long-term treatment effectiveness of monthly olanzapine long-acting injection ( LAI ) with that of oral olanzapine . Outpatients with 2 or more episodes of psychotic worsening in the past 24 months with Positive and Negative Syndrome Scale total score of lower than 70 were randomized to 405 mg/4 weeks of olanzapine LAI ( n = 264 ) or 10 mg/d of oral olanzapine ( n = 260 ) for 2 years of open-label treatment . Dosing thereafter was flexible ( 150-405 mg/4 weeks of LAI vs 5-20 mg/d of oral ) . Primary outcome was time to all-cause discontinuation . At baseline , patients were clinically stable ( mean Positive and Negative Syndrome Scale total score of 57 ) . Seventeen percent of patients had been psychiatrically hospitalized in the previous 6 months , and 4.6 % were rated nonadherent in the month before study entry . The groups did not differ significantly in median time to all-cause discontinuation ( 645 days for LAI , 678 days for oral ; P = 0.61 ) , discontinuation rate ( 53.8 % for LAI , 51.2 % for oral ; P = 0.60 ) , or relapse rate ( 20.1 % for LAI , 18.5 % for oral ; P = 0.66 ) . Postbaseline psychiatric hospitalization rate was low for both groups ( 7.6 % for LAI , 9.2 % for oral ) , but mean hospitalization duration was significantly longer for oral patients ( 1.80 days [ 20 for those hospitalized ] vs 0.43 days [ 6 for those hospitalized ] , P = 0.02 ) . There were no clinically significant group differences in adverse events or safety measures . No post-injection delirium/sedation syndrome events occurred . In conclusion , olanzapine LAI and oral olanzapine were similarly effective and well tolerated for up to 2 years of treatment in patients with schizophrenia . Treatment discontinuation for olanzapine LAI was similar to that of oral olanzapine , despite the 3-hour post-injection observation period and other precautionary procedures related to risk of post-injection delirium/sedation syndrome ."
],
"offsets": [
[
0,
2095
]
]
}
] | [
{
"id": "65402",
"type": "Intervention_Pharmacological",
"text": [
"olanzapine long-acting injection"
],
"offsets": [
[
14,
46
]
],
"normalized": []
},
{
"id": "65403",
"type": "Intervention_Pharmacological",
"text": [
"oral olanzapine"
],
"offsets": [
[
51,
66
]
],
"normalized": []
},
{
"id": "65404",
"type": "Intervention_Pharmacological",
"text": [
"olanzapine long-acting injection ( LAI )"
],
"offsets": [
[
203,
243
]
],
"normalized": []
},
{
"id": "65405",
"type": "Intervention_Pharmacological",
"text": [
"oral olanzapine ."
],
"offsets": [
[
257,
274
]
],
"normalized": []
},
{
"id": "65406",
"type": "Intervention_Pharmacological",
"text": [
"olanzapine LAI"
],
"offsets": [
[
464,
478
]
],
"normalized": []
},
{
"id": "65407",
"type": "Intervention_Pharmacological",
"text": [
"oral olanzapine"
],
"offsets": [
[
51,
66
]
],
"normalized": []
},
{
"id": "65408",
"type": "Intervention_Pharmacological",
"text": [
"LAI"
],
"offsets": [
[
238,
241
]
],
"normalized": []
},
{
"id": "65409",
"type": "Intervention_Pharmacological",
"text": [
"LAI"
],
"offsets": [
[
238,
241
]
],
"normalized": []
},
{
"id": "65410",
"type": "Intervention_Pharmacological",
"text": [
"LAI"
],
"offsets": [
[
238,
241
]
],
"normalized": []
},
{
"id": "65411",
"type": "Intervention_Pharmacological",
"text": [
"olanzapine LAI"
],
"offsets": [
[
464,
478
]
],
"normalized": []
},
{
"id": "65412",
"type": "Intervention_Pharmacological",
"text": [
"olanzapine"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "65413",
"type": "Intervention_Pharmacological",
"text": [
"olanzapine LAI"
],
"offsets": [
[
464,
478
]
],
"normalized": []
},
{
"id": "65414",
"type": "Intervention_Pharmacological",
"text": [
"olanzapine"
],
"offsets": [
[
14,
24
]
],
"normalized": []
},
{
"id": "65415",
"type": "Outcome_Mental",
"text": [
"schizophrenia ."
],
"offsets": [
[
130,
145
]
],
"normalized": []
},
{
"id": "65416",
"type": "Outcome_Mental",
"text": [
"psychiatric"
],
"offsets": [
[
862,
873
]
],
"normalized": []
},
{
"id": "65417",
"type": "Outcome_Mental",
"text": [
"delirium/sedation syndrome"
],
"offsets": [
[
1655,
1681
]
],
"normalized": []
},
{
"id": "65418",
"type": "Outcome_Other",
"text": [
"effective"
],
"offsets": [
[
178,
187
]
],
"normalized": []
},
{
"id": "65419",
"type": "Outcome_Other",
"text": [
"tolerated"
],
"offsets": [
[
1785,
1794
]
],
"normalized": []
},
{
"id": "65420",
"type": "Outcome_Mental",
"text": [
"schizophrenia ."
],
"offsets": [
[
130,
145
]
],
"normalized": []
},
{
"id": "65421",
"type": "Outcome_Other",
"text": [
"Treatment discontinuation"
],
"offsets": [
[
1859,
1884
]
],
"normalized": []
}
] | [] | [] | [] |
65422 | 24781567 | [
{
"id": "65423",
"type": "document",
"text": [
"Sedation depth during spinal anesthesia and survival in elderly patients undergoing hip fracture repair . Low intraoperative Bispectral Index ( BIS ) values may be associated with increased mortality . In a previously reported trial to prevent delirium , we randomized patients undergoing hip fracture repair under spinal anesthesia to light ( BIS > 80 ) or deep ( BIS approximately 50 ) sedation . We analyzed survival of patients in the original trial . Among all patients , mortality was equivalent across sedation groups . However , among patients with serious comorbidities ( Charlson score > 4 ) , 1-year mortality was reduced in the light ( 22.2 % ) vs deep ( 43.6 % ) sedation group ( hazard ratio [ HR ] , 0.43 ; 95 % confidence interval , 0.19-0.97 ; P = 0.04 ) during spinal anesthesia . Similarly , among patients with Charlson score > 6 , 1-year mortality was reduced in the light ( 28.6 % ) vs deep ( 52.6 % ) sedation group ( HR 0.33 ; 95 % confidence interval , 0.12-0.94 ; P = 0.04 ) during spinal anesthesia . Further research on reduced mortality after light sedation during spinal anesthesia is needed ."
],
"offsets": [
[
0,
1123
]
]
}
] | [
{
"id": "65424",
"type": "Intervention_Pharmacological",
"text": [
"spinal anesthesia"
],
"offsets": [
[
22,
39
]
],
"normalized": []
},
{
"id": "65425",
"type": "Intervention_Pharmacological",
"text": [
"spinal anesthesia"
],
"offsets": [
[
22,
39
]
],
"normalized": []
},
{
"id": "65426",
"type": "Intervention_Pharmacological",
"text": [
"light ( BIS > 80 )"
],
"offsets": [
[
336,
354
]
],
"normalized": []
},
{
"id": "65427",
"type": "Intervention_Pharmacological",
"text": [
"deep ( BIS approximately 50 )"
],
"offsets": [
[
358,
387
]
],
"normalized": []
},
{
"id": "65428",
"type": "Intervention_Other",
"text": [
"light"
],
"offsets": [
[
336,
341
]
],
"normalized": []
},
{
"id": "65429",
"type": "Intervention_Other",
"text": [
"deep"
],
"offsets": [
[
358,
362
]
],
"normalized": []
},
{
"id": "65430",
"type": "Intervention_Pharmacological",
"text": [
"sedation"
],
"offsets": [
[
388,
396
]
],
"normalized": []
},
{
"id": "65431",
"type": "Intervention_Pharmacological",
"text": [
"light"
],
"offsets": [
[
336,
341
]
],
"normalized": []
},
{
"id": "65432",
"type": "Intervention_Pharmacological",
"text": [
"deep"
],
"offsets": [
[
358,
362
]
],
"normalized": []
},
{
"id": "65433",
"type": "Intervention_Pharmacological",
"text": [
"sedation"
],
"offsets": [
[
388,
396
]
],
"normalized": []
},
{
"id": "65434",
"type": "Intervention_Pharmacological",
"text": [
"spinal anesthesia"
],
"offsets": [
[
22,
39
]
],
"normalized": []
},
{
"id": "65435",
"type": "Intervention_Pharmacological",
"text": [
"light sedation"
],
"offsets": [
[
1072,
1086
]
],
"normalized": []
},
{
"id": "65436",
"type": "Intervention_Pharmacological",
"text": [
"spinal anesthesia"
],
"offsets": [
[
22,
39
]
],
"normalized": []
},
{
"id": "65437",
"type": "Outcome_Physical",
"text": [
"Sedation depth"
],
"offsets": [
[
0,
14
]
],
"normalized": []
},
{
"id": "65438",
"type": "Outcome_Physical",
"text": [
"intraoperative Bispectral Index ( BIS ) values"
],
"offsets": [
[
110,
156
]
],
"normalized": []
},
{
"id": "65439",
"type": "Outcome_Physical",
"text": [
"hip fracture repair"
],
"offsets": [
[
84,
103
]
],
"normalized": []
},
{
"id": "65440",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
44,
52
]
],
"normalized": []
},
{
"id": "65441",
"type": "Outcome_Mortality",
"text": [
"mortality"
],
"offsets": [
[
190,
199
]
],
"normalized": []
},
{
"id": "65442",
"type": "Outcome_Mortality",
"text": [
"1-year mortality"
],
"offsets": [
[
604,
620
]
],
"normalized": []
},
{
"id": "65443",
"type": "Outcome_Mortality",
"text": [
"1-year mortality"
],
"offsets": [
[
604,
620
]
],
"normalized": []
},
{
"id": "65444",
"type": "Outcome_Mortality",
"text": [
"reduced mortality"
],
"offsets": [
[
1048,
1065
]
],
"normalized": []
},
{
"id": "65445",
"type": "Participant_Condition",
"text": [
"elderly patients undergoing hip fracture repair ."
],
"offsets": [
[
56,
105
]
],
"normalized": []
}
] | [] | [] | [] |
65446 | 24785600 | [
{
"id": "65447",
"type": "document",
"text": [
"Hysteroscopic morcellation compared with electrical resection of endometrial polyps : a randomized controlled trial . OBJECTIVE To evaluate whether hysteroscopic morcellation or bipolar electrosurgical resection is more favorable for removing endometrial polyps in an office setting in terms of feasibility , speed , pain , and acceptability . METHODS A multicenter , single-blind , randomized , controlled trial of office hysteroscopic morcellation compared with electrosurgical resection was conducted . A total of 121 women were randomly allocated to polyp removal by one of the two methods in an office setting . The outcomes assessed were time taken to complete the endometrial polypectomy , defined as the time from insertion to removal of vaginal instrumentation , completeness of polyp removal , acceptability , and pain measured on a 100-mm visual analog scale . RESULTS The median time taken to complete the procedure was 5 minutes and 28 seconds for morcellation compared with 10 minutes and 12 seconds for electrosurgical resection ( P < .001 ) . The polyps were completely removed in 61 out of 62 ( 98 % ) women assigned to morcellation compared with 49 out of 59 ( 83 % ) women treated with electrosurgical resection ( odds ratio 12.5 ; 95 % confidence interval [ CI ] 1.5-100.6 ; P=.02 ) . The mean pain scores during the procedure favored morcellation by 16.1 points on average ( 35.9 compared with 52.0 ; 95 % CI for difference , -24.7 to -7.6 ; P < .001 ) . Overall , 99 % of women found office polypectomy to be acceptable , with only one woman in the electrosurgical resection group considering the procedure unacceptable . CONCLUSION In comparison to electrosurgical resection during hysteroscopic polypectomy , morcellation was significantly quicker , less painful , more acceptable to women , and more likely to completely remove endometrial polyps compared with electrosurgical resection . CLINICAL TRIAL REGISTRATION ClinicalTrials.gov , www.clinicaltrials.gov , NCT01509313 ."
],
"offsets": [
[
0,
2001
]
]
}
] | [
{
"id": "65448",
"type": "Intervention_Surgical",
"text": [
"Hysteroscopic morcellation"
],
"offsets": [
[
0,
26
]
],
"normalized": []
},
{
"id": "65449",
"type": "Intervention_Pharmacological",
"text": [
"electrical resection"
],
"offsets": [
[
41,
61
]
],
"normalized": []
},
{
"id": "65450",
"type": "Intervention_Surgical",
"text": [
"hysteroscopic morcellation"
],
"offsets": [
[
148,
174
]
],
"normalized": []
},
{
"id": "65451",
"type": "Intervention_Surgical",
"text": [
"bipolar electrosurgical resection"
],
"offsets": [
[
178,
211
]
],
"normalized": []
},
{
"id": "65452",
"type": "Intervention_Surgical",
"text": [
"office hysteroscopic morcellation"
],
"offsets": [
[
416,
449
]
],
"normalized": []
},
{
"id": "65453",
"type": "Intervention_Pharmacological",
"text": [
"electrosurgical resection"
],
"offsets": [
[
186,
211
]
],
"normalized": []
},
{
"id": "65454",
"type": "Intervention_Surgical",
"text": [
"morcellation"
],
"offsets": [
[
14,
26
]
],
"normalized": []
},
{
"id": "65455",
"type": "Intervention_Pharmacological",
"text": [
"electrosurgical resection"
],
"offsets": [
[
186,
211
]
],
"normalized": []
},
{
"id": "65456",
"type": "Intervention_Surgical",
"text": [
"morcellation"
],
"offsets": [
[
14,
26
]
],
"normalized": []
},
{
"id": "65457",
"type": "Intervention_Pharmacological",
"text": [
"electrosurgical resection"
],
"offsets": [
[
186,
211
]
],
"normalized": []
},
{
"id": "65458",
"type": "Intervention_Pharmacological",
"text": [
"electrosurgical resection"
],
"offsets": [
[
186,
211
]
],
"normalized": []
},
{
"id": "65459",
"type": "Intervention_Surgical",
"text": [
"morcellation"
],
"offsets": [
[
14,
26
]
],
"normalized": []
},
{
"id": "65460",
"type": "Intervention_Pharmacological",
"text": [
"electrosurgical resection"
],
"offsets": [
[
186,
211
]
],
"normalized": []
},
{
"id": "65461",
"type": "Outcome_Physical",
"text": [
"endometrial polyps"
],
"offsets": [
[
65,
83
]
],
"normalized": []
},
{
"id": "65462",
"type": "Outcome_Other",
"text": [
"feasibility"
],
"offsets": [
[
295,
306
]
],
"normalized": []
},
{
"id": "65463",
"type": "Outcome_Other",
"text": [
"speed"
],
"offsets": [
[
309,
314
]
],
"normalized": []
},
{
"id": "65464",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
317,
321
]
],
"normalized": []
},
{
"id": "65465",
"type": "Outcome_Other",
"text": [
"acceptability"
],
"offsets": [
[
328,
341
]
],
"normalized": []
},
{
"id": "65466",
"type": "Outcome_Other",
"text": [
"time taken to complete the endometrial polypectomy"
],
"offsets": [
[
644,
694
]
],
"normalized": []
},
{
"id": "65467",
"type": "Outcome_Other",
"text": [
"completeness of polyp removal , acceptability"
],
"offsets": [
[
772,
817
]
],
"normalized": []
},
{
"id": "65468",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
317,
321
]
],
"normalized": []
},
{
"id": "65469",
"type": "Outcome_Other",
"text": [
"median time taken to complete the procedure"
],
"offsets": [
[
884,
927
]
],
"normalized": []
},
{
"id": "65470",
"type": "Outcome_Other",
"text": [
"polyps were completely removed"
],
"offsets": [
[
1063,
1093
]
],
"normalized": []
},
{
"id": "65471",
"type": "Outcome_Pain",
"text": [
"mean pain scores"
],
"offsets": [
[
1309,
1325
]
],
"normalized": []
},
{
"id": "65472",
"type": "Outcome_Other",
"text": [
"acceptable"
],
"offsets": [
[
1531,
1541
]
],
"normalized": []
},
{
"id": "65473",
"type": "Outcome_Other",
"text": [
"unacceptable"
],
"offsets": [
[
1629,
1641
]
],
"normalized": []
},
{
"id": "65474",
"type": "Outcome_Other",
"text": [
"quicker"
],
"offsets": [
[
1764,
1771
]
],
"normalized": []
},
{
"id": "65475",
"type": "Outcome_Pain",
"text": [
"painful"
],
"offsets": [
[
1779,
1786
]
],
"normalized": []
},
{
"id": "65476",
"type": "Outcome_Other",
"text": [
"acceptable"
],
"offsets": [
[
1531,
1541
]
],
"normalized": []
},
{
"id": "65477",
"type": "Outcome_Physical",
"text": [
"completely remove endometrial polyps"
],
"offsets": [
[
1835,
1871
]
],
"normalized": []
},
{
"id": "65478",
"type": "Participant_Condition",
"text": [
"endometrial polyps"
],
"offsets": [
[
65,
83
]
],
"normalized": []
}
] | [] | [] | [] |
65479 | 24799074 | [
{
"id": "65480",
"type": "document",
"text": [
"Development and in vitro/in vivo evaluation of immediate release perindopril tablets . Perindopril erbumine ( PE ) is a BCS ( Biopharmaceutics Classification System ) class 3 drug with high solubility and low permeability . It is an inhibitor of the enzyme that converts angiotensin I ( Angiotensin Converting Enzyme , ACE ) into angiotensin II as well as causing the degradation of the vasodilator bradykinin into an inactive heptapeptide . The aim of this study was to develop an alternative drug product by using a different salt of perindopril and to evaluate the bioequivalence between PE , not still licensed , and perindopril arginine ( PA ) , licensed in many countries , and to prepare PE tablets by using direct compression method . Many different formulations were prepared , among which F3-coded formulation was only selected due to releasing of 98.03 % active substance at 45th minute . Bioequivalence study was planned as a cross-designed , randomized , open-labeled , single-dose , single-center study and conducted in 24 male healthy volunteers via peroral route . The results of bioequivalence study were evaluated for Perindopril and Perindoprilat according to Cmax , tmax and AUC criteria . The geometric mean ratios ( 90 % CI ) of perindopril and perindoprilat followed test and reference drug were calculated for AUC0-t and Cmax , 105.946 % ( 100.218-112.002 % ) and 110.437 % ( 102.534-118.948 % ) ; 109.542 % ( 98.364-121.992 % ) and 115.729 % ( 101.031-132.565 % ) , respectively . The 90 % confidence intervals of them were found within the standard bioequivalence range ( 80-125 % ) ."
],
"offsets": [
[
0,
1610
]
]
}
] | [
{
"id": "65481",
"type": "Intervention_Pharmacological",
"text": [
"perindopril tablets"
],
"offsets": [
[
65,
84
]
],
"normalized": []
},
{
"id": "65482",
"type": "Intervention_Pharmacological",
"text": [
"Perindopril erbumine ( PE )"
],
"offsets": [
[
87,
114
]
],
"normalized": []
},
{
"id": "65483",
"type": "Intervention_Pharmacological",
"text": [
"perindopril"
],
"offsets": [
[
65,
76
]
],
"normalized": []
},
{
"id": "65484",
"type": "Intervention_Pharmacological",
"text": [
"F3-coded formulation"
],
"offsets": [
[
799,
819
]
],
"normalized": []
},
{
"id": "65485",
"type": "Intervention_Pharmacological",
"text": [
"Perindopril"
],
"offsets": [
[
87,
98
]
],
"normalized": []
},
{
"id": "65486",
"type": "Intervention_Pharmacological",
"text": [
"Perindoprilat"
],
"offsets": [
[
1152,
1165
]
],
"normalized": []
},
{
"id": "65487",
"type": "Intervention_Pharmacological",
"text": [
"perindopril"
],
"offsets": [
[
65,
76
]
],
"normalized": []
},
{
"id": "65488",
"type": "Intervention_Pharmacological",
"text": [
"perindoprilat"
],
"offsets": [
[
1267,
1280
]
],
"normalized": []
},
{
"id": "65489",
"type": "Outcome_Other",
"text": [
"Cmax"
],
"offsets": [
[
1179,
1183
]
],
"normalized": []
},
{
"id": "65490",
"type": "Outcome_Other",
"text": [
"tmax and AUC criteria"
],
"offsets": [
[
1186,
1207
]
],
"normalized": []
},
{
"id": "65491",
"type": "Outcome_Other",
"text": [
"geometric mean ratios"
],
"offsets": [
[
1214,
1235
]
],
"normalized": []
},
{
"id": "65492",
"type": "Outcome_Other",
"text": [
"AUC0-t"
],
"offsets": [
[
1334,
1340
]
],
"normalized": []
},
{
"id": "65493",
"type": "Outcome_Other",
"text": [
"Cmax"
],
"offsets": [
[
1179,
1183
]
],
"normalized": []
},
{
"id": "65494",
"type": "Outcome_Physical",
"text": [
"bioequivalence range"
],
"offsets": [
[
1575,
1595
]
],
"normalized": []
},
{
"id": "65495",
"type": "Participant_Sample-size",
"text": [
"24"
],
"offsets": [
[
1034,
1036
]
],
"normalized": []
},
{
"id": "65496",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
1037,
1041
]
],
"normalized": []
},
{
"id": "65497",
"type": "Participant_Condition",
"text": [
"healthy volunteers via peroral route"
],
"offsets": [
[
1042,
1078
]
],
"normalized": []
}
] | [] | [] | [] |
65498 | 24803366 | [
{
"id": "65499",
"type": "document",
"text": [
"Virtual reality job interview training in adults with autism spectrum disorder . The feasibility and efficacy of virtual reality job interview training ( VR-JIT ) was assessed in a single-blinded randomized controlled trial . Adults with autism spectrum disorder were randomized to VR-JIT ( n = 16 ) or treatment-as-usual ( TAU ) ( n = 10 ) groups . VR-JIT consisted of simulated job interviews with a virtual character and didactic training . Participants attended 90 % of laboratory-based training sessions , found VR-JIT easy to use and enjoyable , and they felt prepared for future interviews . VR-JIT participants had greater improvement during live standardized job interview role-play performances than TAU participants ( p = 0.046 ) . A similar pattern was observed for self-reported self-confidence at a trend level ( p = 0.060 ) . VR-JIT simulation performance scores increased over time ( R ( 2 ) = 0.83 ) . Results indicate preliminary support for the feasibility and efficacy of VR-JIT , which can be administered using computer software or via the internet ."
],
"offsets": [
[
0,
1072
]
]
}
] | [
{
"id": "65500",
"type": "Intervention_Educational",
"text": [
"Virtual reality job interview training"
],
"offsets": [
[
0,
38
]
],
"normalized": []
},
{
"id": "65501",
"type": "Intervention_Educational",
"text": [
"virtual reality job interview training ( VR-JIT )"
],
"offsets": [
[
113,
162
]
],
"normalized": []
},
{
"id": "65502",
"type": "Intervention_Educational",
"text": [
"VR-JIT"
],
"offsets": [
[
154,
160
]
],
"normalized": []
},
{
"id": "65503",
"type": "Intervention_Control",
"text": [
"treatment-as-usual ( TAU )"
],
"offsets": [
[
303,
329
]
],
"normalized": []
},
{
"id": "65504",
"type": "Intervention_Educational",
"text": [
"VR-JIT consisted of simulated job interviews with a virtual character and didactic training ."
],
"offsets": [
[
350,
443
]
],
"normalized": []
},
{
"id": "65505",
"type": "Intervention_Educational",
"text": [
"VR-JIT"
],
"offsets": [
[
154,
160
]
],
"normalized": []
},
{
"id": "65506",
"type": "Intervention_Educational",
"text": [
"VR-JIT"
],
"offsets": [
[
154,
160
]
],
"normalized": []
},
{
"id": "65507",
"type": "Intervention_Educational",
"text": [
"TAU"
],
"offsets": [
[
324,
327
]
],
"normalized": []
},
{
"id": "65508",
"type": "Intervention_Educational",
"text": [
"VR-JIT"
],
"offsets": [
[
154,
160
]
],
"normalized": []
},
{
"id": "65509",
"type": "Intervention_Educational",
"text": [
"VR-JIT"
],
"offsets": [
[
154,
160
]
],
"normalized": []
},
{
"id": "65510",
"type": "Outcome_Other",
"text": [
"easy to use"
],
"offsets": [
[
524,
535
]
],
"normalized": []
},
{
"id": "65511",
"type": "Outcome_Other",
"text": [
"enjoyable"
],
"offsets": [
[
540,
549
]
],
"normalized": []
},
{
"id": "65512",
"type": "Outcome_Other",
"text": [
"prepared for future interviews ."
],
"offsets": [
[
566,
598
]
],
"normalized": []
},
{
"id": "65513",
"type": "Outcome_Mental",
"text": [
"live standardized job interview role-play performances"
],
"offsets": [
[
650,
704
]
],
"normalized": []
},
{
"id": "65514",
"type": "Outcome_Mental",
"text": [
"self-reported self-confidence"
],
"offsets": [
[
778,
807
]
],
"normalized": []
},
{
"id": "65515",
"type": "Outcome_Mental",
"text": [
"VR-JIT simulation performance scores"
],
"offsets": [
[
841,
877
]
],
"normalized": []
},
{
"id": "65516",
"type": "Outcome_Other",
"text": [
"feasibility"
],
"offsets": [
[
85,
96
]
],
"normalized": []
},
{
"id": "65517",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
101,
109
]
],
"normalized": []
},
{
"id": "65518",
"type": "Participant_Age",
"text": [
"adults"
],
"offsets": [
[
42,
48
]
],
"normalized": []
},
{
"id": "65519",
"type": "Participant_Condition",
"text": [
"autism spectrum disorder"
],
"offsets": [
[
54,
78
]
],
"normalized": []
},
{
"id": "65520",
"type": "Participant_Age",
"text": [
"Adults"
],
"offsets": [
[
226,
232
]
],
"normalized": []
},
{
"id": "65521",
"type": "Participant_Condition",
"text": [
"autism spectrum disorder"
],
"offsets": [
[
54,
78
]
],
"normalized": []
},
{
"id": "65522",
"type": "Participant_Sample-size",
"text": [
"16"
],
"offsets": [
[
295,
297
]
],
"normalized": []
},
{
"id": "65523",
"type": "Participant_Sample-size",
"text": [
"10"
],
"offsets": [
[
336,
338
]
],
"normalized": []
}
] | [] | [] | [] |
65524 | 24807158 | [
{
"id": "65525",
"type": "document",
"text": [
"Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy : a subset analysis from a randomized clinical phase III trial . INTRODUCTION Poor prognosis patients with bulky stage III locally advanced non-small-cell lung cancer may not be offered concurrent chemoradiotherapy ( CRT ) . Following a phase III trial concerning the effect of palliative CRT in inoperable poor prognosis patients , this analysis was performed to explore how tumor size influenced survival and health-related quality of life ( HRQOL ) . METHODS A total of 188 poor prognosis patients recruited in a randomized clinical trial received four courses intravenous carboplatin day 1 and oral vinorelbine day 1 and 8 , at 3-week intervals . The experimental arm ( N = 94 ) received radiotherapy with fractionation 42 Gy/15 , starting at the second chemotherapy course . This subset study compares outcomes in patients with tumors larger than 7 cm ( N = 108 ) versus tumors 7 cm or smaller ( N = 76 ) . RESULTS Among those with tumors larger than 7 cm , the median overall survival in the chemotherapy versus CRT arm was 9.7 and 13.4 months , respectively ( p = 0.001 ) . The 1-year survival was 33 % and 56 % , respectively ( p = 0.01 ) . Except for a temporary decline during treatment , HRQOL was maintained in the CRT arm , regardless of tumor size . Among those who did not receive CRT , patients with tumors larger than 7 cm experienced a gradual decline in the HRQOL . The CRT group had significantly more esophagitis and hospitalizations because of side effects regardless of tumor size . CONCLUSION In patients with poor prognosis and inoperable locally advanced non-small-cell lung cancer , large tumor size should not be considered a negative predictive factor . Except for performance status 2 , patients with tumors larger than 7 cm apparently benefit from CRT ."
],
"offsets": [
[
0,
1906
]
]
}
] | [
{
"id": "65526",
"type": "Intervention_Pharmacological",
"text": [
"palliative chemoradiotherapy :"
],
"offsets": [
[
93,
123
]
],
"normalized": []
},
{
"id": "65527",
"type": "Intervention_Pharmacological",
"text": [
"CRT"
],
"offsets": [
[
339,
342
]
],
"normalized": []
},
{
"id": "65528",
"type": "Intervention_Pharmacological",
"text": [
"intravenous carboplatin"
],
"offsets": [
[
686,
709
]
],
"normalized": []
},
{
"id": "65529",
"type": "Intervention_Pharmacological",
"text": [
"oral vinorelbine"
],
"offsets": [
[
720,
736
]
],
"normalized": []
},
{
"id": "65530",
"type": "Intervention_Pharmacological",
"text": [
"radiotherapy with fractionation 42 Gy/15"
],
"offsets": [
[
814,
854
]
],
"normalized": []
},
{
"id": "65531",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy"
],
"offsets": [
[
880,
892
]
],
"normalized": []
},
{
"id": "65532",
"type": "Intervention_Pharmacological",
"text": [
"CRT"
],
"offsets": [
[
339,
342
]
],
"normalized": []
},
{
"id": "65533",
"type": "Intervention_Pharmacological",
"text": [
"CRT"
],
"offsets": [
[
339,
342
]
],
"normalized": []
},
{
"id": "65534",
"type": "Intervention_Pharmacological",
"text": [
"CRT"
],
"offsets": [
[
339,
342
]
],
"normalized": []
},
{
"id": "65535",
"type": "Intervention_Pharmacological",
"text": [
"CRT"
],
"offsets": [
[
339,
342
]
],
"normalized": []
},
{
"id": "65536",
"type": "Intervention_Pharmacological",
"text": [
"CRT ."
],
"offsets": [
[
1901,
1906
]
],
"normalized": []
},
{
"id": "65537",
"type": "Outcome_Physical",
"text": [
"effect"
],
"offsets": [
[
390,
396
]
],
"normalized": []
},
{
"id": "65538",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
520,
528
]
],
"normalized": []
},
{
"id": "65539",
"type": "Outcome_Physical",
"text": [
"and health-related"
],
"offsets": [
[
529,
547
]
],
"normalized": []
},
{
"id": "65540",
"type": "Outcome_Other",
"text": [
"quality of life"
],
"offsets": [
[
548,
563
]
],
"normalized": []
},
{
"id": "65541",
"type": "Outcome_Physical",
"text": [
"( HRQOL )"
],
"offsets": [
[
564,
573
]
],
"normalized": []
},
{
"id": "65542",
"type": "Outcome_Physical",
"text": [
"compares outcomes in patients with tumors larger than 7 cm ( N = 108 ) versus tumors 7 cm or smaller ( N = 76 )"
],
"offsets": [
[
920,
1031
]
],
"normalized": []
},
{
"id": "65543",
"type": "Outcome_Mortality",
"text": [
"median overall survival"
],
"offsets": [
[
1089,
1112
]
],
"normalized": []
},
{
"id": "65544",
"type": "Outcome_Mortality",
"text": [
"1-year survival"
],
"offsets": [
[
1207,
1222
]
],
"normalized": []
},
{
"id": "65545",
"type": "Outcome_Physical",
"text": [
"HRQOL"
],
"offsets": [
[
566,
571
]
],
"normalized": []
},
{
"id": "65546",
"type": "Outcome_Other",
"text": [
"HRQOL"
],
"offsets": [
[
566,
571
]
],
"normalized": []
},
{
"id": "65547",
"type": "Outcome_Physical",
"text": [
"significantly more esophagitis"
],
"offsets": [
[
1525,
1555
]
],
"normalized": []
},
{
"id": "65548",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
1588,
1600
]
],
"normalized": []
},
{
"id": "65549",
"type": "Participant_Condition",
"text": [
"Poor prognosis patients with inoperable locally advanced NSCLC and large tumors"
],
"offsets": [
[
0,
79
]
],
"normalized": []
},
{
"id": "65550",
"type": "Participant_Condition",
"text": [
"Poor prognosis"
],
"offsets": [
[
0,
14
]
],
"normalized": []
},
{
"id": "65551",
"type": "Participant_Sample-size",
"text": [
"188"
],
"offsets": [
[
595,
598
]
],
"normalized": []
},
{
"id": "65552",
"type": "Participant_Sample-size",
"text": [
"108"
],
"offsets": [
[
985,
988
]
],
"normalized": []
},
{
"id": "65553",
"type": "Participant_Sample-size",
"text": [
"76"
],
"offsets": [
[
1027,
1029
]
],
"normalized": []
},
{
"id": "65554",
"type": "Participant_Condition",
"text": [
"poor prognosis"
],
"offsets": [
[
429,
443
]
],
"normalized": []
},
{
"id": "65555",
"type": "Participant_Condition",
"text": [
"inoperable locally advanced non-small-cell lung cancer"
],
"offsets": [
[
1675,
1729
]
],
"normalized": []
}
] | [] | [] | [] |
65556 | 24817216 | [
{
"id": "65557",
"type": "document",
"text": [
"Reliable LC-MS/MS assay for the estimation of rilpivirine in human plasma : application to a bioequivalence study and incurred sample reanalysis . A simple , precise , and rapid stable isotope dilution liquid chromatography-tandem mass spectrometry method has been developed and validated for the quantification of rilpivirine , a non-nucleoside reverse transcriptase inhibitor in human plasma . Rilpivirine and its deuterated analogue , rilpivirine-d6 , used as an internal standard ( IS ) were quantitatively extracted by liquid-liquid extraction with methyl-tert-butyl ether and diethyl ether solvent mixture from 50 μL plasma . The chromatography was achieved on Gemini C18 ( 150 × 4.6 mm , 5 µm ) analytical column in a run time of 2.2 min . The precursor → product ion transitions for rilpivirine ( m/z 367.1 → 128.0 ) and IS ( m/z 373.2 → 134.2 ) were monitored on a triple quadrupole mass spectrometer in the positive ionization mode . The linearity of the method was established in the concentration range of 0.5-200 ng/mL . The mean extraction recovery for rilpivirine ( 94.9 % ) and IS ( 99.9 % ) from spiked plasma samples was consistent and reproducible . The IS-normalized matrix factors for rilpivirine ranged from 0.98 to 1.02 across three quality controls . Bench top , freeze-thaw , wet extract , and long-term stability of rilpivirine was examined in spiked plasma samples . The application of the method was demonstrated by a bioequivalence study with 25 mg rilpivirine tablet formulation in 40 healthy subjects . The assay reproducibility was shown by reanalysis of 200 study samples and the % change in the concentration of repeat values from the original values was within ±15 % ."
],
"offsets": [
[
0,
1703
]
]
}
] | [
{
"id": "65558",
"type": "Intervention_Pharmacological",
"text": [
"LC-MS/MS assay"
],
"offsets": [
[
9,
23
]
],
"normalized": []
},
{
"id": "65559",
"type": "Intervention_Pharmacological",
"text": [
"rilpivirine-d6"
],
"offsets": [
[
438,
452
]
],
"normalized": []
},
{
"id": "65560",
"type": "Outcome_Physical",
"text": [
"estimation of rilpivirine"
],
"offsets": [
[
32,
57
]
],
"normalized": []
},
{
"id": "65561",
"type": "Outcome_Physical",
"text": [
"range of 0.5-200 ng/mL ."
],
"offsets": [
[
1009,
1033
]
],
"normalized": []
},
{
"id": "65562",
"type": "Outcome_Other",
"text": [
"consistent"
],
"offsets": [
[
1139,
1149
]
],
"normalized": []
},
{
"id": "65563",
"type": "Outcome_Physical",
"text": [
"and"
],
"offsets": [
[
114,
117
]
],
"normalized": []
},
{
"id": "65564",
"type": "Outcome_Other",
"text": [
"reproducible"
],
"offsets": [
[
1154,
1166
]
],
"normalized": []
},
{
"id": "65565",
"type": "Outcome_Physical",
"text": [
". The IS-normalized"
],
"offsets": [
[
1167,
1186
]
],
"normalized": []
},
{
"id": "65566",
"type": "Outcome_Other",
"text": [
"across three quality controls ."
],
"offsets": [
[
1243,
1274
]
],
"normalized": []
},
{
"id": "65567",
"type": "Participant_Condition",
"text": [
"rilpivirine in human plasma :"
],
"offsets": [
[
46,
75
]
],
"normalized": []
},
{
"id": "65568",
"type": "Participant_Condition",
"text": [
"rilpivirine"
],
"offsets": [
[
46,
57
]
],
"normalized": []
},
{
"id": "65569",
"type": "Participant_Condition",
"text": [
"human plasma"
],
"offsets": [
[
61,
73
]
],
"normalized": []
}
] | [] | [] | [] |
65570 | 24821891 | [
{
"id": "65571",
"type": "document",
"text": [
"Sociopsychological tailoring to address colorectal cancer screening disparities : a randomized controlled trial . PURPOSE Interventions tailored to sociopsychological factors associated with health behaviors have promise for reducing colorectal cancer screening disparities , but limited research has assessed their impact in multiethnic populations . We examined whether an interactive multimedia computer program ( IMCP ) tailored to expanded health belief model sociopsychological factors could promote colorectal cancer screening in a multiethnic sample . METHODS We undertook a randomized controlled trial , comparing an IMCP tailored to colorectal cancer screening self-efficacy , knowledge , barriers , readiness , test preference , and experiences with a nontailored informational program , both delivered before office visits . The primary outcome was record-documented colorectal cancer screening during a 12-month follow-up period . Secondary outcomes included postvisit sociopsychological factor status and discussion , as well as clinician recommendation of screening during office visits . We enrolled 1,164 patients stratified by ethnicity and language ( 49.3 % non-Hispanic , 27.2 % Hispanic/English , 23.4 % Hispanic/Spanish ) from 26 offices around 5 centers ( Sacramento , California ; Rochester and the Bronx , New York ; Denver , Colorado ; and San Antonio , Texas ) . RESULTS Adjusting for ethnicity/language , study center , and the previsit value of the dependent variable , compared with control patients , the IMCP led to significantly greater colorectal cancer screening knowledge , self-efficacy , readiness , test preference specificity , discussion , and recommendation . During the followup period , 132 ( 23 % ) IMCP and 123 ( 22 % ) control patients received screening ( adjusted difference = 0.5 percentage points , 95 % CI -4.3 to 5.3 ) . IMCP effects did not differ significantly by ethnicity/language . CONCLUSIONS Sociopsychological factor tailoring was no more effective than nontailored information in encouraging colorectal cancer screening in a multiethnic sample , despite enhancing sociopsychological factors and visit behaviors associated with screening . The utility of sociopsychological tailoring in addressing screening disparities remains uncertain ."
],
"offsets": [
[
0,
2300
]
]
}
] | [
{
"id": "65572",
"type": "Intervention_Educational",
"text": [
"Interventions tailored to sociopsychological factors associated with health behaviors"
],
"offsets": [
[
122,
207
]
],
"normalized": []
},
{
"id": "65573",
"type": "Intervention_Educational",
"text": [
"interactive multimedia computer program ( IMCP )"
],
"offsets": [
[
375,
423
]
],
"normalized": []
},
{
"id": "65574",
"type": "Intervention_Educational",
"text": [
"IMCP tailored to colorectal cancer screening self-efficacy , knowledge , barriers , readiness , test preference , and experiences with a nontailored informational program"
],
"offsets": [
[
626,
796
]
],
"normalized": []
},
{
"id": "65575",
"type": "Outcome_Other",
"text": [
"record-documented colorectal cancer screening during a 12-month follow-up period ."
],
"offsets": [
[
861,
943
]
],
"normalized": []
},
{
"id": "65576",
"type": "Outcome_Other",
"text": [
"postvisit sociopsychological factor status and discussion , as well as clinician recommendation of screening during office visits ."
],
"offsets": [
[
972,
1103
]
],
"normalized": []
},
{
"id": "65577",
"type": "Outcome_Other",
"text": [
"colorectal cancer screening knowledge , self-efficacy , readiness , test preference specificity , discussion , and recommendation ."
],
"offsets": [
[
1570,
1701
]
],
"normalized": []
},
{
"id": "65578",
"type": "Outcome_Other",
"text": [
"screening"
],
"offsets": [
[
58,
67
]
],
"normalized": []
},
{
"id": "65579",
"type": "Participant_Condition",
"text": [
"multiethnic sample"
],
"offsets": [
[
539,
557
]
],
"normalized": []
},
{
"id": "65580",
"type": "Participant_Sample-size",
"text": [
"enrolled 1,164 patients"
],
"offsets": [
[
1107,
1130
]
],
"normalized": []
},
{
"id": "65581",
"type": "Participant_Sample-size",
"text": [
"49.3 % non-Hispanic , 27.2 % Hispanic/English , 23.4 % Hispanic/Spanish )"
],
"offsets": [
[
1170,
1243
]
],
"normalized": []
},
{
"id": "65582",
"type": "Participant_Condition",
"text": [
"multiethnic sample"
],
"offsets": [
[
539,
557
]
],
"normalized": []
}
] | [] | [] | [] |
65583 | 24824660 | [
{
"id": "65584",
"type": "document",
"text": [
"A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder . OBJECTIVES Autism spectrum disorders ( ASDs ) have core impairments in social communication as well as the presence of repetitive , stereotypic behaviors and restricted interests . Older adolescents and young adults are particularly impacted by these deficits . Preclinical data implicate glutamatergic dysfunction in the pathophysiology of ASDs . D-Cycloserine ( DCS ) , a partial glycineB agonist at the N-methyl-D-aspartic acid receptor site , has been shown to improve sociability in mouse models and a small human study . The sensitivity of the obligatory glycineB co-agonist binding site may change with daily administration of DCS as a result of agonist-induced desensitization . The efficacy of a \" pulsed \" once-weekly administration versus \" daily \" administration of DCS was compared . METHODS Males and females , ages 14 to 25 years , with a Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition Text Revision diagnosis of an ASD were enrolled in a double-blind , randomized 10-week trial consisting of 8 weeks of active drug with either weekly or daily administration of 50 mg of DCS followed by a 2-week follow-up visit . RESULTS For the purposes of this study , no statistical or clinical differences existed between the 2 dosage groups on the Aberrant Behavior Checklist subscale 3 , which measures stereotypies/repetitive movements . When combining groups , a statistically significant decrease of 37 % was found from baseline to week 8 when study drug was completed using a linear mixed effects model ( P = 0.003 ) . CONCLUSIONS D-Cycloserine was shown to be effective in improving stereotypic symptoms in older adolescents and young adults with ASDs measured by the Aberrant Behavior Checklist subscale 3 . In addition , DCS was safe and well tolerated ."
],
"offsets": [
[
0,
1907
]
]
}
] | [
{
"id": "65585",
"type": "Intervention_Pharmacological",
"text": [
"D-cycloserine"
],
"offsets": [
[
11,
24
]
],
"normalized": []
},
{
"id": "65586",
"type": "Intervention_Pharmacological",
"text": [
"D-Cycloserine ( DCS )"
],
"offsets": [
[
465,
486
]
],
"normalized": []
},
{
"id": "65587",
"type": "Intervention_Pharmacological",
"text": [
"DCS"
],
"offsets": [
[
481,
484
]
],
"normalized": []
},
{
"id": "65588",
"type": "Intervention_Pharmacological",
"text": [
"D-Cycloserine"
],
"offsets": [
[
465,
478
]
],
"normalized": []
},
{
"id": "65589",
"type": "Intervention_Pharmacological",
"text": [
"DCS"
],
"offsets": [
[
481,
484
]
],
"normalized": []
},
{
"id": "65590",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
808,
816
]
],
"normalized": []
},
{
"id": "65591",
"type": "Outcome_Mental",
"text": [
"Aberrant Behavior Checklist subscale 3 , which measures stereotypies/repetitive movements ."
],
"offsets": [
[
1393,
1484
]
],
"normalized": []
},
{
"id": "65592",
"type": "Outcome_Mental",
"text": [
"stereotypic symptoms"
],
"offsets": [
[
1734,
1754
]
],
"normalized": []
},
{
"id": "65593",
"type": "Outcome_Mental",
"text": [
"Aberrant Behavior Checklist subscale 3 ."
],
"offsets": [
[
1819,
1859
]
],
"normalized": []
},
{
"id": "65594",
"type": "Outcome_Other",
"text": [
"safe and well tolerated ."
],
"offsets": [
[
1882,
1907
]
],
"normalized": []
},
{
"id": "65595",
"type": "Participant_Age",
"text": [
"older adolescents"
],
"offsets": [
[
50,
67
]
],
"normalized": []
},
{
"id": "65596",
"type": "Participant_Age",
"text": [
"young adults"
],
"offsets": [
[
72,
84
]
],
"normalized": []
},
{
"id": "65597",
"type": "Participant_Condition",
"text": [
"autism spectrum disorder"
],
"offsets": [
[
90,
114
]
],
"normalized": []
},
{
"id": "65598",
"type": "Participant_Sex",
"text": [
"Males"
],
"offsets": [
[
922,
927
]
],
"normalized": []
},
{
"id": "65599",
"type": "Participant_Sex",
"text": [
"females"
],
"offsets": [
[
932,
939
]
],
"normalized": []
},
{
"id": "65600",
"type": "Participant_Age",
"text": [
"ages 14 to 25 years ,"
],
"offsets": [
[
942,
963
]
],
"normalized": []
},
{
"id": "65601",
"type": "Participant_Condition",
"text": [
"Diagnostic and Statistical Manual of Mental Disorders"
],
"offsets": [
[
971,
1024
]
],
"normalized": []
},
{
"id": "65602",
"type": "Participant_Condition",
"text": [
"Fourth Edition Text Revision diagnosis of an ASD"
],
"offsets": [
[
1027,
1075
]
],
"normalized": []
}
] | [] | [] | [] |
65603 | 24830566 | [
{
"id": "65604",
"type": "document",
"text": [
"Caudal epidural analgesia using lidocaine alone or in combination with ketamine in dromedary camels Camelus dromedarius . This study was performed to investigate the analgesic effect of lidocaine and a combination of lidocaine and ketamine following epidural administration in dromedary camels . Ten 12-18-month-old camels were randomly divided into two equal groups . In group L , the animals received 2 % lidocaine ( 0.22 mg/kg ) and in group LK the animals received a mixture of 10 % ketamine ( 1 mg/kg ) and 2 % lidocaine ( 0.22 mg/kg ) administered into the first intercoccygeal ( Co1-Co2 ) epidural space while standing . Onset time and duration of caudal analgesia , sedation level and ataxia were recorded after drug administration . Data were analysed by U Mann-Whitney tests and significance was taken as p & lt ; 0.05 . The results showed that epidural lidocaine and co-administration of lidocaine and ketamine produced complete analgesia in the tail , anus and perineum . Epidural administration of the lidocaine-ketamine mixture resulted in mild to moderate sedation , whilst the animals that received epidural lidocaine alone were alert and nervous during the study . Ataxia was observed in all test subjects and was slightly more severe in camels that received the lidocaine-ketamine mixture . It was concluded that epidural administration of lidocaine plus ketamine resulted in longer caudal analgesia in standing conscious dromedary camels compared with the effect of administering lidocaine alone ."
],
"offsets": [
[
0,
1516
]
]
}
] | [
{
"id": "65605",
"type": "Intervention_Pharmacological",
"text": [
"Caudal epidural analgesia"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "65606",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine alone"
],
"offsets": [
[
32,
47
]
],
"normalized": []
},
{
"id": "65607",
"type": "Intervention_Pharmacological",
"text": [
"combination with ketamine"
],
"offsets": [
[
54,
79
]
],
"normalized": []
},
{
"id": "65608",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine and a combination of lidocaine and ketamine"
],
"offsets": [
[
186,
239
]
],
"normalized": []
},
{
"id": "65609",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
32,
41
]
],
"normalized": []
},
{
"id": "65610",
"type": "Intervention_Pharmacological",
"text": [
"ketamine"
],
"offsets": [
[
71,
79
]
],
"normalized": []
},
{
"id": "65611",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
32,
41
]
],
"normalized": []
},
{
"id": "65612",
"type": "Intervention_Pharmacological",
"text": [
"epidural lidocaine"
],
"offsets": [
[
855,
873
]
],
"normalized": []
},
{
"id": "65613",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine and ketamine"
],
"offsets": [
[
217,
239
]
],
"normalized": []
},
{
"id": "65614",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine-ketamine mixture"
],
"offsets": [
[
1015,
1041
]
],
"normalized": []
},
{
"id": "65615",
"type": "Intervention_Pharmacological",
"text": [
"epidural lidocaine"
],
"offsets": [
[
855,
873
]
],
"normalized": []
},
{
"id": "65616",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine-ketamine mixture ."
],
"offsets": [
[
1280,
1308
]
],
"normalized": []
},
{
"id": "65617",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine plus ketamine"
],
"offsets": [
[
1358,
1381
]
],
"normalized": []
},
{
"id": "65618",
"type": "Intervention_Pharmacological",
"text": [
"lidocaine"
],
"offsets": [
[
32,
41
]
],
"normalized": []
}
] | [] | [] | [] |
65619 | 24830937 | [
{
"id": "65620",
"type": "document",
"text": [
"Oral magnesium supplementation improves the metabolic profile of metabolically obese , normal-weight individuals : a randomized double-blind placebo-controlled trial . BACKGROUND AND AIMS We undertook this study to determine the efficacy of oral magnesium supplementation in the improvement of the metabolic profile and blood pressure in metabolically obese , normal-weight ( MONW ) individuals . METHODS A total of 47 MONW individuals with hypomagnesemia were enrolled in clinical a randomized double-blind placebo-controlled trial . Individuals in the intervention group received 30 mL of MgCl2 5 % solution ( equivalent to 382 mg of magnesium ) and individuals in the control group 30 mL of placebo solution , once daily during 4 months . In the absence of obesity or overweight , the presence of fasting glucose levels ≥100 mg/dL , HOMA-IR index ≥3 , triglyceride levels ≥150 mg/dL and/or systolic and diastolic blood pressure ≥140 and 90 mmHg defined the presence of the MONW phenotype . Hypomagnesemia was defined by serum magnesium concentration ≤1.8 mg/dL . RESULTS At basal conditions there were no significant differences between groups . At the end of follow-up , changes in the mean of systolic ( -2.1 vs. 3.9 % mmHg , p < 0.05 ) and diastolic ( -3.8 vs. 7.5 % mmHg , p < 0.05 ) blood pressures , HOMA-IR index ( -46.5 vs. -5.4 % , p < 0.0001 ) , fasting glucose ( -12.3 vs. -1.8 % mg/dL , p < 0.05 ) and triglyceride levels ( -47.4 % vs. 10.1 % mg/dL , p < 0.0001 ) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group . CONCLUSIONS Oral magnesium supplementation improves the metabolic profile and blood pressure of MONW individuals ."
],
"offsets": [
[
0,
1702
]
]
}
] | [
{
"id": "65621",
"type": "Intervention_Pharmacological",
"text": [
"Oral magnesium supplementation"
],
"offsets": [
[
0,
30
]
],
"normalized": []
},
{
"id": "65622",
"type": "Intervention_Pharmacological",
"text": [
"magnesium"
],
"offsets": [
[
5,
14
]
],
"normalized": []
},
{
"id": "65623",
"type": "Intervention_Pharmacological",
"text": [
"MgCl2"
],
"offsets": [
[
591,
596
]
],
"normalized": []
},
{
"id": "65624",
"type": "Intervention_Pharmacological",
"text": [
"magnesium"
],
"offsets": [
[
5,
14
]
],
"normalized": []
},
{
"id": "65625",
"type": "Intervention_Control",
"text": [
"30 mL of placebo solution , once daily during 4 months"
],
"offsets": [
[
685,
739
]
],
"normalized": []
},
{
"id": "65626",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
229,
237
]
],
"normalized": []
},
{
"id": "65627",
"type": "Outcome_Other",
"text": [
"metabolic profile"
],
"offsets": [
[
44,
61
]
],
"normalized": []
},
{
"id": "65628",
"type": "Outcome_Other",
"text": [
"blood pressure"
],
"offsets": [
[
320,
334
]
],
"normalized": []
},
{
"id": "65629",
"type": "Outcome_Mental",
"text": [
"fasting glucose levels"
],
"offsets": [
[
800,
822
]
],
"normalized": []
},
{
"id": "65630",
"type": "Participant_Condition",
"text": [
"metabolically obese , normal-weight individuals :"
],
"offsets": [
[
65,
114
]
],
"normalized": []
}
] | [] | [] | [] |
65631 | 24835171 | [
{
"id": "65632",
"type": "document",
"text": [
"Changes in spinal inhibitory networks induced by furosemide in humans . During neural development in animals , GABAergic and glycinergic neurons are first excitatory , and then become inhibitory in the mature state . This developmental shift is due mainly to strong expression of the cation-chloride K-Cl cotransporter 2 ( KCC2 ) and down-regulation of Na-K-Cl cotransporter 1 ( NKCC1 ) during maturation . The down-regulation of co-transporter KCC2 after spinal cord transection in animals leads to the depolarising ( excitatory ) action of GABA and glycine and thus results in a reduction of inhibitory synaptic efficiency . Furosemide , a loop diuretic , has been shown to selectively and reversibly block inhibitory postsynaptic potentials without affecting excitatory postsynaptic potentials in animal spinal neurons . Moreover , this diuretic has been also demonstrated to block the cation-chloride co-transporters . Here , we used furosemide to demonstrate changes in spinal inhibitory networks in healthy human subjects . Non-invasive electrophysiological techniques were used to assess presynaptic inhibition , postsynaptic inhibition and the efficacy of synaptic transmission between muscle afferent terminals and soleus motoneurons in the spinal cord . Orally administered furosemide , at doses commonly used in the clinic ( 40 mg ) , significantly reduced spinal inhibitory interneuronal activity for at least 70 min from intake compared to control experiments in the same subjects while no changes were observed in the efficacy of synaptic transmission between muscle afferent terminals and soleus motoneurons . The reduction of inhibition was dose-dependent . Our results provide indirect evidence that reversible changes in the cation-chloride transport system induce modulations of inhibitory neuronal activity at spinal cord level in humans ."
],
"offsets": [
[
0,
1859
]
]
}
] | [
{
"id": "65633",
"type": "Intervention_Pharmacological",
"text": [
"furosemide"
],
"offsets": [
[
49,
59
]
],
"normalized": []
},
{
"id": "65634",
"type": "Intervention_Pharmacological",
"text": [
"Furosemide"
],
"offsets": [
[
627,
637
]
],
"normalized": []
},
{
"id": "65635",
"type": "Intervention_Pharmacological",
"text": [
"furosemide"
],
"offsets": [
[
49,
59
]
],
"normalized": []
},
{
"id": "65636",
"type": "Intervention_Pharmacological",
"text": [
"Orally administered furosemide , at doses commonly used in the clinic ( 40 mg"
],
"offsets": [
[
1264,
1341
]
],
"normalized": []
},
{
"id": "65637",
"type": "Outcome_Physical",
"text": [
"spinal inhibitory interneuronal activity"
],
"offsets": [
[
1368,
1408
]
],
"normalized": []
},
{
"id": "65638",
"type": "Outcome_Physical",
"text": [
"reduction of inhibition"
],
"offsets": [
[
1629,
1652
]
],
"normalized": []
},
{
"id": "65639",
"type": "Participant_Condition",
"text": [
"changes"
],
"offsets": [
[
964,
971
]
],
"normalized": []
},
{
"id": "65640",
"type": "Participant_Condition",
"text": [
"spinal inhibitory networks in healthy human subjects"
],
"offsets": [
[
975,
1027
]
],
"normalized": []
}
] | [] | [] | [] |
65641 | 24839882 | [
{
"id": "65642",
"type": "document",
"text": [
"Communication interventions for minimally verbal children with autism : a sequential multiple assignment randomized trial . OBJECTIVE This study tested the effect of beginning treatment with a speech-generating device ( SGD ) in the context of a blended , adaptive treatment design for improving spontaneous , communicative utterances in school-aged , minimally verbal children with autism . METHOD A total of 61 minimally verbal children with autism , aged 5 to 8 years , were randomized to a blended developmental/behavioral intervention ( JASP+EMT ) with or without the augmentation of a SGD for 6 months with a 3-month follow-up . The intervention consisted of 2 stages . In stage 1 , all children received 2 sessions per week for 3 months . Stage 2 intervention was adapted ( by increased sessions or adding the SGD ) based on the child 's early response . The primary outcome was the total number of spontaneous communicative utterances ; secondary measures were the total number of novel words and total comments from a natural language sample . RESULTS Primary aim results found improvements in spontaneous communicative utterances , novel words , and comments that all favored the blended behavioral intervention that began by including an SGD ( JASP+EMT+SGD ) as opposed to spoken words alone ( JASP+EMT ) . Secondary aim results suggest that the adaptive intervention beginning with JASP+EMT+SGD and intensifying JASP+EMT+SGD for children who were slow responders led to better posttreatment outcomes . CONCLUSION Minimally verbal school-aged children can make significant and rapid gains in spoken spontaneous language with a novel , blended intervention that focuses on joint engagement and play skills and incorporates an SGD . Future studies should further explore the tailoring design used in this study to better understand children 's response to treatment . Clinical trial registration information-Developmental and Augmented Intervention for Facilitating Expressive Language ( CCNIA ) ; http : //clinicaltrials.gov/ ; NCT01013545 ."
],
"offsets": [
[
0,
2051
]
]
}
] | [
{
"id": "65643",
"type": "Intervention_Educational",
"text": [
"Communication interventions"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "65644",
"type": "Intervention_Educational",
"text": [
"speech-generating device ( SGD )"
],
"offsets": [
[
193,
225
]
],
"normalized": []
},
{
"id": "65645",
"type": "Intervention_Educational",
"text": [
"blended developmental/behavioral intervention ( JASP+EMT ) with or without the augmentation of a SGD"
],
"offsets": [
[
494,
594
]
],
"normalized": []
},
{
"id": "65646",
"type": "Intervention_Educational",
"text": [
"adding the SGD )"
],
"offsets": [
[
806,
822
]
],
"normalized": []
},
{
"id": "65647",
"type": "Intervention_Educational",
"text": [
"blended behavioral intervention that began by including an SGD ( JASP+EMT+SGD )"
],
"offsets": [
[
1190,
1269
]
],
"normalized": []
},
{
"id": "65648",
"type": "Intervention_Educational",
"text": [
"spoken words alone ( JASP+EMT ) ."
],
"offsets": [
[
1284,
1317
]
],
"normalized": []
},
{
"id": "65649",
"type": "Intervention_Educational",
"text": [
"JASP+EMT+SGD"
],
"offsets": [
[
1255,
1267
]
],
"normalized": []
},
{
"id": "65650",
"type": "Intervention_Educational",
"text": [
"JASP+EMT+SGD"
],
"offsets": [
[
1255,
1267
]
],
"normalized": []
},
{
"id": "65651",
"type": "Intervention_Educational",
"text": [
"SGD"
],
"offsets": [
[
220,
223
]
],
"normalized": []
},
{
"id": "65652",
"type": "Outcome_Mental",
"text": [
"spontaneous , communicative utterances"
],
"offsets": [
[
296,
334
]
],
"normalized": []
},
{
"id": "65653",
"type": "Outcome_Mental",
"text": [
"total number of spontaneous communicative utterances ; secondary measures were the total number of novel words and total comments from a natural language sample ."
],
"offsets": [
[
890,
1052
]
],
"normalized": []
},
{
"id": "65654",
"type": "Outcome_Mental",
"text": [
"spontaneous communicative utterances , novel words , and comments"
],
"offsets": [
[
1103,
1168
]
],
"normalized": []
},
{
"id": "65655",
"type": "Outcome_Mental",
"text": [
"spoken spontaneous language"
],
"offsets": [
[
1603,
1630
]
],
"normalized": []
},
{
"id": "65656",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
49,
57
]
],
"normalized": []
},
{
"id": "65657",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
63,
69
]
],
"normalized": []
},
{
"id": "65658",
"type": "Participant_Age",
"text": [
"school-aged ,"
],
"offsets": [
[
338,
351
]
],
"normalized": []
},
{
"id": "65659",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
63,
69
]
],
"normalized": []
},
{
"id": "65660",
"type": "Participant_Sample-size",
"text": [
"61"
],
"offsets": [
[
410,
412
]
],
"normalized": []
},
{
"id": "65661",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
49,
57
]
],
"normalized": []
},
{
"id": "65662",
"type": "Participant_Age",
"text": [
"aged 5 to 8 years"
],
"offsets": [
[
453,
470
]
],
"normalized": []
},
{
"id": "65663",
"type": "Participant_Age",
"text": [
"school-aged children"
],
"offsets": [
[
1542,
1562
]
],
"normalized": []
}
] | [] | [] | [] |
65664 | 24839884 | [
{
"id": "65665",
"type": "document",
"text": [
"Internet-based , randomized , controlled trial of omega-3 fatty acids for hyperactivity in autism . OBJECTIVE Preliminary evidence suggests that omega-3 fatty acids may reduce hyperactivity in children with autism spectrum disorder ( ASD ) . We sought to examine the feasibility of a novel , Internet-based clinical trial design to evaluate the efficacy of this supplement . METHOD E-mail invitations were sent to parents of children aged 5 to 8 years enrolled in the Interactive Autism Network . All study procedures , including screening , informed consent , and collection of outcome measures took place over the Internet . The primary outcome measures were parent- and teacher-rated changes in hyperactivity on the Aberrant Behavior Checklist ( ABC-H ) . RESULTS During the 6-week recruitment period , 57 children from 28 states satisfied all eligibility criteria and were randomly assigned to 1.3 grams of omega-3 fatty acids or an identical placebo daily for 6 weeks . Outcome assessments were obtained from all 57 participants and 57 teachers , and the study was completed in 3 months . Children in the omega-3 fatty acid group had a greater reduction in hyperactivity ( -5.3 points ) compared to the placebo group ( -2.6 points ) , but the difference was not statistically significant ( 1.9-point greater improvement in the omega-3 group , 95 % CI = -2.2 to 5.2 ) . Adverse events were rare and not associated with omega-3 fatty acids . Participant feedback was positive . CONCLUSION Internet-based , randomized controlled trials of therapies in children with ASD are feasible and may lead to marked reductions in the time and cost of completing trials . A larger sample size is required to definitively determine the efficacy of omega-3 fatty acids . Clinical trial registration information-Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder ; http : //clinicaltrials.gov ; NCT01694667 ."
],
"offsets": [
[
0,
1921
]
]
}
] | [
{
"id": "65666",
"type": "Intervention_Pharmacological",
"text": [
"omega-3 fatty acids"
],
"offsets": [
[
50,
69
]
],
"normalized": []
},
{
"id": "65667",
"type": "Intervention_Pharmacological",
"text": [
"omega-3 fatty acids"
],
"offsets": [
[
50,
69
]
],
"normalized": []
},
{
"id": "65668",
"type": "Intervention_Educational",
"text": [
"E-mail invitations"
],
"offsets": [
[
382,
400
]
],
"normalized": []
},
{
"id": "65669",
"type": "Intervention_Educational",
"text": [
"study procedures , including screening , informed consent , and collection of outcome measures took place over the Internet"
],
"offsets": [
[
501,
624
]
],
"normalized": []
},
{
"id": "65670",
"type": "Intervention_Pharmacological",
"text": [
"omega-3 fatty acids"
],
"offsets": [
[
50,
69
]
],
"normalized": []
},
{
"id": "65671",
"type": "Intervention_Control",
"text": [
"an identical placebo"
],
"offsets": [
[
934,
954
]
],
"normalized": []
},
{
"id": "65672",
"type": "Intervention_Pharmacological",
"text": [
"omega-3 fatty acid"
],
"offsets": [
[
50,
68
]
],
"normalized": []
},
{
"id": "65673",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
947,
954
]
],
"normalized": []
},
{
"id": "65674",
"type": "Intervention_Pharmacological",
"text": [
"omega-3 group"
],
"offsets": [
[
1332,
1345
]
],
"normalized": []
},
{
"id": "65675",
"type": "Intervention_Pharmacological",
"text": [
"omega-3 fatty acids ."
],
"offsets": [
[
1423,
1444
]
],
"normalized": []
},
{
"id": "65676",
"type": "Intervention_Pharmacological",
"text": [
"omega-3 fatty acids ."
],
"offsets": [
[
1423,
1444
]
],
"normalized": []
},
{
"id": "65677",
"type": "Intervention_Pharmacological",
"text": [
"information-Omega-3 Fatty Acids"
],
"offsets": [
[
1788,
1819
]
],
"normalized": []
},
{
"id": "65678",
"type": "Outcome_Physical",
"text": [
"hyperactivity"
],
"offsets": [
[
74,
87
]
],
"normalized": []
},
{
"id": "65679",
"type": "Outcome_Physical",
"text": [
"hyperactivity"
],
"offsets": [
[
74,
87
]
],
"normalized": []
},
{
"id": "65680",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
345,
353
]
],
"normalized": []
},
{
"id": "65681",
"type": "Outcome_Physical",
"text": [
"parent- and teacher-rated changes in hyperactivity on the Aberrant Behavior Checklist ( ABC-H ) ."
],
"offsets": [
[
661,
758
]
],
"normalized": []
},
{
"id": "65682",
"type": "Outcome_Physical",
"text": [
"hyperactivity"
],
"offsets": [
[
74,
87
]
],
"normalized": []
},
{
"id": "65683",
"type": "Outcome_Adverse-effects",
"text": [
"Adverse events"
],
"offsets": [
[
1374,
1388
]
],
"normalized": []
},
{
"id": "65684",
"type": "Outcome_Other",
"text": [
"feedback"
],
"offsets": [
[
1457,
1465
]
],
"normalized": []
},
{
"id": "65685",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
345,
353
]
],
"normalized": []
},
{
"id": "65686",
"type": "Participant_Condition",
"text": [
"hyperactivity in autism ."
],
"offsets": [
[
74,
99
]
],
"normalized": []
},
{
"id": "65687",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
193,
201
]
],
"normalized": []
},
{
"id": "65688",
"type": "Participant_Condition",
"text": [
"autism spectrum disorder ( ASD ) ."
],
"offsets": [
[
207,
241
]
],
"normalized": []
},
{
"id": "65689",
"type": "Participant_Age",
"text": [
"children aged 5 to 8 years"
],
"offsets": [
[
425,
451
]
],
"normalized": []
},
{
"id": "65690",
"type": "Participant_Sample-size",
"text": [
"57"
],
"offsets": [
[
806,
808
]
],
"normalized": []
},
{
"id": "65691",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
193,
201
]
],
"normalized": []
},
{
"id": "65692",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
193,
201
]
],
"normalized": []
},
{
"id": "65693",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
234,
237
]
],
"normalized": []
}
] | [] | [] | [] |
65694 | 24840596 | [
{
"id": "65695",
"type": "document",
"text": [
"A randomized clinical trial comparison between pivotal response treatment ( PRT ) and structured applied behavior analysis ( ABA ) intervention for children with autism . Accumulating studies are documenting specific motivational variables that , when combined into a naturalistic teaching paradigm , can positively influence the effectiveness of interventions for children with autism spectrum disorder ( ASD ) . The purpose of this study was to compare two applied behavior analysis ( ABA ) intervention procedures , a naturalistic approach , pivotal response treatment ( PRT ) with a structured ABA approach in a school setting . A randomized clinical trial design using two groups of children , matched according to age , sex and mean length of utterance was used to compare the interventions . The data showed that the PRT approach was significantly more effective in improving targeted and untargeted areas after 3 months of intervention . The results are discussed in terms of variables that produce more rapid improvements in communication for children with ASD ."
],
"offsets": [
[
0,
1071
]
]
}
] | [
{
"id": "65696",
"type": "Intervention_Educational",
"text": [
"pivotal response treatment ( PRT ) and structured applied behavior analysis ( ABA )"
],
"offsets": [
[
47,
130
]
],
"normalized": []
},
{
"id": "65697",
"type": "Intervention_Educational",
"text": [
"naturalistic teaching paradigm"
],
"offsets": [
[
268,
298
]
],
"normalized": []
},
{
"id": "65698",
"type": "Intervention_Educational",
"text": [
"applied behavior analysis ( ABA ) intervention procedures , a naturalistic approach , pivotal response treatment ( PRT ) with a structured ABA approach"
],
"offsets": [
[
459,
610
]
],
"normalized": []
},
{
"id": "65699",
"type": "Intervention_Educational",
"text": [
"PRT"
],
"offsets": [
[
76,
79
]
],
"normalized": []
},
{
"id": "65700",
"type": "Outcome_Other",
"text": [
"improving targeted and untargeted areas"
],
"offsets": [
[
873,
912
]
],
"normalized": []
},
{
"id": "65701",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
162,
168
]
],
"normalized": []
},
{
"id": "65702",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
148,
156
]
],
"normalized": []
},
{
"id": "65703",
"type": "Participant_Condition",
"text": [
"autism spectrum disorder ( ASD"
],
"offsets": [
[
379,
409
]
],
"normalized": []
},
{
"id": "65704",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
148,
156
]
],
"normalized": []
}
] | [] | [] | [] |
65705 | 24852722 | [
{
"id": "65706",
"type": "document",
"text": [
"Causes of variation in BCG vaccine efficacy : examining evidence from the BCG REVAC cluster randomized trial to explore the masking and the blocking hypotheses . BCG protection varies and in some places ( nearest the equator ) is low or absent . Understanding this variation can inform the efforts to develop new vaccines against tuberculosis . Two main hypotheses are used to explain this variation : under masking , new vaccines are unlikely to increase protection ; under blocking new vaccines have a greater potential to be effective when BCG is not . We conducted a cluster randomized trial to explored the masking and blocking hypotheses by studying BCG vaccine efficacy of neonatal vaccination and when administered for the first or a second ( revaccination ) time at school age in two sites ( Manaus close and Salvador further south from the equator ) . Seven hundred and sixty three state schools were matched on socio economic characteristics of the neighborhood and 239,934 children were randomized to vaccine ( BCG vaccination at school age ) or control group . Protection by first BCG vaccination at school age was high in Salvador ( 34 % , 95 % CI 7-53 % , p=0.017 ) but low in Manaus ( 8 % , 95 % CI t0 39-40 % , p=0.686 ) . For revaccination at school age , protection was modest in Salvador ( 19 % , 95 % CI 3-33 % , p=0.022 ) and absent in Manaus ( 1 % , 95 % CI to 27-23 % , p=0.932 ) . Vaccine efficacy for neonatal vaccination was similar in Salvador ( 40 % , 95 % CI 22-54 % , p < 0.001 ) and Manaus ( 36 % , 95 % CI 11-53 % , p=0.008 ) . Variation in BCG efficacy was marked when vaccine was given at school age but absent at birth , which points towards blocking as the dominant mechanism . New tuberculosis vaccines that overcome or by pass this blocking effect could confer protection in situations where BCG is not protective ."
],
"offsets": [
[
0,
1854
]
]
}
] | [
{
"id": "65707",
"type": "Intervention_Pharmacological",
"text": [
"BCG vaccine"
],
"offsets": [
[
23,
34
]
],
"normalized": []
},
{
"id": "65708",
"type": "Intervention_Pharmacological",
"text": [
"BCG vaccine"
],
"offsets": [
[
23,
34
]
],
"normalized": []
},
{
"id": "65709",
"type": "Intervention_Pharmacological",
"text": [
"BCG vaccination"
],
"offsets": [
[
1023,
1038
]
],
"normalized": []
},
{
"id": "65710",
"type": "Intervention_Control",
"text": [
"control group"
],
"offsets": [
[
1058,
1071
]
],
"normalized": []
},
{
"id": "65711",
"type": "Intervention_Pharmacological",
"text": [
"BCG vaccination"
],
"offsets": [
[
1023,
1038
]
],
"normalized": []
},
{
"id": "65712",
"type": "Intervention_Pharmacological",
"text": [
"BCG"
],
"offsets": [
[
23,
26
]
],
"normalized": []
},
{
"id": "65713",
"type": "Outcome_Other",
"text": [
"efficacy :"
],
"offsets": [
[
35,
45
]
],
"normalized": []
},
{
"id": "65714",
"type": "Outcome_Physical",
"text": [
"protection ;"
],
"offsets": [
[
456,
468
]
],
"normalized": []
},
{
"id": "65715",
"type": "Outcome_Physical",
"text": [
"Protection by first BCG vaccination"
],
"offsets": [
[
1074,
1109
]
],
"normalized": []
},
{
"id": "65716",
"type": "Outcome_Mental",
"text": [
"revaccination at school age"
],
"offsets": [
[
1244,
1271
]
],
"normalized": []
},
{
"id": "65717",
"type": "Outcome_Other",
"text": [
"Vaccine efficacy"
],
"offsets": [
[
1406,
1422
]
],
"normalized": []
},
{
"id": "65718",
"type": "Outcome_Other",
"text": [
"Variation in BCG efficacy"
],
"offsets": [
[
1561,
1586
]
],
"normalized": []
},
{
"id": "65719",
"type": "Participant_Age",
"text": [
"school age"
],
"offsets": [
[
775,
785
]
],
"normalized": []
},
{
"id": "65720",
"type": "Participant_Sample-size",
"text": [
"239,934"
],
"offsets": [
[
977,
984
]
],
"normalized": []
},
{
"id": "65721",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
985,
993
]
],
"normalized": []
}
] | [] | [] | [] |
65722 | 24859114 | [
{
"id": "65723",
"type": "document",
"text": [
"Effect of glycemic load on eating behavior self-efficacy during weight loss . High eating behavior self-efficacy may contribute to successful weight loss . Diet interventions that maximize eating behavior self-efficacy may therefore improve weight loss outcomes . However , data on the effect of diet composition on eating behavior self-efficacy are sparse . To determine the effects of dietary glycemic load ( GL ) on eating behavior self-efficacy during weight loss , body weight and eating behavior self-efficacy were measured every six months in overweight adults participating in a 12-mo randomized trial testing energy-restricted diets differing in GL . All food was provided during the first six months and self-selected thereafter . Total mean weight loss did not differ between groups , and GL-level had no significant effect on eating behavior self-efficacy . In the combined cohort , individuals losing the most weight reported improvements in eating behavior self-efficacy , whereas those achieving less weight loss reported decrements in eating behavior self-efficacy . Decrements in eating behavior self-efficacy were associated with subsequent weight regain when diets were self-selected . While GL does not appear to influence eating behavior self-efficacy , lesser amounts of weight loss on provided-food energy restricted diets may deter successful maintenance of weight loss by attenuating improvements in eating behavior self-efficacy ."
],
"offsets": [
[
0,
1456
]
]
}
] | [
{
"id": "65724",
"type": "Intervention_Pharmacological",
"text": [
"Diet interventions"
],
"offsets": [
[
156,
174
]
],
"normalized": []
},
{
"id": "65725",
"type": "Intervention_Pharmacological",
"text": [
"testing energy-restricted diets differing in GL"
],
"offsets": [
[
610,
657
]
],
"normalized": []
},
{
"id": "65726",
"type": "Intervention_Pharmacological",
"text": [
"provided-food energy restricted diets"
],
"offsets": [
[
1308,
1345
]
],
"normalized": []
},
{
"id": "65727",
"type": "Outcome_Physical",
"text": [
"eating behavior self-efficacy"
],
"offsets": [
[
27,
56
]
],
"normalized": []
},
{
"id": "65728",
"type": "Outcome_Physical",
"text": [
"body weight"
],
"offsets": [
[
470,
481
]
],
"normalized": []
},
{
"id": "65729",
"type": "Outcome_Mental",
"text": [
"eating behavior self-efficacy"
],
"offsets": [
[
27,
56
]
],
"normalized": []
},
{
"id": "65730",
"type": "Outcome_Physical",
"text": [
"Total mean weight loss"
],
"offsets": [
[
741,
763
]
],
"normalized": []
},
{
"id": "65731",
"type": "Outcome_Physical",
"text": [
"eating behavior self-efficacy"
],
"offsets": [
[
27,
56
]
],
"normalized": []
},
{
"id": "65732",
"type": "Outcome_Physical",
"text": [
"eating behavior self-efficacy"
],
"offsets": [
[
27,
56
]
],
"normalized": []
},
{
"id": "65733",
"type": "Outcome_Physical",
"text": [
"weight loss"
],
"offsets": [
[
64,
75
]
],
"normalized": []
},
{
"id": "65734",
"type": "Outcome_Physical",
"text": [
"eating behavior self-efficacy"
],
"offsets": [
[
27,
56
]
],
"normalized": []
},
{
"id": "65735",
"type": "Outcome_Physical",
"text": [
"eating behavior self-efficacy"
],
"offsets": [
[
27,
56
]
],
"normalized": []
},
{
"id": "65736",
"type": "Outcome_Physical",
"text": [
"weight"
],
"offsets": [
[
64,
70
]
],
"normalized": []
},
{
"id": "65737",
"type": "Participant_Age",
"text": [
"adults"
],
"offsets": [
[
561,
567
]
],
"normalized": []
},
{
"id": "65738",
"type": "Participant_Condition",
"text": [
"diets"
],
"offsets": [
[
636,
641
]
],
"normalized": []
},
{
"id": "65739",
"type": "Participant_Age",
"text": [
"."
],
"offsets": [
[
76,
77
]
],
"normalized": []
}
] | [] | [] | [] |
65740 | 2486557 | [
{
"id": "65741",
"type": "document",
"text": [
"The Randomised Intervention Treatment of Angina ( RITA ) Trial protocol : a long term study of coronary angioplasty and coronary artery bypass surgery in patients with angina . The Randomised Intervention Treatment of Angina ( RITA ) Trial is a prospective , randomised study to compare the short term and long term effects of percutaneous transluminal coronary angioplasty and coronary artery bypass surgery . During the study a register of patients undergoing coronary arteriography at the fourteen participating centres is being maintained to assess the overall context of patient recruitment . Patients with arteriographically proven coronary artery disease are considered for the trial if the participating cardiologist and surgeon agree that equivalent revascularisation could be achieved by either treatment method . Patients who satisfy the trial entry criteria are randomised to treatment by coronary angioplasty or coronary artery bypass surgery , with prospective stratification into groups with one , two , or three treatment vessels . Randomisation implies an intention to treat the patient by the assigned procedure and the analysis of long term results will include all randomised cases . The trial will recruit at least 1000 patients who will be followed for five years . The major trial end points include death , new myocardial infarction , and new coronary angioplasty or coronary artery bypass procedures . Other outcome measures include symptom and employment status , quality of life , exercise tolerance , and left ventricular function ."
],
"offsets": [
[
0,
1560
]
]
}
] | [
{
"id": "65742",
"type": "Intervention_Surgical",
"text": [
"coronary angioplasty"
],
"offsets": [
[
95,
115
]
],
"normalized": []
},
{
"id": "65743",
"type": "Intervention_Surgical",
"text": [
"coronary artery bypass surgery"
],
"offsets": [
[
120,
150
]
],
"normalized": []
},
{
"id": "65744",
"type": "Intervention_Surgical",
"text": [
"percutaneous transluminal coronary angioplasty"
],
"offsets": [
[
327,
373
]
],
"normalized": []
},
{
"id": "65745",
"type": "Intervention_Surgical",
"text": [
"coronary artery bypass surgery"
],
"offsets": [
[
120,
150
]
],
"normalized": []
},
{
"id": "65746",
"type": "Intervention_Physical",
"text": [
"coronary arteriography"
],
"offsets": [
[
462,
484
]
],
"normalized": []
},
{
"id": "65747",
"type": "Intervention_Surgical",
"text": [
"coronary angioplasty"
],
"offsets": [
[
95,
115
]
],
"normalized": []
},
{
"id": "65748",
"type": "Intervention_Surgical",
"text": [
"coronary artery bypass surgery"
],
"offsets": [
[
120,
150
]
],
"normalized": []
},
{
"id": "65749",
"type": "Intervention_Physical",
"text": [
"coronary angioplasty"
],
"offsets": [
[
95,
115
]
],
"normalized": []
},
{
"id": "65750",
"type": "Intervention_Physical",
"text": [
"coronary artery bypass procedures"
],
"offsets": [
[
1391,
1424
]
],
"normalized": []
},
{
"id": "65751",
"type": "Outcome_Mortality",
"text": [
"death"
],
"offsets": [
[
1323,
1328
]
],
"normalized": []
},
{
"id": "65752",
"type": "Outcome_Physical",
"text": [
"new myocardial infarction"
],
"offsets": [
[
1331,
1356
]
],
"normalized": []
},
{
"id": "65753",
"type": "Outcome_Physical",
"text": [
"new coronary angioplasty"
],
"offsets": [
[
1363,
1387
]
],
"normalized": []
},
{
"id": "65754",
"type": "Outcome_Physical",
"text": [
"coronary artery bypass procedures"
],
"offsets": [
[
1391,
1424
]
],
"normalized": []
},
{
"id": "65755",
"type": "Outcome_Other",
"text": [
"symptom and employment status"
],
"offsets": [
[
1458,
1487
]
],
"normalized": []
},
{
"id": "65756",
"type": "Outcome_Other",
"text": [
"quality of life"
],
"offsets": [
[
1490,
1505
]
],
"normalized": []
},
{
"id": "65757",
"type": "Outcome_Physical",
"text": [
"exercise tolerance"
],
"offsets": [
[
1508,
1526
]
],
"normalized": []
},
{
"id": "65758",
"type": "Outcome_Physical",
"text": [
"left ventricular function"
],
"offsets": [
[
1533,
1558
]
],
"normalized": []
},
{
"id": "65759",
"type": "Participant_Condition",
"text": [
"angina"
],
"offsets": [
[
168,
174
]
],
"normalized": []
},
{
"id": "65760",
"type": "Participant_Condition",
"text": [
"coronary arteriography"
],
"offsets": [
[
462,
484
]
],
"normalized": []
},
{
"id": "65761",
"type": "Participant_Condition",
"text": [
"arteriographically proven coronary artery disease"
],
"offsets": [
[
612,
661
]
],
"normalized": []
},
{
"id": "65762",
"type": "Participant_Sample-size",
"text": [
"1000"
],
"offsets": [
[
1236,
1240
]
],
"normalized": []
}
] | [] | [] | [] |
65763 | 24874588 | [
{
"id": "65764",
"type": "document",
"text": [
"Effects of surfactant on biofilm formation on silicone nasal splints . Biofilms are sessile communities of bacteria embedded in self-produced extracellular polysaccharide matrix and are considered to be responsible for bacterial infections in humans . Topical surfactant use on silicone nasal splints may have a preventive effect on biofilm formation . The objective of this study is to investigate the effect of surfactant-containing nasal solutions on biofilm formation over the surface of silicone nasal splints . Forty patients were randomized after septoplasty to receive surfactant-containing saline solution ( group 1 ) or saline without surfactant ( group 2 ) . At the postoperative 48th , 72th and 96th hours , pieces of splint samples were taken and prepared for scanning electron microscopic evaluation . Biofilm formation was observed in 3 , 6 and 14 of 20 samples in group 1 ( surfactant used ) and 3 , 14 and 20 of 20 samples in group 2 ( control ) at 48th , 72th and 96th hours , respectively . Biofilm formation incidences of groups at 48th hour were similar ( p > 0.05 ) , whereas it was significantly lower at group 1 regarding 72th and 96th hours ( p < 0.05 ) . Surfactant-containing nasal solutions have an inhibitory effect on biofilm formation over the surface of silicone nasal splints especially after 48 h. Surfactant-containing nasal solutions may have an important role in nasal septal dressing in the future ."
],
"offsets": [
[
0,
1437
]
]
}
] | [
{
"id": "65765",
"type": "Intervention_Pharmacological",
"text": [
"surfactant"
],
"offsets": [
[
11,
21
]
],
"normalized": []
},
{
"id": "65766",
"type": "Intervention_Physical",
"text": [
"silicone nasal splints"
],
"offsets": [
[
46,
68
]
],
"normalized": []
},
{
"id": "65767",
"type": "Intervention_Pharmacological",
"text": [
"Biofilms"
],
"offsets": [
[
71,
79
]
],
"normalized": []
},
{
"id": "65768",
"type": "Intervention_Surgical",
"text": [
"septoplasty"
],
"offsets": [
[
554,
565
]
],
"normalized": []
},
{
"id": "65769",
"type": "Intervention_Pharmacological",
"text": [
"surfactant-containing saline solution ( group"
],
"offsets": [
[
577,
622
]
],
"normalized": []
},
{
"id": "65770",
"type": "Intervention_Pharmacological",
"text": [
"saline without surfactant"
],
"offsets": [
[
630,
655
]
],
"normalized": []
},
{
"id": "65771",
"type": "Intervention_Pharmacological",
"text": [
"Surfactant-containing nasal solutions"
],
"offsets": [
[
1181,
1218
]
],
"normalized": []
},
{
"id": "65772",
"type": "Intervention_Pharmacological",
"text": [
"Surfactant-containing nasal solutions"
],
"offsets": [
[
1181,
1218
]
],
"normalized": []
},
{
"id": "65773",
"type": "Outcome_Other",
"text": [
"Effects of surfactant"
],
"offsets": [
[
0,
21
]
],
"normalized": []
},
{
"id": "65774",
"type": "Outcome_Physical",
"text": [
"biofilm formation ."
],
"offsets": [
[
333,
352
]
],
"normalized": []
},
{
"id": "65775",
"type": "Outcome_Physical",
"text": [
"biofilm formation"
],
"offsets": [
[
25,
42
]
],
"normalized": []
},
{
"id": "65776",
"type": "Outcome_Physical",
"text": [
"silicone nasal splints ."
],
"offsets": [
[
46,
70
]
],
"normalized": []
},
{
"id": "65777",
"type": "Outcome_Other",
"text": [
"scanning electron microscopic evaluation"
],
"offsets": [
[
773,
813
]
],
"normalized": []
},
{
"id": "65778",
"type": "Outcome_Physical",
"text": [
"Biofilm formation"
],
"offsets": [
[
816,
833
]
],
"normalized": []
},
{
"id": "65779",
"type": "Outcome_Physical",
"text": [
"Biofilm formation"
],
"offsets": [
[
816,
833
]
],
"normalized": []
},
{
"id": "65780",
"type": "Outcome_Physical",
"text": [
"biofilm formation"
],
"offsets": [
[
25,
42
]
],
"normalized": []
},
{
"id": "65781",
"type": "Outcome_Physical",
"text": [
"nasal septal dressing"
],
"offsets": [
[
1400,
1421
]
],
"normalized": []
},
{
"id": "65782",
"type": "Participant_Sample-size",
"text": [
"Forty patients"
],
"offsets": [
[
517,
531
]
],
"normalized": []
},
{
"id": "65783",
"type": "Participant_Condition",
"text": [
"septoplasty"
],
"offsets": [
[
554,
565
]
],
"normalized": []
}
] | [] | [] | [] |
65784 | 24878589 | [
{
"id": "65785",
"type": "document",
"text": [
"The effect of arm support combined with rehabilitation games on upper-extremity function in subacute stroke : a randomized controlled trial . BACKGROUND Use of rehabilitation technology , such as ( electro ) mechanical devices or robotics , could partly relieve the increasing strain on stroke rehabilitation caused by an increasing prevalence of stroke . Arm support ( AS ) training showed improvement of unsupported arm function in chronic stroke . OBJECTIVE To examine the effect of weight-supported arm training combined with computerized exercises on arm function and capacity , compared with dose-matched conventional reach training in subacute stroke patients . METHODS In a single-blind , multicenter , randomized controlled trial , 70 subacute stroke patients received 6 weeks of training with either an AS device combined with computerized exercises or dose-matched conventional training ( CON ) . Arm function was evaluated pretraining and posttraining by Fugl-Meyer assessment ( FM ) , maximal reach distance , Stroke Upper Limb Capacity Scale ( SULCS ) , and arm pain via Visual Analogue Scale , in addition to perceived motivation by Intrinsic Motivation Inventory posttraining . RESULTS FM and SULCS scores and reach distance improved significantly within both groups . These improvements and experienced pain did not differ between groups . The AS group reported higher interest/enjoyment during training than the CON group . CONCLUSIONS AS training with computerized exercises is as effective as conventional therapy dedicated to the arm to improve arm function and activity in subacute stroke rehabilitation , when applied at the same dose ."
],
"offsets": [
[
0,
1659
]
]
}
] | [
{
"id": "65786",
"type": "Intervention_Physical",
"text": [
"arm support combined with rehabilitation games"
],
"offsets": [
[
14,
60
]
],
"normalized": []
},
{
"id": "65787",
"type": "Intervention_Physical",
"text": [
"rehabilitation technology"
],
"offsets": [
[
160,
185
]
],
"normalized": []
},
{
"id": "65788",
"type": "Intervention_Educational",
"text": [
"("
],
"offsets": [
[
196,
197
]
],
"normalized": []
},
{
"id": "65789",
"type": "Intervention_Physical",
"text": [
"electro ) mechanical devices or robotics"
],
"offsets": [
[
198,
238
]
],
"normalized": []
},
{
"id": "65790",
"type": "Intervention_Physical",
"text": [
"Arm support ( AS ) training"
],
"offsets": [
[
356,
383
]
],
"normalized": []
},
{
"id": "65791",
"type": "Intervention_Physical",
"text": [
"weight-supported arm training"
],
"offsets": [
[
486,
515
]
],
"normalized": []
},
{
"id": "65792",
"type": "Intervention_Educational",
"text": [
"computerized exercises"
],
"offsets": [
[
530,
552
]
],
"normalized": []
},
{
"id": "65793",
"type": "Intervention_Educational",
"text": [
"conventional reach training"
],
"offsets": [
[
611,
638
]
],
"normalized": []
},
{
"id": "65794",
"type": "Intervention_Educational",
"text": [
"training"
],
"offsets": [
[
375,
383
]
],
"normalized": []
},
{
"id": "65795",
"type": "Intervention_Educational",
"text": [
"AS device combined with"
],
"offsets": [
[
813,
836
]
],
"normalized": []
},
{
"id": "65796",
"type": "Intervention_Physical",
"text": [
"computerized exercises"
],
"offsets": [
[
530,
552
]
],
"normalized": []
},
{
"id": "65797",
"type": "Intervention_Educational",
"text": [
"or"
],
"offsets": [
[
22,
24
]
],
"normalized": []
},
{
"id": "65798",
"type": "Intervention_Control",
"text": [
"dose-matched conventional training ( CON )"
],
"offsets": [
[
863,
905
]
],
"normalized": []
},
{
"id": "65799",
"type": "Intervention_Physical",
"text": [
"training with computerized exercises"
],
"offsets": [
[
1457,
1493
]
],
"normalized": []
},
{
"id": "65800",
"type": "Outcome_Physical",
"text": [
"upper-extremity function"
],
"offsets": [
[
64,
88
]
],
"normalized": []
},
{
"id": "65801",
"type": "Outcome_Physical",
"text": [
"arm function"
],
"offsets": [
[
418,
430
]
],
"normalized": []
},
{
"id": "65802",
"type": "Outcome_Physical",
"text": [
"arm function"
],
"offsets": [
[
418,
430
]
],
"normalized": []
},
{
"id": "65803",
"type": "Outcome_Physical",
"text": [
"capacity"
],
"offsets": [
[
573,
581
]
],
"normalized": []
},
{
"id": "65804",
"type": "Outcome_Pain",
"text": [
"Fugl-Meyer assessment ( FM )"
],
"offsets": [
[
967,
995
]
],
"normalized": []
},
{
"id": "65805",
"type": "Outcome_Pain",
"text": [
"maximal reach distance"
],
"offsets": [
[
998,
1020
]
],
"normalized": []
},
{
"id": "65806",
"type": "Outcome_Pain",
"text": [
"Stroke Upper Limb Capacity Scale ( SULCS )"
],
"offsets": [
[
1023,
1065
]
],
"normalized": []
},
{
"id": "65807",
"type": "Outcome_Pain",
"text": [
"arm pain via Visual Analogue Scale"
],
"offsets": [
[
1072,
1106
]
],
"normalized": []
},
{
"id": "65808",
"type": "Outcome_Physical",
"text": [
"FM"
],
"offsets": [
[
991,
993
]
],
"normalized": []
},
{
"id": "65809",
"type": "Outcome_Physical",
"text": [
"SULCS scores"
],
"offsets": [
[
1209,
1221
]
],
"normalized": []
},
{
"id": "65810",
"type": "Outcome_Physical",
"text": [
"reach distance"
],
"offsets": [
[
1006,
1020
]
],
"normalized": []
},
{
"id": "65811",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
1076,
1080
]
],
"normalized": []
},
{
"id": "65812",
"type": "Outcome_Other",
"text": [
"higher interest/enjoyment"
],
"offsets": [
[
1379,
1404
]
],
"normalized": []
},
{
"id": "65813",
"type": "Outcome_Physical",
"text": [
"arm function"
],
"offsets": [
[
418,
430
]
],
"normalized": []
},
{
"id": "65814",
"type": "Outcome_Physical",
"text": [
"activity"
],
"offsets": [
[
1583,
1591
]
],
"normalized": []
},
{
"id": "65815",
"type": "Participant_Condition",
"text": [
"subacute stroke :"
],
"offsets": [
[
92,
109
]
],
"normalized": []
},
{
"id": "65816",
"type": "Participant_Condition",
"text": [
"subacute stroke patients ."
],
"offsets": [
[
642,
668
]
],
"normalized": []
},
{
"id": "65817",
"type": "Participant_Sample-size",
"text": [
"70"
],
"offsets": [
[
741,
743
]
],
"normalized": []
},
{
"id": "65818",
"type": "Participant_Condition",
"text": [
"subacute stroke"
],
"offsets": [
[
92,
107
]
],
"normalized": []
}
] | [] | [] | [] |
65819 | 24885187 | [
{
"id": "65820",
"type": "document",
"text": [
"Quantitative measurements of HER2 and phospho-HER2 expression : correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab . BACKGROUND Preoperative therapy with chemotherapy and the HER2-targeted monoclonal antibody trastuzumab is valuable for patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers but traditional methods of measuring HER2 expression do not accurately stratify patients for likelihood of response . Quantitative immunofluorescent approaches have the potential to provide a mathematically continuous measure of HER2 . Here we seek to determine whether quantitative measurement of HER2 or phospho-HER2 correlates with likelihood of response to trastuzumab- containing neoadjuvant therapy . METHODS We evaluated core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) ) . Tumor core biopsies were taken before initiation of treatment and 9-13 days after patients received \" run-in \" doses of either single agent trastuzumab or nab-paclitaxel . The AQUA method of quantitative immunofluorescence was used for analysis of in situ protein expression . Patients then received 18 weeks of treatment , followed by surgery to assess pathologic response to the neoadjuvant regimen . RESULTS A HER2 score of 2111 by AQUA analysis has been shown to be equivalent to HER2 3+ by immunohistochemical staining in previous studies . Of 20 evaluable patients , 10 cases who achieved a pathologic complete response ( pathCR ) with neoadjuvant treatment had a mean HER2 level of 10251 compared with 4766 in the patients without pathCR ( p = 0.0021 ) . Measurement of phospho-HER2 showed no difference in pathCR vs non-pathCR groups . In 9 patients who had HER2 levels repeated after a single treatment with trastuzumab there was no evidence of a reduction in the HER2 or phospho-HER2 levels following that exposure . CONCLUSIONS High levels of HER2 are associated with achievement of a pathCR in the preoperative setting , while levels of Phospho-HER2 were not predictive of response . This data suggests that accurate measurement of HER2 may help determine the likelihood of response in the pre-surgical setting . Further validation in larger cohorts is required , but this pilot data shows the feasibility of this approach ."
],
"offsets": [
[
0,
2416
]
]
}
] | [
{
"id": "65821",
"type": "Intervention_Pharmacological",
"text": [
"neoadjuvant chemotherapy and trastuzumab"
],
"offsets": [
[
104,
144
]
],
"normalized": []
},
{
"id": "65822",
"type": "Intervention_Pharmacological",
"text": [
"Preoperative therapy with chemotherapy"
],
"offsets": [
[
158,
196
]
],
"normalized": []
},
{
"id": "65823",
"type": "Intervention_Pharmacological",
"text": [
"HER2-targeted monoclonal antibody trastuzumab"
],
"offsets": [
[
205,
250
]
],
"normalized": []
},
{
"id": "65824",
"type": "Intervention_Pharmacological",
"text": [
"trastuzumab , nab-paclitaxel and carboplatin combination therapy"
],
"offsets": [
[
879,
943
]
],
"normalized": []
},
{
"id": "65825",
"type": "Intervention_Pharmacological",
"text": [
"trastuzumab"
],
"offsets": [
[
133,
144
]
],
"normalized": []
},
{
"id": "65826",
"type": "Intervention_Pharmacological",
"text": [
"nab-paclitaxel"
],
"offsets": [
[
893,
907
]
],
"normalized": []
},
{
"id": "65827",
"type": "Outcome_Physical",
"text": [
"pathologic response"
],
"offsets": [
[
81,
100
]
],
"normalized": []
},
{
"id": "65828",
"type": "Outcome_Physical",
"text": [
"pathologic complete response ( pathCR )"
],
"offsets": [
[
1577,
1616
]
],
"normalized": []
},
{
"id": "65829",
"type": "Outcome_Physical",
"text": [
"Measurement of phospho-HER2"
],
"offsets": [
[
1742,
1769
]
],
"normalized": []
},
{
"id": "65830",
"type": "Outcome_Physical",
"text": [
"in the HER2 or phospho-HER2 levels"
],
"offsets": [
[
1946,
1980
]
],
"normalized": []
},
{
"id": "65831",
"type": "Outcome_Physical",
"text": [
"High levels of"
],
"offsets": [
[
2019,
2033
]
],
"normalized": []
},
{
"id": "65832",
"type": "Outcome_Physical",
"text": [
"levels of Phospho-HER2"
],
"offsets": [
[
2119,
2141
]
],
"normalized": []
},
{
"id": "65833",
"type": "Participant_Condition",
"text": [
"patients with large or locally advanced HER2-positive ( HER2+ ) breast cancers"
],
"offsets": [
[
267,
345
]
],
"normalized": []
},
{
"id": "65834",
"type": "Participant_Condition",
"text": [
"core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab , nab-paclitaxel and carboplatin combination therapy ( BrUOG BR-211B ( NCT00617942 ) )"
],
"offsets": [
[
774,
977
]
],
"normalized": []
}
] | [] | [] | [] |
65835 | 24885551 | [
{
"id": "65836",
"type": "document",
"text": [
"Efficacy and cost-effectiveness of an experimental short-term inpatient Dialectical Behavior Therapy ( DBT ) program : study protocol for a randomized controlled trial . BACKGROUND Borderline Personality Disorder ( BPD ) is a serious psychiatric condition associated with substantial mortality , burden and public health costs . DBT is the treatment model with the largest number of published research articles showing effectiveness . However , some patients are not sufficiently engaged in outpatient treatment while presenting severe parasuicidal behavior , making hospitalization necessary . The Center for Personality Disorders Jelgersma developed an intensive 12-week inpatient DBT program that ( i ) rapidly reduces core borderline symptoms like suicidal behavior , ( ii ) minimizes the negative effects of an inpatient setting , and ( iii ) enhances compliance with outpatient treatment . We evaluate the ( cost- ) effectiveness of this experimental program . METHODS/DESIGN Seventy patients , aged 18 to 45 years with a primary diagnosis of BPD , showing a chronic pattern of parasuicidal gestures and/or reporting high degrees of severity of other borderline symptoms , are randomly allocated to the control and intervention groups . Subjects in the control group receive standard outpatient DBT , provided in one of three regular mental health settings in GGZ Rivierduinen . Subjects in the intervention group receive 12 weeks of intensified inpatient DBT plus six months of standard DBT , provided in the Center for Personality Disorders Jelgersma . The primary outcome is the number of suicide attempts/self-harming acts . Secondary outcomes are severity of other borderline complaints , quality of life , general psychopathological symptoms and health care utilization and productivity costs . Data are gathered using a prospective , two ( group : intervention and control ) by five ( time of measurement ) repeated measures factorial design.Participants will complete three-monthly outcome assessments in the course of therapy : at baseline , and 12 , 24 , 36 and 52 weeks after the start of the treatment . The period of recruitment started in March 2012 and the study will end in December 2014 . DISCUSSION Highly suicidal outpatient patients can pose a dilemma for mental health care professionals . Although hospitalization seems inevitable under some circumstances , it has proven to be harmful in its own right . This paper outlines the background and methods of a randomized trial evaluating the possible surplus value of a short-term inpatient DBT program ."
],
"offsets": [
[
0,
2579
]
]
}
] | [
{
"id": "65837",
"type": "Intervention_Educational",
"text": [
"inpatient Dialectical Behavior Therapy ( DBT )"
],
"offsets": [
[
62,
108
]
],
"normalized": []
},
{
"id": "65838",
"type": "Outcome_Other",
"text": [
"Efficacy and cost-effectiveness"
],
"offsets": [
[
0,
31
]
],
"normalized": []
},
{
"id": "65839",
"type": "Outcome_Other",
"text": [
"( cost- ) effectiveness"
],
"offsets": [
[
912,
935
]
],
"normalized": []
},
{
"id": "65840",
"type": "Outcome_Mental",
"text": [
"the number of suicide attempts/self-harming acts"
],
"offsets": [
[
1584,
1632
]
],
"normalized": []
},
{
"id": "65841",
"type": "Outcome_Mental",
"text": [
"severity of other borderline complaints , quality of life , general psychopathological symptoms"
],
"offsets": [
[
1658,
1753
]
],
"normalized": []
},
{
"id": "65842",
"type": "Outcome_Other",
"text": [
"health care utilization and productivity costs"
],
"offsets": [
[
1758,
1804
]
],
"normalized": []
},
{
"id": "65843",
"type": "Participant_Condition",
"text": [
"Borderline Personality Disorder ( BPD )"
],
"offsets": [
[
181,
220
]
],
"normalized": []
},
{
"id": "65844",
"type": "Participant_Age",
"text": [
"aged 18 to 45 years"
],
"offsets": [
[
1001,
1020
]
],
"normalized": []
},
{
"id": "65845",
"type": "Participant_Condition",
"text": [
"GGZ Rivierduinen"
],
"offsets": [
[
1366,
1382
]
],
"normalized": []
},
{
"id": "65846",
"type": "Participant_Condition",
"text": [
"Personality Disorders Jelgersma"
],
"offsets": [
[
610,
641
]
],
"normalized": []
},
{
"id": "65847",
"type": "Participant_Condition",
"text": [
"Highly suicidal outpatient"
],
"offsets": [
[
2223,
2249
]
],
"normalized": []
}
] | [] | [] | [] |
65848 | 24886549 | [
{
"id": "65849",
"type": "document",
"text": [
"Impact of additional counselling sessions through phone calls on smoking cessation outcomes among smokers in Penang State , Malaysia . BACKGROUND Studies all over the world reported that smoking relapses occur during the first two weeks after a quit date . The current study aimed to assess the impact of the additional phone calls counselling during the first month on the abstinence rate at 3 and 6 months after quit date among smokers in Penang , Malaysia . METHODS The study was conducted at Quit Smoking Clinic of two major hospitals in Penang , Malaysia . All the eligible smokers who attended the clinics between February 1st and October 31st 2012 were invited . Participants were randomly assigned by using urn design method either to receive the usual care that followed in the clinics ( control ) or the usual care procedure plus extra counselling sessions through phone calls during the first month of quit attempt ( intervention ) . RESULTS Participants in our cohort smoked about 14 cigarettes per day on average ( mean = 13.78 ± 7.0 ) . At 3 months , control group was less likely to quit smoking compared to intervention group ( 36.9 % vs. 46.7 % , verified smoking status ) but this did not reach statistical significance ( OR = 0.669 ; 95 % CI = 0.395-1.133 , P = 0.86 ) . However , at 6 months , 71.7 % of the intervention group were successfully quit smoking ( bio-chemically verified ) compared to 48.6 % of the control group ( P < 0.001 ) . The control group were significantly less likely to quit smoking ( OR = 0.375 ; 95 % CI = 0.217-0.645 , P < 0.001 ) . CONCLUSIONS Smoking cessation intervention consisting of phone calls counselling delivered during the first month of quit attempt revealed significantly higher abstinence rates compared with a standard care approach . Therefore , the additional counselling in the first few weeks after stop smoking is a promising treatment strategy that should be evaluated further . TRIAL REGISTRATION TCTR20140504001 ."
],
"offsets": [
[
0,
1984
]
]
}
] | [
{
"id": "65850",
"type": "Intervention_Educational",
"text": [
"additional counselling sessions through phone calls"
],
"offsets": [
[
10,
61
]
],
"normalized": []
},
{
"id": "65851",
"type": "Intervention_Educational",
"text": [
"additional phone calls counselling"
],
"offsets": [
[
309,
343
]
],
"normalized": []
},
{
"id": "65852",
"type": "Outcome_Mental",
"text": [
"smoking cessation outcomes"
],
"offsets": [
[
65,
91
]
],
"normalized": []
},
{
"id": "65853",
"type": "Outcome_Mental",
"text": [
"abstinence rate"
],
"offsets": [
[
374,
389
]
],
"normalized": []
},
{
"id": "65854",
"type": "Outcome_Other",
"text": [
"less likely to quit"
],
"offsets": [
[
1083,
1102
]
],
"normalized": []
},
{
"id": "65855",
"type": "Outcome_Mental",
"text": [
"group were successfully quit smoking ( bio-chemically"
],
"offsets": [
[
1341,
1394
]
],
"normalized": []
},
{
"id": "65856",
"type": "Outcome_Other",
"text": [
"significantly"
],
"offsets": [
[
1485,
1498
]
],
"normalized": []
},
{
"id": "65857",
"type": "Participant_Condition",
"text": [
"smokers in Penang State , Malaysia"
],
"offsets": [
[
98,
132
]
],
"normalized": []
},
{
"id": "65858",
"type": "Participant_Condition",
"text": [
"among smokers in Penang , Malaysia"
],
"offsets": [
[
424,
458
]
],
"normalized": []
},
{
"id": "65859",
"type": "Participant_Condition",
"text": [
"The study was conducted at Quit Smoking Clinic of two major hospitals in Penang , Malaysia"
],
"offsets": [
[
469,
559
]
],
"normalized": []
},
{
"id": "65860",
"type": "Participant_Condition",
"text": [
"All the eligible smokers who attended the clinics between February 1st and October 31st 2012 were invited"
],
"offsets": [
[
562,
667
]
],
"normalized": []
},
{
"id": "65861",
"type": "Participant_Condition",
"text": [
"RESULTS Participants in our cohort smoked about"
],
"offsets": [
[
945,
992
]
],
"normalized": []
},
{
"id": "65862",
"type": "Participant_Condition",
"text": [
"cigarettes per day on average ( mean = 13.78 ± 7.0 )"
],
"offsets": [
[
996,
1048
]
],
"normalized": []
}
] | [] | [] | [] |
65863 | 24887304 | [
{
"id": "65864",
"type": "document",
"text": [
"Effects of ranolazine on quality of life among patients with diabetes mellitus and stable angina ."
],
"offsets": [
[
0,
98
]
]
}
] | [
{
"id": "65865",
"type": "Intervention_Pharmacological",
"text": [
"ranolazine"
],
"offsets": [
[
11,
21
]
],
"normalized": []
},
{
"id": "65866",
"type": "Outcome_Other",
"text": [
"quality of life"
],
"offsets": [
[
25,
40
]
],
"normalized": []
},
{
"id": "65867",
"type": "Participant_Condition",
"text": [
"patients with diabetes mellitus and stable angina"
],
"offsets": [
[
47,
96
]
],
"normalized": []
}
] | [] | [] | [] |
65868 | 24897394 | [
{
"id": "65869",
"type": "document",
"text": [
"The effect of the use of oxytocin on blood loss during different postpartum periods . OBJECTIVE Postpartum hemorrhage is the most important reason for maternal mortality . In developed countries , the reason of 13 % of maternal deaths is postpartum hemorrhage while this percentage reaches more than 30 % in other countries . In this study , the effect of oxytocin use in different times at the 3rd stage of delivery on changes in the postpartum hemoglobin levels was compared . DESIGN AND SETTING In the study , 89 pregnant women to whom oxytocin was administered after placenta separation were studied in Group 1 , 89 pregnant women were included in Group 2 , and oxytocin was administered after delivery of the shoulder . The levels of hemoglobin and hematocrit before and after delivery were quantified . RESULTS The biochemical parameters were examined , there was no significant statistical differences in the levels of hemoglobin and hemotocrit before delivery between the two groups . When compared to Group 1 , Δ-hemoglobin ( P= > 0.001 ) , Δ-hematocrit ( P= > 0.001 ) , the change between the prepartum and postpartum hemoglobin percentage ( P < =0.001 ) , and change between the prepartum and postpartum hemotocrit percentage ( P < =0.001 ) were statistically lower in Group 2 . CONCLUSIONS It was determined that the use of oxytocin after shoulder delivery has more effects on decreasing the amount of postpartum hemorrhage ."
],
"offsets": [
[
0,
1437
]
]
}
] | [
{
"id": "65870",
"type": "Intervention_Pharmacological",
"text": [
"oxytocin"
],
"offsets": [
[
25,
33
]
],
"normalized": []
},
{
"id": "65871",
"type": "Intervention_Pharmacological",
"text": [
"oxytocin"
],
"offsets": [
[
25,
33
]
],
"normalized": []
},
{
"id": "65872",
"type": "Intervention_Pharmacological",
"text": [
"oxytocin was administered after placenta separation"
],
"offsets": [
[
539,
590
]
],
"normalized": []
},
{
"id": "65873",
"type": "Intervention_Pharmacological",
"text": [
"oxytocin was administered after delivery of the shoulder"
],
"offsets": [
[
666,
722
]
],
"normalized": []
},
{
"id": "65874",
"type": "Outcome_Physical",
"text": [
"blood loss during different postpartum periods"
],
"offsets": [
[
37,
83
]
],
"normalized": []
},
{
"id": "65875",
"type": "Outcome_Physical",
"text": [
"postpartum hemoglobin levels"
],
"offsets": [
[
435,
463
]
],
"normalized": []
},
{
"id": "65876",
"type": "Outcome_Physical",
"text": [
"levels of hemoglobin and hematocrit"
],
"offsets": [
[
729,
764
]
],
"normalized": []
},
{
"id": "65877",
"type": "Outcome_Physical",
"text": [
"levels of hemoglobin and hemotocrit"
],
"offsets": [
[
916,
951
]
],
"normalized": []
},
{
"id": "65878",
"type": "Outcome_Physical",
"text": [
"the prepartum and postpartum hemoglobin percentage"
],
"offsets": [
[
1099,
1149
]
],
"normalized": []
},
{
"id": "65879",
"type": "Outcome_Physical",
"text": [
"the prepartum and postpartum hemotocrit percentage"
],
"offsets": [
[
1186,
1236
]
],
"normalized": []
},
{
"id": "65880",
"type": "Outcome_Physical",
"text": [
"of postpartum hemorrhage"
],
"offsets": [
[
1411,
1435
]
],
"normalized": []
},
{
"id": "65881",
"type": "Participant_Condition",
"text": [
"Postpartum hemorrhage"
],
"offsets": [
[
96,
117
]
],
"normalized": []
},
{
"id": "65882",
"type": "Participant_Sample-size",
"text": [
"89"
],
"offsets": [
[
513,
515
]
],
"normalized": []
},
{
"id": "65883",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
525,
530
]
],
"normalized": []
},
{
"id": "65884",
"type": "Participant_Sample-size",
"text": [
"89 pregnant"
],
"offsets": [
[
513,
524
]
],
"normalized": []
},
{
"id": "65885",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
525,
530
]
],
"normalized": []
}
] | [] | [] | [] |
65886 | 24898318 | [
{
"id": "65887",
"type": "document",
"text": [
"Improving adolescent social competence and behavior : a randomized trial of an 11-week equine facilitated learning prevention program . There is growing evidence that promoting social competence in youth is an effective strategy to prevent mental , emotional , and behavioral disorders in adulthood . Research suggests that programs delivered in collaboration with schools are particularly effective when they target social and emotional skill building , utilize an interactive instructional style , provide opportunities for youth participation and self-direction , and include explicit attempts to enhance youth social competence . A relatively new but popular approach that incorporates these characteristics is human animal interaction , which can be implemented in educational settings . We report the results from a randomized clinical trial examining the effects of an 11-week equine facilitated learning ( EFL ) program on the social competence and behavior of 5th-8th grade children . Children ( N = 131 ) were recruited through referral by school counselors and school-based recruitment and then screened for low social competence . Researchers randomly assigned children to an experimental ( n = 53 ) or waitlisted control group ( n = 60 ) . Children in the experimental group participated in an 11-week EFL program consisting of once-weekly , 90-min sessions of individual and team-focused activities , whereas children in the control group served as a wait-listed control and participated 16 weeks later . Parents of children in both groups rated child social competence at pretest and posttest . Three independent raters observed and reported children 's positive and negative behavior using a validated checklist during each weekly session . Results indicated that program participation had a moderate treatment effect ( d = .55 ) on social competence ( p = .02 ) that was independent of pretest levels , age , gender , and referral status . Results showed that higher levels of program attendance predicted children 's trajectories of observed positive ( β = .500 ; p = .003 ) and negative behavior ( β = -.062 ; p < .001 ) over the 11-week program ."
],
"offsets": [
[
0,
2166
]
]
}
] | [
{
"id": "65888",
"type": "Intervention_Psychological",
"text": [
"equine facilitated learning prevention program"
],
"offsets": [
[
87,
133
]
],
"normalized": []
},
{
"id": "65889",
"type": "Intervention_Educational",
"text": [
"promoting social competence"
],
"offsets": [
[
167,
194
]
],
"normalized": []
},
{
"id": "65890",
"type": "Intervention_Educational",
"text": [
"human animal interaction"
],
"offsets": [
[
715,
739
]
],
"normalized": []
},
{
"id": "65891",
"type": "Intervention_Educational",
"text": [
"11-week equine facilitated learning ( EFL ) program"
],
"offsets": [
[
876,
927
]
],
"normalized": []
},
{
"id": "65892",
"type": "Intervention_Control",
"text": [
"waitlisted control group"
],
"offsets": [
[
1215,
1239
]
],
"normalized": []
},
{
"id": "65893",
"type": "Intervention_Psychological",
"text": [
"EFL program"
],
"offsets": [
[
1315,
1326
]
],
"normalized": []
},
{
"id": "65894",
"type": "Intervention_Control",
"text": [
"control group"
],
"offsets": [
[
1226,
1239
]
],
"normalized": []
},
{
"id": "65895",
"type": "Intervention_Control",
"text": [
"wait-listed control"
],
"offsets": [
[
1465,
1484
]
],
"normalized": []
},
{
"id": "65896",
"type": "Outcome_Mental",
"text": [
"child social competence"
],
"offsets": [
[
1560,
1583
]
],
"normalized": []
},
{
"id": "65897",
"type": "Outcome_Mental",
"text": [
"children 's positive and negative behavior"
],
"offsets": [
[
1657,
1699
]
],
"normalized": []
},
{
"id": "65898",
"type": "Outcome_Mental",
"text": [
"Results indicated that program participation had a moderate treatment effect ( d = .55 ) on social competence ( p = .02 ) that was independent of pretest levels , age , gender , and referral status ."
],
"offsets": [
[
1757,
1956
]
],
"normalized": []
},
{
"id": "65899",
"type": "Participant_Age",
"text": [
"adolescent"
],
"offsets": [
[
10,
20
]
],
"normalized": []
},
{
"id": "65900",
"type": "Participant_Age",
"text": [
"youth"
],
"offsets": [
[
198,
203
]
],
"normalized": []
},
{
"id": "65901",
"type": "Participant_Age",
"text": [
"5th-8th grade children"
],
"offsets": [
[
969,
991
]
],
"normalized": []
},
{
"id": "65902",
"type": "Participant_Age",
"text": [
"Children"
],
"offsets": [
[
994,
1002
]
],
"normalized": []
},
{
"id": "65903",
"type": "Participant_Sample-size",
"text": [
"131"
],
"offsets": [
[
1009,
1012
]
],
"normalized": []
}
] | [] | [] | [] |
65904 | 24898574 | [
{
"id": "65905",
"type": "document",
"text": [
"Changes in motor cortex excitability associated with temporal repetitive transcranial magnetic stimulation in tinnitus : hints for cross-modal plasticity ? BACKGROUND Motor cortex excitability was found to be changed after repetitive transcranial magnetic stimulation ( rTMS ) of the temporal cortex highlighting the occurrence of cross-modal plasticity in non-invasive brain stimulation . Here , we investigated the effects of temporal low-frequency rTMS on motor cortex plasticity in a large sample of tinnitus patients . In 116 patients with chronic tinnitus different parameters of cortical excitability were assessed before and after ten rTMS treatment sessions . Patients received one of three different protocols all including 1 Hz rTMS over the left temporal cortex . Treatment response was defined as improvement by at least five points in the tinnitus questionnaire ( TQ ) . Variables of interest were resting motor threshold ( RMT ) , short-interval intra-cortical inhibition ( SICI ) , intracortical facilitation ( ICF ) , and cortical silent period ( CSP ) . RESULTS After rTMS treatment RMT was decreased by about 1 % of stimulator output near-significantly in the whole group of patients . SICI was associated with significant changes with respect to treatment response . The group of treatment responders showed a decrease of SICI over the course of treatment , the group of non-responders the reverse pattern . CONCLUSIONS Minor RMT changes during rTMS treatment do not necessarily suggest the need for systematic re-examination of the RMT for safety and efficacy issues . Treatment response to rTMS was shown to be related to changes in SICI that might reflect modulation of GABAergic mechanisms directly or indirectly related to rTMS treatment effects ."
],
"offsets": [
[
0,
1772
]
]
}
] | [
{
"id": "65906",
"type": "Intervention_Physical",
"text": [
"temporal repetitive transcranial magnetic stimulation"
],
"offsets": [
[
53,
106
]
],
"normalized": []
},
{
"id": "65907",
"type": "Intervention_Physical",
"text": [
"repetitive transcranial magnetic stimulation ( rTMS )"
],
"offsets": [
[
223,
276
]
],
"normalized": []
},
{
"id": "65908",
"type": "Intervention_Physical",
"text": [
"temporal low-frequency rTMS"
],
"offsets": [
[
428,
455
]
],
"normalized": []
},
{
"id": "65909",
"type": "Intervention_Physical",
"text": [
"rTMS"
],
"offsets": [
[
270,
274
]
],
"normalized": []
},
{
"id": "65910",
"type": "Intervention_Physical",
"text": [
"rTMS"
],
"offsets": [
[
270,
274
]
],
"normalized": []
},
{
"id": "65911",
"type": "Intervention_Physical",
"text": [
"rTMS"
],
"offsets": [
[
270,
274
]
],
"normalized": []
},
{
"id": "65912",
"type": "Intervention_Physical",
"text": [
"rTMS"
],
"offsets": [
[
270,
274
]
],
"normalized": []
},
{
"id": "65913",
"type": "Outcome_Physical",
"text": [
"resting motor threshold ( RMT )"
],
"offsets": [
[
912,
943
]
],
"normalized": []
},
{
"id": "65914",
"type": "Outcome_Physical",
"text": [
"short-interval intra-cortical inhibition ( SICI )"
],
"offsets": [
[
946,
995
]
],
"normalized": []
},
{
"id": "65915",
"type": "Outcome_Physical",
"text": [
"intracortical facilitation ( ICF )"
],
"offsets": [
[
998,
1032
]
],
"normalized": []
},
{
"id": "65916",
"type": "Outcome_Physical",
"text": [
"cortical silent period ( CSP )"
],
"offsets": [
[
1039,
1069
]
],
"normalized": []
},
{
"id": "65917",
"type": "Outcome_Physical",
"text": [
"RMT was decreased"
],
"offsets": [
[
1101,
1118
]
],
"normalized": []
},
{
"id": "65918",
"type": "Outcome_Physical",
"text": [
"SICI"
],
"offsets": [
[
989,
993
]
],
"normalized": []
},
{
"id": "65919",
"type": "Outcome_Physical",
"text": [
"decrease of SICI"
],
"offsets": [
[
1330,
1346
]
],
"normalized": []
},
{
"id": "65920",
"type": "Outcome_Physical",
"text": [
"Minor RMT changes"
],
"offsets": [
[
1440,
1457
]
],
"normalized": []
},
{
"id": "65921",
"type": "Participant_Condition",
"text": [
"tinnitus"
],
"offsets": [
[
110,
118
]
],
"normalized": []
},
{
"id": "65922",
"type": "Participant_Condition",
"text": [
"tinnitus"
],
"offsets": [
[
110,
118
]
],
"normalized": []
},
{
"id": "65923",
"type": "Participant_Sample-size",
"text": [
"116"
],
"offsets": [
[
527,
530
]
],
"normalized": []
},
{
"id": "65924",
"type": "Participant_Condition",
"text": [
"tinnitus"
],
"offsets": [
[
110,
118
]
],
"normalized": []
}
] | [] | [] | [] |
65925 | 24898665 | [
{
"id": "65926",
"type": "document",
"text": [
"Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab ."
],
"offsets": [
[
0,
115
]
]
}
] | [
{
"id": "65927",
"type": "Intervention_Pharmacological",
"text": [
"rituximab"
],
"offsets": [
[
56,
65
]
],
"normalized": []
},
{
"id": "65928",
"type": "Intervention_Pharmacological",
"text": [
"tositumomab"
],
"offsets": [
[
73,
84
]
],
"normalized": []
},
{
"id": "65929",
"type": "Intervention_Pharmacological",
"text": [
"iodine I-131 tositumomab"
],
"offsets": [
[
89,
113
]
],
"normalized": []
},
{
"id": "65930",
"type": "Participant_Condition",
"text": [
"with relapsed follicular lymphoma"
],
"offsets": [
[
9,
42
]
],
"normalized": []
}
] | [] | [] | [] |
65931 | 24902456 | [
{
"id": "65932",
"type": "document",
"text": [
"Evaluation of postprocedure cognitive function using 3 distinct standard sedation regimens for endoscopic procedures . The primary purpose of this investigation was to evaluate postprocedure cognitive function associated with 3 distinct standard sedation regimens used for endoscopic procedures . A secondary aim was to identify complications requiring provider interventions . Subjects scheduled for colonoscopies were approached for enrollment the day of their procedure . A convenience sample of 96 subjects was randomly assigned . Cognitive function was recorded on the day of surgery using the Mini-Mental State Examination ( MMSE ) and 24 and 48 hours postoperatively using the Telephone Interview of Cognitive Status ( TICS ) . The propofol plus fentanyl group had a mean TICS score of 34.53 at 24 hours compared with 34.96 at 48 hours ( P = .017 ) . The midazolam plus fentanyl group had a mean TICS score of 34.76 at 24 hours compared with 36.26 at 48 hours ( P = .004 ) . The propofol-alone group had a mean TICS score of 35.09 at 24 hours compared with 35.98 at 48 hours ( P = .924 ) . The results of this investigation indicate that the sedation regimen of propofol alone has the least impact on postprocedure cognitive function . Additionally , the number of jaw lift interventions was significantly higher in both groups who received fentanyl ."
],
"offsets": [
[
0,
1358
]
]
}
] | [
{
"id": "65933",
"type": "Intervention_Physical",
"text": [
"sedation regimens"
],
"offsets": [
[
73,
90
]
],
"normalized": []
},
{
"id": "65934",
"type": "Intervention_Physical",
"text": [
"standard sedation regimens"
],
"offsets": [
[
64,
90
]
],
"normalized": []
},
{
"id": "65935",
"type": "Intervention_Educational",
"text": [
"Mini-Mental State Examination"
],
"offsets": [
[
599,
628
]
],
"normalized": []
},
{
"id": "65936",
"type": "Intervention_Educational",
"text": [
"Telephone Interview of Cognitive Status"
],
"offsets": [
[
684,
723
]
],
"normalized": []
},
{
"id": "65937",
"type": "Intervention_Pharmacological",
"text": [
"propofol plus fentanyl"
],
"offsets": [
[
739,
761
]
],
"normalized": []
},
{
"id": "65938",
"type": "Intervention_Pharmacological",
"text": [
"midazolam plus fentanyl"
],
"offsets": [
[
862,
885
]
],
"normalized": []
},
{
"id": "65939",
"type": "Intervention_Pharmacological",
"text": [
"propofol-alone"
],
"offsets": [
[
986,
1000
]
],
"normalized": []
},
{
"id": "65940",
"type": "Intervention_Pharmacological",
"text": [
"propofol"
],
"offsets": [
[
739,
747
]
],
"normalized": []
},
{
"id": "65941",
"type": "Intervention_Pharmacological",
"text": [
"fentanyl"
],
"offsets": [
[
753,
761
]
],
"normalized": []
},
{
"id": "65942",
"type": "Outcome_Mental",
"text": [
"cognitive function"
],
"offsets": [
[
28,
46
]
],
"normalized": []
},
{
"id": "65943",
"type": "Outcome_Mental",
"text": [
"postprocedure cognitive function"
],
"offsets": [
[
14,
46
]
],
"normalized": []
},
{
"id": "65944",
"type": "Outcome_Mental",
"text": [
"Telephone Interview of Cognitive Status ( TICS )"
],
"offsets": [
[
684,
732
]
],
"normalized": []
},
{
"id": "65945",
"type": "Outcome_Mental",
"text": [
"mean TICS score"
],
"offsets": [
[
774,
789
]
],
"normalized": []
},
{
"id": "65946",
"type": "Outcome_Mental",
"text": [
"mean TICS score"
],
"offsets": [
[
774,
789
]
],
"normalized": []
},
{
"id": "65947",
"type": "Outcome_Mental",
"text": [
"mean TICS score"
],
"offsets": [
[
774,
789
]
],
"normalized": []
},
{
"id": "65948",
"type": "Outcome_Mental",
"text": [
"postprocedure cognitive function"
],
"offsets": [
[
14,
46
]
],
"normalized": []
},
{
"id": "65949",
"type": "Outcome_Other",
"text": [
"number of jaw lift interventions"
],
"offsets": [
[
1262,
1294
]
],
"normalized": []
},
{
"id": "65950",
"type": "Participant_Condition",
"text": [
"scheduled for colonoscopies"
],
"offsets": [
[
387,
414
]
],
"normalized": []
}
] | [] | [] | [] |
65951 | 24910215 | [
{
"id": "65952",
"type": "document",
"text": [
"Intramedullary repair device against volar plating in the reconstruction of extra-articular and simple articular distal radius fractures ; a randomized pilot study . PURPOSE This prospective randomized pilot study reports our institutional experience and early results using Sonoma Wrx ( Sonoma Orthopedic Products , Santa Rosa , CA ) in the treatment of extra-articular and simple intra-articular distal radius fractures . MATERIAL AND METHODS A total of 64 patients , were enrolled in the study . They were considered eligible if they had ; unstable extra-articular distal radius fractures and simple intra-articular distal radius fractures suitable for closed reduction ( AO types ; A2.2 , A2.3 , A3.1 C2.1 , C2.2 ) . Patients in group I received intramedullary fixation using the Sonoma Wrx device and patients in group II received standard volar locking plate fixation . Radiographic criteria of acceptable healing were used for evaluation . RESULTS Two groups were similar in terms of baseline characteristics . Mean time of operation was significantly shorter in Group 1 vs. in group 2 ( 36.81 ± 7.11 vs. 48.97 ± 5.9 minutes , p = 0.001 ) . Time to healing of the fracture was not different between two groups ( 5.45 ± 1.09 vs. 5.70 ± 1.04 weeks for Group 1 vs. 2 , respectively p = 0.36 ) . Overall complications occurred in 9 patients in group 1 and in 15 patients in group 2 ( p = 0.17 ) . Follow-up was completed in all patients with a median time of 12 months and 13 months in group 1 and 2 , respectively . On radiographic evaluation radial inclination , radial height and volar tilt were not significantly different between group 1 and 2 , respectively . There were no significant differences between two groups in regard to wrist rotational degrees measured in last follow-up visit . CONCLUSION Sonoma Wrx Device is reliable and effective in terms of achieving satisfactory outcomes in treatment of distal radius fractures . It may be reasonable to use this device to prevent complications that are related to extensive soft tissue dissection ."
],
"offsets": [
[
0,
2059
]
]
}
] | [
{
"id": "65953",
"type": "Intervention_Surgical",
"text": [
"Intramedullary repair"
],
"offsets": [
[
0,
21
]
],
"normalized": []
},
{
"id": "65954",
"type": "Intervention_Physical",
"text": [
"intramedullary fixation using the Sonoma Wrx device"
],
"offsets": [
[
750,
801
]
],
"normalized": []
},
{
"id": "65955",
"type": "Intervention_Surgical",
"text": [
"standard volar locking plate fixation"
],
"offsets": [
[
836,
873
]
],
"normalized": []
},
{
"id": "65956",
"type": "Intervention_Control",
"text": [
"."
],
"offsets": [
[
164,
165
]
],
"normalized": []
},
{
"id": "65957",
"type": "Participant_Sample-size",
"text": [
"64"
],
"offsets": [
[
456,
458
]
],
"normalized": []
},
{
"id": "65958",
"type": "Participant_Condition",
"text": [
"fractures suitable"
],
"offsets": [
[
633,
651
]
],
"normalized": []
}
] | [] | [] | [] |
65959 | 24913600 | [
{
"id": "65960",
"type": "document",
"text": [
"A brief adherence intervention that improved glycemic control : mediation by patterns of adherence . This study examined whether longitudinal adherence profiles mediated the relationship between a brief adherence intervention and glycemic control among patients with type 2 diabetes . Adherence was assessed using the Medication Event Monitoring System . Longitudinal analysis via growth curve mixture modeling was carried out to classify patients according to patterns of adherence to oral hypoglycemic agents . Hemoglobin A1c assays were used to measure glycemic control as the clinical outcome . Across the whole sample , longitudinal adherence profiles mediated 35.2 % ( 13.2 , 81.0 % ) of the effect of a brief adherence intervention on glycemic control [ from odds ratio ( OR ) = 8.48 , 95 % confidence interval ( CI ) ( 3.24 , 22.2 ) to 4.00 , 95 % CI ( 1.34 , 11.93 ) ] . Our results suggest that patients in the intervention had better glycemic control largely due to their greater likelihood of adherence to oral hypoglycemic agents ."
],
"offsets": [
[
0,
1044
]
]
}
] | [
{
"id": "65961",
"type": "Intervention_Educational",
"text": [
"brief adherence intervention"
],
"offsets": [
[
2,
30
]
],
"normalized": []
},
{
"id": "65962",
"type": "Intervention_Educational",
"text": [
"adherence intervention"
],
"offsets": [
[
8,
30
]
],
"normalized": []
},
{
"id": "65963",
"type": "Intervention_Educational",
"text": [
"Adherence"
],
"offsets": [
[
285,
294
]
],
"normalized": []
},
{
"id": "65964",
"type": "Intervention_Pharmacological",
"text": [
"adherence to oral hypoglycemic agents"
],
"offsets": [
[
473,
510
]
],
"normalized": []
},
{
"id": "65965",
"type": "Outcome_Physical",
"text": [
"glycemic control"
],
"offsets": [
[
45,
61
]
],
"normalized": []
},
{
"id": "65966",
"type": "Outcome_Physical",
"text": [
"glycemic control"
],
"offsets": [
[
45,
61
]
],
"normalized": []
},
{
"id": "65967",
"type": "Outcome_Physical",
"text": [
"glycemic control"
],
"offsets": [
[
45,
61
]
],
"normalized": []
},
{
"id": "65968",
"type": "Outcome_Physical",
"text": [
"glycemic control"
],
"offsets": [
[
45,
61
]
],
"normalized": []
},
{
"id": "65969",
"type": "Participant_Condition",
"text": [
"type 2 diabetes"
],
"offsets": [
[
267,
282
]
],
"normalized": []
}
] | [] | [] | [] |
65970 | 24914426 | [
{
"id": "65971",
"type": "document",
"text": [
"Antibacterial effects of fluoride varnish compared with chlorhexidine plus fluoride in disabled children . PURPOSE To evaluate the effects of fluoride varnish vs a combination of chlorhexidine-thymol varnish plus a gel containing chlorhexidine and fluoride on oral hygiene and caries prevention in disabled children . MATERIALS AND METHODS Ninety patients aged 3-17 years who were treated under general anaesthesia were randomly assigned into three groups as follows : group 1 : Fluor Protector ( 0.1 % fluoride varnish ) ; group 2 : Cervitec Plus ( 1 % chlorhexidine- 1 % thymol varnish ) + Cervitec Gel ( 0.2 % chlorhexidine-0.2 % sodium fluoride ) ; group 3 : control ( toothbrushing only ) . Mutans streptococci ( MS ) and lactobacilli ( LB ) levels , visible plaque index ( VPI ) and gingival bleeding index ( GBI ) were evaluated at four stages : T0 , before general anaesthesia ; T1 , one month after treatment ; T2 , six months after treatment ; T3 , twelve months after treatment . The data were evaluated using Kruskal-Wallis and Mann-Whitney U-tests ( P < 0.05 ) . RESULTS Groups 1 and 2 showed significantly lower scores than group 3 for all parameters at T1 and T2 . No statistically significant difference was detected among any of the the groups at T3 ( P > 0.05 ) . CONCLUSION The use of materials that include both fluoride and chlorhexidine as routine treatment of children with disability may increase the success of restorations by improving oral hygiene , reduce the need for future restorative treatments and thus the need for general anaesthesia ."
],
"offsets": [
[
0,
1570
]
]
}
] | [
{
"id": "65972",
"type": "Intervention_Pharmacological",
"text": [
"Fluor Protector ( 0.1 % fluoride varnish )"
],
"offsets": [
[
479,
521
]
],
"normalized": []
},
{
"id": "65973",
"type": "Intervention_Pharmacological",
"text": [
"Cervitec Plus ( 1 % chlorhexidine- 1 % thymol varnish )"
],
"offsets": [
[
534,
589
]
],
"normalized": []
},
{
"id": "65974",
"type": "Intervention_Pharmacological",
"text": [
"Cervitec Gel ( 0.2 % chlorhexidine-0.2 % sodium fluoride )"
],
"offsets": [
[
592,
650
]
],
"normalized": []
},
{
"id": "65975",
"type": "Outcome_Physical",
"text": [
"Antibacterial effects"
],
"offsets": [
[
0,
21
]
],
"normalized": []
},
{
"id": "65976",
"type": "Outcome_Physical",
"text": [
"Mutans streptococci ( MS ) and lactobacilli ( LB ) levels , visible plaque index ( VPI ) and gingival bleeding index ( GBI )"
],
"offsets": [
[
696,
820
]
],
"normalized": []
},
{
"id": "65977",
"type": "Outcome_Physical",
"text": [
"Kruskal-Wallis and Mann-Whitney U-tests"
],
"offsets": [
[
1021,
1060
]
],
"normalized": []
},
{
"id": "65978",
"type": "Outcome_Other",
"text": [
"significantly lower scores"
],
"offsets": [
[
1106,
1132
]
],
"normalized": []
},
{
"id": "65979",
"type": "Outcome_Other",
"text": [
"No statistically significant difference"
],
"offsets": [
[
1180,
1219
]
],
"normalized": []
},
{
"id": "65980",
"type": "Outcome_Physical",
"text": [
"success of restorations by improving oral hygiene , reduce the need for future restorative treatments and thus the need for general anaesthesia ."
],
"offsets": [
[
1425,
1570
]
],
"normalized": []
},
{
"id": "65981",
"type": "Participant_Age",
"text": [
"children ."
],
"offsets": [
[
96,
106
]
],
"normalized": []
},
{
"id": "65982",
"type": "Participant_Age",
"text": [
"children ."
],
"offsets": [
[
96,
106
]
],
"normalized": []
},
{
"id": "65983",
"type": "Participant_Sample-size",
"text": [
"Ninety patients"
],
"offsets": [
[
340,
355
]
],
"normalized": []
},
{
"id": "65984",
"type": "Participant_Age",
"text": [
"3-17 years"
],
"offsets": [
[
361,
371
]
],
"normalized": []
},
{
"id": "65985",
"type": "Participant_Condition",
"text": [
"anaesthesia"
],
"offsets": [
[
403,
414
]
],
"normalized": []
},
{
"id": "65986",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
96,
104
]
],
"normalized": []
},
{
"id": "65987",
"type": "Participant_Condition",
"text": [
"disability"
],
"offsets": [
[
1397,
1407
]
],
"normalized": []
}
] | [] | [] | [] |
65988 | 24915013 | [
{
"id": "65989",
"type": "document",
"text": [
"Mechanical sensitivity of the human conjunctiva . PURPOSE The aim of this study was to map the sensitivity of the marginal and other conjunctival regions and to investigate changes in the sensitivity of these regions when determined in the morning and evening . METHODS Thirty-five healthy , noncontact lens wearers ( 20 female , 15 male ; age 27.7 ± 7.3 years ) were enrolled . Mechanical sensitivity was measured at 8 locations on the ocular surface and adnexa ( cornea , marginal , bulbar , and tarsal conjunctiva ) using a Cochet-Bonnet esthesiometer ( 0.12-mm diameter filament ) . A subgroup of 11 subjects ( 6 female , 5 male ; age 28.9 ± 9.9 years ) returned after 12 hours when this protocol was repeated . RESULTS The cornea was found to be the most sensitive region ( all P < 0.001 ) . The marginal conjunctiva showed greater sensitivity than did the bulbar and tarsal conjunctiva ( all P < 0.001 ) . The temporal marginal conjunctiva was more sensitive than the central marginal conjunctiva ( all P < 0.05 ) . No difference in marginal conjunctival sensitivity was found between upper and lower eyelids ( all P > 0.05 ) . The upper tarsal conjunctiva was more sensitive than the lower tarsal conjunctiva ( P = 0.04 ) . There was no significant difference in the sensitivity determined in the morning and the evening for any of the locations investigated ( Bonferroni adjusted , P > 0.006 ) . CONCLUSIONS This work has demonstrated that the marginal conjunctiva was the most sensitive of all the conjunctival regions and that this does not alter over the course of the day ."
],
"offsets": [
[
0,
1585
]
]
}
] | [
{
"id": "65990",
"type": "Outcome_Physical",
"text": [
"marginal conjunctiva"
],
"offsets": [
[
801,
821
]
],
"normalized": []
},
{
"id": "65991",
"type": "Outcome_Physical",
"text": [
"marginal conjunctival sensitivity"
],
"offsets": [
[
1039,
1072
]
],
"normalized": []
},
{
"id": "65992",
"type": "Outcome_Physical",
"text": [
"upper tarsal conjunctiva"
],
"offsets": [
[
1138,
1162
]
],
"normalized": []
},
{
"id": "65993",
"type": "Outcome_Physical",
"text": [
"marginal conjunctiva"
],
"offsets": [
[
801,
821
]
],
"normalized": []
}
] | [] | [] | [] |
65994 | 24915929 | [
{
"id": "65995",
"type": "document",
"text": [
"Quantifying narrative ability in autism spectrum disorder : a computational linguistic analysis of narrative coherence . Autism is a neurodevelopmental disorder characterized by serious difficulties with the social use of language , along with impaired social functioning and ritualistic/repetitive behaviors ( American Psychiatric Association in Diagnostic and statistical manual of mental disorders : DSM-5 , 5th edn . American Psychiatric Association , Arlington , 2013 ) . While substantial heterogeneity exists in symptom expression , impairments in language discourse skills , including narrative ( or storytelling ) , are universally observed in autism ( Tager-Flusberg et al . in Handbook on autism and pervasive developmental disorders , 3rd edn . Wiley , New York , pp 335-364 , 2005 ) . This study applied a computational linguistic tool , Latent Semantic Analysis ( LSA ) , to objectively characterize narrative performance in high-functioning individuals with autism and typically-developing controls , across two different narrative contexts that differ in the interpersonal and cognitive demands placed on the narrator . Results indicated that high-functioning individuals with autism produced narratives comparable in semantic content to those produced by controls when narrating from a picture book , but produced narratives diminished in semantic quality in a more demanding narrative recall task . This pattern is similar to that detected from analyses of hand-coded picture book narratives in prior research , and extends findings to an additional narrative context that proves particularly challenging for individuals with autism . Results are discussed in terms of the utility of LSA as a quantitative , objective , and efficient measure of narrative ability ."
],
"offsets": [
[
0,
1782
]
]
}
] | [
{
"id": "65996",
"type": "Intervention_Educational",
"text": [
"computational linguistic tool"
],
"offsets": [
[
819,
848
]
],
"normalized": []
},
{
"id": "65997",
"type": "Intervention_Educational",
"text": [
"Latent Semantic Analysis ( LSA )"
],
"offsets": [
[
851,
883
]
],
"normalized": []
},
{
"id": "65998",
"type": "Outcome_Mental",
"text": [
"narrative ability"
],
"offsets": [
[
12,
29
]
],
"normalized": []
},
{
"id": "65999",
"type": "Outcome_Mental",
"text": [
"narratives"
],
"offsets": [
[
1209,
1219
]
],
"normalized": []
},
{
"id": "66000",
"type": "Outcome_Mental",
"text": [
"narratives"
],
"offsets": [
[
1209,
1219
]
],
"normalized": []
},
{
"id": "66001",
"type": "Outcome_Mental",
"text": [
"narrative ability ."
],
"offsets": [
[
1763,
1782
]
],
"normalized": []
},
{
"id": "66002",
"type": "Participant_Condition",
"text": [
"autism spectrum disorder :"
],
"offsets": [
[
33,
59
]
],
"normalized": []
},
{
"id": "66003",
"type": "Participant_Condition",
"text": [
"Autism"
],
"offsets": [
[
121,
127
]
],
"normalized": []
},
{
"id": "66004",
"type": "Participant_Condition",
"text": [
"high-functioning"
],
"offsets": [
[
939,
955
]
],
"normalized": []
},
{
"id": "66005",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
33,
39
]
],
"normalized": []
},
{
"id": "66006",
"type": "Participant_Condition",
"text": [
"high-functioning"
],
"offsets": [
[
939,
955
]
],
"normalized": []
},
{
"id": "66007",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
33,
39
]
],
"normalized": []
},
{
"id": "66008",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
33,
39
]
],
"normalized": []
}
] | [] | [] | [] |
66009 | 24916506 | [
{
"id": "66010",
"type": "document",
"text": [
"PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) ."
],
"offsets": [
[
0,
1570
]
]
}
] | [
{
"id": "66011",
"type": "Intervention_Pharmacological",
"text": [
"rituximab ( R ) to fludarabine and cyclophosphamide"
],
"offsets": [
[
93,
144
]
],
"normalized": []
},
{
"id": "66012",
"type": "Intervention_Pharmacological",
"text": [
"FC"
],
"offsets": [
[
147,
149
]
],
"normalized": []
},
{
"id": "66013",
"type": "Intervention_Pharmacological",
"text": [
"R-FC"
],
"offsets": [
[
507,
511
]
],
"normalized": []
},
{
"id": "66014",
"type": "Outcome_Physical",
"text": [
"patient outcomes"
],
"offsets": [
[
179,
195
]
],
"normalized": []
},
{
"id": "66015",
"type": "Outcome_Physical",
"text": [
"genome-wide expression"
],
"offsets": [
[
396,
418
]
],
"normalized": []
},
{
"id": "66016",
"type": "Outcome_Mortality",
"text": [
"progression-free survival"
],
"offsets": [
[
958,
983
]
],
"normalized": []
},
{
"id": "66017",
"type": "Outcome_Physical",
"text": [
"R-dependent cell death"
],
"offsets": [
[
1169,
1191
]
],
"normalized": []
},
{
"id": "66018",
"type": "Participant_Condition",
"text": [
"chronic lymphocytic leukemia"
],
"offsets": [
[
50,
78
]
],
"normalized": []
},
{
"id": "66019",
"type": "Participant_Condition",
"text": [
"chronic lymphocytic leukemia"
],
"offsets": [
[
50,
78
]
],
"normalized": []
},
{
"id": "66020",
"type": "Participant_Condition",
"text": [
"CLL"
],
"offsets": [
[
230,
233
]
],
"normalized": []
},
{
"id": "66021",
"type": "Participant_Sample-size",
"text": [
"300"
],
"offsets": [
[
422,
425
]
],
"normalized": []
},
{
"id": "66022",
"type": "Participant_Sample-size",
"text": [
"552"
],
"offsets": [
[
466,
469
]
],
"normalized": []
},
{
"id": "66023",
"type": "Participant_Condition",
"text": [
"CLL"
],
"offsets": [
[
230,
233
]
],
"normalized": []
}
] | [] | [] | [] |
66024 | 2491829 | [
{
"id": "66025",
"type": "document",
"text": [
"Failure of lithium to reduce period of neutropenia during induction therapy of acute myeloid leukemia . Fifty-four patients treated with daunorubicin , cytosine arabinoside and thioquanine for acute myeloid leukemia were randomly assigned to receive oral lithium carbonate 1200 mg daily or no lithium . The duration of neutropenia ( less than 0.5 x 10 ( 9 ) /L ) was similar between controls ( median 22.5 days ) and patients treated with lithium ( median 24 days ) . The number of remissions , relapse-free survival and survival were similar for the lithium treated and control groups of patients . There was no apparent clinical efficacy in the use of lithium to reduce the period of neutropenia in patients undergoing remission induction therapy for acute myeloid leukemia ."
],
"offsets": [
[
0,
777
]
]
}
] | [
{
"id": "66026",
"type": "Intervention_Physical",
"text": [
"induction therapy"
],
"offsets": [
[
58,
75
]
],
"normalized": []
},
{
"id": "66027",
"type": "Intervention_Pharmacological",
"text": [
"daunorubicin"
],
"offsets": [
[
137,
149
]
],
"normalized": []
},
{
"id": "66028",
"type": "Intervention_Pharmacological",
"text": [
"cytosine arabinoside"
],
"offsets": [
[
152,
172
]
],
"normalized": []
},
{
"id": "66029",
"type": "Intervention_Pharmacological",
"text": [
"thioquanine"
],
"offsets": [
[
177,
188
]
],
"normalized": []
},
{
"id": "66030",
"type": "Intervention_Pharmacological",
"text": [
"oral lithium carbonate 1200 mg daily"
],
"offsets": [
[
250,
286
]
],
"normalized": []
},
{
"id": "66031",
"type": "Intervention_Pharmacological",
"text": [
"no lithium"
],
"offsets": [
[
290,
300
]
],
"normalized": []
},
{
"id": "66032",
"type": "Intervention_Pharmacological",
"text": [
"lithium"
],
"offsets": [
[
11,
18
]
],
"normalized": []
},
{
"id": "66033",
"type": "Intervention_Pharmacological",
"text": [
"lithium"
],
"offsets": [
[
11,
18
]
],
"normalized": []
},
{
"id": "66034",
"type": "Intervention_Pharmacological",
"text": [
"lithium"
],
"offsets": [
[
11,
18
]
],
"normalized": []
},
{
"id": "66035",
"type": "Intervention_Physical",
"text": [
"induction therapy"
],
"offsets": [
[
58,
75
]
],
"normalized": []
},
{
"id": "66036",
"type": "Outcome_Physical",
"text": [
"duration of neutropenia"
],
"offsets": [
[
307,
330
]
],
"normalized": []
},
{
"id": "66037",
"type": "Outcome_Physical",
"text": [
"number of remissions"
],
"offsets": [
[
472,
492
]
],
"normalized": []
},
{
"id": "66038",
"type": "Outcome_Mortality",
"text": [
"relapse-free survival"
],
"offsets": [
[
495,
516
]
],
"normalized": []
},
{
"id": "66039",
"type": "Outcome_Mortality",
"text": [
"survival"
],
"offsets": [
[
508,
516
]
],
"normalized": []
},
{
"id": "66040",
"type": "Outcome_Other",
"text": [
"clinical efficacy"
],
"offsets": [
[
622,
639
]
],
"normalized": []
},
{
"id": "66041",
"type": "Participant_Condition",
"text": [
"acute myeloid leukemia"
],
"offsets": [
[
79,
101
]
],
"normalized": []
},
{
"id": "66042",
"type": "Participant_Sample-size",
"text": [
"Fifty-four"
],
"offsets": [
[
104,
114
]
],
"normalized": []
},
{
"id": "66043",
"type": "Participant_Condition",
"text": [
"patients treated with daunorubicin , cytosine arabinoside and thioquanine for acute myeloid leukemia"
],
"offsets": [
[
115,
215
]
],
"normalized": []
}
] | [] | [] | [] |
66044 | 24919102 | [
{
"id": "66045",
"type": "document",
"text": [
"Balance training in elderly women using public parks . This study evaluates the effects of a balance training program developed in public parks on functionality and general state of health in elderly women . It was a randomized controlled trial . Women older than 65 years ( n = 28 ; 68.5 ± 2.9 ) participated in a balance training program that lasted 6 weeks , with sessions taking place twice a week ( 12 exercises/session , 50 min ) . Balance was analyzed by the Berg Balance Scale and Timed Up & Go Test . The generic health status was measured by the SF-12 Health Survey . These tests showed statistically significant differences in the experimental group ( p < .05 ) . Public parks are adequate installations for developing balance ."
],
"offsets": [
[
0,
739
]
]
}
] | [
{
"id": "66046",
"type": "Intervention_Educational",
"text": [
"balance training program"
],
"offsets": [
[
93,
117
]
],
"normalized": []
},
{
"id": "66047",
"type": "Outcome_Physical",
"text": [
"Balance"
],
"offsets": [
[
0,
7
]
],
"normalized": []
},
{
"id": "66048",
"type": "Outcome_Other",
"text": [
"Berg Balance Scale and Timed Up & Go Test"
],
"offsets": [
[
466,
507
]
],
"normalized": []
},
{
"id": "66049",
"type": "Outcome_Physical",
"text": [
"The generic health status"
],
"offsets": [
[
510,
535
]
],
"normalized": []
}
] | [] | [] | [] |
66050 | 24919961 | [
{
"id": "66051",
"type": "document",
"text": [
"Video-feedback Intervention to promote Positive Parenting adapted to Autism ( VIPP-AUTI ) : A randomized controlled trial . In a randomized controlled trial , we evaluated the early intervention program Video-feedback Intervention to promote Positive Parenting adapted to Autism ( VIPP-AUTI ) with 78 primary caregivers and their child ( 16-61 months ) with Autism Spectrum Disorder . VIPP-AUTI is a brief attachment-based intervention program , focusing on improving parent-child interaction and reducing the child 's individual Autism Spectrum Disorder-related symptomatology in five home visits . VIPP-AUTI , as compared with usual care , demonstrated efficacy in reducing parental intrusiveness . Moreover , parents who received VIPP-AUTI showed increased feelings of self-efficacy in child rearing . No significant group differences were found on other aspects of parent-child interaction or on child play behavior . At 3-months follow-up , intervention effects were found on child-initiated joint attention skills , not mediated by intervention effects on parenting . Implementation of VIPP-AUTI in clinical practice is facilitated by the use of a detailed manual and a relatively brief training of interveners ."
],
"offsets": [
[
0,
1218
]
]
}
] | [
{
"id": "66052",
"type": "Intervention_Educational",
"text": [
"Video-feedback Intervention"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "66053",
"type": "Intervention_Educational",
"text": [
"Video-feedback Intervention"
],
"offsets": [
[
0,
27
]
],
"normalized": []
},
{
"id": "66054",
"type": "Intervention_Educational",
"text": [
"VIPP-AUTI"
],
"offsets": [
[
78,
87
]
],
"normalized": []
},
{
"id": "66055",
"type": "Intervention_Educational",
"text": [
"attachment-based intervention program"
],
"offsets": [
[
406,
443
]
],
"normalized": []
},
{
"id": "66056",
"type": "Intervention_Educational",
"text": [
"VIPP-AUTI"
],
"offsets": [
[
78,
87
]
],
"normalized": []
},
{
"id": "66057",
"type": "Intervention_Educational",
"text": [
"VIPP-AUTI"
],
"offsets": [
[
78,
87
]
],
"normalized": []
},
{
"id": "66058",
"type": "Intervention_Educational",
"text": [
"VIPP-AUTI"
],
"offsets": [
[
78,
87
]
],
"normalized": []
},
{
"id": "66059",
"type": "Outcome_Mental",
"text": [
"parent-child interaction"
],
"offsets": [
[
468,
492
]
],
"normalized": []
},
{
"id": "66060",
"type": "Outcome_Mental",
"text": [
"child 's individual Autism Spectrum Disorder-related symptomatology"
],
"offsets": [
[
510,
577
]
],
"normalized": []
},
{
"id": "66061",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
655,
663
]
],
"normalized": []
},
{
"id": "66062",
"type": "Outcome_Other",
"text": [
"increased feelings of self-efficacy"
],
"offsets": [
[
750,
785
]
],
"normalized": []
},
{
"id": "66063",
"type": "Outcome_Other",
"text": [
"No"
],
"offsets": [
[
805,
807
]
],
"normalized": []
},
{
"id": "66064",
"type": "Outcome_Mental",
"text": [
"parent-child interaction or on child play behavior ."
],
"offsets": [
[
869,
921
]
],
"normalized": []
},
{
"id": "66065",
"type": "Outcome_Mental",
"text": [
"child-initiated joint attention skills"
],
"offsets": [
[
981,
1019
]
],
"normalized": []
},
{
"id": "66066",
"type": "Participant_Condition",
"text": [
"Autism"
],
"offsets": [
[
69,
75
]
],
"normalized": []
},
{
"id": "66067",
"type": "Participant_Sample-size",
"text": [
"78 primary caregivers"
],
"offsets": [
[
298,
319
]
],
"normalized": []
},
{
"id": "66068",
"type": "Participant_Age",
"text": [
"child ( 16-61 months )"
],
"offsets": [
[
330,
352
]
],
"normalized": []
},
{
"id": "66069",
"type": "Participant_Condition",
"text": [
"Autism Spectrum Disorder"
],
"offsets": [
[
358,
382
]
],
"normalized": []
}
] | [] | [] | [] |
66070 | 24920862 | [
{
"id": "66071",
"type": "document",
"text": [
"Variations in EEG discharges predict ADHD severity within individual Smith-Lemli-Opitz patients . OBJECTIVE We sought to examine the prevalence of EEG abnormalities in Smith-Lemli-Opitz syndrome ( SLOS ) as well as the relationship between interictal epileptiform discharges ( IEDs ) and within-subject variations in attentional symptom severity . METHODS In the context of a clinical trial for SLOS , we performed cross-sectional and repeated-measure observational studies of the relationship between EEG findings and cognitive/behavioral factors on 23 children ( aged 4-17 years ) . EEGs were reviewed for clinical abnormalities , including IEDs , by readers blinded to participants ' behavioral symptoms . Between-group differences in baseline characteristics of participants with and without IEDs were analyzed . Within-subject analyses examined the association between the presence of IEDs and changes in attention-deficit/hyperactivity disorder ( ADHD ) symptoms . RESULTS Of 85 EEGs , 43 ( 51 % ) were abnormal , predominantly because of IEDs . Only one subject had documented clinical seizures . IEDs clustered in 13 subjects ( 57 % ) , whereas 9 subjects ( 39 % ) had EEGs consistently free of IEDs . While there were no significant group differences in sex , age , intellectual disability , language level , or baseline ADHD symptoms , autistic symptoms tended to be more prevalent in the \" IED \" group ( according to Autism Diagnostic Observation Schedule-2 criteria ) . Within individuals , the presence of IEDs on a particular EEG predicted , on average , a 27 % increase in ADHD symptom severity . CONCLUSIONS Epileptiform discharges are common in SLOS , despite a relatively low prevalence of epilepsy . Fluctuations in the presence of epileptiform discharges within individual children with a developmental disability syndrome may be associated with fluctuations in ADHD symptomatology , even in the absence of clinical seizures ."
],
"offsets": [
[
0,
1946
]
]
}
] | [
{
"id": "66072",
"type": "Intervention_Physical",
"text": [
"EEG discharges"
],
"offsets": [
[
14,
28
]
],
"normalized": []
},
{
"id": "66073",
"type": "Intervention_Physical",
"text": [
"EEG"
],
"offsets": [
[
14,
17
]
],
"normalized": []
},
{
"id": "66074",
"type": "Intervention_Physical",
"text": [
"EEGs"
],
"offsets": [
[
585,
589
]
],
"normalized": []
},
{
"id": "66075",
"type": "Outcome_Physical",
"text": [
"EEG discharges"
],
"offsets": [
[
14,
28
]
],
"normalized": []
},
{
"id": "66076",
"type": "Outcome_Physical",
"text": [
"attention-deficit/hyperactivity disorder ( ADHD ) symptoms ."
],
"offsets": [
[
910,
970
]
],
"normalized": []
},
{
"id": "66077",
"type": "Outcome_Physical",
"text": [
"abnormal"
],
"offsets": [
[
151,
159
]
],
"normalized": []
},
{
"id": "66078",
"type": "Outcome_Adverse-effects",
"text": [
"clinical seizures ."
],
"offsets": [
[
1084,
1103
]
],
"normalized": []
},
{
"id": "66079",
"type": "Outcome_Mental",
"text": [
"sex , age , intellectual disability , language level , or baseline ADHD symptoms , autistic symptoms"
],
"offsets": [
[
1263,
1363
]
],
"normalized": []
},
{
"id": "66080",
"type": "Outcome_Mental",
"text": [
"Autism Diagnostic Observation Schedule-2 criteria )"
],
"offsets": [
[
1428,
1479
]
],
"normalized": []
},
{
"id": "66081",
"type": "Outcome_Mental",
"text": [
"ADHD symptom severity ."
],
"offsets": [
[
1588,
1611
]
],
"normalized": []
},
{
"id": "66082",
"type": "Participant_Condition",
"text": [
"Smith-Lemli-Opitz syndrome ( SLOS )"
],
"offsets": [
[
168,
203
]
],
"normalized": []
},
{
"id": "66083",
"type": "Participant_Sample-size",
"text": [
"23"
],
"offsets": [
[
551,
553
]
],
"normalized": []
},
{
"id": "66084",
"type": "Participant_Age",
"text": [
"aged 4-17 years"
],
"offsets": [
[
565,
580
]
],
"normalized": []
}
] | [] | [] | [] |
66085 | 24925605 | [
{
"id": "66086",
"type": "document",
"text": [
"Chocolate frogs do not increase completion of parent survey : randomised study . Four months into a year-long , national survey assessing parents ' experiences of a child 's diagnosis of autism spectrum disorder , our response fraction was only 23 % . We aimed to determine whether including a chocolate incentive in the postal survey would increase the response fraction . Families enrolled between 15 March and 25 May 2012 were randomised to receive a chocolate frog versus no chocolate frog . Both groups received a written reminder and replacement survey 2 weeks after the survey was posted and up to two telephone reminders thereafter . We analysed the effect of the incentive using χ ( 2 ) tests for the categorical response variable and t-tests for the continuous reminder and length of response variables at the end of ( i ) randomisation and ( ii ) the study ( 1 November 2012 ) . A total of 137 families were randomised in the 6-week period . Parents who received an incentive were more likely to return a completed survey in the 6 weeks than those who did not ( 21 % vs. 6 % , P = 0.009 ) . This effect faded by the end of the study ( 53 % vs. 42 % , P = 0.4 ) . There were no differences between groups at either follow-up in the number of reminders that parents received or the number of days it took parents to return the survey . Including a chocolate-based incentive does not significantly increase response rate in a postal survey over and above standard reminder techniques like posting follow-up survey packs or phoning families ."
],
"offsets": [
[
0,
1549
]
]
}
] | [
{
"id": "66087",
"type": "Intervention_Educational",
"text": [
"Chocolate frogs"
],
"offsets": [
[
0,
15
]
],
"normalized": []
},
{
"id": "66088",
"type": "Intervention_Educational",
"text": [
"chocolate incentive"
],
"offsets": [
[
294,
313
]
],
"normalized": []
},
{
"id": "66089",
"type": "Intervention_Educational",
"text": [
"chocolate frog"
],
"offsets": [
[
454,
468
]
],
"normalized": []
},
{
"id": "66090",
"type": "Intervention_Physical",
"text": [
"versus"
],
"offsets": [
[
469,
475
]
],
"normalized": []
},
{
"id": "66091",
"type": "Intervention_Control",
"text": [
"no chocolate frog"
],
"offsets": [
[
476,
493
]
],
"normalized": []
},
{
"id": "66092",
"type": "Intervention_Educational",
"text": [
"written reminder"
],
"offsets": [
[
519,
535
]
],
"normalized": []
},
{
"id": "66093",
"type": "Outcome_Other",
"text": [
"increase the response fraction ."
],
"offsets": [
[
341,
373
]
],
"normalized": []
},
{
"id": "66094",
"type": "Outcome_Other",
"text": [
"effect"
],
"offsets": [
[
658,
664
]
],
"normalized": []
},
{
"id": "66095",
"type": "Outcome_Other",
"text": [
"χ ( 2 ) tests"
],
"offsets": [
[
688,
701
]
],
"normalized": []
},
{
"id": "66096",
"type": "Outcome_Other",
"text": [
"and t-tests"
],
"offsets": [
[
740,
751
]
],
"normalized": []
},
{
"id": "66097",
"type": "Outcome_Mental",
"text": [
"received"
],
"offsets": [
[
508,
516
]
],
"normalized": []
},
{
"id": "66098",
"type": "Outcome_Mental",
"text": [
"number"
],
"offsets": [
[
1242,
1248
]
],
"normalized": []
},
{
"id": "66099",
"type": "Outcome_Other",
"text": [
"significantly increase response"
],
"offsets": [
[
1392,
1423
]
],
"normalized": []
},
{
"id": "66100",
"type": "Participant_Age",
"text": [
"Families"
],
"offsets": [
[
374,
382
]
],
"normalized": []
},
{
"id": "66101",
"type": "Participant_Sample-size",
"text": [
"A total of 137 families"
],
"offsets": [
[
890,
913
]
],
"normalized": []
}
] | [] | [] | [] |
66102 | 24925924 | [
{
"id": "66103",
"type": "document",
"text": [
"COPD detected with screening : impact on patient management and prognosis . It is uncertain whether screening of older persons for chronic obstructive pulmonary disease ( COPD ) is worthwhile because the effects on patient management and prognosis are unknown . We aimed to assess the short-term consequences of detecting COPD in frail elderly subjects with dyspnoea , considering pulmonary drug use , hospitalisations and all-cause mortality . Community-dwelling frail elderly subjects , aged 65 years and older , with dyspnoea , participating in a screening study on COPD and heart failure were included . Final diagnoses were assigned by an expert panel based on all data from the screening strategy , including spirometry . Follow-up data were collected from the general practitioners . Of the 386 patients , 84 ( 21.8 % ) were received a new diagnosis of COPD . Overall , changes in pulmonary drug prescription during 6 months of follow-up were infrequent ( n = 53 , 13.7 % ; among new cases of COPD , 15 ( 17.9 % ) out of 84 ) . Of all participants , 25.9 % were hospitalised in the first year of follow-up , with the highest rate in patients with newly detected COPD ( 32.1 % ) . Many new cases of COPD could be detected by screening frail elderly subjects with dyspnoea , but the impact on patient management seems limited . Our study underlines the importance of obtaining follow-up data to assess the true impact of a ( screen-detected ) diagnosis of COPD on patient management and outcome ."
],
"offsets": [
[
0,
1501
]
]
}
] | [
{
"id": "66104",
"type": "Intervention_Physical",
"text": [
"spirometry"
],
"offsets": [
[
715,
725
]
],
"normalized": []
},
{
"id": "66105",
"type": "Outcome_Mental",
"text": [
"patient management and prognosis ."
],
"offsets": [
[
41,
75
]
],
"normalized": []
},
{
"id": "66106",
"type": "Outcome_Mental",
"text": [
"patient management and prognosis"
],
"offsets": [
[
41,
73
]
],
"normalized": []
},
{
"id": "66107",
"type": "Outcome_Other",
"text": [
"pulmonary drug use"
],
"offsets": [
[
381,
399
]
],
"normalized": []
},
{
"id": "66108",
"type": "Outcome_Other",
"text": [
"hospitalisations"
],
"offsets": [
[
402,
418
]
],
"normalized": []
},
{
"id": "66109",
"type": "Outcome_Mortality",
"text": [
"all-cause mortality"
],
"offsets": [
[
423,
442
]
],
"normalized": []
},
{
"id": "66110",
"type": "Outcome_Physical",
"text": [
"changes in pulmonary drug prescription"
],
"offsets": [
[
877,
915
]
],
"normalized": []
},
{
"id": "66111",
"type": "Outcome_Other",
"text": [
"hospitalised"
],
"offsets": [
[
1069,
1081
]
],
"normalized": []
},
{
"id": "66112",
"type": "Outcome_Physical",
"text": [
"dyspnoea"
],
"offsets": [
[
358,
366
]
],
"normalized": []
},
{
"id": "66113",
"type": "Outcome_Mental",
"text": [
"patient management"
],
"offsets": [
[
41,
59
]
],
"normalized": []
},
{
"id": "66114",
"type": "Outcome_Mental",
"text": [
"patient management and outcome ."
],
"offsets": [
[
1469,
1501
]
],
"normalized": []
}
] | [] | [] | [] |
66115 | 24926950 | [
{
"id": "66116",
"type": "document",
"text": [
"36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty . CONTEXT We have recently demonstrated short-term ( 6-month ) efficacy and safety of leuprolide acetate 3-month depot 11.25 and 30 mg in children with central precocious puberty ( CPP ) . OBJECTIVE To assess long-term ( 36-month ) hypothalamic-pituitary-gonadal axis suppression and safety of leuprolide acetate 3-month depot 11.25 and 30 mg in children with CPP . DESIGN Open-label , 36-month extension . SETTING Twenty pediatric endocrine centers . PATIENTS Seventy-two children ( mean age , 8.5 ± 1.6 y ; 65 females ) with CPP completed and showed maintenance of LH suppression after a 6-month lead-in study . INTERVENTION Leuprolide acetate depot ( 11.25 or 30 mg ) administered im every 3 months . MAIN OUTCOME MEASURES Peak-stimulated LH , estradiol , T , growth rate , pubertal progression , and adverse events ( AEs ) . RESULTS Twenty-nine of 34 subjects in the 11.25-mg group and 36 of 38 subjects in the 30-mg group had LH values < 4 mIU/mL after day 1 at all time points . All seven subjects who escaped LH suppression at any time still maintained sex steroid concentrations at prepubertal levels and showed no signs of pubertal progression . AEs were comparable between groups , with injection site pain being the most common ( 26.4 % overall ) . No AE led to discontinuation of study drug . The safety profile over 36 months was comparable to that observed during the 6-month pivotal study . CONCLUSIONS The two doses of leuprolide acetate 3-month depot were associated with an acceptable safety profile and provided maintenance of LH suppression in the majority of children with CPP during the 36 months of the study or until readiness for puberty ."
],
"offsets": [
[
0,
1788
]
]
}
] | [
{
"id": "66117",
"type": "Intervention_Pharmacological",
"text": [
"leuprolide acetate 3-month depot"
],
"offsets": [
[
46,
78
]
],
"normalized": []
},
{
"id": "66118",
"type": "Intervention_Pharmacological",
"text": [
"leuprolide acetate 3-month depot"
],
"offsets": [
[
46,
78
]
],
"normalized": []
},
{
"id": "66119",
"type": "Intervention_Pharmacological",
"text": [
"leuprolide acetate 3-month depot"
],
"offsets": [
[
46,
78
]
],
"normalized": []
},
{
"id": "66120",
"type": "Outcome_Physical",
"text": [
"hypothalamic-pituitary-gonadal axis suppression"
],
"offsets": [
[
356,
403
]
],
"normalized": []
},
{
"id": "66121",
"type": "Outcome_Other",
"text": [
"safety"
],
"offsets": [
[
200,
206
]
],
"normalized": []
},
{
"id": "66122",
"type": "Outcome_Physical",
"text": [
"showed maintenance of LH suppression"
],
"offsets": [
[
669,
705
]
],
"normalized": []
},
{
"id": "66123",
"type": "Outcome_Physical",
"text": [
"Peak-stimulated LH"
],
"offsets": [
[
850,
868
]
],
"normalized": []
},
{
"id": "66124",
"type": "Outcome_Physical",
"text": [
"estradiol"
],
"offsets": [
[
871,
880
]
],
"normalized": []
},
{
"id": "66125",
"type": "Outcome_Physical",
"text": [
"T"
],
"offsets": [
[
129,
130
]
],
"normalized": []
},
{
"id": "66126",
"type": "Outcome_Physical",
"text": [
"growth rate"
],
"offsets": [
[
887,
898
]
],
"normalized": []
},
{
"id": "66127",
"type": "Outcome_Physical",
"text": [
"pubertal progression"
],
"offsets": [
[
901,
921
]
],
"normalized": []
},
{
"id": "66128",
"type": "Outcome_Adverse-effects",
"text": [
"adverse events ( AEs )"
],
"offsets": [
[
928,
950
]
],
"normalized": []
},
{
"id": "66129",
"type": "Outcome_Other",
"text": [
"had"
],
"offsets": [
[
1051,
1054
]
],
"normalized": []
},
{
"id": "66130",
"type": "Outcome_Physical",
"text": [
"LH values"
],
"offsets": [
[
1055,
1064
]
],
"normalized": []
},
{
"id": "66131",
"type": "Outcome_Physical",
"text": [
"LH suppression"
],
"offsets": [
[
691,
705
]
],
"normalized": []
},
{
"id": "66132",
"type": "Outcome_Physical",
"text": [
"maintained sex steroid concentrations"
],
"offsets": [
[
1173,
1210
]
],
"normalized": []
},
{
"id": "66133",
"type": "Outcome_Physical",
"text": [
"of pubertal progression"
],
"offsets": [
[
1253,
1276
]
],
"normalized": []
},
{
"id": "66134",
"type": "Outcome_Adverse-effects",
"text": [
"AEs"
],
"offsets": [
[
945,
948
]
],
"normalized": []
},
{
"id": "66135",
"type": "Outcome_Pain",
"text": [
"with injection site pain"
],
"offsets": [
[
1316,
1340
]
],
"normalized": []
},
{
"id": "66136",
"type": "Outcome_Adverse-effects",
"text": [
"No AE"
],
"offsets": [
[
1384,
1389
]
],
"normalized": []
},
{
"id": "66137",
"type": "Outcome_Other",
"text": [
"The safety profile"
],
"offsets": [
[
1429,
1447
]
],
"normalized": []
},
{
"id": "66138",
"type": "Outcome_Other",
"text": [
"an acceptable safety profile"
],
"offsets": [
[
1613,
1641
]
],
"normalized": []
},
{
"id": "66139",
"type": "Outcome_Physical",
"text": [
"provided maintenance of LH suppression"
],
"offsets": [
[
1646,
1684
]
],
"normalized": []
}
] | [] | [] | [] |
66140 | 24928832 | [
{
"id": "66141",
"type": "document",
"text": [
"A randomized , phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck . BACKGROUND Afatinib is an oral , irreversible ErbB family blocker that has shown activity in epidermal growth factor receptor ( EGFR ) -mutated lung cancer . We hypothesized that the agent would have greater antitumor activity compared with cetuximab in recurrent or metastatic ( R/M ) head and neck squamous cell carcinoma ( HNSCC ) patients , whose disease has progressed after platinum-containing therapy . PATIENTS AND METHODS An open-label , randomized , phase II trial was conducted in 43 centers ; 124 patients were randomized ( 1 : 1 ) to either afatinib ( 50 mg/day ) or cetuximab ( 250 mg/m ( 2 ) /week ) until disease progression or intolerable adverse events ( AEs ) ( stage I ) , with optional crossover ( stage II ) . The primary end point was tumor shrinkage before crossover assessed by investigator ( IR ) and independent central review ( ICR ) . RESULTS A total of 121 patients were treated ( 61 afatinib , 60 cetuximab ) and 68 crossed over to stage II ( 32 and 36 respectively ) . In stage I , mean tumor shrinkage by IR/ICR was 10.4 % /16.6 % with afatinib and 5.4 % /10.1 % with cetuximab ( P = 0.46/0.30 ) . Objective response rate was 16.1 % /8.1 % with afatinib and 6.5 % /9.7 % with cetuximab ( IR/ICR ) . Comparable disease control rates were observed with afatinib ( 50 % ) and cetuximab ( 56.5 % ) by IR ; similar results were seen by ICR . Most common grade ≥3 drug-related AEs ( DRAEs ) were rash/acne ( 18 % versus 8.3 % ) , diarrhea ( 14.8 % versus 0 % ) , and stomatitis/mucositis ( 11.5 % versus 0 % ) with afatinib and cetuximab , respectively . Patients with DRAEs leading to treatment discontinuation were 23 % with afatinib and 5 % with cetuximab . In stage II , disease control rate ( IR/ICR ) was 38.9 % /33.3 % with afatinib and 18.8 % /18.8 % with cetuximab . CONCLUSION Afatinib showed antitumor activity comparable to cetuximab in R/M HNSCC in this exploratory phase II trial , although more patients on afatinib discontinued treatment due to AEs . Sequential EGFR/ErbB treatment with afatinib and cetuximab provided sustained clinical benefit in patients after crossover , suggesting a lack of cross-resistance ."
],
"offsets": [
[
0,
2291
]
]
}
] | [
{
"id": "66142",
"type": "Intervention_Pharmacological",
"text": [
"afatinib"
],
"offsets": [
[
33,
41
]
],
"normalized": []
},
{
"id": "66143",
"type": "Intervention_Pharmacological",
"text": [
"cetuximab"
],
"offsets": [
[
49,
58
]
],
"normalized": []
},
{
"id": "66144",
"type": "Outcome_Physical",
"text": [
"antitumor activity"
],
"offsets": [
[
341,
359
]
],
"normalized": []
},
{
"id": "66145",
"type": "Outcome_Other",
"text": [
"tumor shrinkage before crossover assessed by investigator"
],
"offsets": [
[
891,
948
]
],
"normalized": []
},
{
"id": "66146",
"type": "Outcome_Other",
"text": [
"independent central review ( ICR )"
],
"offsets": [
[
960,
994
]
],
"normalized": []
},
{
"id": "66147",
"type": "Outcome_Physical",
"text": [
"mean tumor shrinkage by IR/ICR"
],
"offsets": [
[
1147,
1177
]
],
"normalized": []
},
{
"id": "66148",
"type": "Outcome_Other",
"text": [
"Comparable disease control rates"
],
"offsets": [
[
1365,
1397
]
],
"normalized": []
},
{
"id": "66149",
"type": "Participant_Condition",
"text": [
"metastatic or recurrent squamous cell carcinoma of the head and neck"
],
"offsets": [
[
62,
130
]
],
"normalized": []
},
{
"id": "66150",
"type": "Participant_Condition",
"text": [
"recurrent or metastatic ( R/M ) head and neck squamous cell carcinoma ( HNSCC ) patients"
],
"offsets": [
[
387,
475
]
],
"normalized": []
},
{
"id": "66151",
"type": "Participant_Condition",
"text": [
"disease has progressed after platinum-containing therapy"
],
"offsets": [
[
484,
540
]
],
"normalized": []
},
{
"id": "66152",
"type": "Participant_Sample-size",
"text": [
"124 patients"
],
"offsets": [
[
638,
650
]
],
"normalized": []
},
{
"id": "66153",
"type": "Participant_Sample-size",
"text": [
"121 patients"
],
"offsets": [
[
1016,
1028
]
],
"normalized": []
},
{
"id": "66154",
"type": "Participant_Sample-size",
"text": [
"61 afatinib"
],
"offsets": [
[
1044,
1055
]
],
"normalized": []
},
{
"id": "66155",
"type": "Participant_Sample-size",
"text": [
"60 cetuximab"
],
"offsets": [
[
1058,
1070
]
],
"normalized": []
},
{
"id": "66156",
"type": "Participant_Sample-size",
"text": [
"68 crossed over to stage II"
],
"offsets": [
[
1077,
1104
]
],
"normalized": []
},
{
"id": "66157",
"type": "Participant_Sample-size",
"text": [
"32"
],
"offsets": [
[
1107,
1109
]
],
"normalized": []
},
{
"id": "66158",
"type": "Participant_Sample-size",
"text": [
"36"
],
"offsets": [
[
1114,
1116
]
],
"normalized": []
}
] | [] | [] | [] |
66159 | 24930179 | [
{
"id": "66160",
"type": "document",
"text": [
"The effects of prism adaptation on egocentric metric distance estimation . OBJECTIVE The present experiment evaluated whether training involving throwing transferred to metric distance estimation ( i.e. , describing in feet and inches the distance between oneself and targets ) . BACKGROUND In prior work , we found that metric estimation training negatively transferred to throwing . We explained our results in terms of cognitive intrusion . The present study tested that possibility by swapping our training and transfer tasks . METHOD During pretesting , participants verbally estimated the metric distances between themselves and targets , or they threw a beanbag to targets . During training , participants donned goggles that distorted their vision . While wearing the goggles , they threw a beanbag to targets . Half received feedback . During posttesting , participants removed the distorting goggles and completed the same task that they performed during pretesting . RESULTS The results indicated that the distorting goggles degraded throwing at the beginning of training , visual feedback improved throwing during training , the effects of training with feedback persisted into the throwing posttest , and the effects of training with feedback did not transfer to the verbal metric estimation posttest . CONCLUSION Training involving throwing was effective , but did not transfer to verbal metric distance estimation . This supports our argument that the negative transfer observed in our previous study stemmed from cognitive intrusion . APPLICATION The present experiment suggests that the creation of distance estimation training should begin with a careful analysis of the transfer task , and that distance estimation training programs should explicitly teach trainees that their training will not generalize to all distance estimation tasks ."
],
"offsets": [
[
0,
1859
]
]
}
] | [
{
"id": "66161",
"type": "Intervention_Educational",
"text": [
"verbally estimated the metric distances"
],
"offsets": [
[
572,
611
]
],
"normalized": []
},
{
"id": "66162",
"type": "Intervention_Educational",
"text": [
"threw a beanbag to targets"
],
"offsets": [
[
653,
679
]
],
"normalized": []
},
{
"id": "66163",
"type": "Intervention_Educational",
"text": [
"participants donned goggles"
],
"offsets": [
[
700,
727
]
],
"normalized": []
},
{
"id": "66164",
"type": "Intervention_Educational",
"text": [
"threw a beanbag to targets"
],
"offsets": [
[
653,
679
]
],
"normalized": []
},
{
"id": "66165",
"type": "Intervention_Educational",
"text": [
"goggles"
],
"offsets": [
[
720,
727
]
],
"normalized": []
},
{
"id": "66166",
"type": "Outcome_Other",
"text": [
"effects"
],
"offsets": [
[
4,
11
]
],
"normalized": []
},
{
"id": "66167",
"type": "Outcome_Other",
"text": [
"metric distance estimation ."
],
"offsets": [
[
46,
74
]
],
"normalized": []
},
{
"id": "66168",
"type": "Outcome_Other",
"text": [
"verbal metric estimation"
],
"offsets": [
[
1280,
1304
]
],
"normalized": []
},
{
"id": "66169",
"type": "Outcome_Other",
"text": [
"throwing"
],
"offsets": [
[
145,
153
]
],
"normalized": []
},
{
"id": "66170",
"type": "Outcome_Other",
"text": [
"effective"
],
"offsets": [
[
1359,
1368
]
],
"normalized": []
},
{
"id": "66171",
"type": "Outcome_Other",
"text": [
"verbal metric distance estimation ."
],
"offsets": [
[
1395,
1430
]
],
"normalized": []
},
{
"id": "66172",
"type": "Participant_Condition",
"text": [
"participants verbally estimated the metric distances between themselves and targets , or they threw a beanbag to targets"
],
"offsets": [
[
559,
679
]
],
"normalized": []
},
{
"id": "66173",
"type": "Participant_Condition",
"text": [
"trainees that their training"
],
"offsets": [
[
1776,
1804
]
],
"normalized": []
}
] | [] | [] | [] |
66174 | 24930383 | [
{
"id": "66175",
"type": "document",
"text": [
"Elevation of HDL-C in response to statin treatment is involved in the regression of carotid atherosclerosis . AIM Atherosclerosis is strongly associated with an increased mortality in subjects with diabetes . The carotid intima-media thickness ( IMT ) is commonly measured as a surrogate marker for cardiovascular risk . Statins are well-established protective agents against atherosclerosis and reportedly suppress IMT progression in subjects with diabetes . To clarify the effects of statins on subclinical atherosclerosis , we herein investigated changes in the carotid IMT and lipid profiles in a multi-center , prospective , randomized trial . METHODS Hypercholesterolemic subjects with type 2 diabetes were randomly assigned to open-label treatment with either pravastatin or pitavastatin . The primary endpoint of this study was the IMT change after 36 months of statin treatment . RESULTS A total of 97 subjects ( 51 pitavastatin ; 46 pravastatin ) completed this 36-month study . The LDL-C decreased significantly from 163.4 ± 27.9 mg/dl at baseline to 100.4 ± 19.6 mg/dl at 36 months in the pitavastatin group and from 159.7 ± 25.6 mg/dl to 118.5 ± 22.1 mg/dl in the pravastatin group . The mean IMT showed moderate regression in both the pitavastatin ( -0.070 ± 0.215 mm , P < 0.05 ) and the pravastatin ( -0.067 ± 0.260 mm ) group . However , there was no significant difference in the IMT change between the two groups . When the two groups were combined , the 36-month change in the mean IMT was significantly associated with HDL-C change ( r=-0.24 , P= 0.03 ) . Multiple linear regression analysis revealed the change in HDL-C to be an independent variable showing a positive correlation with the carotid IMT reduction . CONCLUSION The administration of statins for 3 years to subjects with type 2 diabetes resulted in a significant regression of the carotid IMT . An elevation of the plasma HDL-C with statin treatment was closely related to a regression of atherosclerosis ."
],
"offsets": [
[
0,
1991
]
]
}
] | [
{
"id": "66176",
"type": "Intervention_Pharmacological",
"text": [
"statin"
],
"offsets": [
[
34,
40
]
],
"normalized": []
},
{
"id": "66177",
"type": "Intervention_Pharmacological",
"text": [
"pravastatin"
],
"offsets": [
[
767,
778
]
],
"normalized": []
},
{
"id": "66178",
"type": "Intervention_Pharmacological",
"text": [
"pitavastatin"
],
"offsets": [
[
782,
794
]
],
"normalized": []
},
{
"id": "66179",
"type": "Intervention_Pharmacological",
"text": [
"statin"
],
"offsets": [
[
34,
40
]
],
"normalized": []
},
{
"id": "66180",
"type": "Intervention_Pharmacological",
"text": [
"pitavastatin"
],
"offsets": [
[
782,
794
]
],
"normalized": []
},
{
"id": "66181",
"type": "Intervention_Pharmacological",
"text": [
"pravastatin"
],
"offsets": [
[
767,
778
]
],
"normalized": []
},
{
"id": "66182",
"type": "Intervention_Pharmacological",
"text": [
"pitavastatin"
],
"offsets": [
[
782,
794
]
],
"normalized": []
},
{
"id": "66183",
"type": "Intervention_Pharmacological",
"text": [
"pravastatin"
],
"offsets": [
[
767,
778
]
],
"normalized": []
},
{
"id": "66184",
"type": "Outcome_Physical",
"text": [
"carotid intima-media thickness ( IMT )"
],
"offsets": [
[
213,
251
]
],
"normalized": []
},
{
"id": "66185",
"type": "Outcome_Physical",
"text": [
"IMT change"
],
"offsets": [
[
840,
850
]
],
"normalized": []
},
{
"id": "66186",
"type": "Outcome_Physical",
"text": [
"LDL-C"
],
"offsets": [
[
993,
998
]
],
"normalized": []
},
{
"id": "66187",
"type": "Outcome_Other",
"text": [
"The mean"
],
"offsets": [
[
1197,
1205
]
],
"normalized": []
},
{
"id": "66188",
"type": "Outcome_Physical",
"text": [
"in the IMT change"
],
"offsets": [
[
1391,
1408
]
],
"normalized": []
},
{
"id": "66189",
"type": "Outcome_Other",
"text": [
"the mean"
],
"offsets": [
[
1493,
1501
]
],
"normalized": []
},
{
"id": "66190",
"type": "Outcome_Physical",
"text": [
"associated with HDL-C change"
],
"offsets": [
[
1524,
1552
]
],
"normalized": []
},
{
"id": "66191",
"type": "Outcome_Physical",
"text": [
"change in"
],
"offsets": [
[
1483,
1492
]
],
"normalized": []
},
{
"id": "66192",
"type": "Outcome_Physical",
"text": [
"the carotid"
],
"offsets": [
[
561,
572
]
],
"normalized": []
},
{
"id": "66193",
"type": "Outcome_Physical",
"text": [
"the plasma"
],
"offsets": [
[
1896,
1906
]
],
"normalized": []
},
{
"id": "66194",
"type": "Participant_Condition",
"text": [
"carotid atherosclerosis"
],
"offsets": [
[
84,
107
]
],
"normalized": []
},
{
"id": "66195",
"type": "Participant_Condition",
"text": [
"diabetes"
],
"offsets": [
[
198,
206
]
],
"normalized": []
},
{
"id": "66196",
"type": "Participant_Condition",
"text": [
"type 2 diabetes"
],
"offsets": [
[
692,
707
]
],
"normalized": []
},
{
"id": "66197",
"type": "Participant_Sample-size",
"text": [
"97"
],
"offsets": [
[
908,
910
]
],
"normalized": []
},
{
"id": "66198",
"type": "Participant_Sample-size",
"text": [
"51"
],
"offsets": [
[
922,
924
]
],
"normalized": []
},
{
"id": "66199",
"type": "Participant_Sample-size",
"text": [
"46"
],
"offsets": [
[
940,
942
]
],
"normalized": []
}
] | [] | [] | [] |
66200 | 24930546 | [
{
"id": "66201",
"type": "document",
"text": [
"Metal release and metal allergy after total hip replacement with resurfacing versus conventional hybrid prosthesis . BACKGROUND Metal-on-metal ( MOM ) total hip arthroplasties were reintroduced because of the problems with osteolysis and aseptic loosening related to polyethylene wear of early metal-on-polyethylene ( MOP ) arthroplasties . The volumetric wear rate has been greatly reduced with MOM arthroplasties ; however , because of nano-size wear particles , the absolute number has been greatly increased . Thus , a source of metal ion exposure with the potential to sensitize patients is present . We hypothesized that higher amounts of wear particles result in increased release of metal ions and ultimately lead to an increased incidence of metal allergy . METHODS 52 hips in 52 patients ( median age 60 ( 51-64 ) years , 30 women ) were randomized to either a MOM hip resurfacing system ( ReCap ) or a standard MOP total hip arthoplasty ( Mallory Head/Exeter ) . Spot urine samples were collected preoperatively , postoperatively , after 3 months , and after 1 , 2 , and 5 years and tested with inductively coupled plasma-sector field mass spectrometry . After 5 years , hypersensitivity to metals was evaluated by patch testing and lymphocyte transformation assay . In addition , the patients answered a questionnaire about hypersensitivity . RESULTS A statistically significant 10- to 20-fold increase in urinary levels of cobalt and chromium was observed throughout the entire follow-up in the MOM group . The prevalence of metal allergy was similar between groups . INTERPRETATION While we observed significantly increased levels of metal ions in the urine during the entire follow-up period , no difference in prevalence of metal allergy was observed in the MOM group . However , the effect of long-term metal exposure remains uncertain ."
],
"offsets": [
[
0,
1854
]
]
}
] | [
{
"id": "66202",
"type": "Intervention_Physical",
"text": [
"total hip replacement with resurfacing"
],
"offsets": [
[
38,
76
]
],
"normalized": []
},
{
"id": "66203",
"type": "Intervention_Physical",
"text": [
"conventional"
],
"offsets": [
[
84,
96
]
],
"normalized": []
},
{
"id": "66204",
"type": "Intervention_Surgical",
"text": [
"hybrid prosthesis"
],
"offsets": [
[
97,
114
]
],
"normalized": []
},
{
"id": "66205",
"type": "Intervention_Physical",
"text": [
"Metal-on-metal ( MOM ) total"
],
"offsets": [
[
128,
156
]
],
"normalized": []
},
{
"id": "66206",
"type": "Intervention_Surgical",
"text": [
"hip arthroplasties"
],
"offsets": [
[
157,
175
]
],
"normalized": []
},
{
"id": "66207",
"type": "Intervention_Physical",
"text": [
"MOM hip resurfacing system ( ReCap )"
],
"offsets": [
[
871,
907
]
],
"normalized": []
},
{
"id": "66208",
"type": "Intervention_Physical",
"text": [
"standard MOP total hip arthoplasty ( Mallory Head/Exeter )"
],
"offsets": [
[
913,
971
]
],
"normalized": []
},
{
"id": "66209",
"type": "Intervention_Physical",
"text": [
"MOM"
],
"offsets": [
[
145,
148
]
],
"normalized": []
},
{
"id": "66210",
"type": "Intervention_Physical",
"text": [
"MOM"
],
"offsets": [
[
145,
148
]
],
"normalized": []
},
{
"id": "66211",
"type": "Outcome_Physical",
"text": [
"Metal release"
],
"offsets": [
[
0,
13
]
],
"normalized": []
},
{
"id": "66212",
"type": "Outcome_Physical",
"text": [
"metal allergy"
],
"offsets": [
[
18,
31
]
],
"normalized": []
},
{
"id": "66213",
"type": "Outcome_Adverse-effects",
"text": [
"release of metal ions"
],
"offsets": [
[
680,
701
]
],
"normalized": []
},
{
"id": "66214",
"type": "Outcome_Adverse-effects",
"text": [
"incidence of metal allergy"
],
"offsets": [
[
738,
764
]
],
"normalized": []
},
{
"id": "66215",
"type": "Outcome_Adverse-effects",
"text": [
"hypersensitivity to metals"
],
"offsets": [
[
1182,
1208
]
],
"normalized": []
},
{
"id": "66216",
"type": "Outcome_Physical",
"text": [
"hypersensitivity"
],
"offsets": [
[
1182,
1198
]
],
"normalized": []
},
{
"id": "66217",
"type": "Outcome_Physical",
"text": [
"urinary levels of cobalt and chromium"
],
"offsets": [
[
1418,
1455
]
],
"normalized": []
},
{
"id": "66218",
"type": "Outcome_Adverse-effects",
"text": [
"metal allergy"
],
"offsets": [
[
18,
31
]
],
"normalized": []
},
{
"id": "66219",
"type": "Outcome_Physical",
"text": [
"levels of metal ions in the urine"
],
"offsets": [
[
1638,
1671
]
],
"normalized": []
},
{
"id": "66220",
"type": "Outcome_Physical",
"text": [
"prevalence of metal allergy"
],
"offsets": [
[
1524,
1551
]
],
"normalized": []
},
{
"id": "66221",
"type": "Participant_Condition",
"text": [
"total hip replacement with resurfacing"
],
"offsets": [
[
38,
76
]
],
"normalized": []
},
{
"id": "66222",
"type": "Participant_Condition",
"text": [
"Metal-on-metal ( MOM )"
],
"offsets": [
[
128,
150
]
],
"normalized": []
},
{
"id": "66223",
"type": "Participant_Sample-size",
"text": [
"52"
],
"offsets": [
[
775,
777
]
],
"normalized": []
},
{
"id": "66224",
"type": "Participant_Age",
"text": [
"60"
],
"offsets": [
[
811,
813
]
],
"normalized": []
},
{
"id": "66225",
"type": "Participant_Age",
"text": [
"51-64"
],
"offsets": [
[
816,
821
]
],
"normalized": []
},
{
"id": "66226",
"type": "Participant_Age",
"text": [
"30 women"
],
"offsets": [
[
832,
840
]
],
"normalized": []
}
] | [] | [] | [] |
66227 | 24934732 | [
{
"id": "66228",
"type": "document",
"text": [
"A randomized , prospective , parallel group study of laparoscopic versus laparoendoscopic single site donor nephrectomy for kidney donation . Few prospective , randomized studies have assessed the benefits of laparoendoscopic single site donor nephrectomy ( LESS-DN ) over laparoscopic donor nephrectomy ( LDN ) . Our center initiated such a trial in January 2011 , following subjects randomized to LESS-DN versus LDN from surgery through 5 years postdonation . Subjects complete recovery/satisfaction questionnaires at 2 , 6 and 12 months postdonation ; transplant recipient outcomes are also recorded . One hundred subjects ( 49 LESS-DN , 51 LDN ) underwent surgery ; donor demographics were similar between groups , and included a predominance of female , living-unrelated donors , mean age of 47 years who underwent left donor nephrectomy . Operative parameters ( overall time , time to extraction , warm ischemia time , blood loss ) were similar between groups . Conversion to hand-assist laparoscopy was required in 3 LESS-DN ( 6.1 % ) versus 2 LDN ( 3.9 % ; p = 0.67 ) . Questionnaires revealed that 97.2 % of LESS-DN versus 79.5 % of LDN ( p = 0.03 ) were 100 % recovered by 2 months after donation . No significant difference was seen in satisfaction scores between the groups . Recipient outcomes were similar between groups . Our randomized trial comparing LESS donor nephrectomy to LDN confirms that LESS-DN offers a safe alternative to conventional LDN in terms of intra- and post-operative complications . LDN and LESS-DN offer similar recovery and satisfaction after donation ."
],
"offsets": [
[
0,
1592
]
]
}
] | [
{
"id": "66229",
"type": "Intervention_Surgical",
"text": [
"laparoscopic"
],
"offsets": [
[
53,
65
]
],
"normalized": []
},
{
"id": "66230",
"type": "Intervention_Physical",
"text": [
"versus"
],
"offsets": [
[
66,
72
]
],
"normalized": []
},
{
"id": "66231",
"type": "Intervention_Surgical",
"text": [
"laparoendoscopic single site donor nephrectomy"
],
"offsets": [
[
73,
119
]
],
"normalized": []
},
{
"id": "66232",
"type": "Intervention_Surgical",
"text": [
"laparoendoscopic single site donor nephrectomy ( LESS-DN"
],
"offsets": [
[
209,
265
]
],
"normalized": []
},
{
"id": "66233",
"type": "Intervention_Physical",
"text": [
")"
],
"offsets": [
[
266,
267
]
],
"normalized": []
},
{
"id": "66234",
"type": "Intervention_Surgical",
"text": [
"laparoscopic donor nephrectomy ( LDN"
],
"offsets": [
[
273,
309
]
],
"normalized": []
},
{
"id": "66235",
"type": "Intervention_Physical",
"text": [
")"
],
"offsets": [
[
266,
267
]
],
"normalized": []
},
{
"id": "66236",
"type": "Intervention_Surgical",
"text": [
"LESS-DN"
],
"offsets": [
[
258,
265
]
],
"normalized": []
},
{
"id": "66237",
"type": "Intervention_Physical",
"text": [
"versus"
],
"offsets": [
[
66,
72
]
],
"normalized": []
},
{
"id": "66238",
"type": "Intervention_Surgical",
"text": [
"LDN"
],
"offsets": [
[
306,
309
]
],
"normalized": []
},
{
"id": "66239",
"type": "Intervention_Surgical",
"text": [
"LESS-DN"
],
"offsets": [
[
258,
265
]
],
"normalized": []
},
{
"id": "66240",
"type": "Intervention_Surgical",
"text": [
"LDN"
],
"offsets": [
[
306,
309
]
],
"normalized": []
},
{
"id": "66241",
"type": "Intervention_Surgical",
"text": [
"LESS-DN"
],
"offsets": [
[
258,
265
]
],
"normalized": []
},
{
"id": "66242",
"type": "Intervention_Surgical",
"text": [
"LDN"
],
"offsets": [
[
306,
309
]
],
"normalized": []
},
{
"id": "66243",
"type": "Intervention_Surgical",
"text": [
"LESS-DN"
],
"offsets": [
[
258,
265
]
],
"normalized": []
},
{
"id": "66244",
"type": "Outcome_Other",
"text": [
"benefits"
],
"offsets": [
[
197,
205
]
],
"normalized": []
},
{
"id": "66245",
"type": "Outcome_Other",
"text": [
"recovery/satisfaction questionnaires"
],
"offsets": [
[
480,
516
]
],
"normalized": []
},
{
"id": "66246",
"type": "Outcome_Physical",
"text": [
"overall time , time to extraction , warm ischemia time , blood loss"
],
"offsets": [
[
868,
935
]
],
"normalized": []
},
{
"id": "66247",
"type": "Outcome_Physical",
"text": [
"Conversion to hand-assist laparoscopy"
],
"offsets": [
[
968,
1005
]
],
"normalized": []
},
{
"id": "66248",
"type": "Outcome_Other",
"text": [
"were 100 % recovered"
],
"offsets": [
[
1159,
1179
]
],
"normalized": []
},
{
"id": "66249",
"type": "Outcome_Other",
"text": [
"seen in satisfaction"
],
"offsets": [
[
1239,
1259
]
],
"normalized": []
},
{
"id": "66250",
"type": "Outcome_Other",
"text": [
"groups"
],
"offsets": [
[
710,
716
]
],
"normalized": []
},
{
"id": "66251",
"type": "Outcome_Other",
"text": [
"Recipient outcomes"
],
"offsets": [
[
1288,
1306
]
],
"normalized": []
},
{
"id": "66252",
"type": "Outcome_Other",
"text": [
"offers"
],
"offsets": [
[
1420,
1426
]
],
"normalized": []
},
{
"id": "66253",
"type": "Outcome_Other",
"text": [
"similar recovery and satisfaction"
],
"offsets": [
[
1542,
1575
]
],
"normalized": []
},
{
"id": "66254",
"type": "Participant_Condition",
"text": [
"nephrectomy for kidney donation ."
],
"offsets": [
[
108,
141
]
],
"normalized": []
},
{
"id": "66255",
"type": "Participant_Sample-size",
"text": [
"One hundred"
],
"offsets": [
[
605,
616
]
],
"normalized": []
},
{
"id": "66256",
"type": "Participant_Age",
"text": [
"47 years"
],
"offsets": [
[
797,
805
]
],
"normalized": []
},
{
"id": "66257",
"type": "Participant_Condition",
"text": [
"ischemia"
],
"offsets": [
[
909,
917
]
],
"normalized": []
},
{
"id": "66258",
"type": "Participant_Condition",
"text": [
"blood loss"
],
"offsets": [
[
925,
935
]
],
"normalized": []
}
] | [] | [] | [] |
66259 | 2493733 | [
{
"id": "66260",
"type": "document",
"text": [
"Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm . In a single-blind randomized study , the efficacy of intravenous flecainide ( 2 mg/kg/10 minutes ) versus verapamil ( 10 mg/1 minute ) was assessed in 40 patients with paroxysmal atrial fibrillation ( AF ) or atrial flutter ( AFI ) . The treatment was considered successful if sinus rhythm occurred within 1 hour . Of 20 patients receiving flecainide , 14 of 17 ( 82 % ) with AF converted to sinus rhythm , but in 3 patients with AFI flecainide failed . All patients treated with verapamil ( 17 AF , 3 AFI ) showed lower ventricular rates after 1 hour ; however , only 1 ( 6 % ) with AF converted to sinus rhythm and 1 ( 6 % ) converted to AFI . Patients who did not convert to sinus rhythm after treatment with verapamil were treated with flecainide and observed for another hour . After the change to flecainide , 9 of 15 patients ( 60 % ) with AF still converted . Thus , 23 of 32 patients ( 72 % ) with AF and none of 7 with AFI converted to sinus rhythm after treatment with flecainide . Conversion to sinus rhythm was achieved in 19 of 22 patients ( 86 % ) when AF lasted less than 24 hours and in 4 of 10 ( 40 % ) when the arrhythmia lasted greater than 24 hours . Transient adverse effects were noted in 10 patients ( 26 % ) after flecainide . In summary , flecainide is an effective and safe drug for conversion of paroxysmal AF to sinus rhythm , but ineffective for AFI . Verapamil appears to be of no use for conversion of AF or AFI to sinus rhythm ."
],
"offsets": [
[
0,
1585
]
]
}
] | [
{
"id": "66261",
"type": "Intervention_Pharmacological",
"text": [
"Intravenous flecainide"
],
"offsets": [
[
0,
22
]
],
"normalized": []
},
{
"id": "66262",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
30,
39
]
],
"normalized": []
},
{
"id": "66263",
"type": "Intervention_Pharmacological",
"text": [
"intravenous flecainide"
],
"offsets": [
[
177,
199
]
],
"normalized": []
},
{
"id": "66264",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
30,
39
]
],
"normalized": []
},
{
"id": "66265",
"type": "Intervention_Pharmacological",
"text": [
"flecainide"
],
"offsets": [
[
12,
22
]
],
"normalized": []
},
{
"id": "66266",
"type": "Intervention_Pharmacological",
"text": [
"flecainide"
],
"offsets": [
[
12,
22
]
],
"normalized": []
},
{
"id": "66267",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
30,
39
]
],
"normalized": []
},
{
"id": "66268",
"type": "Intervention_Pharmacological",
"text": [
"verapamil"
],
"offsets": [
[
30,
39
]
],
"normalized": []
},
{
"id": "66269",
"type": "Intervention_Pharmacological",
"text": [
"flecainide"
],
"offsets": [
[
12,
22
]
],
"normalized": []
},
{
"id": "66270",
"type": "Intervention_Pharmacological",
"text": [
"flecainide"
],
"offsets": [
[
12,
22
]
],
"normalized": []
},
{
"id": "66271",
"type": "Intervention_Pharmacological",
"text": [
"Verapamil"
],
"offsets": [
[
1506,
1515
]
],
"normalized": []
},
{
"id": "66272",
"type": "Outcome_Other",
"text": [
"efficacy"
],
"offsets": [
[
165,
173
]
],
"normalized": []
},
{
"id": "66273",
"type": "Outcome_Physical",
"text": [
"sinus rhythm"
],
"offsets": [
[
109,
121
]
],
"normalized": []
},
{
"id": "66274",
"type": "Outcome_Physical",
"text": [
"lower ventricular rates"
],
"offsets": [
[
639,
662
]
],
"normalized": []
},
{
"id": "66275",
"type": "Outcome_Physical",
"text": [
"converted ."
],
"offsets": [
[
980,
991
]
],
"normalized": []
},
{
"id": "66276",
"type": "Outcome_Physical",
"text": [
"Conversion to sinus rhythm"
],
"offsets": [
[
1117,
1143
]
],
"normalized": []
},
{
"id": "66277",
"type": "Outcome_Adverse-effects",
"text": [
"Transient adverse effects"
],
"offsets": [
[
1296,
1321
]
],
"normalized": []
},
{
"id": "66278",
"type": "Outcome_Other",
"text": [
"effective and safe drug"
],
"offsets": [
[
1406,
1429
]
],
"normalized": []
},
{
"id": "66279",
"type": "Outcome_Physical",
"text": [
"conversion of AF or AFI"
],
"offsets": [
[
1544,
1567
]
],
"normalized": []
},
{
"id": "66280",
"type": "Participant_Condition",
"text": [
"sinus rhythm"
],
"offsets": [
[
109,
121
]
],
"normalized": []
},
{
"id": "66281",
"type": "Participant_Sample-size",
"text": [
"40"
],
"offsets": [
[
275,
277
]
],
"normalized": []
},
{
"id": "66282",
"type": "Participant_Condition",
"text": [
"paroxysmal atrial fibrillation"
],
"offsets": [
[
64,
94
]
],
"normalized": []
},
{
"id": "66283",
"type": "Participant_Sample-size",
"text": [
"20"
],
"offsets": [
[
442,
444
]
],
"normalized": []
},
{
"id": "66284",
"type": "Participant_Sample-size",
"text": [
"14"
],
"offsets": [
[
477,
479
]
],
"normalized": []
},
{
"id": "66285",
"type": "Participant_Sample-size",
"text": [
"17"
],
"offsets": [
[
483,
485
]
],
"normalized": []
},
{
"id": "66286",
"type": "Participant_Condition",
"text": [
"sinus rhythm"
],
"offsets": [
[
109,
121
]
],
"normalized": []
}
] | [] | [] | [] |
66287 | 24938562 | [
{
"id": "66288",
"type": "document",
"text": [
"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma : a randomized clinical trial . IMPORTANCE Uveal melanoma is characterized by mutations in GNAQ and GNA11 , resulting in mitogen-activated protein kinase pathway activation . OBJECTIVE To assess the efficacy of selumetinib , a selective , non-adenosine triphosphate competitive inhibitor of MEK1 and MEK2 , in uveal melanoma . DESIGN , SETTING , AND PARTICIPANTS Randomized , open-label , phase 2 clinical trial comparing selumetinib vs chemotherapy conducted from August 2010 through December 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the United States and Canada . INTERVENTIONS One hundred one patients were randomized in a 1:1 ratio to receive selumetinib , 75 mg orally twice daily on a continual basis ( n = 50 ) , or chemotherapy ( temozolomide , 150 mg/m2 orally daily for 5 of every 28 days , or dacarbazine , 1000 mg/m2 intravenously every 21 days [ investigator choice ] ; n = 51 ) until disease progression , death , intolerable adverse effects , or withdrawal of consent . After primary outcome analysis , 19 patients were registered and 18 treated with selumetinib without randomization to complete the planned 120-patient enrollment . Patients in the chemotherapy group could receive selumetinib at the time of radiographic progression . MAIN OUTCOMES AND MEASURES Progression-free survival , the primary end point , was assessed as of April 22 , 2013 . Additional end points , including overall survival , response rate , and safety/toxicity , were assessed as of December 31 , 2013 . RESULTS Median progression-free survival among patients randomized to chemotherapy was 7 weeks ( 95 % CI , 4.3-8.4 weeks ; median treatment duration , 8 weeks ; interquartile range [ IQR ] , 4.3-16 weeks ) and among those randomized to selumetinib was 15.9 weeks ( 95 % CI , 8.4-21.1 weeks ; median treatment duration , 16.1 weeks ; IQR , 8.1-25.3 weeks ) ( hazard ratio , 0.46 ; 95 % CI , 0.30-0.71 ; P < .001 ) . Median overall survival time was 9.1 months ( 95 % CI , 6.1-11.1 months ) with chemotherapy and 11.8 months ( 95 % CI , 9.8-15.7 months ) with selumetinib ( hazard ratio , 0.66 ; 95 % CI , 0.41-1.06 ; P = .09 ) . No objective responses were observed with chemotherapy . Forty-nine percent of patients treated with selumetinib achieved tumor regression , with 14 % achieving an objective radiographic response to therapy . Treatment-related adverse events were observed in 97 % of patients treated with selumetinib , with 37 % requiring at least 1 dose reduction . CONCLUSIONS AND RELEVANCE In this hypothesis-generating study of patients with advanced uveal melanoma , selumetinib compared with chemotherapy resulted in a modestly improved progression-free survival and response rate ; however , no improvement in overall survival was observed . Improvement in clinical outcomes was accompanied by a high rate of adverse events . TRIAL REGISTRATION clinicaltrials.gov Identifier : NCT01143402 ."
],
"offsets": [
[
0,
3043
]
]
}
] | [
{
"id": "66289",
"type": "Intervention_Pharmacological",
"text": [
"selumetinib"
],
"offsets": [
[
10,
21
]
],
"normalized": []
},
{
"id": "66290",
"type": "Intervention_Pharmacological",
"text": [
"chemotherapy"
],
"offsets": [
[
25,
37
]
],
"normalized": []
},
{
"id": "66291",
"type": "Intervention_Pharmacological",
"text": [
"selumetinib"
],
"offsets": [
[
10,
21
]
],
"normalized": []
},
{
"id": "66292",
"type": "Intervention_Pharmacological",
"text": [
"selumetinib"
],
"offsets": [
[
10,
21
]
],
"normalized": []
},
{
"id": "66293",
"type": "Intervention_Physical",
"text": [
"chemotherapy"
],
"offsets": [
[
25,
37
]
],
"normalized": []
},
{
"id": "66294",
"type": "Intervention_Pharmacological",
"text": [
"selumetinib"
],
"offsets": [
[
10,
21
]
],
"normalized": []
},
{
"id": "66295",
"type": "Intervention_Pharmacological",
"text": [
"temozolomide"
],
"offsets": [
[
872,
884
]
],
"normalized": []
},
{
"id": "66296",
"type": "Intervention_Pharmacological",
"text": [
"selumetinib"
],
"offsets": [
[
10,
21
]
],
"normalized": []
},
{
"id": "66297",
"type": "Intervention_Pharmacological",
"text": [
"selumetinib"
],
"offsets": [
[
10,
21
]
],
"normalized": []
},
{
"id": "66298",
"type": "Outcome_Other",
"text": [
"Progression-free survival"
],
"offsets": [
[
1413,
1438
]
],
"normalized": []
},
{
"id": "66299",
"type": "Outcome_Other",
"text": [
"overall survival"
],
"offsets": [
[
1536,
1552
]
],
"normalized": []
},
{
"id": "66300",
"type": "Participant_Condition",
"text": [
"uveal melanoma :"
],
"offsets": [
[
70,
86
]
],
"normalized": []
},
{
"id": "66301",
"type": "Participant_Condition",
"text": [
"uveal melanoma"
],
"offsets": [
[
70,
84
]
],
"normalized": []
},
{
"id": "66302",
"type": "Participant_Condition",
"text": [
"metastatic uveal melanoma"
],
"offsets": [
[
608,
633
]
],
"normalized": []
}
] | [] | [] | [] |
66303 | 24939380 | [
{
"id": "66304",
"type": "document",
"text": [
"Electrothermal arthroscopic capsulorrhaphy : old technology , new evidence . A multicenter randomized clinical trial . BACKGROUND Radiofrequency technology for shoulder instability was rapidly adopted despite limited clinical evidence and a poor understanding of its indications . Reports of serious adverse events followed , leading to its abandonment . This paper presents findings from a multicenter randomized clinical trial evaluating the safety and efficacy of electrothermal arthroscopic capsulorrhaphy ( ETAC ) compared with open inferior capsular shift ( ICS ) and reviews the role of randomized trials in adopting new technology . METHODS Patients ( > 14 years ) diagnosed with multidirectional instability or multidirectional laxity with anteroinferior instability and failed nonoperative treatment were enrolled . Patients with bone lesions or labral , biceps anchor , or full-thickness rotator cuff tears were excluded intraoperatively . Outcomes included Western Ontario Shoulder Instability Index , function and recurrent instability at 2 years postoperatively , and surgical times . RESULTS Fifty-four subjects ( mean age , 23 years ; 37 women ) were randomized to ETAC ( n = 28 ) or open ICS ( n = 26 ) . The groups were comparable at baseline , except for external rotation at the side . At 2 years postoperatively , there were no statistically or clinically significant differences between groups for the Western Ontario Shoulder Instability Index ( P = .71 ) , American Shoulder and Elbow Surgeons score ( P = .43 ) , Constant score ( P = .43 ) , and active range of motion . Recurrent instability was not statistically different ( ETAC , 2 ; open , 4 ; P = .41 ) . ETAC ( 23 minutes ) was significantly shorter than open ICS ( 59 minutes ) ( P < .01 ) surgery . Three subjects ( 1 ETAC , 2 open ) had stiff shoulders . CONCLUSIONS At 2 years postoperatively , quality of life and functional outcomes between groups were not clinically different . ETAC had fewer complications and episodes of recurrence compared with open surgery . This evidence reinforces the need to critically evaluate new technology before widespread clinical use ."
],
"offsets": [
[
0,
2157
]
]
}
] | [
{
"id": "66305",
"type": "Intervention_Physical",
"text": [
"Electrothermal arthroscopic capsulorrhaphy"
],
"offsets": [
[
0,
42
]
],
"normalized": []
},
{
"id": "66306",
"type": "Intervention_Physical",
"text": [
"electrothermal arthroscopic capsulorrhaphy ( ETAC )"
],
"offsets": [
[
467,
518
]
],
"normalized": []
},
{
"id": "66307",
"type": "Intervention_Physical",
"text": [
"open inferior capsular shift ( ICS )"
],
"offsets": [
[
533,
569
]
],
"normalized": []
},
{
"id": "66308",
"type": "Outcome_Physical",
"text": [
"Western Ontario Shoulder Instability Index"
],
"offsets": [
[
969,
1011
]
],
"normalized": []
},
{
"id": "66309",
"type": "Outcome_Physical",
"text": [
"function and recurrent instability at 2 years postoperatively"
],
"offsets": [
[
1014,
1075
]
],
"normalized": []
},
{
"id": "66310",
"type": "Outcome_Other",
"text": [
"surgical times"
],
"offsets": [
[
1082,
1096
]
],
"normalized": []
},
{
"id": "66311",
"type": "Outcome_Physical",
"text": [
"external rotation at the"
],
"offsets": [
[
1274,
1298
]
],
"normalized": []
},
{
"id": "66312",
"type": "Outcome_Physical",
"text": [
"Western Ontario Shoulder Instability"
],
"offsets": [
[
969,
1005
]
],
"normalized": []
},
{
"id": "66313",
"type": "Outcome_Physical",
"text": [
"American Shoulder and Elbow Surgeons"
],
"offsets": [
[
1481,
1517
]
],
"normalized": []
},
{
"id": "66314",
"type": "Outcome_Physical",
"text": [
"active range of motion . Recurrent"
],
"offsets": [
[
1571,
1605
]
],
"normalized": []
},
{
"id": "66315",
"type": "Participant_Condition",
"text": [
"shoulder instability"
],
"offsets": [
[
160,
180
]
],
"normalized": []
},
{
"id": "66316",
"type": "Participant_Age",
"text": [
"Patients ( > 14 years )"
],
"offsets": [
[
649,
672
]
],
"normalized": []
},
{
"id": "66317",
"type": "Participant_Condition",
"text": [
"multidirectional instability"
],
"offsets": [
[
688,
716
]
],
"normalized": []
},
{
"id": "66318",
"type": "Participant_Condition",
"text": [
"multidirectional laxity with anteroinferior instability and failed nonoperative treatment"
],
"offsets": [
[
720,
809
]
],
"normalized": []
},
{
"id": "66319",
"type": "Participant_Sample-size",
"text": [
"Fifty-four"
],
"offsets": [
[
1107,
1117
]
],
"normalized": []
},
{
"id": "66320",
"type": "Participant_Age",
"text": [
"mean age , 23 years"
],
"offsets": [
[
1129,
1148
]
],
"normalized": []
},
{
"id": "66321",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
1154,
1159
]
],
"normalized": []
},
{
"id": "66322",
"type": "Participant_Sample-size",
"text": [
"n = 26"
],
"offsets": [
[
1211,
1217
]
],
"normalized": []
}
] | [] | [] | [] |
66323 | 2494948 | [
{
"id": "66324",
"type": "document",
"text": [
"[ Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma . ( Second report ) : 5-year survival rate . Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy ] . In order to examine the efficacy of adjuvant chemotherapy employing mitomycin C ( MMC ) and carmofur ( HCFU ) for patients with noncuratively resected colorectal carcinoma , a cooperative study was performed by 54 institutions in the Kyushu and Chugoku areas of Japan . The criteria for patient selection were as follows : 1 ) Age of 75 years or less and not accompanied by any serious disease . 2 ) Macroscopic diagnosis as being noncuratively resected on completion of the surgical procedure . 3 ) Definitive diagnosis of colorectal carcinomas , histologically . 4 ) No synchronous or metachronous double cancer . The prospective randomized controlled study consisted of two groups . In Group A , the MMC group received bolus intravenous injections of 20 mg MMC on the day of operation and 10 mg the next day , followed by 10 mg every 4 weeks until a total of 100 mg had been administered . In Group B , the MMC + HCFU group received the same treatment in Group A , but with the addition of 600 mg/day of HCFU from the second week , orally for at least one year . Concerning the 69-month survival rate , a better result was observed in the MMC + HCFU group than in the MMC only group ( generalized Wilcoxon test : p less than 0.05 ) . Significantly better survival rates were obtained in those cases with disseminating peritoneal metastasis , hepatic metastasis and stage V cancer in the MMC + HCFU group as when compared with the MMC only group . No significant side effects due to the combined administration of HCFU were recognized . The combined administration of MMC and HCFU was suggested to be a safe and effective adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma ."
],
"offsets": [
[
0,
1933
]
]
}
] | [
{
"id": "66325",
"type": "Intervention_Pharmacological",
"text": [
"[ Mitomycin C plus HCFU"
],
"offsets": [
[
0,
23
]
],
"normalized": []
},
{
"id": "66326",
"type": "Intervention_Pharmacological",
"text": [
"adjuvant chemotherapy"
],
"offsets": [
[
24,
45
]
],
"normalized": []
},
{
"id": "66327",
"type": "Intervention_Pharmacological",
"text": [
"mitomycin C ( MMC )"
],
"offsets": [
[
297,
316
]
],
"normalized": []
},
{
"id": "66328",
"type": "Intervention_Pharmacological",
"text": [
"carmofur ( HCFU )"
],
"offsets": [
[
321,
338
]
],
"normalized": []
},
{
"id": "66329",
"type": "Intervention_Pharmacological",
"text": [
"MMC"
],
"offsets": [
[
311,
314
]
],
"normalized": []
},
{
"id": "66330",
"type": "Intervention_Pharmacological",
"text": [
"MMC"
],
"offsets": [
[
311,
314
]
],
"normalized": []
},
{
"id": "66331",
"type": "Intervention_Pharmacological",
"text": [
"MMC + HCFU group"
],
"offsets": [
[
1139,
1155
]
],
"normalized": []
},
{
"id": "66332",
"type": "Intervention_Pharmacological",
"text": [
"HCFU"
],
"offsets": [
[
19,
23
]
],
"normalized": []
},
{
"id": "66333",
"type": "Intervention_Pharmacological",
"text": [
"MMC + HCFU"
],
"offsets": [
[
1139,
1149
]
],
"normalized": []
},
{
"id": "66334",
"type": "Intervention_Pharmacological",
"text": [
"MMC + HCFU"
],
"offsets": [
[
1139,
1149
]
],
"normalized": []
},
{
"id": "66335",
"type": "Intervention_Pharmacological",
"text": [
"HCFU"
],
"offsets": [
[
19,
23
]
],
"normalized": []
},
{
"id": "66336",
"type": "Intervention_Pharmacological",
"text": [
"MMC"
],
"offsets": [
[
311,
314
]
],
"normalized": []
},
{
"id": "66337",
"type": "Intervention_Pharmacological",
"text": [
"HCFU"
],
"offsets": [
[
19,
23
]
],
"normalized": []
},
{
"id": "66338",
"type": "Outcome_Mortality",
"text": [
"69-month survival rate"
],
"offsets": [
[
1310,
1332
]
],
"normalized": []
},
{
"id": "66339",
"type": "Outcome_Mortality",
"text": [
"survival rates"
],
"offsets": [
[
1487,
1501
]
],
"normalized": []
},
{
"id": "66340",
"type": "Outcome_Adverse-effects",
"text": [
"significant side effects"
],
"offsets": [
[
1682,
1706
]
],
"normalized": []
},
{
"id": "66341",
"type": "Participant_Condition",
"text": [
"noncuratively resected colorectal carcinoma"
],
"offsets": [
[
357,
400
]
],
"normalized": []
},
{
"id": "66342",
"type": "Participant_Sample-size",
"text": [
"54"
],
"offsets": [
[
440,
442
]
],
"normalized": []
},
{
"id": "66343",
"type": "Participant_Condition",
"text": [
"institutions in the Kyushu and Chugoku areas of Japan"
],
"offsets": [
[
443,
496
]
],
"normalized": []
},
{
"id": "66344",
"type": "Participant_Age",
"text": [
"Age of 75"
],
"offsets": [
[
556,
565
]
],
"normalized": []
},
{
"id": "66345",
"type": "Participant_Condition",
"text": [
"colorectal carcinomas"
],
"offsets": [
[
753,
774
]
],
"normalized": []
}
] | [] | [] | [] |
66346 | 24958585 | [
{
"id": "66347",
"type": "document",
"text": [
"Caregiver-mediated intervention for low-resourced preschoolers with autism : an RCT . OBJECTIVES To compare 2 short-term , community caregiver training interventions for preschool-aged children with Autism Spectrum Disorder who had low resources . Low resource was defined by the US Department of Housing and Urban Development low-income index or 1 \" indicator , \" ( e.g. , Medicaid eligibility ) . Child outcomes focused on joint engagement , joint attention , and play . METHODS Participants included 112 families of a child who had Autism Spectrum Disorder who met criteria for being low-resourced and who were randomly assigned to 1 of 2 3-month interventions , group caregiver education or individualized caregiver-mediated intervention ( CMM ) . Children were assessed for social communication skills pre- and post-treatment , and followed up at 3 months . RESULTS All children improved in joint engagement and initiating joint attention , with significantly greater improvement by the CMM group . Outcomes on play skills were mixed , with improvement of symbolic play for the CMM group and no change in functional play skills . Joint engagement maintained over time for the CMM group , and initiating joint attention maintained for both groups over time . CONCLUSIONS This study is among the first randomized trials comparing 2 active interventions with a large sample of low-resourced families . Results suggest improvements in core autism deficits of joint engagement , joint attention , and symbolic play with relatively brief , caregiver-mediated interventions , but additional support is necessary to maintain and generalize these gains over time ."
],
"offsets": [
[
0,
1660
]
]
}
] | [
{
"id": "66348",
"type": "Intervention_Educational",
"text": [
"intervention"
],
"offsets": [
[
19,
31
]
],
"normalized": []
},
{
"id": "66349",
"type": "Intervention_Educational",
"text": [
"community caregiver training interventions"
],
"offsets": [
[
123,
165
]
],
"normalized": []
},
{
"id": "66350",
"type": "Intervention_Educational",
"text": [
"2 3-month interventions"
],
"offsets": [
[
640,
663
]
],
"normalized": []
},
{
"id": "66351",
"type": "Intervention_Educational",
"text": [
"group caregiver education or individualized caregiver-mediated intervention ( CMM )"
],
"offsets": [
[
666,
749
]
],
"normalized": []
},
{
"id": "66352",
"type": "Intervention_Educational",
"text": [
"CMM"
],
"offsets": [
[
744,
747
]
],
"normalized": []
},
{
"id": "66353",
"type": "Intervention_Educational",
"text": [
"CMM"
],
"offsets": [
[
744,
747
]
],
"normalized": []
},
{
"id": "66354",
"type": "Outcome_Physical",
"text": [
"\" indicator"
],
"offsets": [
[
349,
360
]
],
"normalized": []
},
{
"id": "66355",
"type": "Outcome_Mental",
"text": [
"engagement"
],
"offsets": [
[
431,
441
]
],
"normalized": []
},
{
"id": "66356",
"type": "Outcome_Physical",
"text": [
"pre- and post-treatment"
],
"offsets": [
[
807,
830
]
],
"normalized": []
},
{
"id": "66357",
"type": "Outcome_Mental",
"text": [
"joint engagement"
],
"offsets": [
[
425,
441
]
],
"normalized": []
},
{
"id": "66358",
"type": "Outcome_Mental",
"text": [
"initiating joint attention"
],
"offsets": [
[
917,
943
]
],
"normalized": []
},
{
"id": "66359",
"type": "Outcome_Mental",
"text": [
"play skills"
],
"offsets": [
[
1016,
1027
]
],
"normalized": []
},
{
"id": "66360",
"type": "Outcome_Mental",
"text": [
"symbolic play"
],
"offsets": [
[
1061,
1074
]
],
"normalized": []
},
{
"id": "66361",
"type": "Outcome_Mental",
"text": [
"functional play skills"
],
"offsets": [
[
1110,
1132
]
],
"normalized": []
},
{
"id": "66362",
"type": "Outcome_Mental",
"text": [
"joint attention"
],
"offsets": [
[
444,
459
]
],
"normalized": []
},
{
"id": "66363",
"type": "Participant_Age",
"text": [
"preschoolers"
],
"offsets": [
[
50,
62
]
],
"normalized": []
},
{
"id": "66364",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
68,
74
]
],
"normalized": []
},
{
"id": "66365",
"type": "Participant_Age",
"text": [
"preschool-aged children"
],
"offsets": [
[
170,
193
]
],
"normalized": []
},
{
"id": "66366",
"type": "Participant_Condition",
"text": [
"Autism Spectrum Disorder"
],
"offsets": [
[
199,
223
]
],
"normalized": []
},
{
"id": "66367",
"type": "Participant_Sample-size",
"text": [
"112"
],
"offsets": [
[
503,
506
]
],
"normalized": []
},
{
"id": "66368",
"type": "Participant_Age",
"text": [
"child"
],
"offsets": [
[
185,
190
]
],
"normalized": []
},
{
"id": "66369",
"type": "Participant_Condition",
"text": [
"Autism Spectrum Disorder"
],
"offsets": [
[
199,
223
]
],
"normalized": []
}
] | [] | [] | [] |
66370 | 24961537 | [
{
"id": "66371",
"type": "document",
"text": [
"Compared with the intake of commercial vegetable juice , the intake of fresh fruit and komatsuna ( Brassica rapa L. var . perviridis ) juice mixture reduces serum cholesterol in middle-aged men : a randomized controlled pilot study . BACKGROUND Vegetables and fruits are rich in vitamins , minerals and , dietary fiber and contribute to the prevention and improvement of obesity and metabolic syndrome . However , inadequate intake of vegetable and fruit is a concern in Japan.We therefore produced a juice mixture of fresh fruit and komatsuna ( Brassica rapa L. var . perviridis : B. rapa ) with the aim to investigate the effects of this juice mixture on anthropometric data , blood parameters , and dietary intake differences . METHODS This study was performed as a single blind and randomized controlled trial . Subjects were 16 men ( mean age , 46.4 ± 7.1 years ) , and they were divided into two groups ( control group and intervention group ) . The intervention group consumed the juice mixture of fresh fruit and B. rapa . The control group consumed commercial vegetable juice . Subjects consumed juice twice a day throughout the weekday , for 4 weeks . We prepared both juices with an equivalent energy balance . RESULTS Weight and body mass index ( BMI ) of the control group after 4 weeks were significantly increased compared with baseline values . Serum total cholesterol ( T-Chol ) and low-density lipoprotein cholesterol ( LDL-Chol ) of the intervention group after 4 weeks were significantly reduced compared with baseline values . Furthermore , intake of total vegetables and fruits were significantly increased compared with baseline values in both groups . CONCLUSIONS Both vegetable juices contributed to improved intake of total vegetables and fruit . Compared with the intake of commercial vegetable juice , the intake of fresh fruit and B. rapa juice is highly effective in reducing serum cholesterol . Short-term intake of fresh fruit and B. rapa juice was shown to enhance cholesterol metabolism ."
],
"offsets": [
[
0,
2022
]
]
}
] | [
{
"id": "66372",
"type": "Intervention_Physical",
"text": [
"commercial vegetable juice"
],
"offsets": [
[
28,
54
]
],
"normalized": []
},
{
"id": "66373",
"type": "Intervention_Pharmacological",
"text": [
"fresh fruit and komatsuna ( Brassica rapa L."
],
"offsets": [
[
71,
115
]
],
"normalized": []
},
{
"id": "66374",
"type": "Intervention_Physical",
"text": [
"var"
],
"offsets": [
[
116,
119
]
],
"normalized": []
},
{
"id": "66375",
"type": "Intervention_Pharmacological",
"text": [
"perviridis )"
],
"offsets": [
[
122,
134
]
],
"normalized": []
},
{
"id": "66376",
"type": "Intervention_Physical",
"text": [
"fresh fruit and komatsuna"
],
"offsets": [
[
71,
96
]
],
"normalized": []
},
{
"id": "66377",
"type": "Intervention_Educational",
"text": [
"( Brassica rapa L. var"
],
"offsets": [
[
97,
119
]
],
"normalized": []
},
{
"id": "66378",
"type": "Intervention_Pharmacological",
"text": [
"perviridis : B."
],
"offsets": [
[
569,
584
]
],
"normalized": []
},
{
"id": "66379",
"type": "Intervention_Educational",
"text": [
"rapa"
],
"offsets": [
[
108,
112
]
],
"normalized": []
},
{
"id": "66380",
"type": "Outcome_Physical",
"text": [
"anthropometric data , blood parameters"
],
"offsets": [
[
657,
695
]
],
"normalized": []
},
{
"id": "66381",
"type": "Outcome_Physical",
"text": [
"RESULTS Weight and body mass index"
],
"offsets": [
[
1222,
1256
]
],
"normalized": []
},
{
"id": "66382",
"type": "Outcome_Other",
"text": [
"values"
],
"offsets": [
[
1352,
1358
]
],
"normalized": []
},
{
"id": "66383",
"type": "Outcome_Physical",
"text": [
"Serum total cholesterol ( T-Chol )"
],
"offsets": [
[
1361,
1395
]
],
"normalized": []
},
{
"id": "66384",
"type": "Outcome_Physical",
"text": [
"low-density lipoprotein cholesterol ( LDL-Chol )"
],
"offsets": [
[
1400,
1448
]
],
"normalized": []
},
{
"id": "66385",
"type": "Outcome_Other",
"text": [
"intake of total vegetables and"
],
"offsets": [
[
1562,
1592
]
],
"normalized": []
},
{
"id": "66386",
"type": "Outcome_Other",
"text": [
"improved intake of total vegetables and"
],
"offsets": [
[
1725,
1764
]
],
"normalized": []
},
{
"id": "66387",
"type": "Outcome_Physical",
"text": [
"effective in reducing serum cholesterol"
],
"offsets": [
[
1884,
1923
]
],
"normalized": []
},
{
"id": "66388",
"type": "Outcome_Physical",
"text": [
"enhance cholesterol metabolism"
],
"offsets": [
[
1990,
2020
]
],
"normalized": []
},
{
"id": "66389",
"type": "Participant_Age",
"text": [
"middle-aged"
],
"offsets": [
[
178,
189
]
],
"normalized": []
},
{
"id": "66390",
"type": "Participant_Sex",
"text": [
"men"
],
"offsets": [
[
190,
193
]
],
"normalized": []
},
{
"id": "66391",
"type": "Participant_Sample-size",
"text": [
"16"
],
"offsets": [
[
830,
832
]
],
"normalized": []
},
{
"id": "66392",
"type": "Participant_Sex",
"text": [
"men"
],
"offsets": [
[
190,
193
]
],
"normalized": []
},
{
"id": "66393",
"type": "Participant_Age",
"text": [
"mean age , 46.4 ± 7.1 years"
],
"offsets": [
[
839,
866
]
],
"normalized": []
}
] | [] | [] | [] |
66394 | 24964689 | [
{
"id": "66395",
"type": "document",
"text": [
"Self-management improvement program combined with community involvement in Thai hypertensive population : an action research . OBJECTIVE To investigate the effectiveness of a program that utilizes community involvement to improve the self-management strategies among people living with hypertension . MATERIAL AND METHOD Forty-four subjects , aged 35 to 59-year-old , with hypertension in Nakhon Pathom Province , Thailand , were randomly allocated to either an experimental group ( n = 22 ) or a control group ( n = 20 ) . The experimental group attended a program to improve self-management methods based on social cognitive theory ( SCT ) . The program lasted 12 weeks , consisted of 1 1/2 hours meeting once a week , including group meetings and home visit monitoring . Mann-Whitney U test and Friedman test were employed to analyze the program 's effectiveness . RESULTS After the program , the mean rank of the perceived self-efficacy for the self-management strategies was statistically different between the two groups ( p = 0.023 ) . In the experimental group , after the twelve week , the mean rank of perceived self-efficacy and outcome expectancy increased and diastolic blood pressure decreased after the eight week . CONCLUSION The program applied social cognitive theory ( SCT ) to promote self-management techniques , increased the health promoting behavior among hypertensive people ."
],
"offsets": [
[
0,
1401
]
]
}
] | [
{
"id": "66396",
"type": "Intervention_Educational",
"text": [
"Self-management improvement program combined with community involvement"
],
"offsets": [
[
0,
71
]
],
"normalized": []
},
{
"id": "66397",
"type": "Intervention_Educational",
"text": [
"program that utilizes community involvement"
],
"offsets": [
[
175,
218
]
],
"normalized": []
},
{
"id": "66398",
"type": "Intervention_Educational",
"text": [
"self-management strategies"
],
"offsets": [
[
234,
260
]
],
"normalized": []
},
{
"id": "66399",
"type": "Intervention_Educational",
"text": [
"experimental"
],
"offsets": [
[
462,
474
]
],
"normalized": []
},
{
"id": "66400",
"type": "Intervention_Other",
"text": [
"group"
],
"offsets": [
[
475,
480
]
],
"normalized": []
},
{
"id": "66401",
"type": "Intervention_Control",
"text": [
"control group"
],
"offsets": [
[
497,
510
]
],
"normalized": []
},
{
"id": "66402",
"type": "Intervention_Educational",
"text": [
"program to improve self-management methods based on social cognitive theory ( SCT )"
],
"offsets": [
[
558,
641
]
],
"normalized": []
},
{
"id": "66403",
"type": "Intervention_Educational",
"text": [
"group meetings"
],
"offsets": [
[
731,
745
]
],
"normalized": []
},
{
"id": "66404",
"type": "Intervention_Educational",
"text": [
"home visit monitoring"
],
"offsets": [
[
750,
771
]
],
"normalized": []
},
{
"id": "66405",
"type": "Intervention_Educational",
"text": [
"social cognitive theory ( SCT )"
],
"offsets": [
[
610,
641
]
],
"normalized": []
},
{
"id": "66406",
"type": "Intervention_Educational",
"text": [
"self-management techniques"
],
"offsets": [
[
1305,
1331
]
],
"normalized": []
},
{
"id": "66407",
"type": "Outcome_Other",
"text": [
"effectiveness"
],
"offsets": [
[
156,
169
]
],
"normalized": []
},
{
"id": "66408",
"type": "Outcome_Other",
"text": [
"U test"
],
"offsets": [
[
787,
793
]
],
"normalized": []
},
{
"id": "66409",
"type": "Outcome_Other",
"text": [
"Friedman test"
],
"offsets": [
[
798,
811
]
],
"normalized": []
},
{
"id": "66410",
"type": "Outcome_Other",
"text": [
"effectiveness"
],
"offsets": [
[
156,
169
]
],
"normalized": []
},
{
"id": "66411",
"type": "Outcome_Other",
"text": [
"mean rank"
],
"offsets": [
[
900,
909
]
],
"normalized": []
},
{
"id": "66412",
"type": "Outcome_Other",
"text": [
"perceived self-efficacy"
],
"offsets": [
[
917,
940
]
],
"normalized": []
},
{
"id": "66413",
"type": "Outcome_Other",
"text": [
"self-management strategies"
],
"offsets": [
[
234,
260
]
],
"normalized": []
},
{
"id": "66414",
"type": "Outcome_Other",
"text": [
"mean rank of perceived self-efficacy"
],
"offsets": [
[
1099,
1135
]
],
"normalized": []
},
{
"id": "66415",
"type": "Outcome_Other",
"text": [
"outcome expectancy"
],
"offsets": [
[
1140,
1158
]
],
"normalized": []
},
{
"id": "66416",
"type": "Outcome_Physical",
"text": [
"diastolic blood pressure"
],
"offsets": [
[
1173,
1197
]
],
"normalized": []
},
{
"id": "66417",
"type": "Outcome_Mental",
"text": [
"health promoting behavior"
],
"offsets": [
[
1348,
1373
]
],
"normalized": []
},
{
"id": "66418",
"type": "Participant_Condition",
"text": [
"Thai hypertensive"
],
"offsets": [
[
75,
92
]
],
"normalized": []
},
{
"id": "66419",
"type": "Participant_Condition",
"text": [
"hypertension"
],
"offsets": [
[
286,
298
]
],
"normalized": []
},
{
"id": "66420",
"type": "Participant_Sample-size",
"text": [
"Forty-four"
],
"offsets": [
[
321,
331
]
],
"normalized": []
},
{
"id": "66421",
"type": "Participant_Age",
"text": [
"35 to 59-year-old"
],
"offsets": [
[
348,
365
]
],
"normalized": []
},
{
"id": "66422",
"type": "Participant_Condition",
"text": [
"hypertension"
],
"offsets": [
[
286,
298
]
],
"normalized": []
},
{
"id": "66423",
"type": "Participant_Condition",
"text": [
"Nakhon Pathom Province , Thailand"
],
"offsets": [
[
389,
422
]
],
"normalized": []
}
] | [] | [] | [] |
66424 | 24965333 | [
{
"id": "66425",
"type": "document",
"text": [
"Vitamin D supplementation ameliorates hypoinsulinemia and hyperglycemia in static magnetic field-exposed rat . The purpose of this study is to evaluate the effects of vitamin D supplementation on glucose and lipid metabolism in static magnetic field ( SMF ) -exposed rats . Rats exposed to SMF ( 128 mT ; 1 h/day ) during 5 consecutive days showed an increase in plasma glucose level and a decrease in plasma insulin concentration . By contrast , the same treatment failed to alter body weight and plasmatic total cholesterol , high-density lipoprotein ( HDL ) -cholesterol , low-density lipoprotein ( LDL ) -cholesterol , and triglyceride levels . Interestingly , supplementation with vitamin D ( 1,600 IU/100 g , per os ) corrected and restored glycemia and insulinemia in SMF-exposed rats . The same treatment had no effects on lipid metabolism ."
],
"offsets": [
[
0,
849
]
]
}
] | [
{
"id": "66426",
"type": "Intervention_Pharmacological",
"text": [
"Vitamin D supplementation"
],
"offsets": [
[
0,
25
]
],
"normalized": []
},
{
"id": "66427",
"type": "Intervention_Pharmacological",
"text": [
"vitamin D supplementation"
],
"offsets": [
[
167,
192
]
],
"normalized": []
},
{
"id": "66428",
"type": "Intervention_Pharmacological",
"text": [
"vitamin D"
],
"offsets": [
[
167,
176
]
],
"normalized": []
},
{
"id": "66429",
"type": "Outcome_Physical",
"text": [
"hypoinsulinemia and hyperglycemia"
],
"offsets": [
[
38,
71
]
],
"normalized": []
},
{
"id": "66430",
"type": "Outcome_Physical",
"text": [
"glucose and lipid metabolism"
],
"offsets": [
[
196,
224
]
],
"normalized": []
},
{
"id": "66431",
"type": "Outcome_Physical",
"text": [
"plasma glucose level and a decrease in plasma insulin concentration ."
],
"offsets": [
[
363,
432
]
],
"normalized": []
},
{
"id": "66432",
"type": "Outcome_Physical",
"text": [
"body weight and plasmatic total cholesterol , high-density lipoprotein ( HDL ) -cholesterol , low-density lipoprotein ( LDL ) -cholesterol , and triglyceride levels ."
],
"offsets": [
[
482,
648
]
],
"normalized": []
},
{
"id": "66433",
"type": "Outcome_Physical",
"text": [
"glycemia and insulinemia"
],
"offsets": [
[
747,
771
]
],
"normalized": []
},
{
"id": "66434",
"type": "Outcome_Physical",
"text": [
"lipid metabolism ."
],
"offsets": [
[
831,
849
]
],
"normalized": []
},
{
"id": "66435",
"type": "Participant_Condition",
"text": [
"static magnetic field-exposed rat ."
],
"offsets": [
[
75,
110
]
],
"normalized": []
},
{
"id": "66436",
"type": "Participant_Condition",
"text": [
"static magnetic field ( SMF ) -exposed rats ."
],
"offsets": [
[
228,
273
]
],
"normalized": []
},
{
"id": "66437",
"type": "Participant_Condition",
"text": [
"SMF-exposed rats"
],
"offsets": [
[
775,
791
]
],
"normalized": []
}
] | [] | [] | [] |
66438 | 24972577 | [
{
"id": "66439",
"type": "document",
"text": [
"Standardized treatment of Chinese medicine decoction for cancer pain patients with opioid-induced constipation : a multi-center prospective randomized controlled study . OBJECTIVE To observe the efficacy and the influence on quality of life ( QOL ) of syndrome differentiation treatment with Chinese medicine ( CM ) for opioid-induced constipation as well as the safety and influence on analgesic effect of opioids . METHODS Totally 406 cases enrolled from 53 collaborating medical centers were randomly assigned to a CM group and a control group . The CM group were treated with CM decoction based on syndrome differentiation , and the control group were treated with Phenolphthalein Tablet . Both groups were treated for 14 days . Cleveland constipation score ( CCS ) , numerical rating scale ( NRS ) of pain and Chinese version of European Organisation for Research and Treatment of Cancer , Quality of Life Questionnaire-C30 V3.0 ( EORTC QLQ-C30 V3.0 ) were used to evaluate the efficacy , pain controlled and QOL status . RESULTS The comparisons of CCS score reduction and QOL between the two groups after treatment suggested that the improvements of constipation and QOL in the CM group were better than that in the control group ( P < 0.05 ) . The total efficiency of the CM group was better than the control group ( 93.5 % vs. 86.4 % , P < 0.05 ) . There was no significant difference in NRS scores between before and after treatment in both groups . There was no serious drug-related adverse event during the course of study . CONCLUSION CM decoction could effectively treat opioid-induced constipation and improve patients ' QOL at the same time . It is safe and does n't affect the analgesic effect of opioids when treating constipation ."
],
"offsets": [
[
0,
1749
]
]
}
] | [
{
"id": "66440",
"type": "Intervention_Pharmacological",
"text": [
"Chinese medicine decoction"
],
"offsets": [
[
26,
52
]
],
"normalized": []
},
{
"id": "66441",
"type": "Intervention_Pharmacological",
"text": [
"Chinese medicine ( CM )"
],
"offsets": [
[
292,
315
]
],
"normalized": []
},
{
"id": "66442",
"type": "Intervention_Pharmacological",
"text": [
"CM"
],
"offsets": [
[
311,
313
]
],
"normalized": []
},
{
"id": "66443",
"type": "Intervention_Pharmacological",
"text": [
"CM decoction"
],
"offsets": [
[
580,
592
]
],
"normalized": []
},
{
"id": "66444",
"type": "Intervention_Pharmacological",
"text": [
"Phenolphthalein Tablet"
],
"offsets": [
[
669,
691
]
],
"normalized": []
},
{
"id": "66445",
"type": "Intervention_Control",
"text": [
"."
],
"offsets": [
[
168,
169
]
],
"normalized": []
},
{
"id": "66446",
"type": "Intervention_Pharmacological",
"text": [
"CM decoction"
],
"offsets": [
[
580,
592
]
],
"normalized": []
},
{
"id": "66447",
"type": "Participant_Condition",
"text": [
"cancer pain patients with opioid-induced constipation :"
],
"offsets": [
[
57,
112
]
],
"normalized": []
},
{
"id": "66448",
"type": "Participant_Condition",
"text": [
"opioid-induced constipation"
],
"offsets": [
[
83,
110
]
],
"normalized": []
},
{
"id": "66449",
"type": "Participant_Sample-size",
"text": [
"406 cases"
],
"offsets": [
[
433,
442
]
],
"normalized": []
},
{
"id": "66450",
"type": "Participant_Condition",
"text": [
"opioid-induced constipation"
],
"offsets": [
[
83,
110
]
],
"normalized": []
}
] | [] | [] | [] |
66451 | 24973545 | [
{
"id": "66452",
"type": "document",
"text": [
"Riding the rapids : living with autism or disability -- an evaluation of a parenting support intervention for parents of disabled children . Evidence on the effectiveness of interventions to support parents of disabled children to manage their child 's behaviour problems is limited . The aim of this study was to evaluate a group-delivered intervention ( Riding the Rapids ) which was specifically developed for parents of a child with a disability or autistic spectrum condition . This programme has been routinely delivered by a community-based mental health team across an urban , multi-ethnic locality for a number of years . A non-randomised controlled study design comprising an intervention group ( n=48 ) and comparator ( no intervention ) group ( n=28 ) was used to evaluate the effects of the intervention on child behaviour ( Eyberg Child Behaviour Inventory ; parent-set goals ) and parenting efficacy and satisfaction ( Parents Sense of Competence Scale ) at post-intervention and six-month follow-up . Data on costs to the service provider of delivering the intervention were also collected . Receipt of the intervention was associated with significant reductions in parent-reported behaviour problems and significant improvements in parenting efficacy and satisfaction . At six-month follow-up , progress towards achieving parent-set child behaviour goals and parenting satisfaction had been maintained . Post hoc analysis suggests parents who do not have English as a first language may not benefit as much as other parents from this intervention . Findings suggest this is a promising intervention for parents of a child with a disability that is likely to be less resource intensive to service providers than individually delivered interventions . Limitations and implications for future research are discussed ."
],
"offsets": [
[
0,
1831
]
]
}
] | [
{
"id": "66453",
"type": "Intervention_Educational",
"text": [
"parenting support intervention"
],
"offsets": [
[
75,
105
]
],
"normalized": []
},
{
"id": "66454",
"type": "Intervention_Educational",
"text": [
"group-delivered intervention ( Riding the Rapids"
],
"offsets": [
[
325,
373
]
],
"normalized": []
},
{
"id": "66455",
"type": "Intervention_Psychological",
"text": [
")"
],
"offsets": [
[
374,
375
]
],
"normalized": []
},
{
"id": "66456",
"type": "Intervention_Control",
"text": [
"controlled"
],
"offsets": [
[
648,
658
]
],
"normalized": []
},
{
"id": "66457",
"type": "Intervention_Educational",
"text": [
"intervention group"
],
"offsets": [
[
686,
704
]
],
"normalized": []
},
{
"id": "66458",
"type": "Intervention_Control",
"text": [
"comparator ( no intervention )"
],
"offsets": [
[
718,
748
]
],
"normalized": []
},
{
"id": "66459",
"type": "Intervention_Educational",
"text": [
"Eyberg Child Behaviour Inventory"
],
"offsets": [
[
838,
870
]
],
"normalized": []
},
{
"id": "66460",
"type": "Intervention_Educational",
"text": [
"intervention for parents"
],
"offsets": [
[
93,
117
]
],
"normalized": []
},
{
"id": "66461",
"type": "Outcome_Mental",
"text": [
"child behaviour ( Eyberg Child Behaviour Inventory ; parent-set goals )"
],
"offsets": [
[
820,
891
]
],
"normalized": []
},
{
"id": "66462",
"type": "Outcome_Mental",
"text": [
"parenting efficacy and satisfaction"
],
"offsets": [
[
896,
931
]
],
"normalized": []
},
{
"id": "66463",
"type": "Outcome_Mental",
"text": [
"Parents Sense of Competence Scale"
],
"offsets": [
[
934,
967
]
],
"normalized": []
},
{
"id": "66464",
"type": "Outcome_Other",
"text": [
"significant reductions"
],
"offsets": [
[
1156,
1178
]
],
"normalized": []
},
{
"id": "66465",
"type": "Outcome_Other",
"text": [
"parent-reported behaviour problems"
],
"offsets": [
[
1182,
1216
]
],
"normalized": []
},
{
"id": "66466",
"type": "Outcome_Other",
"text": [
"significant improvements in parenting efficacy and satisfaction"
],
"offsets": [
[
1221,
1284
]
],
"normalized": []
},
{
"id": "66467",
"type": "Outcome_Mental",
"text": [
"parent-set child behaviour goals"
],
"offsets": [
[
1339,
1371
]
],
"normalized": []
},
{
"id": "66468",
"type": "Outcome_Mental",
"text": [
"parenting satisfaction"
],
"offsets": [
[
1376,
1398
]
],
"normalized": []
},
{
"id": "66469",
"type": "Outcome_Other",
"text": [
"not benefit"
],
"offsets": [
[
1504,
1515
]
],
"normalized": []
},
{
"id": "66470",
"type": "Participant_Condition",
"text": [
"disabled children"
],
"offsets": [
[
121,
138
]
],
"normalized": []
},
{
"id": "66471",
"type": "Participant_Condition",
"text": [
"disability or autistic spectrum condition"
],
"offsets": [
[
439,
480
]
],
"normalized": []
},
{
"id": "66472",
"type": "Participant_Sample-size",
"text": [
"n=48"
],
"offsets": [
[
707,
711
]
],
"normalized": []
},
{
"id": "66473",
"type": "Participant_Sample-size",
"text": [
"n=28"
],
"offsets": [
[
757,
761
]
],
"normalized": []
}
] | [] | [] | [] |
66474 | 24974254 | [
{
"id": "66475",
"type": "document",
"text": [
"Visual feedback and target size effects on reach-to-grasp tasks in children with autism . This study explores the effects of visual condition and target size during four reach-to-grasp tasks between autistic children and healthy controls . Twenty children with autism and 20 healthy controls participated in the study . Qualisys motion capture system and kinematic measures were used to record movement . Autistic group showed significantly longer movement time , larger normalized jerk score , more movement unit than controls , especially in non-visual feedback and small target blocks . Autistic group also showed significantly larger maximal grip aperture and normalized maximal grip aperture in visual feedback condition than controls . Autistic children demonstrate motor coordination problems and also depend on more visual cuing in high accuracy tasks . Autistic children develop other compensatory skills while performing tasks ."
],
"offsets": [
[
0,
938
]
]
}
] | [
{
"id": "66476",
"type": "Intervention_Other",
"text": [
"Visual feedback"
],
"offsets": [
[
0,
15
]
],
"normalized": []
},
{
"id": "66477",
"type": "Intervention_Other",
"text": [
"target size effects"
],
"offsets": [
[
20,
39
]
],
"normalized": []
},
{
"id": "66478",
"type": "Intervention_Other",
"text": [
"Qualisys motion capture system"
],
"offsets": [
[
320,
350
]
],
"normalized": []
},
{
"id": "66479",
"type": "Intervention_Physical",
"text": [
"kinematic measures"
],
"offsets": [
[
355,
373
]
],
"normalized": []
},
{
"id": "66480",
"type": "Outcome_Physical",
"text": [
"reach-to-grasp tasks"
],
"offsets": [
[
43,
63
]
],
"normalized": []
},
{
"id": "66481",
"type": "Outcome_Physical",
"text": [
"Qualisys motion capture system and kinematic measures"
],
"offsets": [
[
320,
373
]
],
"normalized": []
},
{
"id": "66482",
"type": "Outcome_Physical",
"text": [
"longer movement time , larger normalized jerk score , more movement"
],
"offsets": [
[
441,
508
]
],
"normalized": []
},
{
"id": "66483",
"type": "Outcome_Physical",
"text": [
"larger maximal grip aperture"
],
"offsets": [
[
631,
659
]
],
"normalized": []
},
{
"id": "66484",
"type": "Outcome_Physical",
"text": [
"normalized maximal grip aperture"
],
"offsets": [
[
664,
696
]
],
"normalized": []
},
{
"id": "66485",
"type": "Outcome_Physical",
"text": [
"motor coordination problems"
],
"offsets": [
[
772,
799
]
],
"normalized": []
},
{
"id": "66486",
"type": "Outcome_Physical",
"text": [
"visual cuing"
],
"offsets": [
[
824,
836
]
],
"normalized": []
},
{
"id": "66487",
"type": "Outcome_Physical",
"text": [
"compensatory skills"
],
"offsets": [
[
894,
913
]
],
"normalized": []
},
{
"id": "66488",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
67,
75
]
],
"normalized": []
},
{
"id": "66489",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
81,
87
]
],
"normalized": []
},
{
"id": "66490",
"type": "Participant_Condition",
"text": [
"autistic"
],
"offsets": [
[
199,
207
]
],
"normalized": []
},
{
"id": "66491",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
67,
75
]
],
"normalized": []
},
{
"id": "66492",
"type": "Participant_Condition",
"text": [
"healthy controls"
],
"offsets": [
[
221,
237
]
],
"normalized": []
},
{
"id": "66493",
"type": "Participant_Sample-size",
"text": [
"Twenty"
],
"offsets": [
[
240,
246
]
],
"normalized": []
},
{
"id": "66494",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
67,
75
]
],
"normalized": []
},
{
"id": "66495",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
81,
87
]
],
"normalized": []
},
{
"id": "66496",
"type": "Participant_Sample-size",
"text": [
"20"
],
"offsets": [
[
272,
274
]
],
"normalized": []
},
{
"id": "66497",
"type": "Participant_Condition",
"text": [
"Autistic"
],
"offsets": [
[
405,
413
]
],
"normalized": []
},
{
"id": "66498",
"type": "Participant_Condition",
"text": [
"Autistic"
],
"offsets": [
[
405,
413
]
],
"normalized": []
},
{
"id": "66499",
"type": "Participant_Condition",
"text": [
"Autistic"
],
"offsets": [
[
405,
413
]
],
"normalized": []
},
{
"id": "66500",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
67,
75
]
],
"normalized": []
},
{
"id": "66501",
"type": "Participant_Condition",
"text": [
"Autistic"
],
"offsets": [
[
405,
413
]
],
"normalized": []
},
{
"id": "66502",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
67,
75
]
],
"normalized": []
}
] | [] | [] | [] |
66503 | 24981013 | [
{
"id": "66504",
"type": "document",
"text": [
"The impact of the amount of social evaluation on psychobiological responses to a body image threat . The present study examined the impact of amount of social-evaluative body image threat on psychobiological responses . Women ( N=123 ) were randomized into an individual-threat , group-threat or no-threat condition . Participants completed a measure of state body shame and provided a sample of saliva ( to assess cortisol ) at baseline and following their condition . Both threat conditions had higher baseline-adjusted body shame following the threat compared to the no-threat condition ; however , no difference on baseline-adjusted body shame between the threat conditions was found . The same pattern of results was found for cortisol - both threat conditions had higher baseline-adjusted response cortisol than the no-threat condition , with no significant differences between the threat groups . Findings suggest that the magnitude of psychobiological responses to a social-evaluative body image threat does not differ with the amount of social-evaluative threat ( individual- versus group-threat ) . These findings provide insight into the context of body image threats of women ."
],
"offsets": [
[
0,
1189
]
]
}
] | [
{
"id": "66505",
"type": "Intervention_Educational",
"text": [
"social evaluation"
],
"offsets": [
[
28,
45
]
],
"normalized": []
},
{
"id": "66506",
"type": "Intervention_Educational",
"text": [
"state body shame"
],
"offsets": [
[
354,
370
]
],
"normalized": []
},
{
"id": "66507",
"type": "Participant_Condition",
"text": [
"body image threat ."
],
"offsets": [
[
81,
100
]
],
"normalized": []
},
{
"id": "66508",
"type": "Participant_Sex",
"text": [
"Women"
],
"offsets": [
[
220,
225
]
],
"normalized": []
},
{
"id": "66509",
"type": "Participant_Sample-size",
"text": [
"N=123"
],
"offsets": [
[
228,
233
]
],
"normalized": []
},
{
"id": "66510",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
1182,
1187
]
],
"normalized": []
}
] | [] | [] | [] |
66511 | 24982504 | [
{
"id": "66512",
"type": "document",
"text": [
"Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched , related donor allogeneic HCT . Grades 2-4 acute graft-versus-host disease ( GVHD ) occurs in approximately 35 % of matched , related donor ( MRD ) allogeneic hematopoietic cell transplantation ( HCT ) recipients . We sought to determine if the combination of tacrolimus and sirolimus ( Tac/Sir ) was more effective than tacrolimus and methotrexate ( Tac/Mtx ) in preventing acute GVHD and early mortality after allogeneic MRD HCT in a phase 3 , multicenter trial . The primary end point of the trial was to compare 114-day grades 2-4 acute GVHD-free survival using an intention-to-treat analysis of 304 randomized subjects . There was no difference in the probability of day 114 grades 2-4 acute GVHD-free survival ( 67 % vs 62 % , P = .38 ) . Grades 2-4 GVHD was similar in the Tac/Sir and Tac/Mtx arms ( 26 % vs 34 % , P = .48 ) . Neutrophil and platelet engraftment were more rapid in the Tac/Sir arm ( 14 vs 16 days , P < .001 ; 16 vs 19 days , P = .03 ) . Oropharyngeal mucositis was less severe in the Tac/Sir arm ( peak Oral Mucositis Assessment Scale score 0.70 vs 0.96 , P < .001 ) , but otherwise toxicity was similar . Chronic GVHD , relapse-free survival , and overall survival at 2 years were no different between study arms ( 53 % vs 45 % , P = .06 ; 53 % vs 54 % , P = .77 ; and 59 % vs 63 % , P = .36 ) . Based on similar long-term outcomes , more rapid engraftment , and less oropharyngeal mucositis , the combination of Tac/Sir is an acceptable alternative to Tac/Mtx after MRD HCT . This study was funded by the National Heart , Lung , and Blood Institute and the National Cancer Institute ; and the trial was registered at www.clinicaltrials.gov as # NCT00406393 ."
],
"offsets": [
[
0,
1768
]
]
}
] | [
{
"id": "66513",
"type": "Intervention_Pharmacological",
"text": [
"Tacrolimus/sirolimus vs tacrolimus/methotrexate"
],
"offsets": [
[
0,
47
]
],
"normalized": []
},
{
"id": "66514",
"type": "Intervention_Pharmacological",
"text": [
"tacrolimus and sirolimus ( Tac/Sir )"
],
"offsets": [
[
343,
379
]
],
"normalized": []
},
{
"id": "66515",
"type": "Intervention_Pharmacological",
"text": [
"tacrolimus and methotrexate ( Tac/Mtx )"
],
"offsets": [
[
404,
443
]
],
"normalized": []
},
{
"id": "66516",
"type": "Outcome_Mortality",
"text": [
"114-day grades 2-4 acute GVHD-free survival"
],
"offsets": [
[
599,
642
]
],
"normalized": []
},
{
"id": "66517",
"type": "Outcome_Mortality",
"text": [
"Grades 2-4 GVHD"
],
"offsets": [
[
828,
843
]
],
"normalized": []
},
{
"id": "66518",
"type": "Outcome_Physical",
"text": [
"Neutrophil and platelet engraftment"
],
"offsets": [
[
917,
952
]
],
"normalized": []
},
{
"id": "66519",
"type": "Outcome_Physical",
"text": [
"Oropharyngeal mucositis"
],
"offsets": [
[
1045,
1068
]
],
"normalized": []
},
{
"id": "66520",
"type": "Outcome_Physical",
"text": [
"Oral Mucositis Assessment Scale score"
],
"offsets": [
[
1111,
1148
]
],
"normalized": []
},
{
"id": "66521",
"type": "Outcome_Adverse-effects",
"text": [
"toxicity"
],
"offsets": [
[
1191,
1199
]
],
"normalized": []
},
{
"id": "66522",
"type": "Outcome_Mortality",
"text": [
"Chronic GVHD , relapse-free survival , and overall survival at 2 years"
],
"offsets": [
[
1214,
1284
]
],
"normalized": []
},
{
"id": "66523",
"type": "Participant_Condition",
"text": [
"donor allogeneic HCT"
],
"offsets": [
[
92,
112
]
],
"normalized": []
},
{
"id": "66524",
"type": "Participant_Sample-size",
"text": [
"304"
],
"offsets": [
[
683,
686
]
],
"normalized": []
}
] | [] | [] | [] |
66525 | 24986270 | [
{
"id": "66526",
"type": "document",
"text": [
"The effects of two Chinese herbal medicinal formulae vs. placebo controls for treatment of allergic rhinitis : a randomised controlled trial . BACKGROUND Allergic rhinitis is a chronic illness , affecting 10 to 40 % of the worldwide population . Chinese herbal medicines , the treatment of allergic rhinitis , adopted thousands of years in ancient China , has recently raised much attention among researchers globally . This study evaluates the effects of two Chinese herbal formulae [ Cure-allergic-rhinitis Syrup ( CS ) and Yu-ping-feng San ( YS ) ] in treating undergraduate nursing students with allergic rhinitis over a 3-month follow-up , when compared to a placebo control group . METHODS A double-blind , randomised controlled trial with repeated-measures , three-parallel-groups design was conducted in a random sample of 249 participants recruited from one university in Hong Kong . After baseline measurements , participants were randomly assigned to CS , YS , or placebo groups ( n=83 per group ) . The main outcomes , including symptom severity , quality of life , and body constitution , were measured with self-administered questionnaires at baseline and immediately , 1 and 3 months after the 4-week interventions . RESULTS 240 participants completed the trial , with 9 ( 3.6 % ) drop-outs . The results of Generalised Estimating Equations test followed by pairwise contrasts tests indicated that the participants who received CS showed significantly greater reduction of symptoms ( mean difference of CS vs. placebo=26.13-34.55 , P < 0.0005 ) and improvements in quality of life ( mean difference of CS vs. placebo=12.81-16.76 , P < 0.001 ) , and body constitution in 'Qi-deficiency ' , 'Yang-deficiency ' , and 'Inherited Special ' ( mean difference of CS vs. placebo=7.05-8.12 , 7.56-8.92 , and 4.48-8.10 , P=0.01- < 0.0005 , 0.001-0.004 , and 0.01- < 0.0005 , accordingly , at three post-tests ) . The participants who received YS also indicated significant greater improvements in symptom severity , quality of life , and a few patterns of body constitution when compared to the placebo group . However , its effects were lesser in strength ( i.e. , smaller effect sizes ) , varieties of symptoms , and body constitution and sustainability over the 3 months . CONCLUSIONS The herbal formula CS was found effective to reduce symptoms and enhance quality of life in young adults ( nursing students ) with allergic rhinitis in 'Yang- and/or Qi-deficiency ' body constitution . Further controlled trials of its effects in Chinese and/or Asians with allergic rhinitis in terms of socio-demographic , ethnic and illness characteristics and a longer-term follow-up are recommended . TRIAL REGISTRATION The trial has registered at ClinicalTrials.gov with an ID : NCT02027194 ( 3 January 2014 ) ."
],
"offsets": [
[
0,
2808
]
]
}
] | [
{
"id": "66527",
"type": "Intervention_Pharmacological",
"text": [
"Chinese herbal medicinal formulae"
],
"offsets": [
[
19,
52
]
],
"normalized": []
},
{
"id": "66528",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
57,
64
]
],
"normalized": []
},
{
"id": "66529",
"type": "Intervention_Pharmacological",
"text": [
"Chinese herbal formulae [ Cure-allergic-rhinitis Syrup ( CS )"
],
"offsets": [
[
460,
521
]
],
"normalized": []
},
{
"id": "66530",
"type": "Intervention_Pharmacological",
"text": [
"Yu-ping-feng San ( YS )"
],
"offsets": [
[
526,
549
]
],
"normalized": []
},
{
"id": "66531",
"type": "Intervention_Pharmacological",
"text": [
"CS"
],
"offsets": [
[
517,
519
]
],
"normalized": []
},
{
"id": "66532",
"type": "Intervention_Pharmacological",
"text": [
"YS"
],
"offsets": [
[
545,
547
]
],
"normalized": []
},
{
"id": "66533",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
57,
64
]
],
"normalized": []
},
{
"id": "66534",
"type": "Intervention_Pharmacological",
"text": [
"CS"
],
"offsets": [
[
517,
519
]
],
"normalized": []
},
{
"id": "66535",
"type": "Outcome_Physical",
"text": [
"symptom severity"
],
"offsets": [
[
1041,
1057
]
],
"normalized": []
},
{
"id": "66536",
"type": "Outcome_Physical",
"text": [
"quality of"
],
"offsets": [
[
1060,
1070
]
],
"normalized": []
},
{
"id": "66537",
"type": "Outcome_Physical",
"text": [
"body constitution"
],
"offsets": [
[
1082,
1099
]
],
"normalized": []
},
{
"id": "66538",
"type": "Outcome_Mental",
"text": [
"Generalised Estimating Equations test"
],
"offsets": [
[
1323,
1360
]
],
"normalized": []
},
{
"id": "66539",
"type": "Outcome_Physical",
"text": [
"reduction of symptoms"
],
"offsets": [
[
1475,
1496
]
],
"normalized": []
},
{
"id": "66540",
"type": "Outcome_Other",
"text": [
"improvements in quality of life"
],
"offsets": [
[
1564,
1595
]
],
"normalized": []
},
{
"id": "66541",
"type": "Outcome_Physical",
"text": [
"body constitution in 'Qi-deficiency ' , 'Yang-deficiency ' , and 'Inherited Special '"
],
"offsets": [
[
1664,
1749
]
],
"normalized": []
},
{
"id": "66542",
"type": "Outcome_Physical",
"text": [
"symptom severity"
],
"offsets": [
[
1041,
1057
]
],
"normalized": []
},
{
"id": "66543",
"type": "Outcome_Other",
"text": [
"quality of life"
],
"offsets": [
[
1060,
1075
]
],
"normalized": []
},
{
"id": "66544",
"type": "Outcome_Physical",
"text": [
"body constitution"
],
"offsets": [
[
1082,
1099
]
],
"normalized": []
},
{
"id": "66545",
"type": "Outcome_Physical",
"text": [
"symptoms"
],
"offsets": [
[
1488,
1496
]
],
"normalized": []
},
{
"id": "66546",
"type": "Outcome_Physical",
"text": [
"body constitution"
],
"offsets": [
[
1082,
1099
]
],
"normalized": []
},
{
"id": "66547",
"type": "Outcome_Physical",
"text": [
"symptoms"
],
"offsets": [
[
1488,
1496
]
],
"normalized": []
},
{
"id": "66548",
"type": "Outcome_Other",
"text": [
"quality of life"
],
"offsets": [
[
1060,
1075
]
],
"normalized": []
},
{
"id": "66549",
"type": "Participant_Condition",
"text": [
"allergic rhinitis :"
],
"offsets": [
[
91,
110
]
],
"normalized": []
},
{
"id": "66550",
"type": "Participant_Condition",
"text": [
"Allergic rhinitis"
],
"offsets": [
[
154,
171
]
],
"normalized": []
},
{
"id": "66551",
"type": "Participant_Condition",
"text": [
"allergic rhinitis"
],
"offsets": [
[
91,
108
]
],
"normalized": []
},
{
"id": "66552",
"type": "Participant_Sample-size",
"text": [
"249"
],
"offsets": [
[
831,
834
]
],
"normalized": []
},
{
"id": "66553",
"type": "Participant_Sample-size",
"text": [
"240"
],
"offsets": [
[
1240,
1243
]
],
"normalized": []
}
] | [] | [] | [] |
66554 | 24988118 | [
{
"id": "66555",
"type": "document",
"text": [
"High-dose vitamin D3 supplementation in children and young adults with HIV : a randomized , placebo-controlled trial . BACKGROUND Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity . We aimed to determine 12-month safety and efficacy of daily 7000 IU vitamin D3 ( vitD3 ) versus placebo to sustain increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status in HIV-infected subjects . METHODS This was a double-blind trial of perinatally acquired HIV ( PHIV ) -infected subjects or behaviorally acquired HIV ( BHIV ) -infected subjects ( 5.0-24.9 years ) . Safety , 25 ( OH ) D-related parameters and immune status were assessed at baseline , 3 , 6 and 12 months . RESULTS Fifty-eight subjects enrolled ( 67 % male , 85 % African American and 64 % BHIV ) and 50 completed with no safety concerns . In unadjusted analyses , there were no differences between randomization groups at baseline ; at 3 , 6 and 12 months , 25 ( OH ) D was higher with supplementation than baseline and higher than with placebo ( P < 0.05 ) . In adjusted mixed models , in the supplementation group , the fixed effect of 25 ( OH ) D was higher ( P < 0.001 ) . Percentage of naive T-helper cells ( Th naive % ) were significantly ( P < 0.01 ) and T-helper cells ( CD4 % ) marginally ( P < 0.10 ) increased with supplementation in those taking highly active antiretroviral therapy ( HAART ) , and RNA viral load was reduced ( P ≤ 0.05 ) . In exploratory linear models , change in 25 ( OH ) D predicted RNA viral load at 3 and 12 months and CD4 % at 3 months ( P < 0.05 ) . CONCLUSIONS Daily 7000 IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25 ( OH ) D. Supplementation improved some clinically important HIV immune markers in subjects on HAART . Adjunct therapy with high-dose , daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation ."
],
"offsets": [
[
0,
1993
]
]
}
] | [
{
"id": "66556",
"type": "Intervention_Pharmacological",
"text": [
"vitamin D3 supplementation"
],
"offsets": [
[
10,
36
]
],
"normalized": []
},
{
"id": "66557",
"type": "Intervention_Control",
"text": [
"placebo-controlled trial"
],
"offsets": [
[
92,
116
]
],
"normalized": []
},
{
"id": "66558",
"type": "Intervention_Pharmacological",
"text": [
"7000 IU vitamin D3"
],
"offsets": [
[
327,
345
]
],
"normalized": []
},
{
"id": "66559",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
92,
99
]
],
"normalized": []
},
{
"id": "66560",
"type": "Outcome_Physical",
"text": [
"HIV :"
],
"offsets": [
[
71,
76
]
],
"normalized": []
},
{
"id": "66561",
"type": "Outcome_Other",
"text": [
"safety and efficacy"
],
"offsets": [
[
298,
317
]
],
"normalized": []
},
{
"id": "66562",
"type": "Outcome_Physical",
"text": [
"increased serum 25-hydroxyvitamin D ( 25 ( OH ) D ) and improve immune status"
],
"offsets": [
[
382,
459
]
],
"normalized": []
},
{
"id": "66563",
"type": "Outcome_Other",
"text": [
"Safety"
],
"offsets": [
[
659,
665
]
],
"normalized": []
},
{
"id": "66564",
"type": "Outcome_Other",
"text": [
"25 ( OH ) D-related parameters"
],
"offsets": [
[
668,
698
]
],
"normalized": []
},
{
"id": "66565",
"type": "Outcome_Physical",
"text": [
"immune status"
],
"offsets": [
[
446,
459
]
],
"normalized": []
},
{
"id": "66566",
"type": "Outcome_Other",
"text": [
"safety concerns ."
],
"offsets": [
[
882,
899
]
],
"normalized": []
},
{
"id": "66567",
"type": "Outcome_Physical",
"text": [
"25 ( OH ) D"
],
"offsets": [
[
420,
431
]
],
"normalized": []
},
{
"id": "66568",
"type": "Outcome_Physical",
"text": [
"Percentage of naive T-helper cells ( Th naive % )"
],
"offsets": [
[
1238,
1287
]
],
"normalized": []
},
{
"id": "66569",
"type": "Outcome_Physical",
"text": [
"T-helper cells ( CD4 % )"
],
"offsets": [
[
1324,
1348
]
],
"normalized": []
},
{
"id": "66570",
"type": "Outcome_Physical",
"text": [
"RNA viral load"
],
"offsets": [
[
1473,
1487
]
],
"normalized": []
},
{
"id": "66571",
"type": "Outcome_Physical",
"text": [
"in 25 ( OH ) D predicted RNA viral load"
],
"offsets": [
[
1553,
1592
]
],
"normalized": []
},
{
"id": "66572",
"type": "Outcome_Physical",
"text": [
"and CD4 %"
],
"offsets": [
[
1612,
1621
]
],
"normalized": []
},
{
"id": "66573",
"type": "Outcome_Physical",
"text": [
"increasing 25 ( OH )"
],
"offsets": [
[
1746,
1766
]
],
"normalized": []
},
{
"id": "66574",
"type": "Outcome_Physical",
"text": [
"some clinically important HIV immune markers"
],
"offsets": [
[
1795,
1839
]
],
"normalized": []
},
{
"id": "66575",
"type": "Participant_Age",
"text": [
"children and young adults"
],
"offsets": [
[
40,
65
]
],
"normalized": []
},
{
"id": "66576",
"type": "Participant_Condition",
"text": [
"HIV"
],
"offsets": [
[
71,
74
]
],
"normalized": []
},
{
"id": "66577",
"type": "Participant_Condition",
"text": [
"HIV-infected"
],
"offsets": [
[
174,
186
]
],
"normalized": []
},
{
"id": "66578",
"type": "Participant_Condition",
"text": [
"HIV-infected subjects"
],
"offsets": [
[
463,
484
]
],
"normalized": []
},
{
"id": "66579",
"type": "Participant_Condition",
"text": [
"perinatally acquired HIV ( PHIV ) -infected subjects"
],
"offsets": [
[
528,
580
]
],
"normalized": []
},
{
"id": "66580",
"type": "Participant_Condition",
"text": [
"behaviorally acquired HIV ( BHIV ) -infected subjects"
],
"offsets": [
[
584,
637
]
],
"normalized": []
},
{
"id": "66581",
"type": "Participant_Age",
"text": [
"5.0-24.9 years"
],
"offsets": [
[
640,
654
]
],
"normalized": []
},
{
"id": "66582",
"type": "Participant_Sample-size",
"text": [
"Fifty-eight subjects enrolled"
],
"offsets": [
[
775,
804
]
],
"normalized": []
},
{
"id": "66583",
"type": "Participant_Sex",
"text": [
"67 % male"
],
"offsets": [
[
807,
816
]
],
"normalized": []
},
{
"id": "66584",
"type": "Participant_Sample-size",
"text": [
"85 % African American"
],
"offsets": [
[
819,
840
]
],
"normalized": []
},
{
"id": "66585",
"type": "Participant_Sample-size",
"text": [
"64 %"
],
"offsets": [
[
845,
849
]
],
"normalized": []
},
{
"id": "66586",
"type": "Participant_Sample-size",
"text": [
"50 completed with no safety concerns"
],
"offsets": [
[
861,
897
]
],
"normalized": []
}
] | [] | [] | [] |
66587 | 24988121 | [
{
"id": "66588",
"type": "document",
"text": [
"Traumatic brain injury-related attention deficits : treatment outcomes with lisdexamfetamine dimesylate ( Vyvanse ) . BACKGROUND AND OBJECTIVES Attention deficits are often among the most persistent and debilitating impairments resulting from traumatic brain injury ( TBI ) . This study examined the effects of lisdexamfetamine dimesylate ( Vyvanse ) in treating attention deficits due to moderate-to-severe TBI . It was the first study of lisdexamfetamine dimesylate with this population and , in fact , was the first controlled trial in this area examining a stimulant medication option other than methylphenidate . METHODS This was a 12-week , randomized , double-blind , placebo-controlled , cross-over trial . A total of 22 rigorously selected cases were enrolled , 13 of whom completed the trial . They were 16-42 years of age and had newly acquired attention deficits persisting for 6-34 months post-injury . They were assessed on a broad range of neuropsychological and behavioural measures at baseline , 6-weeks and at 12-weeks . RESULTS AND CONCLUSIONS Positive treatment effects were found involving selective measures of sustained attention , working memory , response speed stability and endurance and in aspects of executive functioning . No major problems with safety or tolerability were observed . Some moderating treatment effects were found from a broad range of pre-treatment subject characteristics and injury variables examined . Avenues for further research and treatment applications in this area are discussed ."
],
"offsets": [
[
0,
1536
]
]
}
] | [
{
"id": "66589",
"type": "Intervention_Pharmacological",
"text": [
"lisdexamfetamine dimesylate ( Vyvanse ) ."
],
"offsets": [
[
76,
117
]
],
"normalized": []
},
{
"id": "66590",
"type": "Intervention_Pharmacological",
"text": [
"lisdexamfetamine dimesylate ( Vyvanse )"
],
"offsets": [
[
76,
115
]
],
"normalized": []
},
{
"id": "66591",
"type": "Intervention_Pharmacological",
"text": [
"lisdexamfetamine dimesylate"
],
"offsets": [
[
76,
103
]
],
"normalized": []
},
{
"id": "66592",
"type": "Intervention_Pharmacological",
"text": [
"methylphenidate ."
],
"offsets": [
[
600,
617
]
],
"normalized": []
},
{
"id": "66593",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
675,
693
]
],
"normalized": []
},
{
"id": "66594",
"type": "Outcome_Mental",
"text": [
"attention deficits :"
],
"offsets": [
[
31,
51
]
],
"normalized": []
},
{
"id": "66595",
"type": "Outcome_Mental",
"text": [
"attention deficits"
],
"offsets": [
[
31,
49
]
],
"normalized": []
},
{
"id": "66596",
"type": "Outcome_Mental",
"text": [
"attention deficits"
],
"offsets": [
[
31,
49
]
],
"normalized": []
},
{
"id": "66597",
"type": "Outcome_Mental",
"text": [
"neuropsychological and behavioural measures"
],
"offsets": [
[
955,
998
]
],
"normalized": []
},
{
"id": "66598",
"type": "Outcome_Mental",
"text": [
"sustained attention , working memory , response speed stability and endurance and in aspects of executive functioning ."
],
"offsets": [
[
1133,
1252
]
],
"normalized": []
},
{
"id": "66599",
"type": "Outcome_Other",
"text": [
"safety or tolerability"
],
"offsets": [
[
1276,
1298
]
],
"normalized": []
},
{
"id": "66600",
"type": "Participant_Condition",
"text": [
"Traumatic brain injury-related"
],
"offsets": [
[
0,
30
]
],
"normalized": []
},
{
"id": "66601",
"type": "Participant_Condition",
"text": [
"TBI"
],
"offsets": [
[
268,
271
]
],
"normalized": []
},
{
"id": "66602",
"type": "Participant_Sample-size",
"text": [
"22"
],
"offsets": [
[
726,
728
]
],
"normalized": []
},
{
"id": "66603",
"type": "Participant_Sample-size",
"text": [
"13"
],
"offsets": [
[
771,
773
]
],
"normalized": []
},
{
"id": "66604",
"type": "Participant_Age",
"text": [
"16-42 years of age"
],
"offsets": [
[
814,
832
]
],
"normalized": []
},
{
"id": "66605",
"type": "Participant_Condition",
"text": [
"attention deficits"
],
"offsets": [
[
31,
49
]
],
"normalized": []
}
] | [] | [] | [] |
66606 | 24992750 | [
{
"id": "66607",
"type": "document",
"text": [
"Comparison of clinical effectiveness of acupuncture and a Western drug on allergic rhinitis : study protocol for a randomized controlled trial . OBJECTIVE To compare the efficacy of an acupuncture regimen for persistent allergic rhinitis ( PER ) , aimed at improving a patient 's mind or Shen in Traditional Chinese Medicine , to that of a second-generation Hi-receptor antagonist , cetirizine hydrochloride . METHODS This multicenter , randomized , controlled clinical trial on PER will be conducted at three institutions in China . The total study period will be 9 weeks . After a 1-week preparatory screening period , 240 eligible participants with PER will be randomized to receive acupuncture or pharmacotherapy ( 1:1 ) for 4 weeks with a 4-week follow-up . The primary outcome will be changes in 7-day average total nasal symptom score . Secondary outcome measures include rhinoconjunctivitis quality of life questionnaire score and total non-nasal symptom score . RESULTS The presence and seriousness of psychological and emotional impairments should be considered in therapeutic programs for allergic rhinitis . No clinical trial for treating allergic rhinitis via acupuncture regulation of psychological and emotional activities has been reported . CONCLUSION The findings of the trial will allow us to determine the effects of the mind ( Shen ) -regulation treatment approach . We will also be able to confirm if the effects of acupuncture are equivalent to those of the conventional drug cetirizine hydrochloride ."
],
"offsets": [
[
0,
1525
]
]
}
] | [
{
"id": "66608",
"type": "Intervention_Physical",
"text": [
"acupuncture"
],
"offsets": [
[
40,
51
]
],
"normalized": []
},
{
"id": "66609",
"type": "Intervention_Pharmacological",
"text": [
"Western drug"
],
"offsets": [
[
58,
70
]
],
"normalized": []
},
{
"id": "66610",
"type": "Intervention_Physical",
"text": [
"acupuncture regimen"
],
"offsets": [
[
185,
204
]
],
"normalized": []
},
{
"id": "66611",
"type": "Intervention_Pharmacological",
"text": [
"Traditional Chinese Medicine"
],
"offsets": [
[
296,
324
]
],
"normalized": []
},
{
"id": "66612",
"type": "Intervention_Pharmacological",
"text": [
"second-generation Hi-receptor antagonist , cetirizine hydrochloride ."
],
"offsets": [
[
340,
409
]
],
"normalized": []
},
{
"id": "66613",
"type": "Intervention_Physical",
"text": [
"acupuncture"
],
"offsets": [
[
40,
51
]
],
"normalized": []
},
{
"id": "66614",
"type": "Intervention_Pharmacological",
"text": [
"pharmacotherapy"
],
"offsets": [
[
701,
716
]
],
"normalized": []
},
{
"id": "66615",
"type": "Intervention_Physical",
"text": [
"acupuncture"
],
"offsets": [
[
40,
51
]
],
"normalized": []
},
{
"id": "66616",
"type": "Intervention_Pharmacological",
"text": [
"cetirizine hydrochloride ."
],
"offsets": [
[
383,
409
]
],
"normalized": []
},
{
"id": "66617",
"type": "Outcome_Other",
"text": [
"clinical effectiveness"
],
"offsets": [
[
14,
36
]
],
"normalized": []
},
{
"id": "66618",
"type": "Outcome_Other",
"text": [
"7-day average total nasal symptom score"
],
"offsets": [
[
802,
841
]
],
"normalized": []
},
{
"id": "66619",
"type": "Outcome_Other",
"text": [
"rhinoconjunctivitis quality of life questionnaire score"
],
"offsets": [
[
879,
934
]
],
"normalized": []
},
{
"id": "66620",
"type": "Outcome_Physical",
"text": [
"and"
],
"offsets": [
[
52,
55
]
],
"normalized": []
},
{
"id": "66621",
"type": "Outcome_Other",
"text": [
"total non-nasal symptom score"
],
"offsets": [
[
939,
968
]
],
"normalized": []
},
{
"id": "66622",
"type": "Participant_Condition",
"text": [
"allergic rhinitis :"
],
"offsets": [
[
74,
93
]
],
"normalized": []
},
{
"id": "66623",
"type": "Participant_Condition",
"text": [
"persistent allergic rhinitis ( PER )"
],
"offsets": [
[
209,
245
]
],
"normalized": []
},
{
"id": "66624",
"type": "Participant_Sample-size",
"text": [
"240"
],
"offsets": [
[
621,
624
]
],
"normalized": []
}
] | [] | [] | [] |
66625 | 24998293 | [
{
"id": "66626",
"type": "document",
"text": [
"Quality of life and fatigue of patients with spinal bone metastases under combined treatment with resistance training and radiation therapy- a randomized pilot trial . BACKGROUND The aim of this trial was to compare the effects of resistance training versus passive physical therapy on quality of life ( QoL ) , fatigue , and emotional distress outcomes during radiation therapy in patients with spinal bone metastases under radiotherapy ( RT ) . METHODS In this randomized trial , 60 patients were treated from September 2011 until March 2013 into one of the two groups : isometric resistance training or physical therapy with thirty patients in each group during RT . EORTC QLQ-BM22 , EORTC QLQ-FA13 , and FBK-R10 were assessed at baseline , three months , and six months after RT . RESULTS Psychosocial aspects in resistance training group ( Arm A ) were significantly improved after three ( p = 0.001 ) and six months ( p = 0.010 ) . Other rated items of the QLQ-BM22 painful site , and pain characteristics were without significant differences . Functional interference showed a positive trend after six months ( p = 0.081 ) . After six months , physical fatigue ( p = 0.013 ) , and interference with daily life ( p = 0.006 ) according to the QLQ-FA13 assessment improved in Arm A significantly . Emotional distress was in Arm A lower after six months ( p = 0.016 ) . The Cohen 's effect size confirmed the clinically significant improvement of these findings . CONCLUSIONS In this group of patients we were able to show that guided isometric resistance training of the paravertebral muscles can improve functional capacity , reduce fatigue and thereby enhance QoL over a 6-months period in patients with stable spinal metastases . The results offer a rationale for future large controlled investigations to confirm these findings . TRIAL REGISTRATION Clinical trial identifier NCT01409720 ."
],
"offsets": [
[
0,
1896
]
]
}
] | [
{
"id": "66627",
"type": "Intervention_Physical",
"text": [
"resistance training"
],
"offsets": [
[
98,
117
]
],
"normalized": []
},
{
"id": "66628",
"type": "Intervention_Physical",
"text": [
"radiation therapy-"
],
"offsets": [
[
122,
140
]
],
"normalized": []
},
{
"id": "66629",
"type": "Intervention_Physical",
"text": [
"resistance training versus passive physical therapy"
],
"offsets": [
[
231,
282
]
],
"normalized": []
},
{
"id": "66630",
"type": "Intervention_Physical",
"text": [
"radiotherapy ( RT ) ."
],
"offsets": [
[
425,
446
]
],
"normalized": []
},
{
"id": "66631",
"type": "Intervention_Physical",
"text": [
"isometric resistance training"
],
"offsets": [
[
573,
602
]
],
"normalized": []
},
{
"id": "66632",
"type": "Intervention_Physical",
"text": [
"physical therapy"
],
"offsets": [
[
266,
282
]
],
"normalized": []
},
{
"id": "66633",
"type": "Intervention_Physical",
"text": [
"RT"
],
"offsets": [
[
440,
442
]
],
"normalized": []
},
{
"id": "66634",
"type": "Intervention_Physical",
"text": [
"RT"
],
"offsets": [
[
440,
442
]
],
"normalized": []
},
{
"id": "66635",
"type": "Intervention_Physical",
"text": [
"resistance training"
],
"offsets": [
[
98,
117
]
],
"normalized": []
},
{
"id": "66636",
"type": "Outcome_Other",
"text": [
"Quality of life and"
],
"offsets": [
[
0,
19
]
],
"normalized": []
},
{
"id": "66637",
"type": "Outcome_Physical",
"text": [
"fatigue"
],
"offsets": [
[
20,
27
]
],
"normalized": []
},
{
"id": "66638",
"type": "Outcome_Other",
"text": [
"quality of life ( QoL ) ,"
],
"offsets": [
[
286,
311
]
],
"normalized": []
},
{
"id": "66639",
"type": "Outcome_Mental",
"text": [
"fatigue , and emotional distress"
],
"offsets": [
[
312,
344
]
],
"normalized": []
},
{
"id": "66640",
"type": "Outcome_Mental",
"text": [
"EORTC QLQ-BM22 , EORTC QLQ-FA13"
],
"offsets": [
[
670,
701
]
],
"normalized": []
},
{
"id": "66641",
"type": "Outcome_Mental",
"text": [
"FBK-R10"
],
"offsets": [
[
708,
715
]
],
"normalized": []
},
{
"id": "66642",
"type": "Outcome_Physical",
"text": [
"physical"
],
"offsets": [
[
266,
274
]
],
"normalized": []
},
{
"id": "66643",
"type": "Outcome_Physical",
"text": [
"interference"
],
"offsets": [
[
1062,
1074
]
],
"normalized": []
},
{
"id": "66644",
"type": "Outcome_Physical",
"text": [
"functional capacity"
],
"offsets": [
[
1609,
1628
]
],
"normalized": []
},
{
"id": "66645",
"type": "Outcome_Physical",
"text": [
"fatigue"
],
"offsets": [
[
20,
27
]
],
"normalized": []
},
{
"id": "66646",
"type": "Participant_Condition",
"text": [
"spinal bone metastases"
],
"offsets": [
[
45,
67
]
],
"normalized": []
},
{
"id": "66647",
"type": "Participant_Condition",
"text": [
"radiation therapy-"
],
"offsets": [
[
122,
140
]
],
"normalized": []
},
{
"id": "66648",
"type": "Participant_Condition",
"text": [
"patients with spinal bone metastases under radiotherapy ( RT )"
],
"offsets": [
[
382,
444
]
],
"normalized": []
},
{
"id": "66649",
"type": "Participant_Sample-size",
"text": [
"60"
],
"offsets": [
[
482,
484
]
],
"normalized": []
}
] | [] | [] | [] |
66650 | 25001365 | [
{
"id": "66651",
"type": "document",
"text": [
"Neck circumference and early stage atherosclerosis : the cardiometabolic risk in Chinese ( CRC ) study . BACKGROUND Neck circumference ( NC ) has been previously related to cardiometabolic risk factors . In this study we examined the association between NC and early stage atherosclerosis in Chinese adults . METHODS The study samples were from a community-based health examination survey in central China . In total 2,318 men and women ( 18-64 y ) were included in the final analyses . Carotid radial pulse wave velocity ( crPWV ) , carotid femoral PWV ( cfPWV ) , carotid artery dorsalis pedis PWV ( cdPWV ) and NC were measured . RESULTS After adjustment for age , sex , lipids , glucose , blood pressure , heart rate , body mass index ( BMI ) , high NC was significantly associated with an increasing trend of cfPWV , cdPWV and crPWV ( P = 0.001 , 0.049 , and 0.038 ; respectively ) . In addition , we found significant interaction between hypertension status and NC level in relation to cfPWV , adjusted for age , sex , BMI , fasting glucose , lipids and heart rate ( P for interaction = 0.034 ) . The associations between NC and cfPWV were significant ( P = 0.02 ) among those with hypertension , but not significant among those without hypertension . CONCLUSIONS Our data showed that high NC was associated with an increased risk of early stage atherosclerosis in Chinese adults , independent of other metabolic risk factors . Hypertension might modify the association between NC and cfPWV ."
],
"offsets": [
[
0,
1498
]
]
}
] | [
{
"id": "66652",
"type": "Intervention_Other",
"text": [
"Neck circumference"
],
"offsets": [
[
0,
18
]
],
"normalized": []
},
{
"id": "66653",
"type": "Intervention_Educational",
"text": [
"study samples were from a community-based health examination survey"
],
"offsets": [
[
321,
388
]
],
"normalized": []
},
{
"id": "66654",
"type": "Intervention_Physical",
"text": [
"Carotid radial pulse wave velocity ( crPWV )"
],
"offsets": [
[
487,
531
]
],
"normalized": []
},
{
"id": "66655",
"type": "Intervention_Other",
"text": [
","
],
"offsets": [
[
418,
419
]
],
"normalized": []
},
{
"id": "66656",
"type": "Intervention_Physical",
"text": [
"carotid femoral PWV ( cfPWV )"
],
"offsets": [
[
534,
563
]
],
"normalized": []
},
{
"id": "66657",
"type": "Intervention_Physical",
"text": [
"carotid artery dorsalis pedis PWV ( cdPWV ) and NC were measured"
],
"offsets": [
[
566,
630
]
],
"normalized": []
},
{
"id": "66658",
"type": "Outcome_Physical",
"text": [
"Carotid radial pulse wave velocity ( crPWV ) , carotid femoral PWV ( cfPWV )"
],
"offsets": [
[
487,
563
]
],
"normalized": []
},
{
"id": "66659",
"type": "Outcome_Physical",
"text": [
"carotid artery dorsalis pedis PWV ( cdPWV )"
],
"offsets": [
[
566,
609
]
],
"normalized": []
},
{
"id": "66660",
"type": "Outcome_Physical",
"text": [
"NC"
],
"offsets": [
[
137,
139
]
],
"normalized": []
},
{
"id": "66661",
"type": "Outcome_Physical",
"text": [
"cfPWV"
],
"offsets": [
[
556,
561
]
],
"normalized": []
},
{
"id": "66662",
"type": "Outcome_Physical",
"text": [
"cdPWV"
],
"offsets": [
[
602,
607
]
],
"normalized": []
},
{
"id": "66663",
"type": "Outcome_Physical",
"text": [
"crPWV"
],
"offsets": [
[
524,
529
]
],
"normalized": []
},
{
"id": "66664",
"type": "Outcome_Physical",
"text": [
"hypertension status"
],
"offsets": [
[
944,
963
]
],
"normalized": []
},
{
"id": "66665",
"type": "Outcome_Physical",
"text": [
"NC level"
],
"offsets": [
[
968,
976
]
],
"normalized": []
},
{
"id": "66666",
"type": "Participant_Condition",
"text": [
"early stage atherosclerosis"
],
"offsets": [
[
23,
50
]
],
"normalized": []
},
{
"id": "66667",
"type": "Participant_Condition",
"text": [
"early stage atherosclerosis"
],
"offsets": [
[
23,
50
]
],
"normalized": []
},
{
"id": "66668",
"type": "Participant_Age",
"text": [
"adults ."
],
"offsets": [
[
300,
308
]
],
"normalized": []
},
{
"id": "66669",
"type": "Participant_Sample-size",
"text": [
"2,318"
],
"offsets": [
[
417,
422
]
],
"normalized": []
},
{
"id": "66670",
"type": "Participant_Sex",
"text": [
"men"
],
"offsets": [
[
423,
426
]
],
"normalized": []
},
{
"id": "66671",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
431,
436
]
],
"normalized": []
},
{
"id": "66672",
"type": "Participant_Age",
"text": [
"18-64 y"
],
"offsets": [
[
439,
446
]
],
"normalized": []
},
{
"id": "66673",
"type": "Participant_Condition",
"text": [
"early stage atherosclerosis"
],
"offsets": [
[
23,
50
]
],
"normalized": []
},
{
"id": "66674",
"type": "Participant_Condition",
"text": [
"Chinese"
],
"offsets": [
[
81,
88
]
],
"normalized": []
}
] | [] | [] | [] |
66675 | 25001543 | [
{
"id": "66676",
"type": "document",
"text": [
"A further investigation of goal-directed intention understanding in young children with autism spectrum disorders . Findings from research investigating goal-directed intention understanding in children with autism spectrum disorders ( ASD ) have been equivocal , in part because of the varying methodologies used across studies . This study compares both object-oriented and social-communicatively cued goal-directed intention understanding in children with ASD and typically-developing children . Relative to matched controls , children with ASD did not exhibit deficits in object-oriented intention understanding . While children with ASD also demonstrated the ability to understand intention when cued by social-communication indicators , typically-developing children differentiated between intentional and unintentional acts at a significantly greater level . Group differences in performance were eliminated if only trials in which children attended to the experimenter 's face were considered . Results suggest that children with ASD have intact object-oriented intention understanding abilities , and are able to use social-communicative cues to understand intention . However , their ability to demonstrate social-communicatively cued intention understanding is limited by a lack of attention to relevant social-communicative information ."
],
"offsets": [
[
0,
1349
]
]
}
] | [
{
"id": "66677",
"type": "Intervention_Educational",
"text": [
"goal-directed intention understanding"
],
"offsets": [
[
27,
64
]
],
"normalized": []
},
{
"id": "66678",
"type": "Intervention_Psychological",
"text": [
"goal-directed intention"
],
"offsets": [
[
27,
50
]
],
"normalized": []
},
{
"id": "66679",
"type": "Intervention_Educational",
"text": [
"understanding"
],
"offsets": [
[
51,
64
]
],
"normalized": []
},
{
"id": "66680",
"type": "Intervention_Psychological",
"text": [
"object-oriented and social-communicatively cued goal-directed intention"
],
"offsets": [
[
356,
427
]
],
"normalized": []
},
{
"id": "66681",
"type": "Intervention_Educational",
"text": [
"understanding"
],
"offsets": [
[
51,
64
]
],
"normalized": []
},
{
"id": "66682",
"type": "Intervention_Psychological",
"text": [
"object-oriented intention"
],
"offsets": [
[
576,
601
]
],
"normalized": []
},
{
"id": "66683",
"type": "Intervention_Educational",
"text": [
"understanding"
],
"offsets": [
[
51,
64
]
],
"normalized": []
},
{
"id": "66684",
"type": "Intervention_Psychological",
"text": [
"social-communicatively cued intention"
],
"offsets": [
[
1217,
1254
]
],
"normalized": []
},
{
"id": "66685",
"type": "Intervention_Educational",
"text": [
"understanding"
],
"offsets": [
[
51,
64
]
],
"normalized": []
},
{
"id": "66686",
"type": "Outcome_Mental",
"text": [
"goal-directed intention understanding"
],
"offsets": [
[
27,
64
]
],
"normalized": []
},
{
"id": "66687",
"type": "Outcome_Mental",
"text": [
"goal-directed intention understanding"
],
"offsets": [
[
27,
64
]
],
"normalized": []
},
{
"id": "66688",
"type": "Outcome_Mental",
"text": [
"object-oriented intention understanding"
],
"offsets": [
[
576,
615
]
],
"normalized": []
},
{
"id": "66689",
"type": "Outcome_Mental",
"text": [
"object-oriented intention understanding"
],
"offsets": [
[
576,
615
]
],
"normalized": []
},
{
"id": "66690",
"type": "Outcome_Mental",
"text": [
"social-communicatively cued intention"
],
"offsets": [
[
1217,
1254
]
],
"normalized": []
},
{
"id": "66691",
"type": "Participant_Age",
"text": [
"young children"
],
"offsets": [
[
68,
82
]
],
"normalized": []
},
{
"id": "66692",
"type": "Participant_Condition",
"text": [
"autism spectrum disorders ."
],
"offsets": [
[
88,
115
]
],
"normalized": []
},
{
"id": "66693",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
74,
82
]
],
"normalized": []
},
{
"id": "66694",
"type": "Participant_Condition",
"text": [
"autism spectrum disorders ( ASD"
],
"offsets": [
[
208,
239
]
],
"normalized": []
},
{
"id": "66695",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
74,
82
]
],
"normalized": []
},
{
"id": "66696",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
236,
239
]
],
"normalized": []
},
{
"id": "66697",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
74,
82
]
],
"normalized": []
},
{
"id": "66698",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
74,
82
]
],
"normalized": []
},
{
"id": "66699",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
236,
239
]
],
"normalized": []
},
{
"id": "66700",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
74,
82
]
],
"normalized": []
},
{
"id": "66701",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
236,
239
]
],
"normalized": []
}
] | [] | [] | [] |
66702 | 25009139 | [
{
"id": "66703",
"type": "document",
"text": [
"Autism Spectrum Social Stories In Schools Trial ( ASSSIST ) : study protocol for a feasibility randomised controlled trial analysing clinical and cost-effectiveness of Social Stories in mainstream schools . INTRODUCTION Current evidence suggests that Social Stories can be effective in tackling problem behaviours exhibited by children with autism spectrum disorder . Exploring the meaning of behaviour from a child 's perspective allows stories to provide social information that is tailored to their needs . Case reports in children with autism have suggested that these stories can lead to a number of benefits including improvements in social interactions and choice making in educational settings . METHODS AND ANALYSIS The feasibility of clinical and cost-effectiveness of a Social Stories toolkit will be assessed using a randomised control framework . Participants ( n=50 ) will be randomised to either the Social Stories intervention or a comparator group where they will be read standard stories for an equivalent amount of time . Statistics will be calculated for recruitment rates , follow-up rates and attrition . Economic analysis will determine appropriate measures of generic health and resource use categories for cost-effectiveness analysis . Qualitative analysis will ascertain information on perceptions about the feasibility and acceptability of the intervention . ETHICS AND DISSEMINATION National Health Service Ethics Approval ( NHS ; ref 11/YH/0340 ) for the trial protocol has been obtained along with NHS Research and Development permission from Leeds and York Partnership NHS Foundation Trust . All adverse events will be closely monitored , documented and reported to the study Data Monitoring Ethics Committee . At least one article in a peer reviewed journal will be published and research findings presented at relevant conferences . TRIAL REGISTRATION NUMBER ISRCTN96286707 ."
],
"offsets": [
[
0,
1908
]
]
}
] | [
{
"id": "66704",
"type": "Intervention_Psychological",
"text": [
"Social Stories"
],
"offsets": [
[
16,
30
]
],
"normalized": []
},
{
"id": "66705",
"type": "Intervention_Psychological",
"text": [
"Social Stories"
],
"offsets": [
[
16,
30
]
],
"normalized": []
},
{
"id": "66706",
"type": "Intervention_Psychological",
"text": [
"Social Stories"
],
"offsets": [
[
16,
30
]
],
"normalized": []
},
{
"id": "66707",
"type": "Intervention_Psychological",
"text": [
"Social Stories intervention or a comparator group"
],
"offsets": [
[
915,
964
]
],
"normalized": []
},
{
"id": "66708",
"type": "Participant_Condition",
"text": [
"autism spectrum disorder"
],
"offsets": [
[
341,
365
]
],
"normalized": []
},
{
"id": "66709",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
327,
335
]
],
"normalized": []
},
{
"id": "66710",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
341,
347
]
],
"normalized": []
},
{
"id": "66711",
"type": "Participant_Sample-size",
"text": [
"n=50"
],
"offsets": [
[
875,
879
]
],
"normalized": []
}
] | [] | [] | [] |
66712 | 25012645 | [
{
"id": "66713",
"type": "document",
"text": [
"The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients - a randomized trial . PURPOSE To compare the effects of resistance training versus passive physical therapy on bone density in the metastatic bone during radiation therapy ( RT ) as combined treatment in patients with spinal bone metastases . Secondly , to quantify pathological fractures after combined treatment . MATERIAL AND METHODS In this randomized trial , 60 patients were allocated from September 2011 until March 2013 into one of the two groups : resistance training ( group A ) or passive physical therapy ( group B ) with thirty patients in each group during RT . Bone density in metastatic and non-metastatic vertebral bone was assessed at baseline , 3 and 6 months after RT . RESULTS Bone density in all metastases increased significantly by 28.3 % ( IQR 11.4-139.0 ) and 80.3 % ( IQR 32.6-250.6 ) after 3 and 6 months in group A ( both p < 0.01 ) . The bone density in group A was significantly increased compared to control group after 3 and 6months ( both p < 0.01 , median 59.7 ; IQR 21.1-98.3 and median 62.9 ; IQR -9.7 to 161.7 ) . The bone density data in group B showed no significant increase over the course of time ( p = 0.289 , median 5.5 , IQR 0.0-62.2 and p = 0.057 , median 52.1 , IQR 0.0-162.7 ) . 23.3 % of the patients in group A and 30.0 % of the patients in group B had pathological fractures , no fracture was assigned to intervention , and no difference between groups after 3 and 6 months was observed ( p = 0.592 and p = 0.604 ) . CONCLUSIONS Our trial demonstrated that resistance training concomitant to RT can improve bone density in spinal bone metastases . This combined treatment is effective , practicable , and without side effects for patients . Importantly , the pathological fracture rate in the intervention group was not increased . The results offer a rationale for future large controlled investigations to confirm these findings . TRIAL REGISTRATION Clinical trial identifier NCT01409720 ."
],
"offsets": [
[
0,
2043
]
]
}
] | [
{
"id": "66714",
"type": "Intervention_Physical",
"text": [
"resistance training"
],
"offsets": [
[
14,
33
]
],
"normalized": []
},
{
"id": "66715",
"type": "Intervention_Educational",
"text": [
"during"
],
"offsets": [
[
34,
40
]
],
"normalized": []
},
{
"id": "66716",
"type": "Intervention_Physical",
"text": [
"radiotherapy"
],
"offsets": [
[
41,
53
]
],
"normalized": []
},
{
"id": "66717",
"type": "Intervention_Physical",
"text": [
"resistance training"
],
"offsets": [
[
14,
33
]
],
"normalized": []
},
{
"id": "66718",
"type": "Intervention_Physical",
"text": [
"passive physical therapy"
],
"offsets": [
[
183,
207
]
],
"normalized": []
},
{
"id": "66719",
"type": "Intervention_Pharmacological",
"text": [
"radiation therapy ( RT )"
],
"offsets": [
[
254,
278
]
],
"normalized": []
},
{
"id": "66720",
"type": "Intervention_Physical",
"text": [
"resistance training"
],
"offsets": [
[
14,
33
]
],
"normalized": []
},
{
"id": "66721",
"type": "Intervention_Physical",
"text": [
"passive physical therapy"
],
"offsets": [
[
183,
207
]
],
"normalized": []
},
{
"id": "66722",
"type": "Intervention_Control",
"text": [
"control"
],
"offsets": [
[
1032,
1039
]
],
"normalized": []
},
{
"id": "66723",
"type": "Intervention_Physical",
"text": [
"resistance training"
],
"offsets": [
[
14,
33
]
],
"normalized": []
},
{
"id": "66724",
"type": "Intervention_Educational",
"text": [
"concomitant to RT"
],
"offsets": [
[
1629,
1646
]
],
"normalized": []
},
{
"id": "66725",
"type": "Outcome_Physical",
"text": [
"spinal bone metastases"
],
"offsets": [
[
57,
79
]
],
"normalized": []
},
{
"id": "66726",
"type": "Outcome_Physical",
"text": [
"bone density in the metastatic bone"
],
"offsets": [
[
211,
246
]
],
"normalized": []
},
{
"id": "66727",
"type": "Outcome_Physical",
"text": [
"Bone density in metastatic and non-metastatic vertebral bone"
],
"offsets": [
[
676,
736
]
],
"normalized": []
},
{
"id": "66728",
"type": "Outcome_Physical",
"text": [
"Bone density in all metastases"
],
"offsets": [
[
798,
828
]
],
"normalized": []
},
{
"id": "66729",
"type": "Outcome_Physical",
"text": [
"bone density"
],
"offsets": [
[
211,
223
]
],
"normalized": []
},
{
"id": "66730",
"type": "Outcome_Physical",
"text": [
"bone density data"
],
"offsets": [
[
1156,
1173
]
],
"normalized": []
},
{
"id": "66731",
"type": "Outcome_Physical",
"text": [
"pathological fractures"
],
"offsets": [
[
366,
388
]
],
"normalized": []
},
{
"id": "66732",
"type": "Outcome_Physical",
"text": [
"bone density"
],
"offsets": [
[
211,
223
]
],
"normalized": []
},
{
"id": "66733",
"type": "Outcome_Adverse-effects",
"text": [
"side effects"
],
"offsets": [
[
1765,
1777
]
],
"normalized": []
},
{
"id": "66734",
"type": "Outcome_Physical",
"text": [
"pathological fracture rate"
],
"offsets": [
[
1811,
1837
]
],
"normalized": []
},
{
"id": "66735",
"type": "Participant_Condition",
"text": [
"spinal bone metastases in cancer patients"
],
"offsets": [
[
57,
98
]
],
"normalized": []
},
{
"id": "66736",
"type": "Participant_Condition",
"text": [
"patients with spinal bone metastases"
],
"offsets": [
[
304,
340
]
],
"normalized": []
},
{
"id": "66737",
"type": "Participant_Sample-size",
"text": [
"60 patients"
],
"offsets": [
[
464,
475
]
],
"normalized": []
}
] | [] | [] | [] |
66738 | 2501509 | [
{
"id": "66739",
"type": "document",
"text": [
"TEN versus TPN following major abdominal trauma -- reduced septic morbidity . Recent animal models suggest that enteral feeding ( TEN ) compared to parenteral nutrition ( TPN ) improves resistance to infection . This prospective clinical trial examined the impact of early TEN vs. TPN in the critically injured . Seventy-five patients with an abdominal trauma index ( ATI ) greater than 15 and less than 40 were randomized at initial laparotomy to receive either TEN ( Vivonex TEN ) or TPN ( Freamine HBC 6.9 % and Trophamine 6 % ) ; both regimens contained 2.5 % fat , 33 % branched chain amino acids , and had a calorie to nitrogen ratio of 150:1 . TEN was delivered via a needle catheter jejunostomy . Nutritional support was initiated within 12 hours postoperatively in both groups , and infused at a rate sufficient to render the patients in positive nitrogen balance . The study groups ( TEN = 29 vs TPN = 30 ) were comparable in age , injury severity and initial metabolic stress . Jejunal feeding was tolerated unconditionally in 25 ( 86 % ) of the TEN group . Nitrogen balance remained equivalent throughout the study period , at day 5 TEN = -0.3 +/- 1.0 vs. TPN 0.1 +/- 0.8 gm/day . Traditional nutritional protein markers ( albumin , transferrin , and retinol binding protein ) were restored better in the TEN group . Infections developed in 5 ( 17 % ) of the TEN patients compared to 11 ( 37 % ) of the TPN group . The incidence of major septic morbidity was 3 % ( 1 = abdominal abscess ) in the TEN group contrasted to 20 % ( 2 = abdominal abscess , 6 = pneumonia ) with TPN . This clinical study demonstrates that TEN is well tolerated in the severely injured , and that early feeding via the gut reduces septic complications in the stressed patient ."
],
"offsets": [
[
0,
1765
]
]
}
] | [
{
"id": "66740",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66741",
"type": "Intervention_Physical",
"text": [
"TPN"
],
"offsets": [
[
11,
14
]
],
"normalized": []
},
{
"id": "66742",
"type": "Intervention_Physical",
"text": [
"enteral feeding ( TEN )"
],
"offsets": [
[
112,
135
]
],
"normalized": []
},
{
"id": "66743",
"type": "Intervention_Physical",
"text": [
"parenteral nutrition ( TPN )"
],
"offsets": [
[
148,
176
]
],
"normalized": []
},
{
"id": "66744",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66745",
"type": "Intervention_Physical",
"text": [
"TPN"
],
"offsets": [
[
11,
14
]
],
"normalized": []
},
{
"id": "66746",
"type": "Intervention_Surgical",
"text": [
"initial laparotomy"
],
"offsets": [
[
426,
444
]
],
"normalized": []
},
{
"id": "66747",
"type": "Intervention_Pharmacological",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66748",
"type": "Intervention_Pharmacological",
"text": [
"TPN"
],
"offsets": [
[
11,
14
]
],
"normalized": []
},
{
"id": "66749",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66750",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66751",
"type": "Intervention_Physical",
"text": [
"TPN"
],
"offsets": [
[
11,
14
]
],
"normalized": []
},
{
"id": "66752",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66753",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66754",
"type": "Intervention_Physical",
"text": [
"TPN"
],
"offsets": [
[
11,
14
]
],
"normalized": []
},
{
"id": "66755",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66756",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66757",
"type": "Intervention_Physical",
"text": [
"TPN"
],
"offsets": [
[
11,
14
]
],
"normalized": []
},
{
"id": "66758",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66759",
"type": "Intervention_Physical",
"text": [
"TPN"
],
"offsets": [
[
11,
14
]
],
"normalized": []
},
{
"id": "66760",
"type": "Intervention_Physical",
"text": [
"TEN"
],
"offsets": [
[
0,
3
]
],
"normalized": []
},
{
"id": "66761",
"type": "Outcome_Other",
"text": [
"tolerated"
],
"offsets": [
[
1009,
1018
]
],
"normalized": []
},
{
"id": "66762",
"type": "Outcome_Physical",
"text": [
"Nitrogen balance"
],
"offsets": [
[
1069,
1085
]
],
"normalized": []
},
{
"id": "66763",
"type": "Outcome_Physical",
"text": [
"nutritional protein markers ( albumin , transferrin , and retinol binding protein )"
],
"offsets": [
[
1205,
1288
]
],
"normalized": []
},
{
"id": "66764",
"type": "Outcome_Adverse-effects",
"text": [
"Infections"
],
"offsets": [
[
1329,
1339
]
],
"normalized": []
},
{
"id": "66765",
"type": "Outcome_Physical",
"text": [
"major septic morbidity"
],
"offsets": [
[
1444,
1466
]
],
"normalized": []
},
{
"id": "66766",
"type": "Participant_Condition",
"text": [
"major abdominal trauma"
],
"offsets": [
[
25,
47
]
],
"normalized": []
},
{
"id": "66767",
"type": "Participant_Condition",
"text": [
"septic morbidity"
],
"offsets": [
[
59,
75
]
],
"normalized": []
},
{
"id": "66768",
"type": "Participant_Condition",
"text": [
"critically injured"
],
"offsets": [
[
292,
310
]
],
"normalized": []
},
{
"id": "66769",
"type": "Participant_Sample-size",
"text": [
"Seventy-five"
],
"offsets": [
[
313,
325
]
],
"normalized": []
},
{
"id": "66770",
"type": "Participant_Condition",
"text": [
"abdominal trauma"
],
"offsets": [
[
31,
47
]
],
"normalized": []
},
{
"id": "66771",
"type": "Participant_Condition",
"text": [
"laparotomy"
],
"offsets": [
[
434,
444
]
],
"normalized": []
},
{
"id": "66772",
"type": "Participant_Condition",
"text": [
"severely injured"
],
"offsets": [
[
1657,
1673
]
],
"normalized": []
}
] | [] | [] | [] |
66773 | 25015354 | [
{
"id": "66774",
"type": "document",
"text": [
"Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa : the 4-year DHAX trial . PURPOSE Docosahexaenoic acid ( DHA ) continues to be evaluated and recommended as treatment and prophylaxis for various diseases . We recently assessed efficacy of high-dose DHA supplementation to slow vision loss in patients with X-linked retinitis pigmentosa ( XLRP ) in a randomized clinical trial . Because DHA is a highly unsaturated fatty acid , it could serve as a target for free-radical induced oxidation , resulting in increased oxidative stress . Biosafety was monitored during the 4-year trial to determine whether DHA supplementation was associated with identifiable risks . METHODS Males ( n = 78 ; 7-31 years ) meeting entry criteria were enrolled . The modified intent-to-treat cohort ( DHA = 33 ; placebo = 27 ) adhered to the protocol ≥ 1 year . Participants were randomized to an oral dose of 30 mg/kg/d DHA or placebo plus a daily multivitamin . Comprehensive metabolic analyses were assessed for group differences . Treatment-emergent adverse events including blood chemistry metabolites were recorded . RESULTS By year 4 , supplementation elevated plasma and red blood cell-DHA 4.4- and 3.6-fold , respectively , compared with the placebo group ( P < 0.00001 ) . Over the trial duration , no significant differences between DHA and placebo groups were found for vitamin A , vitamin E , platelet aggregation , antioxidant activity , lipoprotein cholesterol , or oxidized LDL levels ( all P > 0.14 ) . Adverse events were transient and not considered severe ( e.g. , gastrointestinal [ GI ] irritability , blood chemistry alterations ) . One participant was unable to tolerate persistent GI discomfort . CONCLUSIONS Long-term , high-dose DHA supplementation to patients with XLRP was associated with limited safety risks in this 4-year trial . Nevertheless , GI symptoms should be monitored in all patients taking high dose DHA especially those with personal or family history of GI disturbances . ( ClinicalTrials.gov number , NCT00100230 . ) ."
],
"offsets": [
[
0,
2066
]
]
}
] | [
{
"id": "66775",
"type": "Intervention_Pharmacological",
"text": [
"docosahexaenoic acid"
],
"offsets": [
[
21,
41
]
],
"normalized": []
},
{
"id": "66776",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
815,
822
]
],
"normalized": []
},
{
"id": "66777",
"type": "Outcome_Physical",
"text": [
"vision loss"
],
"offsets": [
[
303,
314
]
],
"normalized": []
},
{
"id": "66778",
"type": "Outcome_Other",
"text": [
"Biosafety"
],
"offsets": [
[
559,
568
]
],
"normalized": []
},
{
"id": "66779",
"type": "Participant_Condition",
"text": [
"X-linked retinitis pigmentosa :"
],
"offsets": [
[
45,
76
]
],
"normalized": []
},
{
"id": "66780",
"type": "Participant_Condition",
"text": [
"patients with X-linked retinitis pigmentosa ( XLRP )"
],
"offsets": [
[
318,
370
]
],
"normalized": []
}
] | [] | [] | [] |
66781 | 25017958 | [
{
"id": "66782",
"type": "document",
"text": [
"Comparison of postoperative short-term complications after laparoscopic transabdominal preperitoneal ( TAPP ) versus Lichtenstein tension free inguinal hernia repair : a randomized trial study . AIM The aim of this randomized trial was to compare short-term postoperative complications of laparoscopic transabdominal preperitoneal ( TAPP ) and Lichtenstein tension free hernia repair . METHODS A total of 120 patients who went inguinal hernia repair at Shahid Sadoughi university training hospital from April 2011 to August 2013 were randomized into two TAPP ( N.=60 ) and Lichtenstein ( N.=60 ) repair group . Follow-up occurred within 6 weeks . The postoperative assessments included pain score ( VAS ) , hematoma/seroma , urinary retention , wound infection incidence , and duration of hospital stay . RESULTS Pain was the most common symptoms in both groups . The TAPP group patients significantly had experienced less postoperative pain than the Lichtenstein group in all moments ( P < 0.05 ) . TAPP group had lower incidence of hematoma ( TAPP , 6.6 % vs. Lichtenstein 13.3 % ; P=0.67 ) , seroma ( TAPP 10 % vs. Lichtenstein 13.3 % ; P=1.00 ) , and infection ( TAPP 0 vs. Lichtenstein 1.6 % ; P=0.67 ) . However , no differences between the 2 groups were found in terms of postoperative complications . In TAPP group mean of hospital stay significantly was less than Lichtenstein group ( TAPP , 8.13±2.19 vs. Lichtenstein , 13.15±1.5 days ; P < 0.001 ) . CONCLUSION The laparoscopic TAPP repair is safer and less complicated approach to inguinal hernia repair . The two main short-term advantages of the laparoscopic TAPP repair with the tension free Lichtenstein repair were less postoperative pain and earlier return to the normal life activities . No difference was seen in overall complications ."
],
"offsets": [
[
0,
1806
]
]
}
] | [
{
"id": "66783",
"type": "Intervention_Physical",
"text": [
"laparoscopic transabdominal preperitoneal ( TAPP ) versus Lichtenstein tension free inguinal hernia repair"
],
"offsets": [
[
59,
165
]
],
"normalized": []
},
{
"id": "66784",
"type": "Intervention_Physical",
"text": [
"laparoscopic transabdominal preperitoneal ( TAPP ) and Lichtenstein tension free hernia repair"
],
"offsets": [
[
289,
383
]
],
"normalized": []
},
{
"id": "66785",
"type": "Intervention_Physical",
"text": [
"inguinal hernia repair"
],
"offsets": [
[
143,
165
]
],
"normalized": []
},
{
"id": "66786",
"type": "Intervention_Physical",
"text": [
"TAPP"
],
"offsets": [
[
103,
107
]
],
"normalized": []
},
{
"id": "66787",
"type": "Intervention_Surgical",
"text": [
"Lichtenstein"
],
"offsets": [
[
117,
129
]
],
"normalized": []
},
{
"id": "66788",
"type": "Intervention_Physical",
"text": [
"Lichtenstein"
],
"offsets": [
[
117,
129
]
],
"normalized": []
},
{
"id": "66789",
"type": "Intervention_Surgical",
"text": [
"Lichtenstein"
],
"offsets": [
[
117,
129
]
],
"normalized": []
},
{
"id": "66790",
"type": "Intervention_Surgical",
"text": [
"Lichtenstein"
],
"offsets": [
[
117,
129
]
],
"normalized": []
},
{
"id": "66791",
"type": "Intervention_Surgical",
"text": [
"Lichtenstein"
],
"offsets": [
[
117,
129
]
],
"normalized": []
},
{
"id": "66792",
"type": "Intervention_Surgical",
"text": [
"Lichtenstein"
],
"offsets": [
[
117,
129
]
],
"normalized": []
},
{
"id": "66793",
"type": "Outcome_Pain",
"text": [
"pain score ( VAS )"
],
"offsets": [
[
686,
704
]
],
"normalized": []
},
{
"id": "66794",
"type": "Outcome_Adverse-effects",
"text": [
"hematoma/seroma"
],
"offsets": [
[
707,
722
]
],
"normalized": []
},
{
"id": "66795",
"type": "Outcome_Physical",
"text": [
"urinary retention"
],
"offsets": [
[
725,
742
]
],
"normalized": []
},
{
"id": "66796",
"type": "Outcome_Adverse-effects",
"text": [
"wound infection incidence"
],
"offsets": [
[
745,
770
]
],
"normalized": []
},
{
"id": "66797",
"type": "Outcome_Other",
"text": [
"duration of hospital stay"
],
"offsets": [
[
777,
802
]
],
"normalized": []
},
{
"id": "66798",
"type": "Outcome_Pain",
"text": [
"Pain"
],
"offsets": [
[
813,
817
]
],
"normalized": []
},
{
"id": "66799",
"type": "Outcome_Pain",
"text": [
"postoperative pain"
],
"offsets": [
[
923,
941
]
],
"normalized": []
},
{
"id": "66800",
"type": "Outcome_Adverse-effects",
"text": [
"hematoma"
],
"offsets": [
[
707,
715
]
],
"normalized": []
},
{
"id": "66801",
"type": "Outcome_Adverse-effects",
"text": [
"seroma"
],
"offsets": [
[
716,
722
]
],
"normalized": []
},
{
"id": "66802",
"type": "Outcome_Adverse-effects",
"text": [
"infection"
],
"offsets": [
[
751,
760
]
],
"normalized": []
},
{
"id": "66803",
"type": "Outcome_Adverse-effects",
"text": [
"postoperative complications"
],
"offsets": [
[
258,
285
]
],
"normalized": []
},
{
"id": "66804",
"type": "Outcome_Other",
"text": [
"mean of hospital stay"
],
"offsets": [
[
1323,
1344
]
],
"normalized": []
},
{
"id": "66805",
"type": "Participant_Condition",
"text": [
"laparoscopic transabdominal preperitoneal ( TAPP ) versus Lichtenstein tension free inguinal hernia repair :"
],
"offsets": [
[
59,
167
]
],
"normalized": []
},
{
"id": "66806",
"type": "Participant_Condition",
"text": [
"complications of laparoscopic transabdominal preperitoneal ( TAPP ) and Lichtenstein tension free hernia repair ."
],
"offsets": [
[
272,
385
]
],
"normalized": []
},
{
"id": "66807",
"type": "Participant_Sample-size",
"text": [
"120"
],
"offsets": [
[
405,
408
]
],
"normalized": []
},
{
"id": "66808",
"type": "Participant_Condition",
"text": [
"inguinal hernia repair"
],
"offsets": [
[
143,
165
]
],
"normalized": []
}
] | [] | [] | [] |
66809 | 25022248 | [
{
"id": "66810",
"type": "document",
"text": [
"Evidence for diminished multisensory integration in autism spectrum disorders . Individuals with autism spectrum disorders ( ASD ) exhibit alterations in sensory processing , including changes in the integration of information across the different sensory modalities . In the current study , we used the sound-induced flash illusion to assess multisensory integration in children with ASD and typically-developing ( TD ) controls . Thirty-one children with ASD and 31 age and IQ matched TD children ( average age = 12 years ) were presented with simple visual ( i.e. , flash ) and auditory ( i.e. , beep ) stimuli of varying number . In illusory conditions , a single flash was presented with 2-4 beeps . In TD children , these conditions generally result in the perception of multiple flashes , implying a perceptual fusion across vision and audition . In the present study , children with ASD were significantly less likely to perceive the illusion relative to TD controls , suggesting that multisensory integration and cross-modal binding may be weaker in some children with ASD . These results are discussed in the context of previous findings for multisensory integration in ASD and future directions for research ."
],
"offsets": [
[
0,
1220
]
]
}
] | [
{
"id": "66811",
"type": "Intervention_Educational",
"text": [
"sound-induced flash illusion"
],
"offsets": [
[
304,
332
]
],
"normalized": []
},
{
"id": "66812",
"type": "Outcome_Physical",
"text": [
"multisensory integration"
],
"offsets": [
[
24,
48
]
],
"normalized": []
},
{
"id": "66813",
"type": "Outcome_Physical",
"text": [
"multisensory integration"
],
"offsets": [
[
24,
48
]
],
"normalized": []
},
{
"id": "66814",
"type": "Participant_Condition",
"text": [
"autism spectrum disorders . Individuals with autism spectrum disorders ( ASD )"
],
"offsets": [
[
52,
130
]
],
"normalized": []
},
{
"id": "66815",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
371,
379
]
],
"normalized": []
},
{
"id": "66816",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
125,
128
]
],
"normalized": []
},
{
"id": "66817",
"type": "Participant_Condition",
"text": [
"typically-developing ( TD ) controls"
],
"offsets": [
[
393,
429
]
],
"normalized": []
},
{
"id": "66818",
"type": "Participant_Sample-size",
"text": [
"Thirty-one"
],
"offsets": [
[
432,
442
]
],
"normalized": []
},
{
"id": "66819",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
125,
128
]
],
"normalized": []
},
{
"id": "66820",
"type": "Participant_Age",
"text": [
"( average age = 12 years"
],
"offsets": [
[
499,
523
]
],
"normalized": []
},
{
"id": "66821",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
125,
128
]
],
"normalized": []
}
] | [] | [] | [] |
66822 | 25022743 | [
{
"id": "66823",
"type": "document",
"text": [
"Weighted blankets and sleep in autistic children -- a randomized controlled trial . OBJECTIVE To assess the effectiveness of a weighted-blanket intervention in treating severe sleep problems in children with autism spectrum disorder ( ASD ) . METHODS This phase III trial was a randomized , placebo-controlled crossover design . Participants were aged between 5 years and 16 years 10 months , with a confirmed ASD diagnosis and severe sleep problems , refractory to community-based interventions . The interventions were either a commercially available weighted blanket or otherwise identical usual weight blanket ( control ) , introduced at bedtime ; each was used for a 2-week period before crossover to the other blanket . Primary outcome was total sleep time ( TST ) recorded by actigraphy over each 2-week period . Secondary outcomes included actigraphically recorded sleep-onset latency , sleep efficiency , assessments of child behavior , family functioning , and adverse events . Sleep was also measured by using parent-report diaries . RESULTS Seventy-three children were randomized and analysis conducted on 67 children who completed the study . Using objective measures , the weighted blanket , compared with the control blanket , did not increase TST as measured by actigraphy and adjusted for baseline TST . There were no group differences in any other objective or subjective measure of sleep , including behavioral outcomes . On subjective preference measures , parents and children favored the weighted blanket . CONCLUSIONS The use of a weighted blanket did not help children with ASD sleep for a longer period of time , fall asleep significantly faster , or wake less often . However , the weighted blanket was favored by children and parents , and blankets were well tolerated over this period ."
],
"offsets": [
[
0,
1814
]
]
}
] | [
{
"id": "66824",
"type": "Intervention_Other",
"text": [
"Weighted blankets"
],
"offsets": [
[
0,
17
]
],
"normalized": []
},
{
"id": "66825",
"type": "Intervention_Other",
"text": [
"weighted-blanket intervention"
],
"offsets": [
[
127,
156
]
],
"normalized": []
},
{
"id": "66826",
"type": "Intervention_Other",
"text": [
"commercially available weighted blanket or otherwise identical usual weight blanket"
],
"offsets": [
[
530,
613
]
],
"normalized": []
},
{
"id": "66827",
"type": "Intervention_Other",
"text": [
"weighted blanket"
],
"offsets": [
[
553,
569
]
],
"normalized": []
},
{
"id": "66828",
"type": "Intervention_Control",
"text": [
"control blanket"
],
"offsets": [
[
1224,
1239
]
],
"normalized": []
},
{
"id": "66829",
"type": "Intervention_Other",
"text": [
"weighted blanket"
],
"offsets": [
[
553,
569
]
],
"normalized": []
},
{
"id": "66830",
"type": "Intervention_Other",
"text": [
"weighted blanket"
],
"offsets": [
[
553,
569
]
],
"normalized": []
},
{
"id": "66831",
"type": "Intervention_Other",
"text": [
"weighted blanket"
],
"offsets": [
[
553,
569
]
],
"normalized": []
},
{
"id": "66832",
"type": "Outcome_Mental",
"text": [
"total sleep time"
],
"offsets": [
[
746,
762
]
],
"normalized": []
},
{
"id": "66833",
"type": "Outcome_Physical",
"text": [
"( TST )"
],
"offsets": [
[
763,
770
]
],
"normalized": []
},
{
"id": "66834",
"type": "Outcome_Physical",
"text": [
"actigraphically recorded sleep-onset latency"
],
"offsets": [
[
848,
892
]
],
"normalized": []
},
{
"id": "66835",
"type": "Outcome_Mental",
"text": [
","
],
"offsets": [
[
289,
290
]
],
"normalized": []
},
{
"id": "66836",
"type": "Outcome_Other",
"text": [
"sleep efficiency"
],
"offsets": [
[
895,
911
]
],
"normalized": []
},
{
"id": "66837",
"type": "Outcome_Mental",
"text": [
"assessments of child behavior"
],
"offsets": [
[
914,
943
]
],
"normalized": []
},
{
"id": "66838",
"type": "Outcome_Mental",
"text": [
"family functioning"
],
"offsets": [
[
946,
964
]
],
"normalized": []
},
{
"id": "66839",
"type": "Outcome_Adverse-effects",
"text": [
"adverse events"
],
"offsets": [
[
971,
985
]
],
"normalized": []
},
{
"id": "66840",
"type": "Outcome_Mental",
"text": [
"TST"
],
"offsets": [
[
765,
768
]
],
"normalized": []
},
{
"id": "66841",
"type": "Outcome_Other",
"text": [
"objective or subjective measure of sleep"
],
"offsets": [
[
1366,
1406
]
],
"normalized": []
},
{
"id": "66842",
"type": "Outcome_Other",
"text": [
"well tolerated"
],
"offsets": [
[
1781,
1795
]
],
"normalized": []
},
{
"id": "66843",
"type": "Participant_Condition",
"text": [
"autistic children -- a"
],
"offsets": [
[
31,
53
]
],
"normalized": []
},
{
"id": "66844",
"type": "Participant_Condition",
"text": [
"severe sleep problems in children with autism spectrum disorder ( ASD ) ."
],
"offsets": [
[
169,
242
]
],
"normalized": []
},
{
"id": "66845",
"type": "Participant_Condition",
"text": [
"Participants were aged between 5 years and 16 years 10 months , with a confirmed ASD diagnosis and severe sleep problems , refractory to community-based interventions ."
],
"offsets": [
[
329,
497
]
],
"normalized": []
}
] | [] | [] | [] |
66846 | 25029834 | [
{
"id": "66847",
"type": "document",
"text": [
"[ Case-controll study on the synergistic effects of electroacupuncture on knee osteoarthritis after arthroscopic debridement ] . OBJECTIVE To study the synergistic effects of electroacupuncture on the treatment of knee osteoarthritis after arthroscopic debridement . METHODS From May 2008 to July 2010 , 78 patients with knee osteoarthritis were randomly divided into two groups . There were 42 patients in the experimental group , including 16 males and 26 females , ranging in age from 41 to 63 years , with an average of ( 53.62 +/- 6.53 ) years ; the disease course ranged from 8 to 24 months , with an average of ( 10.35 +/- 6.42 ) months . The patients were treated with arthroscopic debridement combined with electroacupuncture after operation . There were 36 patients in the control group , including 14 males and 22 females , ranging in age from 40 to 62 years , with an average of ( 54.34 +/- 7.67 ) years ; the disease course ranged from 6 to 25 months , with an average of ( 11.94 +/- 5.13 ) months . Those patients were treated only with arthroscopic debridment . All the patients performed isometric quadriceps femoris contraction exercise and knee flexion and extension activities after operation . The visual analog scale ( VAS ) score and Lysholm knee score were used to evaluate the therapeutic effects . RESULTS All the patients were followed up , and the duration ranged from 12 to 30 months , with an average of 15.6 months . At the final follow-up , VAS score was significantly decreased , and the Lysholm score , except for the item demanding for support , significantly increased , compared with those before surgery respectively in both groups . There was significant difference in VAS score between two groups after treatment . As to Lysholm score , there were significant differences in limp , pain , swelling , stair activity and squat , but there were no significant differences in items of interlocking and instability between two groups after treatment . CONCLUSION Electroacupuncture can effectively improve the clinical symptoms and knee joint 's motor function of knee joints in patients with knee osteoarthritis , as well as the synergistic effects on the treatment of knee osteoarthritis after arthroscopic debridement , leading to a much better long-term therapeutic effect with respect of improving the function of knee joint . This therapy , combined with traditional Chinese medicine and Western Medicine , is worth of clinical application in the treatment of knee osteoarthritis ."
],
"offsets": [
[
0,
2521
]
]
}
] | [
{
"id": "66848",
"type": "Intervention_Physical",
"text": [
"electroacupuncture"
],
"offsets": [
[
52,
70
]
],
"normalized": []
},
{
"id": "66849",
"type": "Intervention_Physical",
"text": [
"arthroscopic debridement"
],
"offsets": [
[
100,
124
]
],
"normalized": []
},
{
"id": "66850",
"type": "Intervention_Physical",
"text": [
"electroacupuncture"
],
"offsets": [
[
52,
70
]
],
"normalized": []
},
{
"id": "66851",
"type": "Intervention_Physical",
"text": [
"arthroscopic debridement"
],
"offsets": [
[
100,
124
]
],
"normalized": []
},
{
"id": "66852",
"type": "Intervention_Physical",
"text": [
"arthroscopic debridement"
],
"offsets": [
[
100,
124
]
],
"normalized": []
},
{
"id": "66853",
"type": "Intervention_Physical",
"text": [
"electroacupuncture"
],
"offsets": [
[
52,
70
]
],
"normalized": []
},
{
"id": "66854",
"type": "Intervention_Physical",
"text": [
"arthroscopic debridment"
],
"offsets": [
[
1051,
1074
]
],
"normalized": []
},
{
"id": "66855",
"type": "Intervention_Physical",
"text": [
"isometric quadriceps femoris contraction exercise"
],
"offsets": [
[
1104,
1153
]
],
"normalized": []
},
{
"id": "66856",
"type": "Intervention_Physical",
"text": [
"knee flexion"
],
"offsets": [
[
1158,
1170
]
],
"normalized": []
},
{
"id": "66857",
"type": "Intervention_Physical",
"text": [
"extension activities"
],
"offsets": [
[
1175,
1195
]
],
"normalized": []
},
{
"id": "66858",
"type": "Outcome_Adverse-effects",
"text": [
"synergistic effects"
],
"offsets": [
[
29,
48
]
],
"normalized": []
},
{
"id": "66859",
"type": "Outcome_Adverse-effects",
"text": [
"synergistic effects"
],
"offsets": [
[
29,
48
]
],
"normalized": []
},
{
"id": "66860",
"type": "Outcome_Mental",
"text": [
"disease course"
],
"offsets": [
[
555,
569
]
],
"normalized": []
},
{
"id": "66861",
"type": "Outcome_Other",
"text": [
"visual analog scale ( VAS ) score and"
],
"offsets": [
[
1218,
1255
]
],
"normalized": []
},
{
"id": "66862",
"type": "Outcome_Physical",
"text": [
"Lysholm knee score"
],
"offsets": [
[
1256,
1274
]
],
"normalized": []
},
{
"id": "66863",
"type": "Outcome_Other",
"text": [
"VAS score"
],
"offsets": [
[
1472,
1481
]
],
"normalized": []
},
{
"id": "66864",
"type": "Outcome_Physical",
"text": [
"Lysholm score"
],
"offsets": [
[
1520,
1533
]
],
"normalized": []
},
{
"id": "66865",
"type": "Outcome_Other",
"text": [
"VAS score"
],
"offsets": [
[
1472,
1481
]
],
"normalized": []
},
{
"id": "66866",
"type": "Outcome_Physical",
"text": [
"Lysholm score"
],
"offsets": [
[
1520,
1533
]
],
"normalized": []
},
{
"id": "66867",
"type": "Outcome_Physical",
"text": [
"limp"
],
"offsets": [
[
1814,
1818
]
],
"normalized": []
},
{
"id": "66868",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
1821,
1825
]
],
"normalized": []
},
{
"id": "66869",
"type": "Outcome_Adverse-effects",
"text": [
"swelling"
],
"offsets": [
[
1828,
1836
]
],
"normalized": []
},
{
"id": "66870",
"type": "Outcome_Physical",
"text": [
"stair activity"
],
"offsets": [
[
1839,
1853
]
],
"normalized": []
},
{
"id": "66871",
"type": "Outcome_Physical",
"text": [
"squat"
],
"offsets": [
[
1858,
1863
]
],
"normalized": []
},
{
"id": "66872",
"type": "Outcome_Physical",
"text": [
"interlocking"
],
"offsets": [
[
1920,
1932
]
],
"normalized": []
},
{
"id": "66873",
"type": "Outcome_Mental",
"text": [
"and"
],
"offsets": [
[
347,
350
]
],
"normalized": []
},
{
"id": "66874",
"type": "Outcome_Physical",
"text": [
"instability"
],
"offsets": [
[
1937,
1948
]
],
"normalized": []
},
{
"id": "66875",
"type": "Outcome_Physical",
"text": [
"clinical symptoms"
],
"offsets": [
[
2044,
2061
]
],
"normalized": []
},
{
"id": "66876",
"type": "Outcome_Physical",
"text": [
"motor function of knee joints"
],
"offsets": [
[
2080,
2109
]
],
"normalized": []
},
{
"id": "66877",
"type": "Participant_Sample-size",
"text": [
"78"
],
"offsets": [
[
304,
306
]
],
"normalized": []
},
{
"id": "66878",
"type": "Participant_Condition",
"text": [
"knee osteoarthritis"
],
"offsets": [
[
74,
93
]
],
"normalized": []
},
{
"id": "66879",
"type": "Participant_Sample-size",
"text": [
"42"
],
"offsets": [
[
392,
394
]
],
"normalized": []
},
{
"id": "66880",
"type": "Participant_Sample-size",
"text": [
"16"
],
"offsets": [
[
442,
444
]
],
"normalized": []
},
{
"id": "66881",
"type": "Participant_Sex",
"text": [
"males"
],
"offsets": [
[
445,
450
]
],
"normalized": []
},
{
"id": "66882",
"type": "Participant_Sample-size",
"text": [
"26"
],
"offsets": [
[
455,
457
]
],
"normalized": []
},
{
"id": "66883",
"type": "Participant_Sex",
"text": [
"females"
],
"offsets": [
[
458,
465
]
],
"normalized": []
},
{
"id": "66884",
"type": "Participant_Age",
"text": [
"41 to 63"
],
"offsets": [
[
488,
496
]
],
"normalized": []
},
{
"id": "66885",
"type": "Participant_Age",
"text": [
"53.62 +/- 6.53"
],
"offsets": [
[
526,
540
]
],
"normalized": []
},
{
"id": "66886",
"type": "Participant_Sample-size",
"text": [
"36"
],
"offsets": [
[
764,
766
]
],
"normalized": []
},
{
"id": "66887",
"type": "Participant_Sample-size",
"text": [
"14"
],
"offsets": [
[
809,
811
]
],
"normalized": []
},
{
"id": "66888",
"type": "Participant_Sex",
"text": [
"males"
],
"offsets": [
[
445,
450
]
],
"normalized": []
},
{
"id": "66889",
"type": "Participant_Sample-size",
"text": [
"22"
],
"offsets": [
[
822,
824
]
],
"normalized": []
},
{
"id": "66890",
"type": "Participant_Sex",
"text": [
"females"
],
"offsets": [
[
458,
465
]
],
"normalized": []
},
{
"id": "66891",
"type": "Participant_Age",
"text": [
"40 to 62"
],
"offsets": [
[
855,
863
]
],
"normalized": []
},
{
"id": "66892",
"type": "Participant_Age",
"text": [
"54.34 +/- 7.67"
],
"offsets": [
[
893,
907
]
],
"normalized": []
},
{
"id": "66893",
"type": "Participant_Condition",
"text": [
"knee osteoarthritis"
],
"offsets": [
[
74,
93
]
],
"normalized": []
}
] | [] | [] | [] |
66894 | 25040756 | [
{
"id": "66895",
"type": "document",
"text": [
"The addition of tramadol to the standard of i.v . acetaminophen and morphine infusion for postoperative analgesia in neonates offers no clinical benefit : a randomized placebo-controlled trial . BACKGROUND Tramadol is used following neonatal cardiac and general surgery . However , its ability to opioid-spare or facilitate earlier extubation in postoperative neonates is unquantified . OBJECTIVE This randomized placebo-controlled trial aimed to assess whether tramadol 's addition to standard analgesia resulted in earlier extubation or reduced analgesic/sedative requirements in postsurgical neonates . METHODS Neonates born ≥32 weeks postmenstrual age received either tramadol [ T ] 2 mg·kg ( -1 ) or placebo [ P ] 6-hourly for up to 5 days postthoracoabdominal surgery in addition to morphine ( commenced at 20 mcg·kg ( -1 ) ·h ( -1 ) ) and 6-hourly i.v . acetaminophen . Time to extubation , morphine and midazolam amounts , hourly pain scores , and seizure activity were compared using an intention-to-treat and per-protocol analysis . RESULTS Seventy-one neonates participated . Median survival time to extubation was similar between the groups ( T 67 h [ 95 % CI 51 , 84 ] vs P 52 h [ 95 % CI 43 , 65 ] ; P = 0.4 ) , and similar numbers were extubated by 96 h ( T 69 % vs P 77 % ; difference -8 % , 95 % CI -28 , 13 % ) . Morphine and midazolam exposure was similar , with low pain scores in both groups ( mean percentage of time with a pain score > 5/20 during the 5 days : T 13 % vs P 11 % , difference in means 2.8 [ 95 % CI -1.8 , 7.6 ] , P = 0.20 ) . Most participants had normal cranial ultrasounds ( T 86 % vs P 86 % ) ; no seizures occurred clinically or electroencephalographically . CONCLUSION Tramadol 's addition to standard analgesia in this small group of postsurgical neonates did not appear to have any positive effect on time to extubation , morphine or midazolam exposure , or pain scores . This questions the benefit of tramadol for postsurgical neonates . Importantly , no seizures occurred in these ill neonates who may potentially be at greater risk of tramadol toxicity compared with adults ."
],
"offsets": [
[
0,
2124
]
]
}
] | [
{
"id": "66896",
"type": "Intervention_Pharmacological",
"text": [
"tramadol"
],
"offsets": [
[
16,
24
]
],
"normalized": []
},
{
"id": "66897",
"type": "Intervention_Pharmacological",
"text": [
"acetaminophen and morphine"
],
"offsets": [
[
50,
76
]
],
"normalized": []
},
{
"id": "66898",
"type": "Intervention_Control",
"text": [
"placebo-controlled"
],
"offsets": [
[
168,
186
]
],
"normalized": []
},
{
"id": "66899",
"type": "Intervention_Pharmacological",
"text": [
"Tramadol"
],
"offsets": [
[
206,
214
]
],
"normalized": []
},
{
"id": "66900",
"type": "Intervention_Pharmacological",
"text": [
"tramadol 's"
],
"offsets": [
[
462,
473
]
],
"normalized": []
},
{
"id": "66901",
"type": "Intervention_Control",
"text": [
"standard analgesia"
],
"offsets": [
[
486,
504
]
],
"normalized": []
},
{
"id": "66902",
"type": "Intervention_Pharmacological",
"text": [
"tramadol"
],
"offsets": [
[
16,
24
]
],
"normalized": []
},
{
"id": "66903",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
168,
175
]
],
"normalized": []
},
{
"id": "66904",
"type": "Outcome_Physical",
"text": [
"acetaminophen"
],
"offsets": [
[
50,
63
]
],
"normalized": []
},
{
"id": "66905",
"type": "Outcome_Physical",
"text": [
"Time to extubation"
],
"offsets": [
[
877,
895
]
],
"normalized": []
},
{
"id": "66906",
"type": "Outcome_Physical",
"text": [
"morphine and midazolam amounts"
],
"offsets": [
[
898,
928
]
],
"normalized": []
},
{
"id": "66907",
"type": "Outcome_Physical",
"text": [
"hourly pain scores"
],
"offsets": [
[
931,
949
]
],
"normalized": []
},
{
"id": "66908",
"type": "Outcome_Physical",
"text": [
"seizure activity"
],
"offsets": [
[
956,
972
]
],
"normalized": []
},
{
"id": "66909",
"type": "Outcome_Mental",
"text": [
"participated"
],
"offsets": [
[
1072,
1084
]
],
"normalized": []
},
{
"id": "66910",
"type": "Outcome_Other",
"text": [
"Median survival time to extubation"
],
"offsets": [
[
1087,
1121
]
],
"normalized": []
},
{
"id": "66911",
"type": "Outcome_Pain",
"text": [
"with low pain scores"
],
"offsets": [
[
1377,
1397
]
],
"normalized": []
},
{
"id": "66912",
"type": "Outcome_Pain",
"text": [
"with a pain score"
],
"offsets": [
[
1439,
1456
]
],
"normalized": []
},
{
"id": "66913",
"type": "Outcome_Physical",
"text": [
"normal cranial ultrasounds"
],
"offsets": [
[
1587,
1613
]
],
"normalized": []
},
{
"id": "66914",
"type": "Outcome_Physical",
"text": [
"86 % ) ; no seizures"
],
"offsets": [
[
1628,
1648
]
],
"normalized": []
},
{
"id": "66915",
"type": "Outcome_Physical",
"text": [
"effect on time to extubation"
],
"offsets": [
[
1837,
1865
]
],
"normalized": []
},
{
"id": "66916",
"type": "Outcome_Physical",
"text": [
"morphine or midazolam exposure"
],
"offsets": [
[
1868,
1898
]
],
"normalized": []
},
{
"id": "66917",
"type": "Outcome_Pain",
"text": [
"pain scores"
],
"offsets": [
[
938,
949
]
],
"normalized": []
},
{
"id": "66918",
"type": "Participant_Condition",
"text": [
"postoperative analgesia in neonates"
],
"offsets": [
[
90,
125
]
],
"normalized": []
},
{
"id": "66919",
"type": "Participant_Condition",
"text": [
"neonatal cardiac"
],
"offsets": [
[
233,
249
]
],
"normalized": []
},
{
"id": "66920",
"type": "Participant_Condition",
"text": [
"general surgery ."
],
"offsets": [
[
254,
271
]
],
"normalized": []
},
{
"id": "66921",
"type": "Participant_Condition",
"text": [
"postsurgical neonates"
],
"offsets": [
[
582,
603
]
],
"normalized": []
},
{
"id": "66922",
"type": "Participant_Condition",
"text": [
"postthoracoabdominal surgery"
],
"offsets": [
[
745,
773
]
],
"normalized": []
},
{
"id": "66923",
"type": "Participant_Sample-size",
"text": [
"Seventy-one"
],
"offsets": [
[
1051,
1062
]
],
"normalized": []
},
{
"id": "66924",
"type": "Participant_Age",
"text": [
"with adults"
],
"offsets": [
[
2111,
2122
]
],
"normalized": []
}
] | [] | [] | [] |
66925 | 25044079 | [
{
"id": "66926",
"type": "document",
"text": [
"Examining the temperature of embryo culture in in vitro fertilization : a randomized controlled trial comparing traditional core temperature ( 37°C ) to a more physiologic , cooler temperature ( 36°C ) . OBJECTIVE To determine whether culture at a more physiologically cooler temperature , as suggested by limited human and animal data , would improve blastulation and pregnancy rates in human clinical IVF . DESIGN Paired randomized controlled trial . SETTING Academic . PATIENT ( S ) Infertile couples ( n=52 ) with a female partner less than 42 years old with eight or more mature oocytes retrieved . INTERVENTION ( S ) Mature oocytes obtained from a single cohort of oocytes were randomly divided into two groups ; one was cultured at 37°C and the other at 36°C from the time of ICSI to the time of embryo transfer or vitrification . Paired embryo transfers were accomplished by transferring one euploid embryo from each group . DNA fingerprinting was used as needed to determine the outcome for each embryo . MAIN OUTCOME MEASURE ( S ) Rate of development of expanded blastocysts suitable for transfer or vitrification ( primary outcome ) , fertilization , aneuploidy , and sustained implantation . RESULT ( S ) A total of 805 mature oocytes were cultured ; 399 at 36°C and 406 at 37°C . Paired analysis demonstrated a higher rate of usable blastocyst formation per zygote at 37°C ( 48.4 % ) vs. at 36°C ( 41.2 % ) . Rates of fertilization , aneuploidy , and sustained implantation were equivalent . CONCLUSION ( S ) IVF culture at 36°C does not improve clinically relevant parameters of embryo development or sustained implantation rates . CLINICAL TRIAL REGISTRATION NUMBER NCT01506089 ."
],
"offsets": [
[
0,
1694
]
]
}
] | [
{
"id": "66927",
"type": "Intervention_Other",
"text": [
"cultured at 37°C"
],
"offsets": [
[
727,
743
]
],
"normalized": []
},
{
"id": "66928",
"type": "Intervention_Other",
"text": [
"36°C"
],
"offsets": [
[
195,
199
]
],
"normalized": []
},
{
"id": "66929",
"type": "Outcome_Physical",
"text": [
"Rate of development of expanded blastocysts suitable for transfer or vitrification ( primary outcome )"
],
"offsets": [
[
1041,
1143
]
],
"normalized": []
},
{
"id": "66930",
"type": "Outcome_Physical",
"text": [
"fertilization , aneuploidy , and sustained implantation"
],
"offsets": [
[
1146,
1201
]
],
"normalized": []
},
{
"id": "66931",
"type": "Outcome_Physical",
"text": [
"rate of usable blastocyst formation per zygote"
],
"offsets": [
[
1331,
1377
]
],
"normalized": []
},
{
"id": "66932",
"type": "Outcome_Physical",
"text": [
"Rates of fertilization , aneuploidy , and sustained implantation"
],
"offsets": [
[
1422,
1486
]
],
"normalized": []
},
{
"id": "66933",
"type": "Participant_Condition",
"text": [
"in vitro fertilization :"
],
"offsets": [
[
47,
71
]
],
"normalized": []
}
] | [] | [] | [] |
66934 | 25044819 | [
{
"id": "66935",
"type": "document",
"text": [
"Reducing the psychological distress of family caregivers of home based palliative care patients : longer term effects from a randomised controlled trial . BACKGROUND Palliative care incorporates comprehensive support of family caregivers because many of them experience burden and distress . However , evidence-based support initiatives are few . PURPOSE We evaluated a one-to-one psychoeducational intervention aimed at mitigating the distress of caregivers of patients with advanced cancer receiving home-based palliative care . We hypothesised that caregivers would report decreased distress as assessed by the General Health Questionnaire ( GHQ ) . METHOD A randomised controlled trial comparing two versions of the delivery of the intervention ( one face-to-face home visit plus telephone calls versus two visits ) plus standard care to a control group ( standard care only ) across four sites in Australia . RESULTS Recruitment to the one visit condition was 57 , the two visit condition 93 , and the control 148 . We previously reported non-significant changes in distress between times 1 ( baseline ) and 2 ( 1-week post-intervention ) but significant gains in competence and preparedness . We report here changes in distress between times 1 and 3 ( 8-week post-death ) . There was significantly less worsening in distress between times 1 and 3 in the one visit intervention group than in the control group ; however , no significant difference was found between the two visit intervention and the control group . CONCLUSIONS These results are consistent with the aim of the intervention , and they support existing evidence demonstrating that relatively short psychoeducational interventions can help family caregivers who are supporting a dying relative . The sustained benefit during the bereavement period may also have positive resource implications , which should be the subject of future inquiry ."
],
"offsets": [
[
0,
1912
]
]
}
] | [
{
"id": "66936",
"type": "Intervention_Educational",
"text": [
"one-to-one psychoeducational"
],
"offsets": [
[
370,
398
]
],
"normalized": []
},
{
"id": "66937",
"type": "Intervention_Educational",
"text": [
"two versions of the delivery of the intervention ( one face-to-face home visit plus telephone calls versus two visits ) plus standard care to a control group ( standard care only )"
],
"offsets": [
[
700,
880
]
],
"normalized": []
},
{
"id": "66938",
"type": "Outcome_Mental",
"text": [
"psychological distress"
],
"offsets": [
[
13,
35
]
],
"normalized": []
},
{
"id": "66939",
"type": "Outcome_Mental",
"text": [
"mitigating the distress of caregivers"
],
"offsets": [
[
421,
458
]
],
"normalized": []
},
{
"id": "66940",
"type": "Outcome_Mental",
"text": [
"decreased distress as assessed by the General Health Questionnaire ( GHQ ) ."
],
"offsets": [
[
576,
652
]
],
"normalized": []
},
{
"id": "66941",
"type": "Outcome_Mental",
"text": [
"distress"
],
"offsets": [
[
27,
35
]
],
"normalized": []
},
{
"id": "66942",
"type": "Outcome_Mental",
"text": [
"competence and preparedness ."
],
"offsets": [
[
1169,
1198
]
],
"normalized": []
},
{
"id": "66943",
"type": "Outcome_Mental",
"text": [
"distress"
],
"offsets": [
[
27,
35
]
],
"normalized": []
},
{
"id": "66944",
"type": "Outcome_Mental",
"text": [
"worsening in distress"
],
"offsets": [
[
1309,
1330
]
],
"normalized": []
},
{
"id": "66945",
"type": "Participant_Condition",
"text": [
"palliative care patients"
],
"offsets": [
[
71,
95
]
],
"normalized": []
},
{
"id": "66946",
"type": "Participant_Condition",
"text": [
"cancer receiving home-based palliative care"
],
"offsets": [
[
485,
528
]
],
"normalized": []
},
{
"id": "66947",
"type": "Participant_Sample-size",
"text": [
"57"
],
"offsets": [
[
965,
967
]
],
"normalized": []
},
{
"id": "66948",
"type": "Participant_Sample-size",
"text": [
"93"
],
"offsets": [
[
994,
996
]
],
"normalized": []
},
{
"id": "66949",
"type": "Participant_Condition",
"text": [
"control"
],
"offsets": [
[
136,
143
]
],
"normalized": []
}
] | [] | [] | [] |
66950 | 25045936 | [
{
"id": "66951",
"type": "document",
"text": [
"Egg intake during carbohydrate restriction alters peripheral blood mononuclear cell inflammation and cholesterol homeostasis in metabolic syndrome . Egg yolk contains bioactive components that improve plasma inflammatory markers and HDL profiles in metabolic syndrome ( MetS ) under carbohydrate restriction . We further sought to determine whether egg yolk intake affects peripheral blood mononuclear cell ( PBMC ) inflammation and cholesterol homeostasis in MetS , as HDL and its associated lipid transporter ATP-binding cassette transporter A1 ( ABCA1 ) reduce the inflammatory potential of leukocytes through modulation of cellular cholesterol content and distribution . Thirty-seven men and women classified with MetS consumed a moderate carbohydrate-restricted diet ( 25 % -30 % of energy ) for 12 weeks , in addition to consuming either three whole eggs per day ( EGG ) or the equivalent amount of yolk-free egg substitute ( SUB ) . Interestingly , lipopolysaccharide-induced PBMC IL-1β and TNFα secretion increased from baseline to week 12 in the SUB group only , despite increases in PBMC toll-like receptor 4 ( TLR4 ) mRNA expression in the EGG group . Compared to baseline , ABCA1 and 3-hydroxy-3-methyl-glutaryl ( HMG ) -CoA reductase mRNA expression increased by week 12 in the EGG group only , whereas changes in PBMC total cholesterol positively correlated with changes in lipid raft content . Together , these findings suggest that intake of whole eggs during carbohydrate restriction alters PBMC inflammation and cholesterol homeostasis in MetS ."
],
"offsets": [
[
0,
1563
]
]
}
] | [
{
"id": "66952",
"type": "Intervention_Pharmacological",
"text": [
"Egg intake"
],
"offsets": [
[
0,
10
]
],
"normalized": []
},
{
"id": "66953",
"type": "Intervention_Pharmacological",
"text": [
"egg yolk intake"
],
"offsets": [
[
349,
364
]
],
"normalized": []
},
{
"id": "66954",
"type": "Intervention_Pharmacological",
"text": [
"moderate carbohydrate-restricted diet"
],
"offsets": [
[
734,
771
]
],
"normalized": []
},
{
"id": "66955",
"type": "Intervention_Pharmacological",
"text": [
"either three whole eggs per day ( EGG"
],
"offsets": [
[
837,
874
]
],
"normalized": []
},
{
"id": "66956",
"type": "Intervention_Control",
"text": [
"equivalent amount of yolk-free egg substitute ( SUB"
],
"offsets": [
[
884,
935
]
],
"normalized": []
},
{
"id": "66957",
"type": "Outcome_Physical",
"text": [
"peripheral blood mononuclear cell ( PBMC ) inflammation"
],
"offsets": [
[
373,
428
]
],
"normalized": []
},
{
"id": "66958",
"type": "Outcome_Physical",
"text": [
"lipopolysaccharide-induced PBMC IL-1β and TNFα secretion increased"
],
"offsets": [
[
956,
1022
]
],
"normalized": []
},
{
"id": "66959",
"type": "Outcome_Physical",
"text": [
"PBMC toll-like receptor 4 ( TLR4 ) mRNA expression"
],
"offsets": [
[
1093,
1143
]
],
"normalized": []
},
{
"id": "66960",
"type": "Outcome_Physical",
"text": [
"baseline , ABCA1 and 3-hydroxy-3-methyl-glutaryl ( HMG ) -CoA reductase mRNA expression increased"
],
"offsets": [
[
1175,
1272
]
],
"normalized": []
},
{
"id": "66961",
"type": "Outcome_Physical",
"text": [
"in PBMC total cholesterol"
],
"offsets": [
[
1324,
1349
]
],
"normalized": []
},
{
"id": "66962",
"type": "Outcome_Physical",
"text": [
"alters PBMC inflammation and cholesterol homeostasis"
],
"offsets": [
[
1501,
1553
]
],
"normalized": []
},
{
"id": "66963",
"type": "Participant_Sample-size",
"text": [
"Thirty-seven"
],
"offsets": [
[
675,
687
]
],
"normalized": []
},
{
"id": "66964",
"type": "Participant_Sex",
"text": [
"men"
],
"offsets": [
[
688,
691
]
],
"normalized": []
},
{
"id": "66965",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
696,
701
]
],
"normalized": []
},
{
"id": "66966",
"type": "Participant_Condition",
"text": [
"MetS"
],
"offsets": [
[
270,
274
]
],
"normalized": []
}
] | [] | [] | [] |
66967 | 25047312 | [
{
"id": "66968",
"type": "document",
"text": [
"Intramuscular compared to intravenous midazolam for paediatric sedation : A study on cardiopulmonary safety and effectiveness . BACKGROUND Sedation in children remains a controversial issue in emergency departments ( ED ) . Midazolam , as a benzodiazepine is widely used for procedural sedation among paediatrics . We compared the effectiveness and safety of two forms of midazolam prescription ; intramuscular ( IM ) and intravenous ( IV ) . PATIENTS AND METHODS A cohort study was conducted on two matched groups of 30 children referred to our ED between 2010 and 2011 . The first group received IM midazolam ( 0.3 mg/kg ) and the second group received IV midazolam ( 0.15 mg/kg ) for sedation . For evaluating effectiveness , sedation , irritation and cooperation score were followed every 15 min for 60 min and for safety assessment , vital signs and O 2 saturation were observed . RESULTS Mean age was 6.18 ± 2.88 years and 31 patients ( 51.7 % ) were male . All patients were sedated completely after using first dose . There was an overall complication rate of 68.3 % . 35 ( 58.3 % ) patients presented euphoria as the most common complication , but there was no statistical difference between the two groups ( P = 0.396 ) . Cases who received IV midazolam became sedated faster than those received IM midazolam ( P > 0.001 ) . The vital signs including heart rate , respiratory rate , systolic blood pressure and O 2 saturation changed significantly between and within groups during the sedation ( P < 0.05 ) . CONCLUSION Both forms of midazolam , IM and IV , are effective and safe for paediatric sedation in ED . Although the sedative with IV form might appear sooner , IM form of midazolam can be effectively used in patient with limited IV access . Patients are better to observe closely for psychological side-effects ."
],
"offsets": [
[
0,
1832
]
]
}
] | [
{
"id": "66969",
"type": "Intervention_Pharmacological",
"text": [
"Intramuscular compared to intravenous midazolam"
],
"offsets": [
[
0,
47
]
],
"normalized": []
},
{
"id": "66970",
"type": "Intervention_Pharmacological",
"text": [
"Midazolam"
],
"offsets": [
[
224,
233
]
],
"normalized": []
},
{
"id": "66971",
"type": "Intervention_Pharmacological",
"text": [
"benzodiazepine"
],
"offsets": [
[
241,
255
]
],
"normalized": []
},
{
"id": "66972",
"type": "Intervention_Pharmacological",
"text": [
"midazolam prescription ; intramuscular ( IM ) and intravenous ( IV ) ."
],
"offsets": [
[
372,
442
]
],
"normalized": []
},
{
"id": "66973",
"type": "Intervention_Pharmacological",
"text": [
"IM midazolam"
],
"offsets": [
[
598,
610
]
],
"normalized": []
},
{
"id": "66974",
"type": "Intervention_Pharmacological",
"text": [
"IV midazolam"
],
"offsets": [
[
655,
667
]
],
"normalized": []
},
{
"id": "66975",
"type": "Outcome_Physical",
"text": [
"effectiveness"
],
"offsets": [
[
112,
125
]
],
"normalized": []
},
{
"id": "66976",
"type": "Outcome_Physical",
"text": [
"sedation"
],
"offsets": [
[
63,
71
]
],
"normalized": []
},
{
"id": "66977",
"type": "Outcome_Mental",
"text": [
"irritation and cooperation score"
],
"offsets": [
[
740,
772
]
],
"normalized": []
},
{
"id": "66978",
"type": "Outcome_Physical",
"text": [
"safety assessment , vital signs and O 2 saturation"
],
"offsets": [
[
819,
869
]
],
"normalized": []
},
{
"id": "66979",
"type": "Outcome_Other",
"text": [
"were sedated"
],
"offsets": [
[
977,
989
]
],
"normalized": []
},
{
"id": "66980",
"type": "Outcome_Other",
"text": [
"an overall complication rate"
],
"offsets": [
[
1036,
1064
]
],
"normalized": []
},
{
"id": "66981",
"type": "Outcome_Adverse-effects",
"text": [
"presented euphoria"
],
"offsets": [
[
1100,
1118
]
],
"normalized": []
},
{
"id": "66982",
"type": "Outcome_Other",
"text": [
"became sedated"
],
"offsets": [
[
1264,
1278
]
],
"normalized": []
},
{
"id": "66983",
"type": "Outcome_Physical",
"text": [
"including heart rate , respiratory rate , systolic blood pressure and O 2 saturation"
],
"offsets": [
[
1351,
1435
]
],
"normalized": []
},
{
"id": "66984",
"type": "Outcome_Other",
"text": [
"are effective and safe"
],
"offsets": [
[
1568,
1590
]
],
"normalized": []
},
{
"id": "66985",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
151,
159
]
],
"normalized": []
},
{
"id": "66986",
"type": "Participant_Sample-size",
"text": [
"30"
],
"offsets": [
[
518,
520
]
],
"normalized": []
},
{
"id": "66987",
"type": "Participant_Condition",
"text": [
"ED between 2010 and 2011"
],
"offsets": [
[
546,
570
]
],
"normalized": []
},
{
"id": "66988",
"type": "Participant_Age",
"text": [
"Mean age was 6.18 ± 2.88 years"
],
"offsets": [
[
894,
924
]
],
"normalized": []
},
{
"id": "66989",
"type": "Participant_Sample-size",
"text": [
"31"
],
"offsets": [
[
929,
931
]
],
"normalized": []
},
{
"id": "66990",
"type": "Participant_Sex",
"text": [
"male"
],
"offsets": [
[
957,
961
]
],
"normalized": []
}
] | [] | [] | [] |
66991 | 25048751 | [
{
"id": "66992",
"type": "document",
"text": [
"Transcervical Foley 's catheter versus Cook balloon for cervical ripening in stillbirth with a scarred uterus : a randomized controlled trial . OBJECTIVE To compare the efficacy and safety of the use of transcervical Foley 's catheter versus Cook cervical ripening balloon in pregnant women with stillbirth , unfavorable cervix and scarred uterus . DESIGN Randomized controlled study . SETTING El Minia University Hospital , El Minia , Egypt . PATIENTS AND METHODS Two-hundred pregnant women with stillbirth , unfavorable cervix and scarred uterus were recruited into this study . They were randomized into two groups . In group I ( n = 100 ) , cervical ripening was done using Foley 's catheter . In group II ( n = 100 ) , cervical ripening was done using Cook cervical ripening balloon . MAIN OUTCOME MEASURES Balloon insertion to delivery interval , successful ripening rate , cesarean delivery rate , maternal adverse events and maternal satisfaction . RESULTS Time from balloon insertion to expulsion and from balloon insertion to delivery was significantly shorter in Foley 's catheter group . However , the difference between the two groups regarding time from balloon insertion to active labor , time from balloon expulsion to delivery , cervical ripening , cesarean section , instrumental delivery , pain score , need for analgesia , hospital stay and maternal satisfaction was not statistically significant . CONCLUSIONS Foley 's catheter and Cook cervical ripening balloon are comparable regarding efficacy and safety profile when used to ripen the cervix in pregnant women with stillbirth , unfavorable cervix and scarred uterus . However , Foley 's catheter has a shorter induction to delivery interval and is relatively cheaper device ."
],
"offsets": [
[
0,
1750
]
]
}
] | [
{
"id": "66993",
"type": "Intervention_Physical",
"text": [
"Transcervical Foley 's catheter"
],
"offsets": [
[
0,
31
]
],
"normalized": []
},
{
"id": "66994",
"type": "Intervention_Physical",
"text": [
"Cook balloon"
],
"offsets": [
[
39,
51
]
],
"normalized": []
},
{
"id": "66995",
"type": "Intervention_Physical",
"text": [
"transcervical Foley 's catheter"
],
"offsets": [
[
203,
234
]
],
"normalized": []
},
{
"id": "66996",
"type": "Intervention_Physical",
"text": [
"Cook cervical ripening balloon"
],
"offsets": [
[
242,
272
]
],
"normalized": []
},
{
"id": "66997",
"type": "Intervention_Physical",
"text": [
"Foley 's catheter"
],
"offsets": [
[
14,
31
]
],
"normalized": []
},
{
"id": "66998",
"type": "Intervention_Physical",
"text": [
"Cook cervical ripening balloon"
],
"offsets": [
[
242,
272
]
],
"normalized": []
},
{
"id": "66999",
"type": "Intervention_Physical",
"text": [
"Foley 's catheter"
],
"offsets": [
[
14,
31
]
],
"normalized": []
},
{
"id": "67000",
"type": "Intervention_Physical",
"text": [
"Cook cervical"
],
"offsets": [
[
242,
255
]
],
"normalized": []
},
{
"id": "67001",
"type": "Outcome_Other",
"text": [
"efficacy and safety"
],
"offsets": [
[
169,
188
]
],
"normalized": []
},
{
"id": "67002",
"type": "Outcome_Other",
"text": [
"Balloon insertion to delivery interval"
],
"offsets": [
[
812,
850
]
],
"normalized": []
},
{
"id": "67003",
"type": "Outcome_Other",
"text": [
"successful ripening rate"
],
"offsets": [
[
853,
877
]
],
"normalized": []
},
{
"id": "67004",
"type": "Outcome_Other",
"text": [
"cesarean delivery rate"
],
"offsets": [
[
880,
902
]
],
"normalized": []
},
{
"id": "67005",
"type": "Outcome_Adverse-effects",
"text": [
"maternal adverse events"
],
"offsets": [
[
905,
928
]
],
"normalized": []
},
{
"id": "67006",
"type": "Outcome_Other",
"text": [
"maternal satisfaction"
],
"offsets": [
[
933,
954
]
],
"normalized": []
},
{
"id": "67007",
"type": "Outcome_Other",
"text": [
"Time from balloon insertion to expulsion"
],
"offsets": [
[
965,
1005
]
],
"normalized": []
},
{
"id": "67008",
"type": "Outcome_Other",
"text": [
"balloon insertion to delivery"
],
"offsets": [
[
1015,
1044
]
],
"normalized": []
},
{
"id": "67009",
"type": "Outcome_Other",
"text": [
"time from balloon insertion to active labor"
],
"offsets": [
[
1158,
1201
]
],
"normalized": []
},
{
"id": "67010",
"type": "Outcome_Other",
"text": [
"time from balloon expulsion to delivery"
],
"offsets": [
[
1204,
1243
]
],
"normalized": []
},
{
"id": "67011",
"type": "Outcome_Other",
"text": [
"cervical ripening"
],
"offsets": [
[
56,
73
]
],
"normalized": []
},
{
"id": "67012",
"type": "Outcome_Other",
"text": [
"cesarean section"
],
"offsets": [
[
1266,
1282
]
],
"normalized": []
},
{
"id": "67013",
"type": "Outcome_Other",
"text": [
"instrumental delivery"
],
"offsets": [
[
1285,
1306
]
],
"normalized": []
},
{
"id": "67014",
"type": "Outcome_Pain",
"text": [
"pain score"
],
"offsets": [
[
1309,
1319
]
],
"normalized": []
},
{
"id": "67015",
"type": "Outcome_Pain",
"text": [
"need for analgesia"
],
"offsets": [
[
1322,
1340
]
],
"normalized": []
},
{
"id": "67016",
"type": "Outcome_Other",
"text": [
"hospital stay"
],
"offsets": [
[
1343,
1356
]
],
"normalized": []
},
{
"id": "67017",
"type": "Outcome_Other",
"text": [
"maternal satisfaction"
],
"offsets": [
[
933,
954
]
],
"normalized": []
},
{
"id": "67018",
"type": "Outcome_Other",
"text": [
"efficacy and safety profile"
],
"offsets": [
[
1509,
1536
]
],
"normalized": []
},
{
"id": "67019",
"type": "Outcome_Physical",
"text": [
"induction to delivery interval"
],
"offsets": [
[
1685,
1715
]
],
"normalized": []
},
{
"id": "67020",
"type": "Participant_Condition",
"text": [
"cervical ripening in stillbirth with a scarred uterus :"
],
"offsets": [
[
56,
111
]
],
"normalized": []
},
{
"id": "67021",
"type": "Participant_Condition",
"text": [
"pregnant"
],
"offsets": [
[
276,
284
]
],
"normalized": []
},
{
"id": "67022",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
285,
290
]
],
"normalized": []
},
{
"id": "67023",
"type": "Participant_Condition",
"text": [
"cervix and scarred uterus"
],
"offsets": [
[
321,
346
]
],
"normalized": []
},
{
"id": "67024",
"type": "Participant_Sample-size",
"text": [
"Two-hundred"
],
"offsets": [
[
465,
476
]
],
"normalized": []
},
{
"id": "67025",
"type": "Participant_Condition",
"text": [
"pregnant"
],
"offsets": [
[
276,
284
]
],
"normalized": []
},
{
"id": "67026",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
285,
290
]
],
"normalized": []
},
{
"id": "67027",
"type": "Participant_Condition",
"text": [
"with stillbirth , unfavorable cervix and scarred uterus"
],
"offsets": [
[
291,
346
]
],
"normalized": []
}
] | [] | [] | [] |
67028 | 25053766 | [
{
"id": "67029",
"type": "document",
"text": [
"Effects of a music therapy group intervention on enhancing social skills in children with autism . BACKGROUND Research indicates that music therapy can improve social behaviors and joint attention in children with Autism Spectrum Disorder ( ASD ) ; however , more research on the use of music therapy interventions for social skills is needed to determine the impact of group music therapy . OBJECTIVE To examine the effects of a music therapy group intervention on eye gaze , joint attention , and communication in children with ASD . METHOD Seventeen children , ages 6 to 9 , with a diagnosis of ASD were randomly assigned to the music therapy group ( MTG ) or the no-music social skills group ( SSG ) . Children participated in ten 50-minute group sessions over a period of 5 weeks . All group sessions were designed to target social skills . The Social Responsiveness Scale ( SRS ) , the Autism Treatment Evaluation Checklist ( ATEC ) , and video analysis of sessions were used to evaluate changes in social behavior . RESULTS There were significant between-group differences for joint attention with peers and eye gaze towards persons , with participants in the MTG demonstrating greater gains . There were no significant between-group differences for initiation of communication , response to communication , or social withdraw/behaviors . There was a significant interaction between time and group for SRS scores , with improvements for the MTG but not the SSG . Scores on the ATEC did not differ over time between the MTG and SSG . CONCLUSIONS The results of this study support further research on the use of music therapy group interventions for social skills in children with ASD . Statistical results demonstrate initial support for the use of music therapy social groups to develop joint attention ."
],
"offsets": [
[
0,
1811
]
]
}
] | [
{
"id": "67030",
"type": "Intervention_Educational",
"text": [
"music therapy group intervention"
],
"offsets": [
[
13,
45
]
],
"normalized": []
},
{
"id": "67031",
"type": "Intervention_Educational",
"text": [
"music therapy"
],
"offsets": [
[
13,
26
]
],
"normalized": []
},
{
"id": "67032",
"type": "Intervention_Educational",
"text": [
"music therapy"
],
"offsets": [
[
13,
26
]
],
"normalized": []
},
{
"id": "67033",
"type": "Intervention_Educational",
"text": [
"music therapy group ( MTG )"
],
"offsets": [
[
632,
659
]
],
"normalized": []
},
{
"id": "67034",
"type": "Intervention_Educational",
"text": [
"no-music social skills group ( SSG )"
],
"offsets": [
[
667,
703
]
],
"normalized": []
},
{
"id": "67035",
"type": "Intervention_Control",
"text": [
"."
],
"offsets": [
[
97,
98
]
],
"normalized": []
},
{
"id": "67036",
"type": "Intervention_Educational",
"text": [
"MTG"
],
"offsets": [
[
654,
657
]
],
"normalized": []
},
{
"id": "67037",
"type": "Outcome_Mental",
"text": [
"social skills"
],
"offsets": [
[
59,
72
]
],
"normalized": []
},
{
"id": "67038",
"type": "Outcome_Mental",
"text": [
"social skills"
],
"offsets": [
[
59,
72
]
],
"normalized": []
},
{
"id": "67039",
"type": "Outcome_Physical",
"text": [
"eye gaze"
],
"offsets": [
[
466,
474
]
],
"normalized": []
},
{
"id": "67040",
"type": "Outcome_Mental",
"text": [
", joint attention , and communication"
],
"offsets": [
[
475,
512
]
],
"normalized": []
},
{
"id": "67041",
"type": "Outcome_Other",
"text": [
"Social Responsiveness Scale ( SRS ) , the Autism Treatment Evaluation Checklist ( ATEC ) , and video analysis of sessions"
],
"offsets": [
[
850,
971
]
],
"normalized": []
},
{
"id": "67042",
"type": "Outcome_Mental",
"text": [
"joint attention with peers and"
],
"offsets": [
[
1084,
1114
]
],
"normalized": []
},
{
"id": "67043",
"type": "Outcome_Physical",
"text": [
"eye gaze"
],
"offsets": [
[
466,
474
]
],
"normalized": []
},
{
"id": "67044",
"type": "Outcome_Mental",
"text": [
"towards persons"
],
"offsets": [
[
1124,
1139
]
],
"normalized": []
},
{
"id": "67045",
"type": "Outcome_Mental",
"text": [
"initiation of communication"
],
"offsets": [
[
1257,
1284
]
],
"normalized": []
},
{
"id": "67046",
"type": "Outcome_Other",
"text": [
","
],
"offsets": [
[
257,
258
]
],
"normalized": []
},
{
"id": "67047",
"type": "Outcome_Mental",
"text": [
"response to communication"
],
"offsets": [
[
1287,
1312
]
],
"normalized": []
},
{
"id": "67048",
"type": "Outcome_Other",
"text": [
", or"
],
"offsets": [
[
1313,
1317
]
],
"normalized": []
},
{
"id": "67049",
"type": "Outcome_Mental",
"text": [
"social withdraw/behaviors"
],
"offsets": [
[
1318,
1343
]
],
"normalized": []
},
{
"id": "67050",
"type": "Outcome_Other",
"text": [
"."
],
"offsets": [
[
97,
98
]
],
"normalized": []
},
{
"id": "67051",
"type": "Outcome_Other",
"text": [
"SRS scores"
],
"offsets": [
[
1409,
1419
]
],
"normalized": []
},
{
"id": "67052",
"type": "Outcome_Other",
"text": [
"Scores on the ATEC"
],
"offsets": [
[
1470,
1488
]
],
"normalized": []
},
{
"id": "67053",
"type": "Outcome_Mental",
"text": [
"social skills"
],
"offsets": [
[
59,
72
]
],
"normalized": []
},
{
"id": "67054",
"type": "Outcome_Mental",
"text": [
"joint attention"
],
"offsets": [
[
181,
196
]
],
"normalized": []
},
{
"id": "67055",
"type": "Outcome_Physical",
"text": [
"."
],
"offsets": [
[
97,
98
]
],
"normalized": []
},
{
"id": "67056",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
76,
84
]
],
"normalized": []
},
{
"id": "67057",
"type": "Participant_Condition",
"text": [
"autism"
],
"offsets": [
[
90,
96
]
],
"normalized": []
},
{
"id": "67058",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
76,
84
]
],
"normalized": []
},
{
"id": "67059",
"type": "Participant_Condition",
"text": [
"Autism Spectrum Disorder ( ASD )"
],
"offsets": [
[
214,
246
]
],
"normalized": []
},
{
"id": "67060",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
76,
84
]
],
"normalized": []
},
{
"id": "67061",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
241,
244
]
],
"normalized": []
},
{
"id": "67062",
"type": "Participant_Sample-size",
"text": [
"Seventeen"
],
"offsets": [
[
543,
552
]
],
"normalized": []
},
{
"id": "67063",
"type": "Participant_Age",
"text": [
"children , ages 6 to 9"
],
"offsets": [
[
553,
575
]
],
"normalized": []
},
{
"id": "67064",
"type": "Participant_Age",
"text": [
"children"
],
"offsets": [
[
76,
84
]
],
"normalized": []
},
{
"id": "67065",
"type": "Participant_Condition",
"text": [
"ASD"
],
"offsets": [
[
241,
244
]
],
"normalized": []
}
] | [] | [] | [] |
67066 | 25056444 | [
{
"id": "67067",
"type": "document",
"text": [
"Prior experience with a pain stimulus as a predictor of placebo analgesia . Placebo effects are important in pain reduction , but the effects are inconsistent . Prior experience with a pain stimulus may moderate placebo analgesia . The current study tests the effect of prior experience with a pain stimulus on placebo analgesia during a laboratory pain task . Healthy normotensive undergraduates ( 66 women , 68 men ) who either did or did not report prior experience with pain from submerging a limb in cold water were enrolled . In the laboratory , an experimenter applied an inert , medicinal-smelling cream to participants ' non-dominant hand . Participants randomized to the no-expectation group were told that the cream was a hand cleanser . Participants randomized to the placebo expectation group were told that the cream would reduce the pain associated with the cold pressor task . Participants then completed the cold pressor task and reported their pain on the short form of the McGill Pain Questionnaire . Analysis of variance revealed a main effect of expectation ( p < .05 ) , such that participants in the placebo expectation group reported less pain . An interaction was also found between expectation and prior experience ( p < .05 ) , such that participants with prior experience with pain from cold water immersion showed no difference in pain reports between expectation groups . In a pain context , prior experience with the pain stimulus may prevent a placebo expectation from reducing the experience of pain ."
],
"offsets": [
[
0,
1534
]
]
}
] | [
{
"id": "67068",
"type": "Intervention_Control",
"text": [
"Placebo"
],
"offsets": [
[
76,
83
]
],
"normalized": []
},
{
"id": "67069",
"type": "Intervention_Pharmacological",
"text": [
"medicinal-smelling cream"
],
"offsets": [
[
587,
611
]
],
"normalized": []
},
{
"id": "67070",
"type": "Intervention_Pharmacological",
"text": [
"cream was a hand cleanser"
],
"offsets": [
[
721,
746
]
],
"normalized": []
},
{
"id": "67071",
"type": "Intervention_Control",
"text": [
"placebo"
],
"offsets": [
[
56,
63
]
],
"normalized": []
},
{
"id": "67072",
"type": "Intervention_Pharmacological",
"text": [
"cream"
],
"offsets": [
[
606,
611
]
],
"normalized": []
},
{
"id": "67073",
"type": "Intervention_Educational",
"text": [
"cold pressor task"
],
"offsets": [
[
873,
890
]
],
"normalized": []
},
{
"id": "67074",
"type": "Intervention_Educational",
"text": [
"cold pressor task"
],
"offsets": [
[
873,
890
]
],
"normalized": []
},
{
"id": "67075",
"type": "Outcome_Physical",
"text": [
"analgesia"
],
"offsets": [
[
64,
73
]
],
"normalized": []
},
{
"id": "67076",
"type": "Outcome_Pain",
"text": [
"pain reduction"
],
"offsets": [
[
109,
123
]
],
"normalized": []
},
{
"id": "67077",
"type": "Outcome_Pain",
"text": [
"analgesia"
],
"offsets": [
[
64,
73
]
],
"normalized": []
},
{
"id": "67078",
"type": "Outcome_Physical",
"text": [
"placebo analgesia"
],
"offsets": [
[
56,
73
]
],
"normalized": []
},
{
"id": "67079",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
24,
28
]
],
"normalized": []
},
{
"id": "67080",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
24,
28
]
],
"normalized": []
},
{
"id": "67081",
"type": "Outcome_Pain",
"text": [
"pain"
],
"offsets": [
[
24,
28
]
],
"normalized": []
},
{
"id": "67082",
"type": "Outcome_Mental",
"text": [
"McGill Pain Questionnaire"
],
"offsets": [
[
992,
1017
]
],
"normalized": []
},
{
"id": "67083",
"type": "Outcome_Pain",
"text": [
"less pain"
],
"offsets": [
[
1158,
1167
]
],
"normalized": []
},
{
"id": "67084",
"type": "Outcome_Pain",
"text": [
"with pain"
],
"offsets": [
[
469,
478
]
],
"normalized": []
},
{
"id": "67085",
"type": "Outcome_Pain",
"text": [
"difference in pain reports"
],
"offsets": [
[
1346,
1372
]
],
"normalized": []
},
{
"id": "67086",
"type": "Outcome_Other",
"text": [
"the experience of pain"
],
"offsets": [
[
1510,
1532
]
],
"normalized": []
},
{
"id": "67087",
"type": "Participant_Condition",
"text": [
"pain stimulus"
],
"offsets": [
[
24,
37
]
],
"normalized": []
},
{
"id": "67088",
"type": "Participant_Age",
"text": [
"undergraduates"
],
"offsets": [
[
382,
396
]
],
"normalized": []
},
{
"id": "67089",
"type": "Participant_Sample-size",
"text": [
"66"
],
"offsets": [
[
399,
401
]
],
"normalized": []
},
{
"id": "67090",
"type": "Participant_Sex",
"text": [
"women"
],
"offsets": [
[
402,
407
]
],
"normalized": []
},
{
"id": "67091",
"type": "Participant_Sample-size",
"text": [
"68"
],
"offsets": [
[
410,
412
]
],
"normalized": []
},
{
"id": "67092",
"type": "Participant_Sex",
"text": [
"men"
],
"offsets": [
[
404,
407
]
],
"normalized": []
},
{
"id": "67093",
"type": "Participant_Condition",
"text": [
"pain stimulus"
],
"offsets": [
[
24,
37
]
],
"normalized": []
}
] | [] | [] | [] |
67094 | 25062129 | [
{
"id": "67095",
"type": "document",
"text": [
"Contact lens lipid spoliation of hydrogel and silicone hydrogel lenses . PURPOSE The purpose of the study was to measure contact lens lipid spoliation of silicone hydrogel PureVision ( balafilcon A ) and hydrogel Acuvue 2 ( etafilcon A ) contact lenses worn for 10 hours single use ( DD ) and 7 days of extended wear ( EW ) . METHODS Two similar study populations ( DD , n = 55 ; EW , n = 53 ) , were enrolled at four study sites . In each population , a bilateral , randomized , crossover ( lens material ) , subject-masked experimental design was followed . Worn contact lenses were analyzed for lipid uptake using high-performance liquid chromatography by two laboratories : Alcon Laboratories ( right lens total uptake ) and OTG Research & Consultancy ( left lens total uptake and individual lipid classes ) . RESULTS Lipid uptake was different for the two materials : total lipid ( p < 0.007 ) , cholesterol esters ( p < 0.001 ) , cholesterol ( p < 0.001 EW only ) , and triglycerides/phospholipids ( p < 0.001 ) were higher for balafilcon A , whereas fatty acid ( p < 0.0025 EW only ) was higher for etafilcon A . The ratio of the extracted lipids was also different : higher percentages of triglycerides/phospholipids ( p < 0.001 ) and cholesterol ( p < 0.001 EW only ) for balafilcon A and higher percentages of fatty acids/di- and monoglycerides ( p < 0.014 ) for etafilcon A . CONCLUSIONS Total lipid uptake was highly material dependent . Both laboratories measured a greater uptake of lipids by the silicone hydrogel than the hydrogel material , a difference that was evident after only 10 hours of DD . Total lipid uptake was greater after 7 days of EW compared with 10 hours of DD . Of interest for contact lens spoliation and its avoidance was the differential lipid uptake profile , indicating material selectivity . Whereas greater differentiation between materials was possible after 7 days of EW for each material , the lipid uptake profile was similar for DD and EW , indicating a greater material effect than a wear modality effect ."
],
"offsets": [
[
0,
2054
]
]
}
] | [
{
"id": "67096",
"type": "Intervention_Physical",
"text": [
"contact lens lipid spoliation of silicone hydrogel PureVision ( balafilcon A )"
],
"offsets": [
[
121,
199
]
],
"normalized": []
},
{
"id": "67097",
"type": "Intervention_Physical",
"text": [
"hydrogel Acuvue 2 ( etafilcon A ) contact lenses"
],
"offsets": [
[
204,
252
]
],
"normalized": []
},
{
"id": "67098",
"type": "Outcome_Physical",
"text": [
"Lipid uptake"
],
"offsets": [
[
822,
834
]
],
"normalized": []
},
{
"id": "67099",
"type": "Outcome_Physical",
"text": [
"total lipid"
],
"offsets": [
[
873,
884
]
],
"normalized": []
},
{
"id": "67100",
"type": "Outcome_Physical",
"text": [
"cholesterol esters"
],
"offsets": [
[
901,
919
]
],
"normalized": []
},
{
"id": "67101",
"type": "Outcome_Physical",
"text": [
"cholesterol"
],
"offsets": [
[
901,
912
]
],
"normalized": []
},
{
"id": "67102",
"type": "Outcome_Physical",
"text": [
"triglycerides/phospholipids"
],
"offsets": [
[
976,
1003
]
],
"normalized": []
},
{
"id": "67103",
"type": "Outcome_Physical",
"text": [
"fatty acid"
],
"offsets": [
[
1057,
1067
]
],
"normalized": []
},
{
"id": "67104",
"type": "Outcome_Physical",
"text": [
"ratio of the extracted lipids"
],
"offsets": [
[
1124,
1153
]
],
"normalized": []
},
{
"id": "67105",
"type": "Outcome_Physical",
"text": [
"triglycerides/phospholipids"
],
"offsets": [
[
976,
1003
]
],
"normalized": []
},
{
"id": "67106",
"type": "Outcome_Physical",
"text": [
"cholesterol"
],
"offsets": [
[
901,
912
]
],
"normalized": []
},
{
"id": "67107",
"type": "Outcome_Physical",
"text": [
"fatty acids/di- and monoglycerides"
],
"offsets": [
[
1320,
1354
]
],
"normalized": []
},
{
"id": "67108",
"type": "Outcome_Physical",
"text": [
"Total lipid uptake"
],
"offsets": [
[
1399,
1417
]
],
"normalized": []
},
{
"id": "67109",
"type": "Outcome_Physical",
"text": [
"uptake of lipids"
],
"offsets": [
[
1487,
1503
]
],
"normalized": []
},
{
"id": "67110",
"type": "Outcome_Physical",
"text": [
"Total lipid uptake"
],
"offsets": [
[
1399,
1417
]
],
"normalized": []
},
{
"id": "67111",
"type": "Participant_Condition",
"text": [
"contact lenses"
],
"offsets": [
[
238,
252
]
],
"normalized": []
},
{
"id": "67112",
"type": "Participant_Condition",
"text": [
"extended wear ( EW )"
],
"offsets": [
[
303,
323
]
],
"normalized": []
},
{
"id": "67113",
"type": "Participant_Sample-size",
"text": [
"55"
],
"offsets": [
[
375,
377
]
],
"normalized": []
},
{
"id": "67114",
"type": "Participant_Sample-size",
"text": [
"53"
],
"offsets": [
[
389,
391
]
],
"normalized": []
}
] | [] | [] | [] |
67115 | 25066648 | [
{
"id": "67116",
"type": "document",
"text": [
"Complex decongestive therapy and taping for patients with postmastectomy lymphedema : a randomized controlled study . PURPOSE The purpose of our study was to investigate the effects of Kinesio Taping ( ® ) Application with Complex Decongestive Therapy ( CDT ) in patients with lymphedema . MATERIALS AND METHODS 45 patients were randomly divided into 3 groups ( CDT including Bandage , CDT including Bandage + Kinesio Tape ( ® ) , CDT including Kinesio Tape ( ® ) without bandage ) . Assessments included the severity of the symptoms such as pain , discomfort , heaviness , tension , stiffness and weakness . Bilateral circumference measurements were done for evaluation of the edema . RESULTS Symptoms were decreased in all three groups ( p < 0.05 ) . CDT was found effective only during treatment in arm volume ( p < 0.05 ) . Kinesio Taping ( ® ) applied with CDT had effect of decreasing edema after 10 days of treatment period ( p < 0.05 ) and for control period ( p < 0.05 ) . Only the application of Kinesio Taping ( ® ) group also had significant decrease at edema ( p < 0.05 ) . CONCLUSION Kinesio Taping ( ® ) Application along with CDT may have a better effect on decreasing lymphedema which can stimulate the reduction of edema for long term effects ."
],
"offsets": [
[
0,
1262
]
]
}
] | [
{
"id": "67117",
"type": "Intervention_Physical",
"text": [
"Complex decongestive therapy"
],
"offsets": [
[
0,
28
]
],
"normalized": []
},
{
"id": "67118",
"type": "Outcome_Pain",
"text": [
"the severity of the symptoms such as pain"
],
"offsets": [
[
505,
546
]
],
"normalized": []
},
{
"id": "67119",
"type": "Outcome_Pain",
"text": [
"discomfort"
],
"offsets": [
[
549,
559
]
],
"normalized": []
},
{
"id": "67120",
"type": "Outcome_Pain",
"text": [
"heaviness"
],
"offsets": [
[
562,
571
]
],
"normalized": []
},
{
"id": "67121",
"type": "Outcome_Physical",
"text": [
"tension"
],
"offsets": [
[
574,
581
]
],
"normalized": []
},
{
"id": "67122",
"type": "Outcome_Physical",
"text": [
"stiffness"
],
"offsets": [
[
584,
593
]
],
"normalized": []
},
{
"id": "67123",
"type": "Outcome_Physical",
"text": [
"weakness"
],
"offsets": [
[
598,
606
]
],
"normalized": []
},
{
"id": "67124",
"type": "Outcome_Physical",
"text": [
"Bilateral circumference"
],
"offsets": [
[
609,
632
]
],
"normalized": []
},
{
"id": "67125",
"type": "Outcome_Physical",
"text": [
"arm volume"
],
"offsets": [
[
802,
812
]
],
"normalized": []
},
{
"id": "67126",
"type": "Outcome_Physical",
"text": [
"decreasing edema"
],
"offsets": [
[
880,
896
]
],
"normalized": []
},
{
"id": "67127",
"type": "Outcome_Physical",
"text": [
"decrease at edema"
],
"offsets": [
[
1054,
1071
]
],
"normalized": []
},
{
"id": "67128",
"type": "Outcome_Physical",
"text": [
"decreasing lymphedema"
],
"offsets": [
[
1174,
1195
]
],
"normalized": []
},
{
"id": "67129",
"type": "Outcome_Other",
"text": [
"reduction"
],
"offsets": [
[
1220,
1229
]
],
"normalized": []
},
{
"id": "67130",
"type": "Participant_Condition",
"text": [
"patients with postmastectomy lymphedema :"
],
"offsets": [
[
44,
85
]
],
"normalized": []
},
{
"id": "67131",
"type": "Participant_Condition",
"text": [
"in patients with lymphedema"
],
"offsets": [
[
260,
287
]
],
"normalized": []
},
{
"id": "67132",
"type": "Participant_Sample-size",
"text": [
"METHODS 45 patients"
],
"offsets": [
[
304,
323
]
],
"normalized": []
},
{
"id": "67133",
"type": "Participant_Sample-size",
"text": [
"randomly divided into 3 groups"
],
"offsets": [
[
329,
359
]
],
"normalized": []
},
{
"id": "67134",
"type": "Participant_Condition",
"text": [
"decreasing lymphedema"
],
"offsets": [
[
1174,
1195
]
],
"normalized": []
}
] | [] | [] | [] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.